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By Leigh F. Johnson 
 
Sexually transmitted infections (STIs) have been shown to increase the probability of 
HIV transmission, but there remains much uncertainty regarding the role of STI 
treatment in HIV prevention. This thesis aims to develop a mathematical model to 
estimate the prevalence of STIs in South Africa, the contribution of STIs to the spread 
of HIV, and the effects of changes in sexual behaviour and changes in STI treatment.  
 
A deterministic model is developed to simulate the transmission of HIV and six other 
STIs (syphilis, genital herpes, chancroid, gonorrhoea, chlamydial infection and 
trichomoniasis), as well as the incidence of bacterial vaginosis and vaginal candidiasis 
in women. The model is fitted to national HIV prevalence survey data, STI prevalence 
data from sentinel surveys and data from sexual behaviour surveys, using Bayesian 
techniques.  
 
Model results suggest that South Africa has some of the highest STI prevalence levels 
in the world, but that certain STIs – notably syphilis, chancroid, gonorrhoea and 
trichomoniasis – have declined in prevalence since the mid-1990s, following the 
introduction of syndromic management programmes and increases in condom use. 
STIs account for more than half of new HIV infections, and genital herpes is the most 
significant STI promoting the transmission of HIV. Syndromic management 
programmes reduced HIV incidence in South Africa by 3-10% over the decade 
following their introduction (1994-2004). Further reductions in HIV incidence could 
be achieved by promoting patient-initiated treatment of genital herpes, by addressing 
rising levels of drug resistance in gonococcal isolates, and by encouraging prompt 
health seeking for STIs. Concurrent partnerships are a major factor driving HIV 
transmission, accounting for 74-87% of new HIV infections over the 1990-2000 
period. Halving unprotected sex in non-spousal relationships would reduce HIV 












This thesis contributes to the understanding of HIV/AIDS epidemiology in South 
Africa by quantifying the contribution of various behavioural and biological factors to 
HIV transmission. This thesis also highlights several opportunities for reducing the 
future incidence of HIV. In addition, this thesis advances the assessment of 
uncertainty in STI models by proposing a Bayesian approach to incorporating sexual 
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Many of the definitions given below are adapted from the Oxford Concise Medical 
Dictionary (E.A. Martin (ed.), 5th edition, 2000, Oxford University Press, Oxford 
UK). 
 
Acyclovir: an antiviral drug used in the treatment of genital herpes 
Amsel’s criteria: a method for diagnosing bacterial vaginosis, based on a 
constellation of clinical signs (abnormal discharge, amine test, presence of clue cells 
on microscopy and high vaginal pH) 
Antigen: any substance/organism which the body regards as foreign, and against 
which the body produces antibodies 
Assortative mixing: a pattern of sexual mixing in which individuals in a particular 
risk group tend to form partnerships with individuals in the same risk group 
Asymptomatic: not experiencing symptoms of infection. A person who is 
asymptomatic may nevertheless have signs of infection. 
 
Bacterial vaginosis: a condition brought about by changes in the vaginal flora, which 
may lead to symptoms of vaginal discharge 
Basic reproductive number (R0): the number of secondary infections that the 
average infected individual would be expected to generate before they die or cease to 
be infectious, if all of their contacts were susceptible 
Bayesian statistics: a branch of statistics concerned with combining experts’ prior 
knowledge about particular parameters and data concerning those parameters 
 
Calibration: the process of setting model parameters so that they are consistent with 
empirical evidence, and so that the resulting model outputs are consistent with 
observations 
Candidiasis: the presence of Candida yeasts in moist areas of the body. The presence 












CD4+ count: a measure of the strength of the immune system. A healthy adult would 
usually have a CD4+ count of >800/µl, while an adult sick with AIDS would typically 
have a CD4+ count of <200/µl. 
CD4+ T-lymphocytes: T-lymphocytes with CD4 receptors, also known as ‘helper T 
cells’ due to their role in directing either the cellular or humoral immune response. 
HIV infects these cells and other immune cells with CD4 receptors. 
Cellular immunity: the immune response in which cytotoxic T-lymphocytes (CTLs) 
play a crucial role (also known as cell-mediated immunity) 
Cervical ectopy: the presence of columnar epithelial cells (which normally line the 
endocervix) in the ectocervix. Unlike the squamous epithelium, the columnar 
epithelium comprises a single layer of cells and is therefore easier for HIV to 
penetrate. 
Cervicitis: inflammation of the cervix, usually as a result of chlamydial infection or 
gonorrhoea 
Challenge: experimental injection of infectious material into a subject 
Chancroid: an STI associated with genital ulcers, caused by the bacteria 
Haemophilus ducreyi. Also known as ‘soft sore’. 
Chlamydial infection: an STI associated with cervical discharges in women and 
urethritis in men, caused by the bacteria Chlamydia trachomatis 
Ciprofloxacin: an antibiotic commonly used in the treatment of gonorrhoea 
Commensal: an organism that neither harms nor benefits its host 
Core group: a small sub-population with a high risk of infection, which is usually 
regarded as being significant in both the initial spread and long-term persistence of 
infection in the general population 
Concurrency: (in the context of STI epidemiology) the state of having more than one 
current sexual partner 
Contact tracing: identifying sexual partners of individuals seeking treatment, and 
providing treatment to them 
Cross-sectional study: a study that measures the prevalence of disease in a sample of 
individuals, at a point in time (compare with ‘longitudinal study’) 
Culture: a population of microorganisms grown in a solid or liquid laboratory 












Cytokines: protein molecules released by cells when activated by an antigen, which 
play an important role in directing the immune response to the antigen 
Cytomegalovirus (CMV): a chronic viral infection that can be transmitted sexually, 
although commonly acquired in childhood. Symptoms are usually mild, but in 
immuno-compromised individuals symptoms can be severe. 
 
Deterministic: (in the context of disease modelling) calculating expected outcomes in 
cohorts of individuals who share the same characteristics, without allowing for 
random variation 
Diagnostic technique: technique used to diagnose infection or disease, e.g. culture, 
microscopy, serology, antigen detection, genome detection 
Direct immunofluorescence (DIF): an antigen detection method used to diagnose 
chlamydial infection 
Discharge: pus or mucus exuded from the urethra, cervix or vagina, often indicating 
infection of the reproductive tract 
Donovanosis: a rare bacterial STI that is associated with symptoms of genital 
ulceration. Also known as granuloma inguinale. 
Dose-response effect: an effect of a particular exposure (‘dose’) on an outcome 
(‘response’); the greater the level of exposure, the greater the effect on the outcome. 
Dysuria: painful urination 
 
Enzyme immunoassay (EIA): an antigen detection method 
Enzyme-linked immunosorbent assay (ELISA): a method used to detect antibodies 
to a particular infection 
Epithelium: tissue covering the external surface of the body and hollow surfaces such 
as the vagina and anus 
 
Fixed effects model: (in the context of meta-analysis) a method for pooling the 
results from several studies, which is based on the assumption that the variable being 
estimated is the same across populations, and that differences between study estimates 
are due only to sampling variation (compare with ‘random effects model’)  
Frequency-dependent model: a model in which the probability of acquiring 











infection in the pool of potential contacts and is independent of the prevalence among 
existing contacts 
 
Genital ulcer disease (GUD): presence of ulcers, blisters or lesions on the genitals. 
This is often due to infection with chancroid, syphilis or herpes, though in rare 
instances it may be due to other STIs such as lymphogranuloma venereum or 
donovanosis. 
Gonorrhoea: an STI associated with cervical discharges in women and urethritis in 
men, caused by the bacteria Neisseria gonorrhoeae. Also known as ‘clap’ or ‘drop’. 
Granuloma inguinale: See donovanosis. 
 
Hepaptitis B virus: a virus that can be transmitted sexually or through injections with 
contaminated needles. In developing countries, the virus is commonly acquired in 
childhood. Some chronically infected individuals develop liver disease. 
Herpes simplex virus (HSV): a chronic viral infection that causes intermittent 
ulcers/blisters. There are two types: type 1, which usually causes blisters on the lips 
(‘cold sores’), and type 2, which is usually transmitted sexually, causing blisters in the 
genital area. 
High power field: microscopic examination at a 1000× magnification 
Human papillomavirus (HPV): a chronic viral STI. There are many different types, 
some of which cause genital warts and some of which can cause cancer of the cervix, 
penis and anus. 
Humoral immunity: the immune response in which B-lymphocytes play a crucial 
role, by producing antibodies (compare with ‘cellular immunity’) 
 
Incubation period: the time between infection and the appearance of symptoms 
Inoculation: the introduction of a small quantity of infectious material into the body 
(usually in the context of immunization or challenge experiments) 
 
Lactobacilli: bacteria that occur naturally in the vagina, which protect against 
infection 
Lattice model: See ‘percolation model’ 











Leucocyte (also known as ‘white blood cell’): any blood cell with a nucleus, involved 
in protecting the body against infection. There are three main types of leucocyte: 
granulocytes (also known as polymorphonuclear leucocytes), lymphocytes and 
monocytes. 
Ligase chain reaction (LCR): a genome detection method, highly sensitive in 
detecting most infections 
Likelihood function: the probability of observing a particular set of values, if it is 
assumed that observations follow a specified distributional form 
Longitudinal study: a study that follows a cohort of individuals over a period of time 
and measures the incidence of death or disease in that cohort (compare with ‘cross-
sectional study’) 
Lower abdominal pain (LAP): a symptom of pelvic inflammatory disease 
Lymphocyte: a type of white blood cell. There are broadly two types of lymphocyte: 
B lymphocytes (involved in the humoral immune response) and T lymphocytes 
(involved mainly in the cellular immune response). T lymphocytes can be classified 
as cytotoxic T lymphocytes (CTLs), helper T lymphocytes or suppressor T 
lymphocytes. 
Lymphogranuloma venereum (LGV): a bacterial STI that causes genital ulcers. It is 
caused by a strain of Chlamydia trachomatis that differs from that which causes 
discharges (chlamydial infection). 
 
Macrophages: large cells that engulf and digest bacteria, protozoa, cells and cell 
debris. They have CD4 receptors, which make them potential targets for HIV. 
Male circumcision (MC): removal of the foreskin of the penis 
Markov Chain Monte Carlo (MCMC): a method for simulating the posterior 
distribution in a Bayesian analysis, when it is not possible to calculate the posterior 
distribution analytically. Each sequence of sampled parameter combinations is a 
Markov chain, i.e. the probability that the next parameter combination in a sequence 
takes on a particular set of values depends only on the last parameter combination and 
not previous ones. 
Mass treatment: a once-off campaign to treat all individuals in a particular 












Meta-analysis: a technique to estimate the ‘average’ value of a particular quantity by 
pooling results from different studies 
Meta-regression: a meta-analysis that attempts to account for variation in estimates 
of a quantity between studies by performing a regression, with study characteristics as 
explanatory variables 
Metronidazole: antibiotic commonly used to treat trichomoniasis and bacterial 
vaginosis 
Metropolis algorithm: a Markov Chain Monte Carlo technique in which the jumping 
distribution (the distribution used to sample the next parameter combination in the 
sequence) is symmetric. The method can be extended to allow for asymmetric 
jumping distributions (the Metropolis-Hastings algorithm). 
Microscopy: identification of microorganisms by microscopic examination 
Mucopurulent: containing mucus and pus 
Mucosa/mucous membrane: the moist membrane lining many cavities, e.g. the 
vagina 
Murine models: experiments in mice 
Mycoplasma genitalium: a bacterial infection of the genital tract that is often 
associated with urethritis and cervicitis 
 
Network model: a model of STI transmission that can be represented graphically. In 
graph theory terms, each node (‘vertex’) of the graph represents an individual, and 
each connection between nodes (‘edge’) represents a sexual partnership. 
Non-gonococcal urethritis (NGU): urethritis in which no gonococcal infection is 
apparent 
Non-specific urethritis (NSU): urethritis in which neither gonococcal nor chlamydial 
infection is apparent 
Non-synctium-inducing (NSI) HIV: the HIV phenotype most frequently involved in 
the sexual transmission of HIV. The NSI phenotype infects mainly macrophages, 
whereas the synctium-inducing (SI) phenotype infects mainly CD4+ T lymphocytes. 
Non-treponemal test: a test that detects antibodies to syphilis (the test usually ceases 
to produce positive results a few months after the individual is cured of syphilis) 
Nugent’s score: a method for diagnosing bacterial vaginosis, based on a scoring 
system that takes into account the relative levels of Lactobacillus, Bacteroides, 












Pair formation model: an STI model in which pairs of partnered individuals are 
modelled separately from single individuals, and pairs are classified according to the 
infection statuses of both partners 
Pelvic inflammatory disease (PID): inflammation of the uterus, fallopian tubes and 
ovaries, often due to gonococcal or chlamydial infection ascending into the upper 
reproductive tract 
Percolation model: a model for examining how an infection spreads (‘percolates’) 
through a population from a single infected individual, assuming all individuals have 
the same number of susceptible contacts, and assuming a constant probability of 
transmission per contact 
Periodic presumptive treatment (PPT): provision of treatment to all individuals in a 
particular group at regular intervals, regardless of their disease status. Treatment is 
provided presumptively because of the high risk of infection in the particular group. 
Phenotype: the characteristics of an organism that result from interactions between its 
genes and its environment 
Placebo: a pharmacologically inactive substance often given to subjects in the control 
arm of a randomized control trial 
Polymerase chain reaction (PCR): a genome detection method, highly sensitive in 
detecting most infections 
Polymorphonuclear leucocyte (PMNL): a type of white blood cell (leucocyte) 
having a nucleus that is divided into lobes. Also known as a granulocyte. 
Population attributable fraction (PAF) or risk (PAR): the proportion of new cases 
of a particular disease that can be attributed to a particular risk factor, in a given 
population 
Posterior: (in the context of Bayesian analysis) a probability density function 
representing the range of likely parameter values or model outputs, after integrating 
expert prior knowledge about the parameter(s) and data concerning the parameter(s) 
or model outputs 
Prior: (in the context of Bayesian analysis) a probability density function 
representing experts’ a priori beliefs about the range of likely parameter values, 
specified prior to the data in the current analysis being known 
Prospective study: See ‘longitudinal study’. 











Protozoa: a group of single-cell microorganisms, many of which exist in humans as 
parasites 
 
Random effects model: (in the context of meta-analysis) a method for pooling the 
results from several studies, which is based on the assumption that the variable being 
estimated varies between populations. The mean produced from a random effects 
model represents the average value of the variable across populations, and the 
confidence interval around this mean is wider than that produced using a fixed effects 
model. 
Randomized controlled trial (RCT): a study in which the effect of a particular 
treatment or intervention on a particular outcome is assessed by randomly allocating 
subjects to either receive the intervention (the ‘intervention arm’) or not receive the 
intervention (the ‘control arm’) 
Rapid plasma reagin (RPR): a non-treponemal antibody test commonly used to test 
for syphilis 
 
Sampling Importance Resampling (SIR): a method for simulating the posterior 
distribution in a Bayesian analysis, when it is not possible to calculate the posterior 
distribution exactly. Parameter combinations are sampled from the prior, the 
likelihood function is calculated for each parameter combination, and then a 
‘resample’ of parameter combinations is drawn from the original sample, using the 
likelihood values as weights. 
Screening: actively testing and treating individuals for infection even when they do 
not have symptoms 
Sensitivity: the probability that a diagnostic method detects infection in an infected 
individual 
Seroconversion: the time at which an individual begins to produce antibodies to a 
particular pathogen, detectable on antibody tests 
Serodiscordant couple: a couple in which one partner (the ‘index partner’) has a 
particular infection (usually determined serologically) and the other partner does not 
have the infection 
Serology: the study of blood serum, or the detection of antibodies to pathogens in 
blood serum 











Sexually transmitted infection (STI) or disease (STD): an infection or disease that 
is sexually transmitted. The term ‘STD’ is usually used more specifically to refer to 
symptomatic infection. In the past, the term ‘venereal disease’ (VD) was used. 
Shedding: See ‘viral shedding’ 
Specificity: the probability that an uninfected individual tests negative on a particular 
diagnostic test 
Social desirability bias: the tendency to report behaviour that is considered socially 
desirable, rather than actual behaviour 
Spontaneous resolution: the disappearance of infection in the absence of treatment, 
often due to the host immune response 
STI cofactor effect: the factor by which the HIV transmission probability is 
multiplied in the presence of an STI 
Stochastic: (in the context of disease modelling) calculating numbers of events for 
each individual separately, allowing for random variation in outcomes (compare with 
‘deterministic’) 
Super-infection: the acquisition of an infection when one is already infected with 
another strain of the same infection 
Symptomatic: experiencing symptoms 
Syndromic management: a set of treatment protocols that recommend treatment 
according to the particular signs and symptoms (syndrome) with which the patient 
presents, rather than according to microbiological assessment of the infectious agent 
Syphilis: an STI associated with genital ulcers in its primary stage, skin lesions in its 
secondary stage and potentially fatal complications of the neurological and 
cardiovascular systems in its tertiary stage. The disease is caused by the bacteria 
Treponema pallidum. 
 
Titre: a measure of the amount of antibody present in a serum sample (the reciprocal 
of the weakest dilution at which the antibody can be detected) 
Treponemal test: a test that detects antibodies to syphilis (the test usually continues 
to produce positive results even after the individual is cured of syphilis) 
Trichomoniasis: an STI associated with vaginal discharges in women and urethritis 












Urethritis: inflammation of the urethra, often defined in clinical terms as five or more 
polymorphonuclear leucocytes per high power field (in men). Symptoms include 
urethral discharge, though urethritis can be asymptomatic. 
 
Vaginal candidiasis: See ‘vulvovaginal candidiasis’ 
Vaginal flora: organisms occurring in the vagina 
Vaginitis: inflammation of the vagina, often associated with increased vaginal 
discharge, dysuria and itching 
Validation: the process of checking that model outputs are consistent with 
observations, after having set the model parameters on the basis of other data sources 
(compare with ‘calibration’) 
Viral load: concentration of virus, in either blood plasma or other specimens (e.g. 
semen) 
Viral shedding: the detectable presence of virus, usually (in the case of STIs) in 
specimens collected from the reproductive tract 
Vulvovaginal candidiasis (VVC): infection of the vulva/vagina by Candida yeasts, 
which can cause symptoms of itching and discharge 
 
Western blot: a diagnostic technique based on the detection of proteins associated 
with a particular pathogen 
White blood cell (WBC): See ‘leucocyte’. 
 












Chapter 1: Introduction 
 
In the year 2000, unsafe sex was responsible for approximately 6.3% of the global 
burden of disease, making it the second-most significant risk factor after childhood 
and maternal undernutrition (Ezzati et al, 2002). The significance of this risk factor 
was particularly profound in the African region, accounting for 19.4% of the total 
burden of disease in Africa. In South Africa, the contribution of unsafe sex to the 
burden of disease is even larger; a recent comparative risk assessment study estimates 
that in the year 2000, 31.5% of the burden of disease was attributable to unsafe sex, 
making unsafe sex by far the most significant risk factor in South Africa (Norman et 
al, 2007). Most of this burden is directly attributable to HIV/AIDS, though other 
sexually transmitted infections (STIs) also comprise an important element. 
Interventions to limit the spread of HIV and other STIs are therefore urgently needed 
in South Africa. 
 
Prior to the emergence of HIV/AIDS, the public health significance of STIs lay 
largely in their effect on infertility, adverse pregnancy outcomes and mortality and 
morbidity of infants born to infected women. The morbidity associated with most 
STIs is generally of short duration in adults, though there are notable exceptions, such 
as syphilis and human papillomavirus (the cause of cervical cancer). With the 
emergence of HIV/AIDS, there has been renewed interest in other STIs, due to a 
growing body of evidence showing that the probability of HIV transmission is 
enhanced in the presence of other STIs. This interaction between HIV and other STIs 
was first hypothesized in the late 1980s, when it was noted that HIV was present in 
high concentrations in the genital ulcers of individuals who were co-infected with 
HIV and ulcerative STIs (Kreiss et al, 1989; Plummer et al, 1990) and that individuals 
experiencing genital ulcers were at a significantly increased risk of acquiring HIV, 
even after controlling for behavioural factors (Cameron et al, 1989; Plummer et al, 
1991). Subsequent studies showed that non-ulcerative STIs and asymptomatic STIs 
also played a role in HIV transmission, and a series of systematic reviews have 
documented the growing evidence of the effect of STIs on HIV transmission 
(Wasserheit 1992; Fleming and Wasserheit 1999; Rotchford et al, 2000; Røttingen et 












In recognition of the importance of untreated STIs in the transmission of HIV, and the 
difficulties associated with treating STIs in many developing countries, the World 
Health Organization (WHO) developed a new strategy for treating STIs, referred to as 
syndromic management (World Health Organization 1991). This strategy aims to treat 
all patients presenting with STIs according to the symptoms (or syndrome) with 
which they present, at their first point of contact with the health system, rather than 
deferring treatment until the results of laboratory tests are available. Apart from the 
obvious benefit to the patient of receiving immediate treatment, this strategy 
circumvents problems that may be experienced with limited laboratory facilities and 
coordination of test results (major problems in many developing countries), the high 
cost of laboratory tests and the limited sensitivity of laboratory tests. However, it 
requires that patients be treated for all possible infections that may be causing a 
particular syndrome, and this often implies “over-treatment”. 
 
Trials that have examined the effect of improved STI treatment on HIV incidence 
have produced mixed results. The first such trial, which assessed the effect of 
syndromic management in Mwanza (Tanzania), showed a roughly 40% reduction in 
HIV incidence as a result of syndromic management (Grosskurth et al, 1995; Hayes et 
al, 1995a). However, a later trial of syndromic management combined with 
information and education campaigns, in the Masaka district of Uganda, failed to 
show any effect of the intervention on HIV incidence (Kamali et al, 2003). Another 
trial of mass antibiotic treatment provided to all adults in Rakai (Uganda) at ten-
monthly intervals also did not reduce significantly the incidence of HIV (Wawer et al, 
1999). Trials of monthly STI treatment among commercial sex workers in Côte 
d’Ivoire (Ghys et al, 2001) and Kenya (Kaul et al, 2004) have also failed to detect any 
significant reduction in HIV incidence. The optimism that followed the Mwanza trial 
has thus been gradually replaced by growing scepticism regarding the role of STI 
treatment in HIV prevention, and there remains much confusion regarding the reasons 
for the discrepant trial outcomes. 
 
South Africa has historically had very high STI prevalence levels (Kark 1949), but 
HIV/AIDS emerged later in South Africa than in most other African countries. In 











by 2005, prevalence had risen to 30.2% (Department of Health 2006), coinciding with 
a dramatic rise in mortality levels (Dorrington et al, 2001; Bradshaw et al, 2004a). A 
number of factors account for the severity of the South African HIV/AIDS epidemic. 
The migrant labour system, which became entrenched under colonial administration 
and apartheid, disrupted stable sexual relationships, thus creating social conditions 
that would foster the transmission of HIV and other STIs (Lurie 2000; Jochelson et al, 
1991). Sexual behaviour patterns in South Africa are characterized by a high degree 
of concurrency (Parker et al, 2007), a high frequency of transactional and commercial 
sex (Dunkle et al, 2004), and entry into marriage at a relatively late age (Bongaarts 
2007) – all of which are thought to be significant risk factors for HIV. The low socio-
economic position of women and the high levels of urbanization in South Africa are 
other social factors that may be responsible for the high level of HIV prevalence in 
South Africa. Biological factors have also been an important determinant of the 
spread of HIV; in addition to the role of STIs, already described, male circumcision 
has been shown to be protective against HIV and other STIs (Weiss et al, 2008; Weiss 
et al, 2006). The relatively low prevalence of male circumcision in South Africa 
therefore also partially explains the relatively high HIV prevalence (Williams et al, 
2006a).  
 
Recognizing that untreated STIs were a significant factor driving the spread of HIV in 
South Africa, the South African Department of Health introduced syndromic 
management protocols in the public health sector in the mid-1990s, at the same time 
that it started increasing the distribution and promotion of male condoms.   
Unfortunately, however, there was no mechanism in place to monitor whether the 
syndromic management programme was having any impact. South African STI 
prevalence data have been – and continue to be – obtained from independently 
conducted studies in different communities, based on different sampling strategies 
and different diagnostic procedures. This makes it difficult to compare STI prevalence 
estimates from different studies, and it is even more challenging to establish whether 
there has been any change in STI prevalence levels over time. With the exception of 
the national antenatal clinic survey estimates of syphilis prevalence (Department of 
Health 2006), there are no nationally representative estimates of the prevalence of 











has been no attempt to integrate the available STI prevalence data in South Africa to 
form a clear picture of the state of STIs and HIV-STI interactions in South Africa. 
 
Data problems have also bedevilled the assessment of the role of sexual behaviour in 
the spread of HIV in South Africa. Although many studies have gathered data on 
sexual behaviour (Eaton et al, 2003), these studies have generally been specific to 
particular communities or particular risk groups, and prior to the 1998 Demographic 
and Health Survey (Department of Health 1999), no surveys provided nationally 
representative sexual behaviour data. In the last decade, however, there have been 
several nationally representative surveys of sexual behaviour in South Africa, and 
over the same period a substantial body of international literature has emerged, which 
has aimed to quantify bias in self-reported sexual behaviour. Given these significant 
advances in our knowledge of sexual behaviour, it should now be possible to assess 
which aspects of sexual behaviour are contributing most to the spread of HIV in South 
Africa, and which changes in sexual behaviour would achieve the greatest reduction 
in HIV and STI prevalence. 
 
This thesis aims to address four questions. Firstly, what is the prevalence of various 
STIs in South Africa and how are STI prevalence levels changing over time? 
Secondly, to what extent have STIs promoted the spread of HIV in South Africa, and 
which STIs are currently the most significant drivers of HIV transmission? Thirdly, 
how effective have past improvements in STI treatment been in limiting the spread of 
HIV, and how can changes to current STI treatment practices limit the further spread 
of HIV? Lastly, which sexual risk behaviours are contributing most significantly to 
the transmission of HIV and other STIs in South Africa?  
 
To answer these questions, it is necessary to develop a mathematical model to 
simulate the spread of HIV and other STIs in South Africa. Mathematical models 
have been used extensively to gain insights into the transmission of infectious 
diseases and their impact. They have been used to formulate and test hypotheses about 
disease transmission and progression, to interpret epidemiological data, to make 
predictions about the future spread of infectious diseases, and to assess the 
appropriateness of different prevention and treatment strategies (Hethcote 2000; 











assumptions that are made about the behavioural and biological processes affecting 
the transmission and progression of disease, and it is therefore important that 
assumptions be based on the best available evidence. It is also important that model 
outputs be validated against epidemiological data, to ensure that the model produces 
reasonably realistic results. This thesis therefore aims to develop a mathematical 
model of HIV and other STIs in South Africa, that incorporates the best available data 
on STI epidemiology, and that can be used to answer the questions outlined above. 
 
In modelling STIs other than HIV, the focus of this thesis is limited to those STIs that 
are most frequently associated with genital ulcers (syphilis, genital herpes and 
chancroid) and with genital discharges or dysuria (gonorrhoea, chlamydial infection 
and trichomoniasis). In addition, bacterial vaginosis and vaginal candidiasis, which 
cause vaginal discharges, are modelled. These last two infections, which occur only in 
women, are usually not considered sexually transmissible, but are often considered 
together with the listed non-ulcerative STIs because of the similarity of the symptoms 
they produce. These eight genital tract infections have all been shown to increase 
significantly the risk of HIV acquisition (Røttingen et al, 2001), and are the primary 
targets of the syndromic management protocols. Other STIs are excluded from this 
analysis either because they are relatively rare (e.g. donovanosis, lymphogranuloma 
venereum), because there is little evidence to suggest that they increase the risk of 
HIV transmission (e.g. human papillomavirus, Mycoplasma genitalium) or because 
they are not usually associated with genital symptoms (e.g. hepatitis B, 
cytomegalovirus). As the focus of this thesis is on the role of STIs in the sexual 
transmission of HIV, the effects of certain STIs on the risk of infertility and adverse 
pregnancy outcomes, and mother-to-child transmission of STIs are also beyond the 
scope of this thesis. 
 
This thesis begins with a brief review of mathematical models of STIs and the 
modelling of interactions between HIV and other STIs. Chapter 3 is then devoted to 
describing the basic structure of the model developed to address the four questions 
listed previously, and the default parameter values are described and motivated. In 
chapter 4, the model is fitted, firstly just to the available sexual behaviour and HIV 
prevalence data (ignoring STIs) and then to the available STI prevalence data 











in STI and HIV prevalence. In chapter 5, the analysis is extended to allow for the 
effect of STIs on the probability of HIV transmission, and proportions of HIV 
infections attributable to other STIs are calculated. The potential effects of 
interventions – improvements in STI treatment and changes in sexual behaviour – are 
then evaluated in chapter 6. Finally, key results, policy implications, strengths, 












Chapter 2: Literature review: Mathematical models of STIs, 




Mathematical modelling of infectious diseases began in the 1760s with Daniel 
Bernoulli’s modelling of smallpox (Linder 1936). Since then, mathematical models 
have been developed to simulate the spread of a wide range of other infectious 
diseases, such as bubonic plague, measles, tuberculosis, malaria and influenza – to 
name but a few examples. These mathematical models have bee  developed to 
address a range of questions that cannot be answered through the use of traditional 
epidemiological methods. For example, what proportion of the population needs to be 
vaccinated in order to avoid outbreaks of a particular infectious disease? What is the 
predicted future incidence of a disease, considering possible changes to factors that 
may favour or inhibit its transmission? How rapidly can an infection be expected to 
spread when it is introduced into a population for the first time?  Central to answering 
these questions is an appreciation of the non-linearity of infectious disease dynamics; 
because the rate at which new infections occurs depends on the prevalence of the 
infection, the percentage reduction in incidence that follows a particular intervention 
is not proportional to the percentage reduction in susceptibility, except in the very 
short term. 
 
Models of infectious disease transmission can be distinguished from models that 
calculate disease incidence independently of transmission parameters. The latter body 
of modelling work is typically concerned with fitting functional forms to time series 
data – usually reported numbers of cases or estimated levels of prevalence – in order 
to characterize changes in disease incidence over time and age differences in disease 
incidence. Such models require no assumptions about the transmission process, and 
indeed are often used in the modelling of non-infectious diseases such as cancer 
(Robertson et al, 1999). Applications of these ‘curve fitting’ models to 











transmission (Anderson and May 1992), and they continue to be a popular tool for 
analysing epidemiological data because they require relatively few assumptions. 
 
Mathematical models of infectious diseases vary greatly, and can be classified in a 
number of ways. In their classic text on infectious disease modelling, Anderson and 
May (1992) start by classifying modelling work according to the type of infection that 
is modelled, distinguishing between models of microparasites (viruses, bacteria and 
protozoa) and models of macroparasites (helminth and arthropod infections), and 
distinguishing between directly transmitted infections and indirectly transmitted 
infections (transmitted between humans by ‘vectors’ such as mosquitoes and fleas). In 
Hethcote’s review of infectious disease modelling (Hethcote 2000), the primary 
distinction that is made is the distinction between epidemic models (models of disease 
outbreaks that typically persist in a population for less than a year) and endemic 
models (models of diseases that can be expected to persist in a population for longer 
than a year). A distinction is also made between the ‘standard incidence model’, in 
which the incidence of infection is assumed to be proportional to the prevalence of 
infection; and the ‘mass action model’, in which the incidence of infection is assumed 
to be proportional to the number of infected individuals, so that incidence rates will 
tend to be higher in large populations than in small populations. Disease models are 
also sometimes classified as compartmental or distributional (Garnett 2002); a 
compartmental model, for example, might split the population into infected and 
uninfected individuals, while a distributional model might model the distribution of 
parasite loads within the infected individuals. 
 
Mathematical models of STI transmission were first developed in the 1970s (Cooke 
and Yorke 1973; Hethcote and Yorke 1984), in response to concern over the dramatic 
increases in the number of reported gonorrhoea cases in the USA during the 1960s 
and 1970s. Although earlier ‘curve fitting’ models had been applied to trichomoniasis 
prevalence data (Ipsen and Feigl 1970), these did not make assumptions about the STI 
transmission process. Models of STI transmission are based on the standard incidence 
model rather than the mass action model. However, unlike most other models of 
infectious disease, STI models usually make separate assumptions about rates of 
contact between individuals and the probability of transmission per contact; models of 











which is the product of the rate of contact and the probability of transmission per 
contact. The separation of the rate of contact and the probability of transmission is 
probably due to contacts being easier to define and measure in the context of STIs 
than in the context of other infectious diseases. STI models are usually endemic 
models, and because they are projected for relatively long periods, they usually allow 
for demographic processes (birth and death) and loss of immunity over time. 
 
Since the emergence of HIV as a new STI in the early 1980s, interest in STI 
modelling has grown considerably. While models of other STIs have generally been 
quite simple, due to the lack of information on the transmission and natural history of 
these infections, the large amount of empirical research into the epidemiology of HIV 
has permitted a degree of sophistication and complexity in HIV models that is 
unmatched by models of other infections. The volume of literature relating to STI 
modelling is now enormous, and several reviews have been published on various 
aspects of HIV and STI modelling (Garnett and Anderson 1996; Anderson and 
Garnett 2000; Cassels et al, 2008). 
 
The purpose of this chapter is to provide an overview of the themes that have been 
most commonly tackled in the STI modelling literature and a commentary on the 
approaches that have most frequently been adopted. Section 2.2 outlines the types of 
STI models and critically examines the assumptions about sexual behaviour and STI 
transmission implicit in these different classes of models. Section 2.3 then describes 
the approaches that are most commonly adopted in modelling the natural history of 
sexually transmitted infection. In section 2.4, approaches to modelling interactions 
between HIV and other STIs are discussed, and in section 2.5, models of STI 
treatment are reviewed, with a focus on the important conclusions relating to HIV and 
















2.2 Approaches to modelling sexual behaviour and STI 
transmission 
 
Models of sexual behaviour and STI transmission can be classified as either stochastic 
individual-based models (‘micro-simulation’ models) or deterministic ‘macro-
simulation’ models. The former assign distinct characteristics to each individual in the 
modelled population and generate events such as partnership formation and 
transmission of infection randomly, at the individual level. The latter group of models 
divide the population into cohorts of individuals, on the basis of factors such as 
disease status, sexual behaviour and age, and simulate the expected numbers of events 
in each cohort. In cases in which it is possible to construct deterministic and 
stochastic versions of the same STI model, deterministic models have generally been 
found to produce results consistent with the average results produced by their 
stochastic analogues (Chick et al, 2000; Kretzschmar and Morris 1996; Eames and 
Keeling 2002; Mode 1991; Koopman et al, 2000). However, when an STI is very 
close to the threshold of persistence in a population, deterministic models can over-
estimate the average STI prevalence that would be expected, because they typically 
do not allow for the possibility of the STI becoming extinct (Gallop et al, 2002). 
 
Although deterministic models have the advantage of being easier to calibrate and 
parameterize than stochastic models, they are more limited in their ability to handle 
the complexities of sexual behaviour and STI transmission, and all rely on 
approximations of some sort in order to represent these dynamics. Figure 2.1 is a 
schematic representation of the various types of deterministic models, which differ 
according to the nature of the approximations made. In static network models (which 
include lattice models and percolation models), the network of sexual relationships 
remains fixed over the course of the simulation, i.e. partnership formation and 
dissolution are not modelled explicitly (Wu and Bradley 1991; Eames and Keeling 
2002). The focus of these models is therefore the dynamics of STI transmission and 
resolution over relatively short time intervals, rather than the longer term spread of 










































Figure 2.1: Deterministic models of sexual behaviour and STI transmission 
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Frequency-dependent models1 are models in which the probability of acquiring 
infection over a small time step is proportional to the prevalence of infection in the 
pool of potential partners. Individuals are not grouped according to the infection 
status of their partner(s), so that in each cohort, the probability of acquiring infection 
over a short time step is effectively independent of the infection status of the 
individual’s current partner(s). It has been argued that this is unrealistic, particularly 
in the case of STIs with high transmission probabilities (e.g. gonorrhoea), for which 
one would expect a high degree of correlation between the infection statuses of 
individuals and their partners (Lloyd-Smith et al, 2004). Pair formation models 
provide an alternative way of modelling STI transmission dynamics, by defining 
cohorts according to the infection status of partner(s), so that there are effectively 
cohorts of couples (stratified according to the infection status of both partners) in 
addition to cohorts of single individuals. It has been shown that under certain 
conditions pair formation models can produce significantly lower estimates of STI 
prevalence than frequency-dependent models (Eames and Keeling 2002; Lloyd-Smith 
et al, 2004). This is a cause for concern, as the majority of STI models follow the 
frequency-dependent approach. 
 
However, pair formation models also have limitations, and are not necessarily the 
‘gold standard’ in comparisons with frequency-dependent models. Most pair 
formation models are models of serial monogamy, which do not allow for the 
possibility that some individuals may have more than one current partner (Dietz and 
Hadeler 1988; Lloyd-Smith et al, 2004). This is a significant limitation, as several 
studies have shown that even after controlling for average rates of partnership 
formation or average infectivity, high levels of concurrency in a sexual network are 
associated with significantly higher STI prevalence levels (Morris and Kretzschmar 
1997; Ghani et al, 1997; Eames and Keeling 2004; Koopman et al, 2000). In recent 
years there have been several attempts to extend pair formation models to allow for 
concurrency. These models estimate changes in the numbers of coinfected or singly 
infected pairs from ‘triples’ (groups of three individuals comprising a ‘polygamous’ 
individual and their two sexual partners). In order to estimate the change in the 
                                                 
1 The term ‘frequency-dependent model’ is used in some papers (Thrall and Antonvics 1997; Lloyd-
Smith et al, 2004), and although the term is not widely used, we use it here in the absence of a better 












numbers of triples, it is necessary to estimate the number of ‘quadruples’, and so the 
system can expand to include quintuples etc. To prevent the system of differential 
equations becoming unmanageable, ‘moment closure approximations’ have been 
proposed, which limit the analysis to triples (Ferguson and Garnett 2000; Bauch and 
Rand 2000; Eames and Keeling 2004). These approximations are based on the 
assumption that in any given triple, the infection statuses of the two partners of the 
polygamous individual are independent, conditional upon the infection status of the 
polygamous individual. Bauch and Rand (2000) have shown that this approximation 
works reasonably well for STIs with low transmission probabilities and long average 
durations, but that it can significantly exaggerate the prevalence of STIs with high 
transmission probabilities and short average durations. 
 
Most frequency-dependent models are models of serial monogamy. Usually this is 
implicit in the assumption that the probability of acquiring infection from a partner 
depends only on the partner’s infection status at the start of the relationship; it is also 
implicit in the absence of any assumptions about the average duration of partnerships, 
which would determine the extent of overlap between partnerships. Very few attempts 
have been made to allow for concurrency within the frequency-dependent approach 
(Watts and May 1992; Garnett and Anderson 1996). Some modellers have avoided 
the serial monogamy vs concurrency question by working with a rate of sexual 
contact rather than a rate of partnership formation, effectively assuming that sex acts 
occur at random between members of certain sub-populations (Bongaarts 1989; De 
Gruttola and Mayer 1988). This is the standard approach used in modelling the 
incidence of other infectious diseases (Hethcote 2000). De Gruttola and Mayer (1988) 
have argued that this approach is reasonable when the probability of transmission per 
sex act is substantially lower than the inverse of the average number of sex acts per 
partnership. This condition would generally hold for HIV, but not necessarily for 
other STIs. 
 
Deterministic frequency-dependent models of serial monogamy can be distinguished 
according to whether they model STI transmission using per-partnership probabilities 
(the traditional approach) or probabilities of transmission per sex act. Since coital 
frequency is not always positively correlated with the number of partners (Nordvik 











more realistic in some settings. However, Garnett and Anderson (1993) observe that 
in the case of HIV, the cumulative HIV infection probability is not linearly related to 
the cumulative number of sexual encounters with the infected partner, and argue that 
it is therefore reasonable to assume a per-partnership transmission probability, 
without reference to the coital frequency in the partnership. Limited evidence suggests 
that similar non-linearities exist in the case of herpes (Wald et al, 2001; Corey et al, 
2004), chlamydial infection and gonorrhoea (Lin et al, 1998; Hooper et al, 1978), 
which might justify the use of per-partnership transmission probabilities in modelling 
these STIs.  
 
Although many STI models assume homogeneity in sexual behaviour patterns, it is 
well recognized that models should allow for heterogeneity in sexual behaviour in 
order to model STI spread realistically. Garnett and Anderson (1993), for example, 
have shown that a model with heterogeneous sexual behaviour produces a more rapid 
growth in HIV prevalence but a lower endemic HIV prevalence than a model of 
homogeneous sexual behaviour with the same average rate of partner acquisition, and 
the HIV prevalence trend predicted by the former model is much more typical of the 
prevalence trends observed in sub-Saharan African countries. Much STI modelling 
work has focused on the significant role of ‘core groups’ of individuals with high 
rates of partner change (typically sex workers and their clients), in spreading and 
sustaining STI epidemics (Hethcote and Yorke 1984; Ghani and Aral 2005; Auvert et 
al, 2000; Stigum et al, 1994; Brunham and Plummer 1990). Although this has been a 
popular avenue of research, some critics have argued that this focus on high risk 
groups rather than high risk behaviours is stigmatizing and unhelpful (Wojcicki and 
Malala 2001; Varga 1997a), and others have argued that sexual behaviour patterns in 
the broader population may play a more important role in STI transmission dynamics 
(Helleringer and Kohler 2007). Korenromp et al (2000a) have used the STDSIM 
model to show that HIV prevalence may rise to very high levels in some populations 
in the absence of a ‘core group’ of sex workers and clients, while in other populations 
HIV prevalence may remain at relatively low levels in spite of high levels of 
commercial sex activity. 
 
A few deterministic STI models allow for heterogeneity in sexual behaviour by 











(Kault 1992; Engen 1992; Anderson and May 1992), but most allow for heterogeneity 
by dividing the population into discrete ‘risk groups’, with each risk group being 
characterized by different rates of partner acquisition. In such cases it is important to 
specify the extent to which different risk groups interact with one another, and several 
approaches have been proposed (Gupta et al, 1989; Hyman and Li 1997; Tan and 
Xiang 1996). Sexual mixing patterns are usually characterized as being ‘assortative’ 
(individuals tend to form partnerships with individuals in the same risk group), 
‘disassortative’ (individuals tend to choose their partners from other risk groups) or 
random (individuals have no preference regarding the risk group of their partner) 
(Garnett and Anderson 1996). Trends in STI prevalence have been shown to be very 
sensitive to both the form of sexual mixing (Doherty et al, 2006; Kretzschmar and 
Morris 1996; Merli et al, 2006; Garnett and Anderson 1996; Stigum et al, 1994) and 
the ‘balancing rule’ that is used to adjust desired rates of partnership formation when 
there are imbalances in demand for relationships between risk groups. As an example 
of the latter, Garnett and Anderson (1993) predict that if women’s rates of entry into 
partnership were determined entirely by male demand for partnerships, the differences 
in HIV prevalence between males and females are likely to be much greater than they 
would be if men’s rates of partner acquisition were determined entirely by female 
demand for partnerships. Most models allow for this balancing process to be 
dynamically updated; this can be particularly important in HIV/AIDS models, since 
AIDS mortality is likely to change the population structure and the relative numbers 
of individuals in different risk groups. Significant reductions in rates of partner 
acquisition can occur as a result of the imbalances in demand for relationships that 
develop over the course of an HIV/AIDS epidemic (Gupta et al, 1989; Garnett and 
Anderson 1993), and observed reductions in rates of partner acquisition are therefore 
not always attributable to the success of interventions. 
 
Although most deterministic STI models do not allow for stratification of the 
population by age, there have been some attempts to explore the significance of age 
variation in sexual behaviour and age mixing patterns. For example, Anderson et al 
(1992) have shown that the demographic impact of HIV/AIDS is likely to be greater 
when sexual activity is more heavily concentrated at younger ages. Anderson et al 
also show that the demographic impact of HIV/AIDS is likely to be much greater if 











partnerships with individuals of the same age. However, other analyses have 
suggested that HIV prevalence is not very sensitive to assumed levels of mixing 
between age groups (Hallett et al, 2007; Garnett and Anderson 1993). 
 
In addition to stratification by age and risk group, several other stratifications of 
sexually active populations have been proposed. A number of modellers have 
considered stratification by geographic location (Coffee et al, 2007; Eames and 
Keeling 2004; Dorrington 2000), ethnic group (Turner et al, 2004; Dorrington 2000; 
Morris 1991; Tan and Xiang 1996) and genetic characteristics (Sullivan et al, 2001). 
There have also been some attempts to stratify populations on the basis of marital 
status. Both Bongaarts (1989) and John (1991) introduce this stratification by 
adopting a pair formation approach to modelling HIV in marital unions (effectively 
assuming that there are no concurrent partnerships among married individuals), while 
using a frequency-dependent approach to model HIV transmission in pre-marital 
sexual relationships. Most stochastic models distinguish between spousal 
relationships, non-spousal relationships and once-off encounters (including contacts 
between sex workers and clients) (Robinson et al, 1997; Korenromp et al, 2000a; 
Bracher et al, 2004). Deterministic models of STI transmission, on the other hand, 
tend to model only one type of sexual relationship. This is a significant limitation, as 
patterns of sexual behaviour are likely to differ substantially between married and 
unmarried individuals, with important implications for STI transmission dynamics. 
 
It is worth noting that a number of STI models avoid assumptions about sexual 
behaviour and STI transmission altogether, by using data on STI prevalence or STI 
cases to ‘back-calculate’ the STI incidence rate. Examples are the Spectrum model, 
which projects the impact of HIV/AIDS by calculating rates of HIV incidence from 
estimated HIV prevalence levels (Stover 2004), models that are fitted to HIV 
prevalence data by assuming that trends in HIV incidence follow a particular 
functional form (Low-Beer and Stoneburner 1997; Salomon and Murray 2001), and 
numerous models that ‘back-calculate’ rates of HIV incidence from reported numbers 
of AIDS cases (Brookmeyer and Liao 1990; Gilks et al, 1999; Tan and Ye 2000). 
Because of the substantial delay between HIV infection and AIDS, and because of 











recent HIV incidence, and models parameterized in this way can only be used to make 
short-term projections of trends in AIDS mortality and HIV prevalence.  
 
In summary, a wide variety of different approaches have been adopted in modelling 
STI transmission. Individual-based stochastic models have the advantage of being 
more flexible and are capable of achieving greater realism than deterministic models, 
but the large number of parameters required in order to achieve this can be a problem, 
particularly since stochastic models are difficult to calibrate to observed data. 
Deterministic models rely on various simplifying assumptions and/or approximations 
in order to estimate average rates of STI incidence in cohorts of individuals. While 
these simplifying assumptions are reasonable in many scenarios, they can lead to 
unrealistic results for certain STIs in certain populations. Despite these limitations, 
both stochastic and deterministic models are capable of yielding important insights 
into the relationship between sexual behaviour and STIs, particularly with respect to 
the role of heterogeneity in sexual contact patterns and the role of patterns of mixing 
between different sub-populations in sustaining the spread of STIs. 
 
2.3 Modelling the natural history of STIs 
 
Models of infectious diseases in humans tend to follow a similar format in their 
presentation of the course of infection and resolution of infection. This common 
format, often referred to as the MSEIR model (Hethcote 2000), is illustrated in Figure 
2.2. The population is divided into groups of individuals who are susceptible to 
infection (S), individuals who are infected and infectious (I), individuals who are 
infected but not yet infectious (E), and individuals who are uninfected but not 
susceptible, either because they are immune to reinfection following a previous 
infection (R), or because they acquired antibodies from their mothers at birth (M). 
Infants are assumed to lose their maternally acquired antibodies rapidly, at rate φ . 
Susceptible individuals are assumed to become infected at rate λ, progress from 
infected to infectious at rate θ and then recover at rate γ. Individuals are assumed to be 












STI models do not consider the ‘maternally acquired immunity’ state, since any 
maternally acquired antibodies would wane many years before the initiation of sexual 
activity, and would therefore not be significant in the overall STI transmission 
dynamics. Although most STIs can be transmitted from women to their newborn at 
birth, with potentially fatal or disabling consequences for the infant, STI models 
usually do not allow for mother-to-child transmission of infection, except in the case 
of models designed to assess the demographic impact of HIV/AIDS (John 1991; 
Bongaarts 1989; Dorrington 2000; Garnett and Anderson 1993; Leclerc and Garenne 
2007).  
 
M(t) S(t) E(t) I(t) R(t)
Births
µ µ µ µ µ
λ γφ θ
M(t) = # individuals with passive immunity (from mothers) at time t
S(t) = # individuals susceptible to infection at time t
E(t) = # individuals “exposed” (infected but not infectious) at time t
I(t) = # individuals who are infectious at time t
R(t) = # individuals who are recovered at time t, with permanent 
infection-acquired immunity




Figure 2.2: The MSEIR model 
Source: Hethcote (2000)  
 
STI models also generally omit the ‘E’ state, representing individuals who have 
acquired infection but are not yet infectious. This is probably because most STIs have 
an incubation phase that is very short relative to the overall duration of untreated 
infection, and the incubation phase is therefore not important. A possible exception is 
syphilis, which has an average incubation period of roughly one month (Garnett et al, 











(Pourbohloul et al, 2003; Garnett et al, 1997). In the early years of HIV research, 
several modellers speculated that there might be a similar non-infectious incubation 
phase in the case of HIV infection, and this is reflected in a number of the early 
HIV/AIDS models (De Gruttola and Mayer 1988; Watts and May 1992; Tan and 
Xiang 1996). Subsequent research demonstrated that in fact levels of infectiousness in 
the first few months of HIV infection are extremely high (Wawer et al, 2005; Pilcher 
et al, 2004), and any delay between the acquisition of HIV infection and HIV 
infectiousness would therefore be negligible. 
 
Unlike many other diseases, STIs are generally believed to confer little (if any) 
immunity against reinfection, and hence virtually all STI models assume that 
individuals return to the ‘susceptible’ state immediately after recovering from the STI 
(Lena et al, 2005). Two exceptions are syphilis and chlamydial infection. A number 
of models allow for temporary immunity against reinfection after recovery from 
syphilis, and these models show that the average duration of this protection can 
significantly affect the prevalence of syphilis in the population (Korenromp et al, 
2000b; Garnett et al, 1997; Pourbohloul et al, 2003). A few models also allow for 
reduced susceptibility to reinfection after recovery from chlamydial infection (White 
et al, 2004; Garnett and Anderson 1996; Brunham et al, 2005). These assumptions are 
supported by empirical evidence (Magnuson et al, 1956; Brunham et al, 1996; Arno 
et al, 1994), but as there is little evidence of immunity after recovery in the case of 
other STIs, models of other STIs generally omit the ‘R’ state. 
 
Although STI models generally simplify the MSEIR model by omitting the ‘M’, ‘E’ 
and ‘R’ states, most STI models also extend the MSEIR model by allowing for 
heterogeneity within the ‘I’ state. The early modelling work of Hethcote and Yorke 
(1984) has been particularly influential. In their modelling of gonorrhoea, Hethcote 
and Yorke split the infectious state into a symptomatic state (short average duration as 
a result of treatment) and an asymptomatic state (long average duration), assuming 
that symptomatic and asymptomatic infections are equally infectious, and assuming 
no movement occurs between the asymptomatic and symptomatic states. This became 
the standard approach for much subsequent modelling of gonorrhoea, chancroid and 
chlamydial infection, with almost all modellers making the same assumptions about 











absence of any difference in infectiousness between symptomatic and asymptomatic 
infection (Rowley and Berkley 1998; Korenromp et al, 2000b; Kretzschmar et al, 
1996; Garnett et al, 1999; Bracher et al, 2004). It is possible that switches between 
symptomatic and asymptomatic infection states may occur (Grosskurth et al, 1996; 
McCutchan 1984; Schachter 1978; Rahm et al, 1988) and that symptomatic and 
asymptomatic infections may differ in their transmissibility, but these assumptions 
have never been sensitivity-tested in models of short-term acute STIs. 
 
In the cases of herpes, syphilis and HIV, a number of more sophisticated models of 
infection and infectiousness have been developed. Several models of genital herpes 
reflect the periodic nature of HSV-2 infection by allowing for frequent switches 
between symptomatic and asymptomatic states (Newton and Kuder 2000; Korenromp 
et al, 2002b) or between infectious and non-infectious states (Gershengorn and 
Blower 2000; Blower et al, 1998; Blower et al, 2004). Models of syphilis tend to 
track progression of infected individuals through the primary, secondary and latent 
stages of infection, in most cases assuming that infectiousness is limited to the 
primary and secondary disease stages (Garnett et al, 1997; Pourbohloul et al, 2003; 
Rowley and Berkley 1998; Korenromp et al, 2000b). Models of HIV/AIDS typically 
allow for a very high level of infectiousness in the first few months of infection, 
followed by a long asymptomatic phase in which infectiousness is low, followed by a 
‘pre-AIDS’ symptomatic phase in which HIV infectiousness is increased, and finally 
an AIDS phase in which sexual activity is assumed to cease (Robinson et al, 1997; 
Boily et al, 2002; Hallett et al, 2007; Coffee et al, 2007). The relative significance of 
the high HIV infectiousness in the early and late stages of infection has been assessed 
in a number of studies, and has been found to be a highly significant factor affecting 
the pattern of HIV spread (Koopman et al, 1997; Rapatski et al, 2005; Anderson 
1996). 
 
It is well recognized that the natural history and infectiousness of various STIs may be 
changing over time, in response to selection pressures brought about by treatment, 
changes in sexual behaviour and demographic changes. Several modellers have 
attempted to predict these evolutionary changes, usually by comparing two different 
strains of the same infection and applying the principle of “competitive exclusion” 











that if there is perfect homogeneity in sexual behaviour, competing strains of the same 
STI cannot coexist in the long-term equilibrium with constant population size unless 
both strains have the same basic reproductive number (Castillo-Chavez et al, 1996; 
Lipsitch and Nowak 1995). However, if there is heterogeneity in sexual behaviour, it 
is possible for strains with different R0 values to coexist by selecting different ‘niches’ 
(Li et al, 2003). In addition, Lipsitch and Nowak (1995) show that if fertility rates are 
constant and the population is growing exponentially, coexistence of competing 
strains is possible in the equilibrium, with less virulent strains being favoured the 
higher the rate of partner change and the lower the fertility rate. Paradoxically, 
though, higher rates of partner change favour the more virulent strains in the early 
phases of the epidemic, when the competing strains are introduced into the population 
for the first time, and it is therefore possible that the strain that spreads most rapidly at 
first may ultimately be competitively excluded by the less virulent strain (Lipsitch and 
Nowak 1995). Other studies have modelled the effects of competition between strains 
with different symptom severity (Turner and Garnett 2002) and between strains with 
different modes of transmission (Thrall and Antonovics 1997).  
 
Most of the modelling of the evolution of STIs is limited by the assumptions of 
homogeneous sexual behaviour and competitive exclusion. It is likely that protection 
against super-infection by competing strains would not be absolute (Turner and 
Garnett 2002). In fact, different strains could operate synergistically if prior infection 
with one strain increases susceptibility to a different strain – a phenomenon referred 
to as “original antigenic sin” (Lena et al, 2005). Another limitation of models of 
competitive exclusion is that most do not dynamically model the processes by which 
new strains arise, i.e. through genetic mutations of existing strains (Lipsitch and 
Nowak 1995). The extent to which different strains actually compete is therefore 
probably exaggerated by the existing models, but these models nevertheless provide a 
useful framework for understanding evolutionary pressures. 
 
2.4 Modelling HIV-STI interactions 
 
Numerous studies have shown that HIV transmission probabilities are significantly 











level, this effect can be allowed for in HIV models by assuming higher HIV 
transmission probabilities in those risk groups in which STI prevalence is likely to be 
highest (Nagelkerke et al, 2002; Dorrington 2000), or by assuming a constant STI 
prevalence and an increased rate of HIV incidence associated with it (Rehle et al, 
1998; Brown and Peerapatanapokin 2004; Merli et al, 2006). However, since STI 
prevalence levels are likely to change over time, a better approach is to model the 
transmission and resolution of other STIs explicitly, linking them to the transmission 
of HIV through an assumed ‘STI cofactor’. Most models of HIV-STI interactions 
adopt this approach, with the STI cofactor taking the form of a multiple by which the 
probability of HIV transmission is increased in the presence of the STI. 
 
There is great diversity in the range of cofactor assumptions that have been made in 
different models, and Table 2.3.1 summarizes the assumptions made in a selection of 
HIV-STI interaction models. In much of the early modelling work, which was 
strongly influenced by the cofactor estimates of Hayes et al (1995b), it was assumed 
that the HIV transmission probability per act of sex was increased dramatically in the 
presence of other STIs – by as much as 100-fold (Robinson et al, 1997; Rehle et al, 
1998; Bernstein et al, 1998; Korenromp et al, 2000b). However, since the publication 
of a systematic review of STI cofactors by Røttingen  et al (2001) and an analysis of 
the biases affecting STI cofactor estimation (Korenromp et al, 2001), most modellers 
have used more conservative assumptions about the extent to which the HIV 
transmission probability per sex act is increased in the presence of other STIs 
(Bracher et al, 2003; Korenromp et al, 2002c; Williams et al, 2006b; Coffee et al, 
2007). In some cases the cofactor multiples are relatively low because they are 
assumed to apply to the probability of HIV transmission per partnership, not per sex 
act (Over and Piot 1996; Renton et al, 1998; Boily et al, 2002; Blower and Ma 2004). 
Since HIV transmission can occur at any point in a relationship, while an acute STI is 
likely to be present for a relatively short period of time, it makes sense to assume STIs 
would have a smaller effect on the probability of HIV transmission per partnership 
than on the probability of HIV transmission per sex act. 
 
In most models, the STI cofactor is assumed to be larger in the case of STIs causing 
ulcerative symptoms than in the case of non-ulcerative STIs. Although genital ulcer 











symptoms (Sexton et al, 2005; Røttingen et al, 2001), the STIs that cause ulcerative 
symptoms are – with the exception of chancroid – mostly asymptomatic. Korenromp 
et al (2002c) and Bracher et al (2003) assume that syphilis and herpes increase HIV 
transmission probabilities only when they are symptomatic/infectious, but other 
models effectively assume that the STI cofactor is the same in all stages of infection. 
This latter assumption is probably unrealistic, as there is no disruption of epithelial 
barriers or increased immune activation in the genital tract for most of the 
asymptomatic stages of syphilis and herpes, and it therefore seems likely that any STI 
cofactor would be lower than in the symptomatic disease stages. 
 
Although most models assume STIs have the same effect on the probability of HIV 
transmission whether they are present in the HIV-positive or the HIV-negative 
partner, a number of modellers assume that STIs have more of an effect on HIV 
susceptibility than on HIV infectiousness, or ignore the effect of STIs on HIV 
infectiousness completely (Bracher et al, 2003; Coffee et al, 2007; Rehle et al, 1998; 
Brown and Peerapatanapokin 2004). This reflects the greater uncertainty regarding 
the effects of STIs on HIV infectiousness; while meta-analyses have shown 
convincingly that STIs increase HIV susceptibility (Sexton et al, 2005; Røttingen et 
al, 2001), only gonorrhoea has been found to increase HIV infectiousness 
significantly in meta-analytic reviews (Rotchford et al, 2000). However, the effect of 
STIs on HIV infectiousness may well be more important than the effect of HIV 
susceptibility. The STDSIM model, for example, suggests that the proportion of HIV 
infections attributable to curable STIs in HIV-infected individuals exceeds the 
proportion attributable to curable STIs in HIV-negative individuals (Orroth et al, 
2006). This is probably because curable STIs tend to cluster in high-risk individuals, 













Table 2.3.1: Multiples by which HIV transmission probabilities are increased in the 
presence of different STIs: assumptions from different studies 
Study STI/STI type 
STI cofactor if STI present in Per sex act/ 
partnership HIV- partner HIV+ partner 
Over & Piot 
(1996) 
Chancroid 5 5 Per partnership 
Syphilis 5 5  
Chlamydia 2 2  
Gonorrhoea 3 3  
Robinson et al  
(1997) 
Ulcerative 10-100 10-100 Per sex act 
Non-ulcerative 2-5 2-5  
Rehle et al 
(1998) 
Ulcerative 30 (f), 60 (m) - Per sex act 
Non-ulcerative 10 -  
Korenromp  
et al (2000b) 
Chancroid 100 100 Per sex act 
Syphilis 100* 100*  
Chlamydia 10 10  
Gonorrhoea 10 10  
Korenromp 
et al (2002c) 
Chancroid 25 25 Per sex act 
Herpes 10† 10†  
Syphilis 10* 10*  
Chlamydia 5 5  
Gonorrhoea 5 5  
Bracher et al 
(2003) 
 
Chancroid 2* - Per sex act 
Herpes 2.75* -  
Syphilis 2.5* -  
Chlamydia 2.25* -  
Gonorrhoea 2* 2*  
BV 1.5* -  
Williams et al 
(2006b) 
Herpes 3.3 3.3 Per sex act 
Gonorrhoea 2 2  
Coffee et al 
(2007) 
Herpes 4 2 Per sex act 
Gonorrhoea 3 2  
* Applies only when the STI-infected partner is infectious. † Applies only during the symptomatic 












Simulations suggest that a high proportion of HIV infections can be attributed to the 
effect of other STIs on HIV transmission probabilities. Over the course of the 
HIV/AIDS epidemic, the proportion of incident HIV infections attributable to curable 
STIs usually declines (Robinson et al, 1997; Orroth et al, 2006; Freeman et al, 2007), 
in part because the individuals acquiring HIV in the nascent phase of the HIV/AIDS 
epidemic are likely to be ‘high risk’ individuals who have a high prevalence of other 
STIs, and in part because the prevalence of curable STIs can be expected to decline 
over the course of the HIV/AIDS epidemic in response to interventions and behaviour 
change. Genital herpes, on the other hand, is expected to account for an increasingly 
high proportion of incident HIV cases as the HIV/AIDS epidemic matures (Freeman 
et al, 2007; Orroth et al, 2006), as the HIV and HSV-2 viruses are mutually 
enhancing, HSV-2 becoming more symptomatic and more transmissible in the 
presence of HIV coinfection.  
 
Although much attention has focused on the effect of STIs on the probability of HIV 
transmission, there has been little analysis of the effect of HIV on other STIs. It might 
be expected that increases in mortality due to AIDS would disproportionately affect 
‘high risk’ groups, and thus bring about a reduction in the prevalence of other STIs, 
even in the absence of interventions (Kault 1992; Chesson et al, 2003). Conversely, 
reductions in AIDS mortality due to antiretroviral treatment might be expected to lead 
to increases in STI prevalence, even in the absence of any ‘behavioural disinhibition’ 
(Boily et al, 2004).  
 
There is little clarity regarding the effect of HIV infection on susceptibility to other 
STIs, duration of STIs, severity of STI symptoms or effectiveness of STI treatment, 
and consequently most modellers assume STI parameters are unaltered by HIV 
infection. Korenromp et al (2002b) allow for an effect of HIV on HSV-2, assuming 
that the HSV-2 recurrences are twice as frequent and persist twice as long during the 
symptomatic stages of HIV infection. On the basis of these assumptions they predict 
that the incidence of herpetic ulcers would increase by 25% over the first 20 years of 
the HIV/AIDS epidemic in a typical African setting, while the overall seroprevalence 
of HSV-2 would remain roughly unchanged. A greater effect might be predicted if it 











hence HSV-2 infectiousness), as some have argued (Paz-Bailey et al, 2007a). The 
effects of HIV on HSV-2 can therefore be particularly significant. 
 
2.5 Modelling the effect of STI treatment 
 
Many STI modelling studies have examined the potential effects of improvements in 
STI treatment on the incidence of STIs. The STI treatment strategies that are most 
commonly modelled are: 
• Improvements in the quality and availability of treatment for symptomatic 
individuals who seek treatment (e.g. syndromic management) 
• Contact tracing (treating sexual partners of individuals seeking treatment) 
• Screening and presumptive treatment (actively testing and treating individuals 
beyond the STI clinic setting, even if they do not have STI symptoms) 
• Suppressive/episodic treatment of chronic STIs to reduce their 
transmissibility. 
Each of these strategies is considered in turn, and finally their relative effects on HIV 
incidence are discussed. 
 
Models suggest that improvements in the quality and availability of treatment for 
individuals attending STI clinics are likely to be most effective in reducing the 
prevalence of STIs that are highly symptomatic, such as chancroid, but would have 
relatively modest effects on STIs that are mostly asymptomatic, such as chlamydial 
infection (Korenromp et al, 2002c; Kretzschmar et al, 1996). In many models, the 
effects of these improvements in symptomatic STI treatment are modelled by 
assuming a reduction in the average duration of infection (Robinson et al, 1995; 
Turner et al, 2004; Garnett et al, 1999), while in others it is assumed that treatment is 
sought at a particular rate (Kretzschmar et al, 1996; Garnett et al, 1997; Gershengorn 
and Blower 2000). There are also models in which an assumed fraction of STI cases 
get correctly treated (Bernstein et al, 1998; Korenromp et al, 2000b), which is 
mathematically equivalent to assuming a rate of treatment seeking if it is assumed that 
this rate is constant with respect to the duration of infection (Bowden and Garnett 
2000). Most models implicitly assume that if treatment is sought, the STI is correctly 











treatment do not include parameters to determine the probability that the infected 
individual recognizes signs of infection, the rate at which the symptomatic individual 
seeks treatment, the source from which the individual seeks treatment, the probability 
that the visited source provides the correct treatment, and the probability that 
treatment is effective. Breaking down the probability of cure into these components 
would make models of STI treatment more useful to policymakers, particularly in 
developing countries in which STI treatment is sub-optimal. 
 
Relatively few models have assessed the effects of contact tracing, probably because 
it is difficult to represent the effects of contact tracing in frequency-dependent 
deterministic models, which do not link the infection statuses of individuals and their 
partners. Kretzschmar et al (1996) found, when modelling a Dutch heterosexual 
population, that treating all sexual partners of symptomatic individuals would be the 
most effective treatment strategy for reducing the incidence of chlamydial infection 
and gonorrhoea. A greater reduction may be gained from treating the source from 
which the symptomatic individual acquired their infection than from treating the 
partner to whom the symptomatic individual has transmitted their infection (Hethcote 
and Yorke 1984), as the former would be expected to have the higher level of sexual 
activity. 
 
Two types of screening are typically modelled: periodic screening (mass treatment) 
and continuous screening. Models suggest that mass treatment can significantly 
reduce the prevalence of acute STIs in the short term, although STI prevalence levels 
usually return to baseline levels in the absence of repeated mass treatment at regular 
intervals (Bowden and Garnett 2000; Pourbohloul et al, 2003; Korenromp et al, 
2000b). This ‘rebound’ in STI prevalence is most rapid when the STI has a high 
transmission probability, when migration of infected individuals into the intervention 
community is high, and when there is little or no immunity against reinfection after 
recovery (Pourbohloul et al, 2003; Boily et al, 2000; Korenromp et al, 2000b). 
Repeating mass treatment at regular intervals would lead to a more sustained 
reduction in STI prevalence, particularly when targeted at those sub-populations with 
the highest levels of asymptomatic infection. For example, it has been shown in the 
cases of gonorrhoea, trichomoniasis and chlamydial infection, that periodic screening 











al, 1996; Bowden and Garnett 2000), and this is probably because the prevalence of 
asymptomatic infection in women is substantially higher than that in men, for all three 
STIs. Continuous screening is usually modelled by assuming a constant rate at which 
all individuals get treated, regardless of whether they are symptomatic or 
asymptomatic.  
 
In the case of HIV and HSV-2, which are treatable but not curable, modelling work 
has focused on the likely effect of long-term treatment on the transmissibility of these 
infections. Models suggest that highly active antiretroviral treatment (HAART) could 
substantially reduce the incidence of HIV and possibly even lead to its eradication 
over the long term (Law et al, 2001; Velasco-Hernandez et al, 2002; Blower et al, 
2000). However, these models typically assume a very high level of HAART 
coverage and assume that HAART is initiated in the relatively early stages of disease. 
In developing countries, where access to HAART is poor and most individuals only 
start treatment in the very late stages of disease, the impact of HAART on HIV 
incidence is likely to be relatively modest (Johnson and Dorrington 2006). The impact 
of antiviral treatment on the incidence of genital herpes is also likely to be modest, 
unless very high levels of coverage are achieved (White and Garnett 1999; 
Gershengorn and Blower 2000; Williams et al, 2007) or treatment is limited to those 
infected individuals who have high frequencies of viral shedding (Blower et al, 2004). 
The impact of treatment on the incidence of HSV-2 and HIV is also likely to be 
curbed by the development of drug-resistant strains of these viruses (Nagelkerke et al, 
2002; Gershengorn and Blower 2000; Velasco-Hernandez et al, 2002), and could 
potentially be negated by adoption of riskier sexual practices in response to reduced 
fear of infection (Blower et al, 2000; Law et al, 2001). 
 
Because of the significant effect of STIs on HIV transmission probabilities, much 
modelling work has examined the potential effect of improved STI treatment on HIV 
incidence. A large body of work by the STDSIM group has attempted to explain the 
contradictory findings of the STI treatment trials conducted in Mwanza, Rakai and 
Masaka: while the Mwanza study showed that syndromic management could achieve 
a roughly 40% reduction in HIV incidence (Grosskurth et al, 1995), the mass 
treatment trial conducted in Rakai was found to have no effect on HIV incidence 











reduction in HIV incidence in communities in which syndromic management was 
introduced (Kamali et al, 2003). Analyses conducted using the STDSIM model 
suggest that most of the differences between these trials can be attributed to 
differences between study populations rather than differences between interventions 
(White et al, 2004). The Mwanza trial was conducted at a relatively early stage in the 
HIV/AIDS epidemic, when there was still a high prevalence of curable STIs, while 
the Rakai and Masaka studies were conducted in Uganda, at a relatively advanced 
stage in its HIV/AIDS epidemic, when the prevalence of curable STIs had already 
reduced significantly as a result of behaviour change (Orroth et al, 2003a; Orroth et 
al, 2003b). STDSIM and other models suggest that the effect of STI treatment on HIV 
incidence reduces as the HIV/AIDS epidemic matures and as behaviour change 
reduces the prevalence of other STIs (Korenromp et al, 2002a; Korenromp et al, 
2005; Boily et al, 2002). The disappointing results from the Rakai trial are not 
evidence that mass treatment is less effective than syndromic management in reducing 
HIV incidence; in fact, mass treatment is likely to be more effective than syndromic 
management in reducing HIV incidence over the short term (Korenromp et al, 2000b; 
White et al, 2004; Korenromp et al, 2005), and mass treatment would have been 
significantly more effective in the earlier stages of the Rakai epidemic and in the 
absence of preceding behaviour change (Korenromp et al, 2002a; Korenromp et al, 
2005). This is an important example of the utility of simulation models in explaining 
observations that traditional epidemiological techniques would be incapable of 
explaining. 
 
Recent work by Brunham and colleagues has explored the potential treatment 
implications of “arrested immunity” (Brunham and Rekart 2008). It has been 
observed in many STI inoculation experiments that immune responses tend to be 
weaker if treatment is received soon after infection than if treatment is received long 
after infection has occurred (Magnuson et al, 1956; Schmidt et al, 2001; Su et al, 
1999), and on the basis of this it has been hypothesized that STI treatment 
programmes may ultimately fail to have a substantial impact on STI prevalence 
because they weaken the immune responses that would have developed in the absence 
of treatment. Brunham et al (2005) demonstrate this using a model of a chlamydial 
treatment intervention; their model suggests that improving treatment of chlamydial 











ultimately prevalence is likely to return to a level close to baseline once population 
levels of chlamydial immunity have reduced substantially. The potential implications 
of the arrested immunity phenomenon still need to be explored for STIs that are 
usually associated with weaker immune responses. 
 
In summary, most models of STI treatment interventions have focused on the 
potential effects of improved treatment of symptomatic STIs, and the potential effects 
of screening or mass treatment programmes. The general consensus is that 
improvement in treatment of symptomatic STIs is likely to be most effective in the 
elimination of STIs that are mostly symptomatic, while screening and mass treatment 
would be substantially more effective control strategies for STIs that are mostly 
asymptomatic. If the objective of the STI treatment intervention is to reduce HIV 
incidence, the effectiveness of the intervention is also likely to depend on the stage of 
the HIV/AIDS epidemic at the time that the intervention is introduced and the extent 
of behaviour change preceding the STI treatment programme. 
 
2.6 Limitations of existing models 
 
This review has identified three broad areas in which STI modelling could be further 
refined. Firstly, deterministic models of sexual behaviour could be extended to gain a 
more nuanced understanding of the behavioural factors driving STI transmission. 
Traditionally, deterministic STI models have divided the population into risk groups 
that represent different average levels of sexual risk behaviour. Although this is a 
useful means of modelling heterogeneity in sexual behaviour, there is much 
heterogeneity that is not captured within this model structure. Most importantly, risk 
groups are not differentiated on the basis of marital status. It is also usually assumed 
that individuals do not move between risk groups over time, and there is thus no 
allowance for temporary increases in sexual risk behaviour (for example, following 
the dissolution of a long-term partnership). In addition, relatively few deterministic 
models have allowed for concurrent partnerships explicitly. Deterministic models 
have therefore allowed only a limited understanding of the role of sexual behaviour in 
the transmission of HIV and other STIs. These models have usually emphasized the 











population level, but there has been little consideration of the role of sexual risk 
behaviours in the broader population. There is clearly a need for deterministic models 
that more accurately represent the changing levels of sexual risk behaviour over the 
life course, to provide a better understanding of the role of factors such as concurrent 
partnerships, late marriage, early sexual debut and commercial sex. 
 
There is also potential for further research into the progression of sexually transmitted 
infection. Early models of gonorrhoea classified individuals as being either 
symptomatic or asymptomatic, with no allowance for movements between these states 
and no allowance for immunity upon recovery (Hethcote and Yorke 1984). This has 
become the standard model for the natural history of acute short-term STIs, but there 
has been little examination of whether alternative assumptions about the natural 
history of infection and immunity may yield greater consistency with empirical 
observations. Such analysis is important, as assumptions about these variables can 
influence significantly the modelled impact of improvements in STI treatment and 
changes in sexual behaviour, and thus the policy implications of mathematical model 
results. 
 
Another potential area for further STI modelling work is in the understanding of 
obstacles to prompt and effective STI treatment in developing countries. STI models 
have usually assumed either that a particular proportion of STIs are effectively cured, 
or that infections resolve at a particular rate as a result of treatment. There has been 
little attempt to model in more detail the factors that contribute to low rates of 
effective treatment: delays in health seeking, health seeking from unqualified 
providers of treatment, low adoption of syndromic management protocols, drug 
shortages and antibiotic failure. Modelling of each of these factors would significantly 











Chapter 3: Method for modelling HIV and STIs in South Africa 
 
The objective of this thesis is to develop a mathematical model that can be used to 
estimate the prevalence of STIs in South Africa, their contribution to the spread of 
HIV, and the likely effects of changes in STI treatment and changes in sexual 
behaviour. In order to achieve this, it is necessary to make several refinements to the 
standard deterministic model of STI transmission that has traditionally been used. As 
discussed in Chapter 2, these refinements include more detailed modelling of changes 
in sexual risk behaviour over time, more detailed modelling of the determinants of 
effective STI treatment, and consideration of alternative models of STI natural 
history. The purpose of this chapter is to describe the mathematical model used to 
simulate the spread of HIV and other STIs in South Africa and discuss the literature 
upon which the various assumptions are based. This includes a description of the 
demographic assumptions, sexual behaviour assumptions and assumptions regarding 
HIV and other STIs.  
 
3.1 Demographic assumptions and model structure 
 
The demographic component of the model is based on the ASSA2003 AIDS and 
Demographic model (Dorrington et al, 2006), a combined cohort component 
projection and HIV/AIDS model of the South African population. The demographic 
parameters in the ASSA2003 model have been determined using data from the 1970, 
1996 and 2001 censuses, vital registration data from 1985 onwards and the 1998 
Demographic and Health Survey (DHS). The ‘lite’ version of the ASSA2003 model, 
which is based on the summing of the estimates obtained for each of the four 
population groups in South Africa, is used in all analyses. As the purpose of the 
current model is not to predict the demographic impact of HIV/AIDS, but rather to 
understand the factors driving the transmission of HIV and other STIs in South 
Africa, a number of demographic simplifications are made. 
 
The population is divided into separate age and sex cohorts. Individuals over the age 











individuals below the age of 10 are grouped by individual age, to allow for the more 
accurate modelling of paediatric AIDS and non-AIDS mortality (both of which are 
strongly age-dependent). As in the ASSA2003 model, the projection begins at the 
middle of 1985, a few years ahead of the first reported heterosexual AIDS cases in 
South Africa (Schoub et al, 1988). The profile of the population at the middle of 1985 
is obtained directly from the ASSA2003 model, which estimates the 1985 population 
to be 32.3 million.  
 
Within each of the five-year age cohorts, the cohort is further split by current sexual 
activity status, and each of these sexual activity cohorts is split by HIV status and 
stage of HIV infection. Finally, within each HIV status/stage sub-cohort, proportions 
in each STI state are calculated separately for each STI. These calculations are 
performed independently for each STI, i.e. it is assumed that for an individual of a 
particular age and sex, within a particular sexual activity state and a particular HIV 
infection state, the risk of infection with one STI is independent of the risk of 
infection with other STIs. The frequency with which individuals move between these 
various cohorts can be altered by the user of the model, but in the analyses considered 
here, the following frequencies apply: 
• Movements between STI states are calculated at ‘weekly’ intervals (four times 
per month). 
• Movements between HIV states are calculated at monthly intervals in the 
initial analysis presented in section 4.1, but at weekly intervals in the analysis 
presented in section 4.2. 
• Movements between sexual activity states, including mortality and 
widowhood, are calculated at monthly intervals. 
• Births and movements between age cohorts are calculated at annual intervals. 
 
Non-AIDS mortality rates vary by age, sex and year, and are obtained from the 
ASSA2003 model, which produces demographic output by individual age. For each 
year, the mortality rate in each age five-year band is calculated as the number of non-
AIDS deaths in that age band divided by the number of individuals in that age band at 
the start of the year, as estimated by the ASSA2003 model. This annual probability of 











mortality hazard (for the relevant HIV states), and applied at monthly intervals. The 
life expectancy at birth, in 1985, is estimated by the ASSA2003 model to be 62.4 
years, with relatively little change up to 1995. 
 
Fertility rates in HIV-negative women vary by age and year, and are also calculated 
from the ASSA2003 model, which predicts a total fertility rate of 4.2 in 1985, 
reducing to 3.3 by 1995. For each year, the fertility rate in HIV-negative women in a 
particular five-year age band is calculated as the weighted average ASSA2003 
fertility rate in HIV-negative women, where the weights are the numbers of women at 
each individual age. The fertility rates in HIV-positive women are calculated by 
applying a reduction factor to the corresponding fertility rates in HIV-negative 
women of the same age. These reduction factors have been set to vary by HIV stage, 
based on estimates of the annual reduction in the rate of fertility per year of HIV 
infection (Johnson et al, 2007) and the observed effects of antiretroviral treatment on 
fertility (Blair et al, 2004). The reduction factor is 1.00 for women in the acute stage 
of HIV infection, 0.92 for women in the asymptomatic phase of infection, 0.80 in the 
pre-AIDS symptomatic phase, 0.73 in the AIDS phase and 0.94 in women receiving 
antiretroviral treatment. The proportion of births that are male is set at 50.39%, as in 
the ASSA2003 model. 
 
No allowance is made for migration into or out of South Africa. As the net number of 
migrants into South Africa over the 1985-2000 period is estimated by the ASSA2003 
model to be some 1.1 million, this will lead to under-estimation of the rate of 
population growth and the total population size and a slight distortion in the 
distribution of the population by age. 
 
The proportion of each age group moving into the next age group, at the end of each 
year, varies by sex, age band, sexual experience and HIV stage. These probabilities 
are also calculated using the ASSA2003 model. In most cases, the proportion of a 
particular five-year age group that moves into the next age group in the following year 
is calculated from the ASSA2003 model for five different years (1985, 1995, 2005, 
2015 and 2025), and the assumed probability of movement into the next age group is 












3.2 Sexual behaviour assumptions 
 
This section begins with a brief description of the structure of the sexual behaviour 
model, which includes an explanation of the different sexual activity states defined in 
the model, and the methods used to calculate the rates of transition between these 
states. This is followed by an explanation of the sexual behaviour parameter values. 
Although the parameter values are based on empirical data as far as possible, many of 
these parameter values cannot be determined precisely, and it is therefore necessary to 
perform a Bayesian analysis in order to assess the range of parameter values that are 
consistent with sexual behaviour data and HIV prevalence data. Where there is 
significant uncertainty around the value of a particular parameter, a prior distribution 
is assigned, and the plausible values for this parameter are then assessed in the 
Bayesian analysis described in section 4.1. 
 
3.2.1 Sexual activity states and types of sexual relationship 
 
Sexual behaviour is modelled by dividing the population into two sexual activity 
classes: individuals who have a propensity to engage in commercial sex and/or 
concurrent partnerships (‘high risk’), and individuals who never engage in such 
relationships (‘low risk’). The proportions of the population in each class are set 
separately for males and females, based on data collected in sexual behaviour surveys. 
In the 2005 HSRC household survey, the proportions of sexually experienced 
unmarried men who reported more than one current partner varied between 12% and 
18% over the 15 to 59 age range, and the corresponding proportions in unmarried 
women varied between 1% and 3% (Shisana et al, 2005). These are likely to be 
underestimates of the proportions of individuals with a propensity for concurrent 
partnerships, as individuals tend to under-report multiple partnerships in face-to-face 
interviews (Gregson et al, 2004; Gregson et al, 2002b; Rogers et al, 2005; Mensch et 
al, 2003), and not all individuals who have a propensity for concurrent partnerships 
would currently have multiple partners (Carter et al, 2007). The ‘high risk proportion’ 
has therefore been set at 35% in males and 25% in females. Some studies in Gauteng 











Jewkes et al, 2002), but when these higher proportions were used in the model, the 
resulting HIV prevalence trends were found to be unrealistic. 
 
Three types of sexual relationship are modelled: short-term relationships, long-term 
(spousal) relationships and contacts between sex workers and their clients. It is 
assumed that all spousal relationships start off as short-term relationships, i.e. it is 
only possible to enter the married state from the short-term relationship state. It 
follows from the definitions of the sex activity classes above that individuals in the 
‘low risk’ group only enter short-term and spousal relationships, and never have more 
than one current relationship. For the sake of simplicity, it is assumed that individuals 
in the ‘high risk’ group never have more than two concurrent spousal or short-term 
relationships, though ‘high risk’ men can continue to have contact with sex workers, 
even when they already have two sexual partners. Women in the ‘high risk’ group can 
also enter a ‘sex worker’ class, and it is assumed (again in the interests of simplicity) 
that none of these women are in short-term or spousal relationships. No allowance is 
made for polygyny, as it is uncommon in South Africa (Budlender et al, 2004). There 
is also no allowance made for homosexual relationships, as there is hardly any 
research on these relationships in the South African setting. 
 
A multi-state approach is adopted in modelling sexual behaviour. Each sexual activity 
state is defined in terms of the nature of the relationship(s) the individual is currently 
in. Figure 3.2.1 shows the states that are defined for women in the ‘high risk’ group 
and the possible movements between these states. The multi-state model used for men 
in the ‘high risk’ group is identical to that shown in Figure 3.2.1, except that there is 
no ‘Sex worker’ state. The model that is used to model sexual behaviour in the male 
and female ‘low risk’ groups is the same as that shown in Figure 3.2.1, but with the 
shaded cells omitted. 
 
Individuals move between these states over time, based on a transition probability 
matrix, the elements of which are set age-specifically and updated on a monthly basis. 
The rates at which partnerships are formed by men and women are adjusted so that 
the numbers of partnerships of each type are consistent between men and women. For 
example, the rate at which men in the high risk group form short-term partnerships 











women in the low risk group form short-term partnerships with men in the high risk 
group. The weight given to male and female rates of partnership formation are 
determined by a ‘gender equality factor’, which can take on any value between 0 and 
1 (0 implying that rates of partnership formation are determined only by male desires, 
and 1 implying that rates are determined solely by female desires). The default value 
of this gender equality factor is set at 0.5. A more detailed mathematical explanation 









































Figure 3.2.1: Multi-state model of sexual behaviour of ‘high risk’ females 
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3.2.2 Rates of short-term partnership formation 
 
Rates of short-term partnership formation are assumed to vary according to age, sex, 
HIV disease stage, propensity for concurrent partners, and the characteristics of the 
individual’s existing partnership(s). Suppose )(,,, xc
s
ljig  is the rate at which an 
individual of sex g wishes to form new short-term partnerships if they are in risk 
group i, aged x, in HIV disease state s, and in relationship type l with a partner in 
group j (if the individual is currently single, j = 0 and the l subscript is omitted). The 
approach adopted is to specify this parameter for a ‘baseline’ group (single HIV-
negative individuals in the high risk group, who are aged 15 to 19), and then to 
assume a series of multiplicative adjustments to allow for the effects of age, risk 
group, HIV disease stage, and nature of current relationship(s). 
 
The desired rate of partner acquisition in the baseline female group can be estimated 
from data collected by Jewkes et al (2001) among pregnant and non-pregnant 
adolescent females in a South African community with a high prevalence of HIV. 
Women who had ended their first sexual relationship and subsequently entered a 
second relationship were asked about the time interval between the two relationships. 
The cumulative proportion entering new relationships at different durations since 
break-up is shown in Figure 3.2.2, together with predictions of the cumulative 
proportions forming new partnerships when the time to a new partnership is 
exponentially distributed with a mean of 25 or 40 days. It is assumed that the desired 
rate of partner acquisition in the 15-19-year old female high risk group is 14.6 per 
annum, which is equivalent to a mean interval between partnerships of 25 days – this 
is consistent with the intervals reported by pregnant adolescent females, who can 
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Figure 3.2.2: Cumulative proportions of young females entering new partnerships 
 
Similar data for South African men are not readily available, but it would be expected 
that the mean intervals between partnerships would be greater in the case of male 
adolescents than female adolescents, considering that rates of secondary abstinence 
are higher in young males than in young females (Shisana et al, 2005; Reproductive 
Health Research Unit 2004; Human Sciences Research Council 2002). It is assumed 
that the desired rate of partner acquisition in the 15-19-year old male high risk group 
is 7.3 per annum, half of the rate in females. Although the choice of parameter is to 
some extent arbitrary, the model is only sensitive to this parameter if the assumed 
effects of risk group and existing partnerships on rates of partnership formation are 
held constant. Since these parameters are allowed to vary in the uncertainty analysis 
(as discussed below), it is acceptable to fix the baseline parameter at 7.3. 
 
To allow for the effect of age on the rate of partner acquisition, the relative rates of 
partner acquisition at different ages are determined using a scaled gamma density: 
 
 





















,  (3.1) 
 
where gλ  and gα  are the parameters for the gamma density, and x is the mid-point of 
the age range. Initial maximum likelihood fits of the model to HIV prevalence data 











reasonably stable across a range of scenarios. The averages of these gamma means 
and variances were therefore used in setting gλ  and gα : values of 0.1486 and 3.98 
were assumed for males and values of 0.2272 and 4.14 were assumed for females2. 
 
The rate at which individuals wish to acquire new partners if they have no propensity 
for concurrent partnerships is assumed to be a constant multiple of the corresponding 
rate at which single individuals with a propensity for concurrent partnerships wish to 




g , differs for males and females 
but is assumed to be constant with respect to age and HIV disease stage. Although 
there are no published data indicating plausible values for this multiple, it would be 
expected that the multiple would be less than 1, and a uniform (0, 1) prior has 
therefore been assigned to this parameter, for both males and females. 
 
Individuals with a propensity for concurrent partnerships are assumed to acquire new 
partners at a lower rate if they already have one partner than if they are single. The 




ljg  is specified separately for males and females in non-
spousal (l = 1) and spousal (l = 2) relationships, but is assumed to be constant with 
respect to the individual’s age, HIV disease stage and the risk group of the partner. As 
there are no published data indicating the likely magnitudes of these parameters, 
uniform (0, 1) priors have been assigned to each of the four parameters. 
 
The rates of partner acquisition discussed thus far relate only to individuals who are 
already sexually experienced. For virgins, separate parameters are specified to 
determine the rates at which first sexual contact occurs. Studies conducted in South 
Africa and Zimbabwe suggest that the rate at which ‘low risk’ individuals (however 
they may be defined) initiate their first sexual contact is typically between 0.24 and 
0.59 times that in ‘high risk’ individuals, with an average of 0.5 (Dunkle et al, 2004; 
Mpofu et al, 2006; Pettifor et al, 2004b). It is therefore assumed that virgins with no 
propensity for multiple partnerships acquire their first sexual contact at a rate equal to 
half of that in virgins who subsequently enter the high risk group. The desired rates of 
first sexual contact in the high risk group are shown in Table 3.2.1; these have been 
                                                 
2 The corresponding means and standard deviations are 26.8 and 13.45 respectively for males, and 18.2 











determined to be consistent with the reported rates of sexual experience in the 2005 
HSRC household survey, on the assumption that young women under-report sexual 
experience and young men slightly exaggerate their sexual experience (Mensch et al, 
2003; Hewett et al, 2004; Turner et al, 1998). All individuals are assumed to be 
sexually experienced by age 30. 
 
Table 3.2.1: Desired annual rates of first sexual contact in the high risk group 
Age group 10-14 15-19 20-24 25-29 
Male 0.01 0.25 0.78 1.00 
Female 0.05 0.47 0.95 1.00 
 
3.2.3 Rates of marriage 
 
Several authors have noted that marriage in South Africa occurs at a later age than is 
typically the case in most other African countries (Bongaarts 2006; Garenne 2004; 
Bakilana 2005). In the model, rates of marriage are assumed for each five-year age 
group, for males and females separately, with these rates being chosen in such a way 
that the modelled proportions of individuals who are married at each age are roughly 
consistent with the corresponding proportions from the 1996 Census, 2001 Census 
and 2007 Community Survey. Following the convention in the Demographic and 
Health Surveys, ‘marriage’ refers to both formal marriages and cohabiting 















































































Figure 3.2.3: Assumed annual rates of marriage by age and sex 
 
Although average rates of marriage at each age are constrained to remain constant at 
the levels shown in Figure 3.2.3, rates of marriage also vary in relation to the current 
number of non-spousal partners and the individual’s risk group. As noted previously, 
individuals can only enter the married state from the short-term partnership state, and 
thus the rate of marriage is assumed to be proportional to the number of current short-
term partnerships, after controlling for age, sex, risk group and risk group of 
partner(s). The relationship between risk group and rate of marriage is more difficult 
to determine; although there are some African studies suggesting that propensity for 
concurrent partnerships and transactional sex are associated with lower rates of 
marriage (White et al, 2000; Dunkle et al, 2004), there are also some studies showing 
the risk of HIV to be elevated in married individuals after controlling for age (Zuma 
et al, 2003; Auvert et al, 2001b; Clark 2004), and it is thus unclear whether ‘high risk’ 
individuals do indeed take longer to marry. It is therefore assumed that average age-
specific rates of marriage (not controlling for number of short-term partners or risk 
group of partners) are the same in individuals in the high and low risk groups. 
 
In order to ensure that the average rates of marriage in the high risk and low risk 
groups are the same at each age, it is necessary to vary the rates of marriage in 
relation to the risk group of the partner. The rate at which a man in risk group i 




































,     (3.2) 
 
where ),(,,, tyN ljig  is the number of relationships of type l (1 = short-term, 2 = long-
term) between individuals of sex g and age y in group i, and individuals of the 
opposite sex in group j, at time t. The numbers of long-term relationships at time 0 
(1985) are set on the assumption that the rate of marriage is the same in high and low 
risk groups and the degree of assortative mixing is the same in long-term and short-
term relationships (see section 3.2.6). This adjustment ensures that the proportions of 
married partners in the high and low risk groups remain consistent with the initial 
proportions, and prevents the higher rates of short-term partner acquisition in the high 
risk group from leading to higher rates of marriage in the high risk group. 
 
3.2.4 Average durations of partnerships 
 
The average length of non-marital relationships is difficult to estimate reliably from 
surveys, as individuals who are asked questions about their “most recent partner” are 
likely to report on their main current partner rather than on current or recent casual 
partners. The most reliable estimates are obtained from surveys in which individuals 
are asked about the duration of all partnerships over a particular period, or a specific 
partnership (e.g. the respondent’s first sexual partnership). African surveys in which 
such questions have been asked have estimated the median duration of non-marital 
relationships to be between 3 and 12 months (Ferry et al, 2001; Jewkes et al, 2001; 
Nnko et al, 2004), with the mean durations of current relationships substantially 
exceeding the mean durations of recently ended relationships (Nnko et al, 2004). It is 
assumed that the average duration of non-marital relationships is 6 months, and that 
the rate of relationship termination is constant with respect to the relationship 
duration.  
 
The rates at which spousal relationships are terminated are also difficult to estimate, 











et al, 2004; Reniers 2003). Registered divorce statistics can be used to approximate 
rates of divorce in South Africa, although these are likely to understate the true rate at 
which spousal relationships are terminated. This is partly because reporting of 
divorces is incomplete (Bah 1999), and partly because our definition of spousal 
relationships includes unmarried cohabiting partners, who might be expected to have 
a higher rate of separation than that in formal marriages (Porter et al, 2004). In 
addition, many formal marriages end in separation, which may precede divorce by 
several years (van Tonder 1985), and union dissolution is therefore often not reflected 
in published divorce statistics. In the model it is therefore assumed that rates of 
spousal union dissolution are two times the age-specific rates of divorce estimated 
from published divorce statistics in 2004 (Statistics South Africa 2006). Although this 
chosen multiple of two is somewhat arbitrary, the model results are not sensitive to 
this parameter if the married proportion of the population is held constant. Figure 































































Figure 3.2.4: Assumed annual rates of dissolution of spousal relationships, by age and 
sex 
 
3.2.5 Commercial sex 
 
Rates of male contact with commercial sex workers are assumed to depend on male 











the proportion of the general male population engaging in commercial sex, but the 
average proportion of men reporting sex with sex workers in the last 12 months has 
been estimated at 6.3% in other southern African countries (Caraël et al, 2006). This 
is probably an under-estimate of the true proportion of men having sex with sex 
workers, as men appear to under-report such sexual contacts in face-to-face interviews 
(Des Jarlais et al, 1999; Lau et al, 2003; Morison et al, 2001). Taking into account the 
levels of social desirability bias measured in various studies, it is assumed that men 
aged 15 to 49 have on average 0.126 acts of sex with sex workers per annum (twice 
the average proportion reporting sex worker contact). In the high-risk group, the 
frequency of sex with sex workers at age x is assumed to be proportional to a gamma 
density of the form 
 
 ( )( ) ( )( )05.6/10exp1005.6 131.331.3 −−− −− xx ,    (3.3) 
 
where the parameters 6.05 and 3.31 were determined in such a way that the relative 
frequencies of sex worker contact by age were consistent with those estimated by 
Caraël et al (2006) for other southern African countries. The frequency of sex worker 
contact, relative to that in men who currently have no sexual partner, is assumed to be 
reduced by 50% in men who have one non-spousal partner, by 70% in men who have 
one spousal partner, by 80% in men who have two non-spousal partners, and by 90% 
in men who have one spousal partner as well as one non-spousal partner. 
 
Women tend to engage in commercial sex work for short periods, mainly out of 
economic necessity, and the average duration of sex work in African countries is 
typically estimated to be between one and four years (Rees et al, 2000; Morison et al, 
2001; Abdool Karim et al, 1995). It is therefore assumed that sex workers discontinue 
sex work at a constant rate of 0.5 per annum. Women are assumed to become sex 
workers at a rate sufficient to meet the male demand for commercial sex, with the 
relative rates of entry into sex work at different ages being determined in such a way 
that the age distribution of sex workers is consistent with that observed in a study of 
sex workers in Johannesburg (Rees et al, 2000). Studies suggest that South African 
sex workers usually have between 20 and 25 sex acts with clients per week (Ramjee 











basis of this evidence it is assumed that sex workers have an average of 1 000 sex acts 
with clients per annum. 
 
3.2.6 Preferences regarding partner age and sex activity class 
 
The approach to modelling interactions between the high risk and low risk groups 
follows that described by Garnett and Anderson (1996). If ijρ  is the desired 
proportion of new partners in group j, for an individual in group i, then this is 




















εδερ 1 ,     (3.4) 
 
where ijδ  = 1 if i = j and 0 otherwise, jN  is the number of potential partners in group 
j, and jc  is the rate at which individuals in group j wish to form partnerships (for the 
more formal model exposition, see Appendix A). The parameter ε is referred to as the 
‘degree of assortative mixing’, and can take on any value between 0 and 1. When ε is 
0, sexual mixing is said to be perfectly assortative, i.e. individuals only form 
relationships with partners in the same group. When ε is 1, sexual mixing is random, 
and individuals have no preferences regarding the sex activity class of their partner. 
Although it is difficult to estimate this parameter reliably, data from the U.S. (Garnett 
et al, 1996; Manhart et al, 2002) and Sweden (Granath et al, 1991) suggest that sexual 
mixing is only weakly assortative, with most estimates lying between 0.75 and 0.95, 
and one estimate at 0.65 (Laumann et al, 1994). However, data collected from 
Botswana suggest that ε may be as low as 0.53 (Carter et al, 2007). In addition, it has 
been demonstrated that empirical estimates of ε are likely to be significant over-
estimates, due to sampling biases (Ghani et al, 1998). There is thus substantial 
uncertainty regarding the true value of ε, and this parameter has therefore been 
assigned a beta prior with a mean of 0.6 and a standard deviation of 0.15. 
 
Proportions of partners in each five-year age band are specified separately for males 











10 and 50 these proportions are estimated from women’s reports of their husband’s 
age in the 1998 Demographic and Health Survey (Department of Health 1999), and 
from gamma fits to age differences between men and women in non-spousal 
partnerships (a gamma distribution with mean 3 and variance 9 gives a good fit to 
non-spousal partner age differences in South African studies (Williams et al, 2000; 
Hallman 2004; Kelly 2000; Shisana et al, 2005)). The weights given to the spousal 
and non-spousal partner age distributions at each female age are determined by the 
relative numbers of married and sexually active unmarried women at the relevant age. 
In the case of women over the age of 50, there are no data on partner age differences, 
but it is assumed that the negative linear relationship between female age and 
husband’s age difference observed in the 1998 DHS continues at older ages (see 
Figure 3.2.5), and the resulting age distribution for spousal partners is assumed to 
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Figure 3.2.5: Observed and assumed mean age differences between married partners 
Source: 1998 Demographic and Health Survey 
 
In the case of males, the proportions of female partners in each age group are 
determined from the corresponding calculations for females, i.e. by tabulating the 
total numbers of partnerships between women of age x and men of age y at the start of 
the projection, it is possible to determine the proportion of female partners in each age 
group, for men of age y. Men who have sex with sex workers are assumed to have no 
preference regarding the age of the sex worker. Although this is probably not realistic, 











hence any allowance for age preferences in the context of commercial sex would have 
little effect on the results of the model. 
 
3.2.7 Frequency of sex  
 
The method most commonly used to determine coital frequency in sexual behaviour 
surveys is to ask individuals about the number of times they have had sex in the last 
four weeks. Estimates of the daily probability of sex in married women, obtained 
using this method, typically lie between 0.098 and 0.240 in southern and eastern 
Africa (Brown 2000; Blanc and Rutenberg 1991). However, these reported 
frequencies are likely to over-estimate the true coital frequency among married 
individuals, as several studies have found that when coital frequency is recorded over 
shorter time intervals (over which there is likely to be less recall bias), reported coital 
frequency is lower (Hornsby and Wilcox 1989; Lagarde et al, 1995; Høgsborg and 
Aaby 1992). It has also been found that coital frequencies among married women 
reduce significantly as they age (Brewis and Meyer 2005). On the basis of these 
studies, it is assumed that the average marital coital frequency among married women 
aged 20 to 24 is five times per month, and that this frequency reduces exponentially 
with respect to age, halving with every 20-year increase in age. For each male age, the 
monthly number of sex acts between men and their wives are determined from the 
assumed age-specific frequencies for married women, based on the assumed 
distribution of female partner ages. 
 
In contrast to married individuals, unmarried individuals and individuals with high 
rates of partner change tend to report numbers of sex acts in the last four weeks close 
to or less than those estimated over shorter time intervals (Leigh et al, 1998; Allen et 
al, 2007; McAuliffe et al, 2007). In a survey of South African youth, Kelly (2000) 
found that the average number of sex acts per four-week period was three among 
those who were sexually active and in non-cohabiting relationships. Although data 
from other African countries suggest lower coital frequencies experienced by 
unmarried individuals (Meekers and Van Rossem 2005), this estimate of three sex 
acts per month is used in the model for all non-spousal partnerships. In the absence of 
any data concerning the relationship between age and coital frequency in non-spousal 











assumed to affect the incidence of non-spousal partnerships rather than the frequency 
of sex within non-spousal relationships). The assumed frequencies of sex in spousal 
and non-spousal partnerships result in numbers of sex acts that are roughly consistent 
with the aggregate reported coital frequencies in the 15-24 and 25-49 age bands in the 
2005 HSRC Household Survey (Shisana et al, 2005). 
 
3.2.8 Condom usage 
 
Rates of condom use are assumed to depend on the individual’s age and sex and the 
nature of the relationship they are currently in. Rates of condom use are also assumed 
to increase over time, as there is strong evidence of trends towards greater condom 
use in South Africa, particularly among youth (Bradshaw et al, 2004b). The approach 
taken is to calculate ),(,2 txlγ , the probability that a woman aged x uses a condom in a 
single act of sex with a partner of type l at time t, as a function of a ‘baseline’ rate of 
condom usage, )13,15(1,2γ , which is the probability of condom use for a woman aged 
15-19 in a short-term relationship in 1998 (t = 13)3. The following formula is used to 
















































  (3.5) 
 
where 
( )lχexp  = the odds of using a condom in relationship type l, relative to that in short-
term relationhips (l = 1), in 1998; 
( )lνexp  = the factor by which the odds of condom use increases, per year of age; 
( )ilκexp  = the initial odds of using a condom in relationship type l, before the onset of 
behaviour change, relative to the odds in 1998; 
( )ulκexp  = the ultimate odds of using a condom in relationship type l, once behaviour 
change is at its maximum, relative to the odds in 1998; 
                                                 
3 1998 (t = 13) has been chosen as the ‘baseline’ because 1998 is the year for which the most condom 











lM  = the median time to behaviour change in relationships of type l, i.e. the time at 
which the log odds of condom use is half-way between its initial and ultimate levels; 
lQ  = the Weibull shape parameter controlling the speed of behaviour change in 
relationships of type l. 
 
The logistic transformation avoids rates of condom use greater than 100%, and 
facilitates a ‘logistic regression’ interpretation of the condom parameters. The 
probability of condom use in the baseline group, )13,15(1,2γ , was initially set at 0.2 on 
the basis of the 1998 DHS (Department of Health 1999). The remaining parameters 
have been set on the basis of national survey data (Kaufman 1996; Department of 
Health 1999; Department of Health 2004b; Shisana et al, 2005) and data collected 
from sex workers (Jochelson et al, 1991; Williams et al, 2003; Rees et al, 2000; 
Peltzer et al, 2004), and are summarized in Table 3.2.2. The Weibull shape parameter, 




lκ  and lM , by noting that when t = 13, the 
term in the square brackets of equation (3.5) must be equal to zero. 
 




(l = 1) 
Long-term 
partnerships 
(l = 2) 
Sex worker- 
client sex 
(l = 3) 
Effect of relationship type on odds 
of condom use at baseline 
( )lχexp  1.00 0.46 6.00 
Increase in log odds of condom 
use per year increase in age 
lν  -0.025 -0.025 0 
Ratio of initial odds of condom 
use to baseline odds (in 1998) 
( )ilκexp  0.07 0.07 0.17 
Ratio of ultimate odds of condom 
use to baseline odds (in 1998) 
( )ulκexp  7.5 3.5 6.0 
Median time to behaviour change 
(in years since 1985) 
lM  12.3 11.0 13.02 
Speed of behaviour change 
lQ  3.50 2.97 5.22 
 
Although the assumptions about the use of condoms in spousal and non-spousal 











condoms at last intercourse, this could over-estimate the true proportion of sex acts in 
which condoms are used, if individuals with higher coital frequencies tend to use 
condoms less frequently (Pettifor et al, 2004a). A better measure of the proportion of 
sex acts in which condoms are used might be the proportion of individuals who used 
condoms if they had sex in the last day, since this is less likely to be affected by recall 
bias and more likely to reflect differences in coital frequencies between condom users 
and non-users. Meekers and Van Rossem (2005) compared this alternative measure 
with the more commonly used ‘condom at last sex’ measure, and found that the 
former measure usually gave lower proportions, the median ratio of the former 
proportion to the latter being 0.58. When fitting the model to HIV prevalence data, it 
was found that setting the baseline condom use at 0.20 (consistent with the ‘condom 
at last sex’ measure) yielded a much steeper decline in HIV prevalence among youth 
in recent years than has been observed, but setting the baseline condom use at 0.12 
(consistent with the bias estimated by Meekers and Van Rossem) yielded a more 
plausible HIV prevalence trend in youth. The baseline condom use has therefore been 
set at 0.12. 
 
Equation (3.5) specifies the probability of condom use among females only. To ensure 
that male and female assumptions are consistent, the probability that a male uses a 
condom in a short-term or long-term relationship is calculated as  
 
 ),()|(),( ,21,1 tyxyftx l
y
l γγ ∑= ,     (3.6) 
 
where )|(1 xyf  is the probability that the female partner is aged y, if the male is aged 
x. The rate of condom use among clients of sex workers is the same as that estimated 
for sex workers, with no age dependency. 
 
3.2.9 The effect of HIV symptoms and treatment on sexual behaviour 
 
Although there is much evidence to suggest that women generally have fewer sexual 
partners as they enter the later stages of HIV disease (Ross et al, 2004; Terceira et al, 
2003; Hankins et al, 1998; Greenblatt et al, 1999), there is little data concerning the 











relationships. The few studies that have been conducted suggest that coital frequency 
within partnerships is only slightly reduced as individuals experience more advanced 
disease (Ross et al, 2004; Terceira et al, 2003). Similarly, the initiation of highly 
active antiretroviral treatment (HAART) appears to be associated with increases in the 
proportion of individuals who report sexual activity, but not with changes in coital 
frequency among those who are sexually active (Bunnell et al, 2006; Moatti et al, 
2003). It is therefore assumed that the rate at which individuals acquire new sexual 
partners reduces as they experience more severe symptoms, but the frequency of sex 
within partnerships is assumed to be unaffected by the HIV status or HIV disease 
stage of either partner. The factors by which the desired partner acquisition rates in 
uninfected individuals are multiplied, in order to obtain the rates in each HIV stage, 
are shown in Table 3.2.3. These have been set at the same level as the factors used to 
adjust coital frequencies in the corresponding HIV stages in the ASSA2003 model. 
 
HIV disease stage is also assumed to affect the rate at which women become sex 
workers, and the rate at which women discontinue sex work. Although there is 
evidence to suggest that women are more likely to discontinue sex work in the more 
advanced HIV disease stages (McClelland et al, 2006), little is known about the effect 
of HIV symptoms on the rate of entry into sex work. The effects are therefore 
assumed to be the same as those on rates of partner acquisition. The assumed factors 
by which the HIV-negative rates of sex worker entry and exit are multiplied, in each 
HIV stage, are shown in Table 3.2.3. 
 











Partner acquisition rate 1.00 1.00 0.65 0.25 0.80 
Entry into sex work 1.00 1.00 0.65 0.25 0.80 
Exit from sex work 1.00 1.00 1.50 3.00 2.00 
 
Evidence suggests that the frequency of condom use increases after individuals learn 
they are HIV-positive (Voluntary HIV-1 Counselling and Testing Efficacy Study 











der Straten et al, 2000). However, in the interests of mathematical simplicity, no 
allowance is made in the model for changes in condom use over the course of HIV 
infection. 
 
3.3 HIV/AIDS and STI assumptions 
 
This section outlines the assumptions made about the biology of HIV and other STIs. 
Section 3.3.1 outlines the assumptions made about the course of infection, and section 
3.3.2 describes the modelling of STI transmission and STI incidence. This is 
followed, in section 3.3.3, by a description of the assumed effect of HIV co-infection 
on the course of STIs. Finally, in section 3.3.4, assumptions about STI treatment in 
South Africa are explained. As in section 3.2, many of the parameters cannot be 
determined reliably based on the limited evidence available, and we therefore adopt a 
Bayesian approach to determine the likely parameter values. For those parameters that 
are considered most uncertain, prior distributions are chosen to represent a priori 
uncertainty regarding plausible parameter values. In most cases, beta and gamma 
priors are used, as these are natural distributions for parameters defined on the ranges 
[0, 1] and [0, ∞) respectively. 
 
3.3.1 HIV/AIDS and STI natural history 
 
This section describes the disease states used to represent the natural history of each 
STI, and the assumptions regarding the rates of transition between the various disease 
states. Multi-state model diagrams are presented for each STI, considered 
independently of other STIs and demographic processes. For ease of representation, 
subscripts and superscripts indicating sex, relationship status, risk group and STI are 
omitted from symbols introduced here, as are age and time arguments. Parameters 
determining the rate at which individuals seek treatment (υ), the effectiveness of 
treatment (ψ) and the rate at which individuals are cured of STIs through screening (η) 
are introduced in the multi-state diagrams, but their explanation is deferred until 
section 3.3.4. The parameter λ, representing the incidence of infection, is also 
introduced in the diagrams, but the method used to calculate it is deferred to section 











3.3.1.1 Syphilis (Treponema pallidum) 
 
Syphilis is traditionally characterized as starting with a painless genital ulcer (primary 
syphilis) and then progressing to rashes and lesions on other parts of the body 
(secondary syphilis), after which individuals enter a long asymptomatic phase. This 
asymptomatic phase may be followed several years later by severe damage to the 
cardiovascular system, central nervous system and other parts of the body (tertiary 
syphilis) in a minority of individuals. The model developed here follows this scheme, 
but does not allow for progression to tertiary syphilis, as the frequent use of 
antibiotics to treat other infections prevents the progression of most latent syphilis 
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Figure 3.3.1: Multi-state model of the natural history of syphilis  
 
Based on a re-analysis of data collected in France in the nineteenth century, Garnett et 
al (1997) estimate that the average duration of the incubation period is 31 days, and 
the average interval between the onset of primary and secondary symptoms is 46 
days. These estimates are consistent with the ranges quoted in most other sources 
(Rowley and Berkley 1998; Goh 2005; Merck 1999). It is therefore assumed that the 
average duration of the incubation period ( 11 σ ) is 31 days and the average duration 
of primary syphilis ( 21 σ ) is 46 days, in the absence of treatment. Data regarding the 
duration of secondary syphilis are very scarce, with only one Norwegian study cited 
by Garnett et al (1997) suggesting that the average duration of secondary syphilis 











parameter 31 σ . Following the approach of Korenromp et al (2000b), it is assumed 
that in the absence of screening, individuals remain in the latent phase for 10 years on 
average ( 41 σ ) before experiencing either spontaneous resolution of syphilis or cure 
due to treatment of other infections. 
 
Because the model is calibrated to seroprevalence data, it is necessary to make 
assumptions about the presence of syphilis antibodies in different stages of infection. 
In the incubation phase, all individuals are assumed to be seronegative, as it takes 
some time for syphilis antibodies to develop. In the primary stage, between 29% and 
43% of patients experiencing genital ulcers due to syphilis are seronegative on non-
treponemal tests (Orle et al, 1996; Morse et al, 1997). For the sake of simplicity, it is 
assumed that all individuals in the primary syphilis phase are seropositive, though 
there is implicit allowance for the limited sensitivity of the n n-treponemal tests in 
primary syphilis in the diagnostic sensitivity assumptions (discussed in Appendix D). 
In all subsequent phases (stages 3 to 6 in Figure 3.3.1), individuals are assumed to be 
seropositive.  
 
Individuals who are cured of syphilis usually remain seropositive for several months. 
The rate of seroreversion is more rapid in patients treated in earlier disease stages, and 
the model therefore has two ‘post-treatment’ states to represent individuals who are 
still seropositive after treatment in early syphilis and those who are still seropositive 
after recovery from latent syphilis. Data collected by Rolfs et al (1997) suggest that 
the mean time to seroreversion or a more than two-fold reduction in RPR titre is 0.81 
years for patients treated in early latent syphilis, and 0.37 years in patients treated in 
primary or secondary syphilis. Similar data collected by Schroeter et al (1972) 
suggest that the average time to seroreversion is 0.70 years for patients treated in 
primary syphilis and 1.84 years for patients treated in secondary syphilis. In the model 
it is assumed that the average time to seroreversion after treatment of latent syphilis 
( 61 σ ) is one year and the average time to seroreversion after treatment of early 
syphilis ( 51 σ ) is six months. It is also assumed that a proportion (φ) of individuals 
successfully treated in primary syphilis immediately return to the seronegative state; 
this proportion is set at 0.4, roughly in line with the proportion of individuals who are 











‘recovered seropositive’ states (states 5 and 6) are assumed to be protected against 
syphilis reinfection, based on evidence suggesting that individuals previously infected 
with syphilis acquire a degree of immunity (Magnuson et al, 1956).  
 
Table 3.3.1 summarizes the parameter values specified previously, and shows the 
prior distributions chosen for those parameters considered in the Bayesian analysis 
described in section 4.2. 
 
Table 3.3.1: Syphilis parameters 
Parameter Symbol
Prior distribution 
Type Mean Std dev.
Average time (in weeks) from     
     Infection to primary 11 σ  - 4.4
* - 
     Primary to secondary 21 σ  Gamma 6.6 2.0 
     Secondary to latent 31 σ  Gamma 15.6 4.0 
     Latent to spontaneous resolution 41 σ  Gamma 520 150 
     Recovery in early disease to seronegative 51 σ  Gamma 26.0 8.0 
     Recovery in latent infection to seronegative 61 σ  Gamma 52.0 16.0 
Proportion of primary cases seronegative 
     immediately after successful treatment 
φ Beta 0.40 0.10 
* Fixed parameter, not included in Bayesian analysis. 
 
3.3.1.2 Genital herpes (herpes simplex virus type 2) 
 
Genital herpes is a chronic condition caused by herpes simplex virus type 2 (HSV-2), 
and characterized by periodic recurrences of ulcers in the genital region, which 
become less frequent as the duration of infection increases. Although it is commonly 
assumed that all individuals who acquire HSV-2 experience ulcerative symptoms, the 
majority of HSV-2–seropositive individuals report never having experienced these 
symptoms, and would therefore never seek treatment for genital herpes. In order to 
assess the health-seeking behaviours associated with genital herpes realistically, the 
model therefore splits those acquiring HSV-2 into those who never experience 











proportions of HSV-2–seropositive individuals who report having ever experienced 
herpes symptoms range from 9% in the USA (Fleming et al, 1997), to 27% in female 
university students in the US (Koutsky et al, 1990) and 30% among blood donors in 
London (Cowan et al, 1996). In a study of Zimbabwean men, it was found that in the 
year of HSV-2 seroconversion, when HSV-2 recurrences are believed to be most 
severe, only 15% of men reported experiencing herpes symptoms (McFarland et al, 
1999). Since the latter study is most relevant to the African context, the assumption 
made in the model is that the proportion of individuals acquiring HSV-2 who 


























λ(1 – φ) 
σ1 + υψ σ3 + υψ 
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Figure 3.3.2: Multi-state model of the natural history of HSV-2 
 
The ulcers that develop following initial infection with HSV-2 usually last two to 
three weeks. In individuals previously infected with HSV-1, first episodes of HSV-2 
ulcers have been estimated to last for a median of 15 days by Koelle et al (1992) and 
for a mean of 16 days by Corey et al (1983). Subsequent ulcers are of shorter 
duration; estimates of the median ulcer duration lie between 3 and 6 days (Wald et al, 
2000; Schacker et al, 1998b), while estimates of the mean duration lie between 6 and 
11 days (Brown et al, 1985; Corey et al, 1983; Rattray et al, 1978). Assuming that 
ulcer durations are exponentially distributed (so that median durations tend to be 
shorter than mean durations), the mean durations of the primary and subsequent ulcers 












Estimates of the annual number of recurrences occurring soon after infection range 
between 3.5 and 6.3 (Koelle et al, 1992; Corey et al, 1983; Benedetti et al, 1999), 
with recurrences tending to be more frequent in men than in women (Benedetti et al, 
1994; Corey et al, 1983; Obasi et al, 1999). Consistent with the approach of 
Korenromp et al (2002b), it is assumed that the rate at which symptomatic recurrences 
occur, ξ, is twice as high in men as in women. This rate is set at 3 per annum in 
women and 6 per annum in men. To model the effect of recurrences becoming less 
frequent as the duration of infection increases, it is assumed that individuals progress 
from the ‘transiently asymptomatic’ state to the ‘permanently asymptomatic’ state at 
rate σ2. Benedetti et al (1999) have found that the average annual number of 
recurrences reduces by 13% and 8% per annum in primary and recurrent herpes cases 
respectively, and it is therefore assumed that individuals who are initially 
symptomatic enter the permanently asymptomatic state at a rate σ2 of 0.1 per annum. 
 
Table 3.3.2 summarizes the parameter values specified previously, and shows the 
prior distributions chosen for those parameters considered in the Bayesian analysis. 
 
Table 3.3.2: Genital herpes parameters 
Parameter Symbol
Prior distribution 
Type Mean Std dev.
Proportion of cases becoming symptomatic φ Beta 0.15 0.05 
Annual incidence of symptomatic recurrences 
     in the transiently asymptomatic state 
    
        Males ξ Gamma 6.0 1.0 
        Females  Gamma 3.0 0.5 
Average duration of primary ulcer (weeks) 11 σ  - 2.6
* - 
Average duration of recurrent ulcer (weeks) 31 σ  - 1.1
* - 
Annual rate of transition from transiently  
     asymptomatic to permanently asymptomatic
2σ  Gamma 0.1 0.02 














3.3.1.3 Gonorrhoea (Neisseria gonorrhoeae) 
 
Gonorrhoea is an acute bacterial STI causing urethral discharge and dysuria in men 
and cervical discharge and dysuria in women. The modelled progression of infection 
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Figure 3.3.3: Multi-state model of the natural history of gonorrhoea  
 
A high proportion of men become symptomatic after acquiring gonorrhoea. In studies 
of men followed after known exposure to gonorrhoea, symptoms developed in 57 of 
58 infected men observed by Harrison et al (1979), and in all 11 infected men 
observed by Schmidt et al (2001). Studies of men attending STI clinics also suggest 
high upper bounds on symptomatic proportions, with between 83% and 98% of men 
with gonorrhoea reporting symptoms (Buimer et al, 1996; Price et al, 2004; Joyner et 
al, 2000; Hobbs et al, 1999). Data on gonorrhoea in women are less clear; Platt et al 
(1983) found that 10 out of 19 women infected with gonorrhoea by their male partners 
had ‘normal’ gynaecological examinations, while Korenromp et al (2002d) estimated 
that fewer than 40% of women acquiring gonorrhoea developed symptoms. The 
assumption made here is that the proportion of newly infected individuals who 
develop symptoms (φ1) is 40% in women and 90% in men. 
 
Very few studies have been conducted to determine the rate at which gonococcal 
infections resolve. In a review by Korenromp et al (2002d), only two such studies 











basis of the one study conducted in men, the average duration of untreated infection 
was estimated to be 16.9 weeks, while on the basis of the other study in women, the 
average duration of untreated infection was estimated to be 15.3 weeks. Another 
study, conducted in 28 men who were asymptomatically infected with gonorrhoea, 
reported the proportion of men whose infections resolved spontaneously after variable 
follow-up times (Handsfield et al, 1974). Using the same method as that used by 
Korenromp et al, the average duration of untreated infection in this study is estimated 
to be 12.2 weeks. Although the model allows for differences in rates of spontaneous 
resolution between asymptomatic and symptomatic gonorrhoea cases, and between 
men and women, the same assumed average duration of infection (15 weeks if left 
untreated) is assumed in all cases, in the absence of strong evidence to suggest that 
such differences exist. 
 
There is some evidence to suggest that individuals who have been infected with 
gonorrhoea may develop a degree of immunity. In a study of Kenyan sex workers, 
Plummer et al (1989) found that women infected with a particular strain were 
significantly less likely to be reinfected with the same strain, and that the incidence of 
gonorrhoea infection decreased as the duration of sex work increased. Moodley et al 
(2002) found that women reinfected with gonorrhoea shortly after successful 
treatment were in almost all cases infected with a different strain from that initially 
acquired, which also suggests that there may be strain-specific immunity. However, 
Schmidt et al (2001) found that men who had been experimentally inoculated and 
treated  for gonorrhoea two weeks previously were as likely to acquire gonorrhoea 
upon subsequent challenge as men who had not been previously inoculated, which 
suggests that any immunity that exists after successful treatment is likely to be 
relatively weak. In the baseline scenario, it is assumed that none of the individuals 
successfully treated for gonorrhoea are immune after recovery (φ2 = 0), but those who 
experience spontaneous resolution are resistant to reinfection for a short time ( 31 σ  = 
1 year). The effect of alternative assumptions about immune protection is explored in 
section 4.3.  
 
Table 3.3.3 summarizes the parameter values specified previously, and shows the 












Table 3.3.3: Gonorrhoea parameters 
Parameter Symbol
Prior distribution 
Type Mean Std dev
Proportion of cases becoming symptomatic     
     Male φ1 Beta 0.90 0.05 
     Female  Beta 0.40 0.15 
Average duration of untreated infection (weeks)     
     Male 11 σ
* Gamma 15.0 5.0 
     Female  Gamma 15.0 5.0 
Average duration of immunity (weeks) 31 σ  Gamma 52.0 26.0 
Proportion immune after successful treatment φ2 - 0.0† - 
* Same parameter is used for symptomatic duration (1/σ1) and asymptomatic duration (1/σ2). † Fixed 
parameter, not included in Bayesian analysis. 
 
3.3.1.4 Chlamydial infection (Chlamydia trachomatis) 
 
Like gonorrhoea, chlamydial infection is a bacterial infection that causes urethritis in 
men and cervicitis in women. Chlamydial infection differs from gonorrhoea in that it 
is asymptomatic in a high proportion of cases. Studies of men with chlamydial 
infection attending STI clinics have found that approximately 50% report symptoms 
(Joyner et al, 2000; Krieger et al, 1993a; Buimer et al, 1996), and in a study of female 
STI clinic attenders with chlamydial infection, only 35% reported symptoms (Buimer 
et al, 1996). These proportions are likely to represent upper bounds on the proportions 
of infections that become symptomatic, as asymptomatically infected individuals are 
less likely to attend STI clinics than symptomatic individuals. In an analysis of 
Ugandan data, Korenromp et al (2002d) estimated that the proportion of chlamydial 
infections that become symptomatic is less than 35% in men and less than 25% in 
females, with best estimates being only 11% and 6% in males and females 
respectively. 
 
The multi-state model used to model the natural history of chlamydial infection is 











of new infections that become symptomatic (φ1) is assumed to be 30% in males and 
15% in females, on the basis of the above evidence.  
 
A significant number of studies have measured rates at which untreated chlamydial 
infection resolves, and these are reviewed by Korenromp et al (2002d) and Golden et 
al (2000). In seven studies of men with symptomatic chlamydial infection, the 
average mean duration of infection estimated by Korenromp et al is 113 days, in the 
absence of treatment. Similar rates of spontaneous resolution were observed in a large 
study of female chlamydial cases; 51 out of 69 women (mostly symptomatic) were 
found to still be culture-positive for chlamydia between 4 and 45 days after initial 
diagnosis (Parks et al, 1997). Korenromp et al estimate from these data that the 
implied average duration of chlamydial infection in the absence of treatment is 128 
days. However, another large study of untreated chlamydial infection found 
significantly lower rates of spontaneous resolution; in this study, 68 out of 85 initially 
asymptomatic teenage girls were found to still be culture-positive for chlamydia 90 
days after initial diagnosis (Rahm et al, 1988). Using the method of Korenromp et al, 
this implies an average duration of untreated infection equal to 764 days. Recent 
studies that use more sensitive diagnostic techniques estimate the proportion of 
asymptomatically infected women who experience spontaneous resolution within one 
year to be 54% (Molano et al, 2005)  and 45% (Morré et al, 2002), suggesting 
average durations of 470 days and 616 days respectively. It therefore appears that 
symptomatic infections tend to resolve more rapidly than asymptomatic infections, in 
the absence of treatment. It is thus assumed that the average duration of chlamydial 
infection is 16 weeks in symptomatic cases and 90 weeks in asymptomatic cases. 
 
There is substantial evidence of partial immunity to reinfection after resolution of 
chlamydial infection, though much of the evidence is from animal experiments (Su et 
al, 1999; Johansson and Lycke 2001; Golden et al, 2000). Brunham et al (1996) 
suggest that an accumulation of immunity to different chlamydial strains would result 
in overall immunity over time, and support this with evidence from Kenyan sex 
workers, who were found to be less susceptible to chlamydial infection the greater the 
duration of sex work. Cellular immune responses to Chlamydia trachomatis have 
been found to be significantly associated with older age (Arno et al, 1994), and 











of STI patients with a low prevalence of chlamydial infection than in groups with a 
high prevalence of chlamydial infection, which suggests that past chlamydial 
infection may partially protect against reinfection (Schachter et al, 1983). However, 
immunity appears to wane over time; Katz et al (1987) observed that men and women 
who had been treated for chlamydial infection within the last six months were 
significantly less likely to experience chlamydial infection than those who had been 
treated more than six months previously. Immunity may also be weaker when 
treatment is initiated early in infection; in a study of mice, for example, Su et al 
(1999) observed that the earlier chlamydial treatment was initiated, the weaker the 
immune response was, and the more susceptible the mice were to chlamydial 
reinfection. In the baseline scenario, it is assumed that all individuals who experience 
spontaneous resolution are temporarily immune, but only half of successfully treated 
individuals are immune. The average duration of immunity is assumed to be ten years. 
Alternative models of immunity are considered in section 4.3. 
 
Table 3.3.4 summarizes the parameter values specified previously, and shows the 
prior distributions chosen for those parameters considered in the Bayesian analysis. 
 
Table 3.3.4: Parameters for chlamydial infection 
Parameter Symbol
Prior distribution 
Type Mean Std dev.
Proportion of cases becoming symptomatic     
     Male φ1 Beta 0.30 0.15 
     Female  Beta 0.15 0.08 
Average duration of untreated infection      
     Symptomatic (weeks) 11 σ  Gamma 16.0 5.0 
     Asymptomatic (weeks) 21 σ  Gamma 90.0 15.0 
Average duration of immunity (weeks) 31 σ  Gamma 520 200 















3.3.1.5 Chancroid (Haemophilus ducreyi) 
 
Chancroid is a bacterial STI that causes genital ulcers. Although little is known about 
its natural history, the model structure is assumed to be the same as that used for 
gonorrhoea (Figure 3.3.3).  
 
Evidence suggests that a high proportion of chancroid infections in women are 
symptomatic. Plummer et al (1983) detected ulcers in 10 out of 13 Kenyan women 
who had been infected with chancroid by their partners, and in 5 out of 10 Kenyan sex 
workers who were infected with chancroid. In another study of sex workers in the 
Gambia, ulcers were found upon examination in 8 out of 12 women with chancroid 
(Hawkes et al, 1995). It is assumed that the proportion of female chancroid cases that 
become symptomatic (φ1) is 70%. In the absence of any data for males, the 
corresponding proportion for male chancroid cases is set at 90%, since STIs tend to be 
more symptomatic in men than in women.  
 
Data on the rate at which chancroid resolves in the absence of treatment are scarce, 
though Ronald and Plummer (1985) state that symptoms usually resolve within one to 
three months of infection. It is therefore assumed that the average duration of 
symptomatic infection ( 11 σ )  is two months, and in the absence of data on the rate at 
which asymptomatic infections resolve, the same assumption is made for the average 
duration of asymptomatic chancroid ( 21 σ ). Infection with chancroid is generally not 
believed to confer protection against reinfection (Lewis 2000), as individuals who are 
successfully treated do not appear to be protected when subsequently challenged 
under experimental conditions (Al-Tawfiq et al, 1999; Spinola et al, 1994). However, 
it is possible that individuals who experience spontaneous resolution may be partially 
protected against reinfection. It is therefore assumed that there is no immunity 
following successful treatment of chancroid (i.e. φ2 = 0), but individuals who 
experience spontaneous resolution are assumed to be immune to reinfection for one 












No Bayesian analysis is conducted in the case of chancroid, due to the lack of reliable 
prevalence data (see section 4.2). There are thus no prior distributions specified to 
represent uncertainty regarding the chancroid parameters. 
 
3.3.1.6 Trichomoniasis (Trichomonas vaginalis) 
 
Trichomoniasis is a protozoan infection that causes urethral discharges and prostatitis 
in men, and vaginal discharges in women. The model used to represent the natural 
history of this infection is the same as that used to represent the natural history of 
gonorrhoea and chlamydial infection (see Figure 3.3.3). 
 
There appears to be significant heterogeneity in the rates at which trichomoniasis 
resolves. Studies of symptomatic males suggest symptomatic infection may resolve 
after an average of 10 to 20 days (Price et al, 2003; Weston and Nicol 1963), while 
other studies suggest that men may be asymptomatically infected with trichomoniasis 
for an average of 50 days (Krieger et al, 1993b) or an average of more than 140 days 
(Watson-Jones et al, 2000). The largest study of the natural history of asymptomatic 
trichomoniasis in untreated women suggests an average duration of two years or more 
(Klebanoff et al, 2001), but some experts have argued that the average duration of 
untreated infection in females is likely to be considerably longer (as much as 15 
years), on the basis of the monotonically increasing prevalence of trichomoniasis with 
respect to age in some populations (Ipsen and Feigl 1970; Bowden and Garnett 2000). 
In the model it is assumed that the average duration of untreated asymptomatic 
infection is 20 weeks in males and 150 weeks in females. The average duration of 
untreated symptomatic infection is assumed to be 2 weeks in males and 15 weeks in 
females (although there is no evidence to support the latter assumption, it seems likely 
that if symptomatic infections in men resolve more swiftly than asymptomatic 
infections, the same would be true for women). 
 
There is much uncertainty regarding the proportion of trichomoniasis infections that 
become symptomatic. Studies of STI clinic attenders have reported symptomatic 
proportions of between 42% and 73% in males (Price et al, 2004; Krieger et al, 
1993a; Joyner et al, 2000; Hobbs et al, 1999) and 42% in females (Wølner-Hanssen et 











with trichomoniasis reported symptoms, as compared with 23% of men with no 
trichomoniasis (Watson-Jones et al, 2000). However, in a large survey of Kenyan 
women attending antenatal clinics (Thomas et al, 1996), it was found that the 
proportion of trichomoniasis-infected women who reported symptoms (33%) was 
similar to that in uninfected women (26%). The evidence therefore suggests that the 
infection is more frequently symptomatic in males than in females. It is assumed in 
the baseline scenario that trichomoniasis infections become symptomatic in 40% of 
males and 30% of females. 
 
There is little evidence to suggest that infection with trichomoniasis confers protective 
immunity (Petrin et al, 1998). Studies of women treated for trichomoniasis have often 
noted rapid reinfection after cure (Lyng and Christensen 1981; Ackers 1990), which 
suggests that there is little immunity after treatment. However, Abrahams et al (1996) 
found that it was possible to induce a strong protective immune response in untreated 
mice. Ackers (1990) suggests that immunity to trichomoniasis could be acquired 
gradually, which might explain the absence of strong immune responses after 
treatment in the early stages of trichomoniasis infection. It is therefore assumed that 
individuals who are successfully treated or trichomoniasis are not immune after 
recovery, but that individuals who experience spontaneous resolution are immune for 
an average of one year following resolution. Alternative models of immunity to 
trichomoniasis are considered in section 4.3. 
 
Table 3.3.5 summarizes the parameter values specified previously, and shows the 












Table 3.3.5: Trichomoniasis parameters 
Parameter Symbol
Prior distribution 
Type Mean Std dev.
Proportion of cases becoming symptomatic     
     Male φ1 Beta 0.40 0.10 
     Female  Beta 0.30 0.10 
Average duration of untreated infection      
     Symptomatic males (weeks) 11 σ  Gamma 2.0 0.7 
     Symptomatic females (weeks) Gamma 20.0 7.0 
     Asymptomatic males (weeks) 21 σ  Gamma 15.0 5.0 
     Asymptomatic females (weeks) Gamma 150 50.0 
Average duration of immunity (weeks) 31 σ  Gamma 52.0 26.0 
Proportion immune after successful treatment φ2 - 0.0* - 
* Fixed parameter, not included in Bayesian analysis. 
 
3.3.1.7 Bacterial vaginosis 
 
Bacterial vaginosis is a condition that occurs frequently in women, sometimes 
producing symptoms of vaginitis, but more often asymptomatic. Unlike the other 
diseases considered here, there is no single organism that can be isolated as the cause 
of the disease. The disease is defined in terms of the relative abnormality of the 
vaginal flora, not in terms of any absolute marker. Nugent et al (1991) have proposed 
a ten-point scoring method for grading the extent of this abnormality, and have 
proposed that a score of 7 or higher be consider defining of ‘bacterial vaginosis’, 
while a score of 3 or less should be considered ‘normal’ and a score of 4 to 6 should 
be considered ‘intermediate’. The model developed here follows this three-stage 
approach to categorizing women on the basis of their vaginal flora patterns. Suppose 
that women’s progression through the three different disease states can be represented 
by a Markov chain, with pij representing the transition probability from state i to state 
j in a one-week period (states 1, 2 and 3 represent normal, intermediate and bacterial 
vaginosis states respectively). These transition probabilities can be estimated from 












The largest of these studies that uses Nugent’s scoring method is that of Hillier et al 
(1992b). In this study, vaginal flora were assessed in pregnant women at 23 to 26 
weeks gestation, and then again at 31 to 36 weeks gestation (no woman received 
antibiotic treatment between baseline and follow-up). Table 3.3.6 shows the numbers 
of women in each of the three groups at follow-up according to the vaginal flora 
pattern at baseline, and the maximum likelihood estimates of the pij values estimated 
from these data. (For the purpose of calculating the likelihood, it is assumed that 
follow-up occurred 9 weeks after baseline, and that the number of women in each of 
the three groups at 9 weeks is multinomially distributed.) The p13 value has been 
constrained to zero in order to simplify the modelling of bacterial vaginosis incidence 
later. The results suggest that the average duration of untreated bacterial vaginosis 
( )ln(1 33p− ) is 17 weeks, while the average length of time that a woman remains in 
the ‘normal’ state ( )ln(1 11p− ) is 33 weeks. The stationary probabilities for the 
normal, intermediate and bacterial vaginosis states are 0.49, 0.19 and 0.32 
respectively.  
 
Table 3.3.6: Numbers of women according to vaginal flora patterns at baseline and 
follow-up, and corresponding estimates of weekly transition probabilities 
Vaginal flora 
pattern at  
baseline 








Normal 404 61 37 0.970 0.030 0 
Intermediate 36 45 38 0.063 0.843 0.094 
BV 17 27 97 0.008 0.050 0.943 
 
The model developed here extends the basic three-stage model by allowing for a 
distinction between symptomatic and asymptomatic bacterial vaginosis. The possible 
movements between the various states are represented in Figure 3.3.4. The continuous 
weekly rates of transition between these states in the absence of treatment, ijσ , have 
been estimated from the pij values in the previous table, with 030.012 =σ , 
069.021 =σ , 008.04131 == σσ , and 051.04232 == σσ . It is thus assumed that 
symptomatic and asymptomatic infections resolve spontaneously at the same rate. 











become asymptomatic (Dhar et al, 1994), it is assumed in the baseline scenario that 
there are no movements between the symptomatic and asymptomatic bacterial 
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σ42 + η2 
σ31 + η1 + υψ1 
σ32 + η2 +  
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Figure 3.3.4: Multi-state model of the natural history of bacterial vaginosis  
 
The proportion of incident cases that become symptomatic, φ, is difficult to estimate. 
Eschenbach et al (1988) found that among 311 women attending STI clinics with 
bacterial vaginosis (diagnosed using a method similar to Nugent’s scoring method), 
50% reported symptoms of increased discharge, and this suggests an upper bound on 
φ. However, in a smaller sample of 29 family planning clinic attenders with bacterial 
vaginosis (diagnosed using Nugent’s method), Wilkinson et al (1997) found that the 
proportion reporting symptoms (41%) was no different from that in women who did 
not have bacterial vaginosis (39%). This suggests that the proportion of women who 
develop symptoms could be very low, and the proportion φ is therefore set at 25%. 
 
Table 3.3.7 summarizes the parameter values specified previously, and shows the 
















Table 3.3.7: Bacterial vaginosis parameters 
Parameter Symbol 
Prior distribution 
Type Mean Std dev. 
Proportion of cases becoming symptomatic φ1 Beta 0.25 0.10 
Weekly rates of transition      
     Bacterial vaginosis to normal flora 4131 ,σσ  Gamma 0.008 0.003 
     Bacterial vaginosis to intermediate flora 4232 ,σσ  Gamma 0.051 0.015 
     Normal flora to intermediate flora 12σ  Gamma 0.030 0.010 
     Intermediate flora to normal flora 21σ  Gamma 0.069 0.020 
     Intermediate flora to bacterial vaginosis* λ Gamma 0.100 0.030 
* See explanation in section 3.3.2.2. 
 
3.3.1.8 Vulvovaginal candidiasis 
 
Vulvovaginal candidiasis is a common disease in women, most often associated with 
symptoms of itching and vaginal discharge. It is caused by various Candida species 
(also known as yeasts), most common among them being Candida albicans. These 
Candida species can inhabit the vaginal mucosa either as commensals (not causing 
symptoms) or as pathogens (Calderone and Fonzi 2001), but it is not clear why some 
yeast colonies become pathogenic, while others remain in a commensal state for long 
periods. To reflect the dual nature of the infection, the model developed here divides 
women infected with Candida into ‘asymptomatic candidiasis’ and ‘symptomatic 
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The incidence of yeast infection (parameter λ) varies between settings, but is 
consistently high. Barbone et al (1990) measured a yeast incidence of 77.1 per 100 
person years (PY) in women recruited from STI clinics in the US, and Ohmit et al 
(2003) found the incidence of yeast infection in HIV-negative US women to be 35.1 
per 100 PY. The incidence of yeast infection in women recruited from health facilities 
in Durban and Hlabisa (South Africa) has been estimated at 37.7 and 54.3 per 100 PY 
respectively (Dladla-Qwabe et al, 2005). In another African study, conducted among 
sex workers in Kenya, the incidence of yeast infection was 55.6 per 100 PY 
(McClelland et al, 2005). These estimates are probably under-estimates of the true 
incidence of yeast infection, as (a) low follow-up frequencies (e.g. semi-annually in 
the case of Ohmit et al and quarterly in the case of Dladla-Qwabe et al) may be 
expected to lead to under-estimation of incidence, and (b) the microscopy and culture 
methods used in these studies have limited sensitivity. It is therefore assumed that the 
incidence of yeast infection is 0.8 per annum. 
 
Studies suggest that symptomatic candidiasis infections resolve more rapidly, in the 
absence of treatment, than asymptomatic infections (del Palacio et al, 2000; Ohmit et 
al, 2003). Some yeast colonies may persist for long periods of time, even after 
appropriate treatment, with colonies being too small to be detected by culture 
methods. It has been suggested that this may account for the frequent ‘relapse’ of 
symptoms after treatment in women with recurrent vulvovaginal candidiasis (Sobel et 
al, 2004; Sobel 1993; El-Din et al, 2001). The approach taken to modelling 
vulvovaginal candidiasis is therefore to model ‘asymptomatic candidiasis’ as an 
intermediate state between ‘uninfected’ and ‘symptomatic candidiasis’. It is thus 
assumed that women who are symptomatic would still be asymptomatically colonized 
with Candida after spontaneous resolution of symptoms. The rate at which symptoms 
resolve ( 2σ ) is estimated to be 4.3 per annum, based on the study of Brown et al 
(1986), which found that 25 out of 70 women ceased to experience vulvovaginal 
candidiasis symptoms over a one-month period. The rate at which asymptomatic 
infection resolves ( 1σ ) is more difficult to estimate, as it is very dependent on the 
sensitivity of the culture methods used, especially at short follow-up durations. In a 











annum. Parameter 1σ  is set at 2 per annum, in order to make allowance for the under-
estimation associated with the low frequency of follow-up in this study. 
 
The incidence of symptomatic vulvovaginal candidiasis appears to be lower than the 
incidence of yeast infection. Ohmit et al (2003) measured an incidence in HIV-
negative women of 3.7 per 100 PY, though again, this is probably an under-estimate 
due to the low frequency of follow-up. Fennema et al (1995) measured an incidence 
of symptomatic candidiasis of 10.7 per 100 PY in a cohort of HIV-negative sex 
workers, based on STI clinic attendances (this too may be an under-estimate, as not all 
women experiencing candidiasis symptoms would have sought treatment). Self-
reported cumulative incidence rates, over a one-year period, have been estimated at 
between 29% and 39% (Fleming et al, 2006; Foxman et al, 2000), but these self-
reports are generally not regarded as reliable, and are likely to over-estimate the true 
incidence of symptomatic infection if women often experience vulvovaginal 
symptoms due to other conditions. It is assumed that the incidence of symptomatic 
candidiasis is 0.15 per annum, which is equivalent to setting the ξ parameter to 0.53 
per annum. (This equivalence follows by noting that in the steady-state equilibrium, 
ignoring treatment, the incidence of symptomatic infection in all asymptomatic 
women, *λ , is ( )1σλλξ + . The assumed values of λ and 1σ , 0.8 and 2 respectively, 
were substituted into this equation in order to solve for ξ.) 
 
Table 3.3.8 summarizes the parameter values specified previously, and shows the 












Table 3.3.8: Vulvovaginal candidiasis parameters 
Parameter Symbol 
Prior distribution 
Type Mean Std dev. 
Average duration of symptoms (weeks) 21 σ  Gamma 12.0 3.0 
Average time to clearance of asymptomatic  
     infection (weeks) 
11 σ  Gamma 26.0 6.0 
Annual incidence of yeast infection λ Gamma 0.80 0.20 
Annual incidence of symptoms (in all  
     asymptomatic women)† 
*λ  Gamma 0.15 0.05 




The model developed here follows the approach to staging HIV/AIDS progression 
recommended by the Centre for Disease Control (CDC) and World Health 
Organization (WHO). Individuals with HIV are categorized as being either 
asymptomatic (equivalent to WHO clinical stages I and II, or CDC stage A), 
experiencing pre-AIDS symptoms (WHO clinical stage III, roughly equivalent to 
CDC stage B) or having progressed to AIDS (WHO clinical stage IV or CDC stage 
C). In addition, individuals who are infected are assumed to remain in an ‘acute 
infection’ phase for the first few months after acquiring HIV, during which time they 
are highly infectious. A proportion of individuals are assumed to initiate highly active 
antiretroviral treatment (HAART) at the time that they progress to AIDS. This pattern 













































Figure 3.3.6: Multi-state model of the natural history of HIV 
 
Models of HIV/AIDS in Africa have usually assumed average HIV survival times of 
less than 10 years in the absence of treatment (Robinson et al, 1997; Bracher et al, 
2004; Korenromp et al, 2002c). However, HIV survival times in South Africa appear 
to be longer (Glynn et al, 2005), and in a recent analysis of HIV prevalence and vital 
registration data in South Africa it was estimated that the mean HIV survival time, for 
an untreated individual infected at age 29, was 11.5 years (Johnson et al, 2007). This 
value of 11.5 years is used as the assumed mean survival time, in the absence of 
treatment. In the interests of simplicity, no allowance is made for age variation in HIV 
survival rates, although there is evidence to suggest that older individuals have shorter 
survival times than individuals infected at young ages (Collaborative Group on AIDS 
Incubation and HIV Survival 2000). 
 
The length of time spent in each stage of HIV disease is highly variable. In fitting 
simple Markov models to data from studies that have estimated rates of transition 
between clinical stages in the pre-HAART era, it has been estimated that on average 
47% of HIV survival time is spent in WHO stages 1 and 2, 36% of survival time is 
spent in WHO stage 3, and the remaining 17% of time is spent in WHO stage 4 
(Johnson and Dorrington 2006). The assumptions made here are therefore that the 
mean length of time spent in the AIDS phase ( 41 σ ) is 96.15.1117.0 =×  years, and 
the mean length of time spent in the pre-AIDS phase ( 31 σ ) is 14.45.1136.0 =×  
years. The period of high infectiousness following acquisition of HIV appears to 











2006), and the mean duration of the acute infection phase ( 11 σ ) is therefore set at 3 
months. The remainder of the HIV survival time, in the absence of antiretroviral 
treatment, is spent in the asymptomatic phase (mean duration of 5.16 years). 
 
To model the effect of HAART, it is assumed that a proportion of individuals 
progressing to AIDS, φ, start treatment. This parameter varies over time, and the 
values in each year are set to be the same as the corresponding rates of HAART 
rollout in the ASSA2003 AIDS and Demographic model (Actuarial Society of South 
Africa 2005). The rates of rollout in the ASSA2003 model have been set to produce 
results consistent with reported numbers on HAART in the South African private and 
public health sectors up to 2005, and thereafter rollout rates increase to 50% of all 
individuals progressing to AIDS by mid-2008, remaining constant at this level in 
subsequent years. In reality, not all individuals starting HAART would do so at the 
time that they experience their first AIDS-defining illness, and most treatment 
guidelines recommend earlier initiation of antiretroviral treatment (World Health 
Organization 2004). However, this timing assumption is made in order to ensure 
consistency with the ASSA2003 modelling of treatment initiation.  
 
HAART has been shown to reduce the mortality rate by 78% in a US study (Palella et 
al, 1998), and by 90% in a South African study (Badri et al, 2004). It is assumed that 
the AIDS mortality rate is educed by 85% after starting HAART, so that the 
continuous mortality rate after starting HAART (σ5) is 077.0)85.01(4 =−σ  per 
annum. This is higher than the rates of mortality of 0.01 to 0.03 per annum typically 
measured after the first six months on HAART (Nachega et al, 2006; Lohse et al, 
2007; ART-LINC Collaboration and ART-CC groups 2006), but lower than the rate 
of around 0.1 per annum typically experienced in the first six months on HAART 
(ART-LINC Collaboration and ART-CC groups 2006). Estimates from these studies 
may be biased towards understatement of mortality, due to the high rates of loss to 
follow-up often experienced (Rosen et al, 2007), and it is therefore appropriate that 
the assumed AIDS mortality rate on HAART should be higher than that usually 
measured after the first six months on HAART. Discontinuation of antiretroviral 












3.3.2 HIV/AIDS and STI transmission 
 
This section describes and motivates the various assumptions made about STI 
incidence. In general, a constant probability of transmission per act of sex is assumed 
for each STI, and this probability is then multiplied by various adjustment factors to 
represent the effects of age, disease stage, condom use, risk group and partnership 
type. A more detailed mathematical explanation of the method used to model STI 
transmission is given in Appendix B. In the case of bacterial vaginosis and 
vulvovaginal candidiasis, which are generally not considered to be sexually 
transmissible, a constant incidence rate is assumed. 
 
3.3.2.1 Probability of STI transmission per act of sex 
 
Table 3.3.9 summarizes the assumptions made about the STI transmission 
probabilities per act of sex. As these transmission probabilities are extremely difficult 
to determine with any degree of certainty, these parameters are included in the 
Bayesian analysis in chapter 4. Beta priors have been specified for all the transmission 
probabilities, and the table shows the means and standard deviations of these beta 
priors. These prior distributions have been set with reference to both empirical 
evidence (discussed below) and parameter values that have been found to yield 
plausible results in other modelling studies (Orroth et al, 2007; Bracher et al, 2003; 
Korenromp et al, 2000b; Korenromp et al, 2002b; Ghani and Aral 2005; White et al, 
2004; Williams et al, 2006b).  
 
In the case of the non-viral STIs, empirical estimates of transmission probabilities 
tend to lie at the upper end of the distributions specified in Table 3.3.9. (Empirical 
estimates of transmission probabilities per sex act have been derived in the case of 
gonorrhoea (Hooper et al, 1978; Holmes et al, 1970; Platt et al, 1983), chlamydial 
infection (Lin et al, 1998), syphilis (Schroeter et al, 1971) and chancroid (Plummer et 
al, 1983).) The prior distributions have been set in this way because the empirical 
estimates are all derived from contact tracing studies and studies of male exposure to 
sex workers, which are likely to over-estimate transmission probabilities. Contact 
tracing studies are likely to over-estimate transmission probabilities because the index 











studies of male exposure to sex workers are likely to over-estimate transmission 
probabilities because men tend to under-report the extent of their contact with sex 
workers (Des Jarlais et al, 1999; Lau et al, 2003). Mathematical models tend to 
assume lower transmission probabilities than those estimated empirically in order to 
obtain plausible STI prevalence estimates. 
 
Table 3.3.9: Prior distributions on the probability of STI transmission per act of sex 
STI 
Male-to-female Female-to-male 
Mean Std dev. Mean Std dev. 
Gonorrhoea 0.40 0.10 0.20 0.05 
Chlamydial infection 0.16 0.10 0.12 0.06 
Syphilis 0.18 0.05 0.15 0.05 
Chancroid 0.20a - 0.20a - 
Trichomoniasis 0.15 0.08 0.04 0.02 
HSV-2 (asymptomatic)     
   CSW-client relationships 0.002 0.0005 -b - 
   Short-term relationships 0.0075 0.0010 0.0025 0.0005 
   Long-term relationships 0.0009 0.00015 0.00015 0.00003 
HIV (ignoring STI cofactors)     
   CSW-client relationships 0.003a - 0.030a - 
   Short-term relationships 0.012 0.005 0.010 0.003 
   Long-term relationships 0.002 0.00075 0.002 0.00075 
CSW = commercial sex worker. 
a Fixed parameter, not included in Bayesian analysis. b Female-to-male transmission probability is 
assumed to be the same in short-term and CSW-client relationships. 
 
In the case of the viral STIs, HIV and HSV-2, there is strong evidence to suggest that 
the probability of transmission per sex act reduces as the cumulative number of sex 
acts with the infected partner increases (Downs and De Vincenzi 1996; Saracco et al, 
1993; Padian et al, 1990; Wald et al, 2001; Corey et al, 2004). This phenomenon may 
be explained by heterogeneity between individuals, both in terms of susceptibility and 
infectiousness, i.e. partnerships in which transmission does not occur after a large 
number of exposures are likely to be partnerships in which the transmission risk per 











protective immune response. Studies in sex workers have demonstrated that some 
women develop HIV-specific T-cell responses that appear to protect against HIV 
infection (Rowland-Jones et al, 1998), and HSV-specific T-cell responses have also 
been identified in HSV-negative women (Posavad et al, 2003). Because of this 
heterogeneity in transmission probabilities, transmission probabilities are assumed to 
differ according to the relationship type. 
 
Estimates of HIV and HSV-2 transmission probabilities per act of sex are usually 
calculated from the cumulative risk of infection over some period, since both 
infections are incurable. Supposing that the risk of transmission per act of sex is β, the 
probability of condom use per act of sex is γ, the average number of sex acts over the 
period of interest is n, and the STI prevalence among partners is θ, the cumulative 
probability of STI transmission over the period can be crudely estimated as 
 
 ( )n)1(11 γθβ −−− .       (3.7) 
 
The probability of transmission per act of sex, β, can thus be estimated from the 
cumulative probability of transmission, if information on sexual behaviour and STI 
prevalence among partners is available. Estimates of HIV and HSV-2 transmission 
probabilities per act of sex in short-term relationships, calculated using this formula, 
are shown in Table 3.3.10. The client-to-sex worker HIV transmission probability is 
assumed to be 0.003, on the basis of the estimates of Ramjee et al (2005) and Hayes 
et al (1995b), while the male-to-female transmission probability in short-term 
relationships is assumed to be higher, at 0.012, based on two South African studies 
that have estimated the probability of HIV transmission per partnership in young 
women (Auvert et al, 2001a; Pettifor et al, 2007); the lower assumed susceptibility in 
sex workers can be justified on the basis of possible resistance to HIV in highly 
exposed individuals. The sex worker-to-client probability of HIV transmission is set 
at 0.03 per act of sex, on the basis of a study of military recruits in Thailand, for 
whom contact with sex workers was the main HIV risk factor (Mastro et al, 1994); 
higher transmission probabilities have been estimated among male contacts of sex 
workers in Kenya (Cameron et al, 1989). Estimates of the female-to-male HIV 











around 0.01 per act of sex (Baeten et al, 2005; Auvert et al, 2005), and the prior mean 
for this parameter has therefore been set at 0.01. The prior distributions on the HSV-2 
transmission probabilities in Table 3.3.9 are lower than the corresponding empirical 
estimates in Table 3.3.10, as the former relate only to asymptomatic infection, and the 
substantial increase in transmission probability in the symptomatic phases of infection 
renders the overall probability of transmission more consistent with the empirical 
estimates. 
 
Table 3.3.10: Estimates of HIV and HSV-2 transmission probabilities per act of sex, 
in short-term partnerships  
Parameter Population  Reference STI 
Cum. %
infected 




South Africa Ramjee et al 
(2005) 
HIV 14.7% 0.25a 1212c 0.89c 0.0047 
 0.56b 1212 0.89 0.0021 
HSV-2 35% 0.63d 1212 0.89 0.0042 
Kenya Hayes et al 
(1995b) 




South Africa Pettifor et al 
(2007) 
HIV 74%f 1.00 82 - 0.016 
      
Auvert et al 
(2001a) 
HIV 49%f 1.00 82 - 0.008 




South Africa Auvert et al 
(2005) 
HIV 2.1% 0.25a 8 - 0.0106 
Short-term 
transmission g 
USA Wald et al 
(2006) 
HSV-2 50% 1.00 40 - 0.017 
a Arbitrarily chosen. b Based on Ramjee and Gouws (2002). c Based on Ramjee et al (1999). d Based on 
HSV-2 prevalence in mineworkers (Ndhlovu et al, 2005). e Excluding sex workers experiencing genital 
ulcers. f Probability of transmission per partnership with an HIV-positive individual. g Relates to both 
males and females combined. 
 
Probabilities of HIV and HSV-2 transmission per sex act in spousal partnerships are 
estimated from studies of serodiscordant couples, most of whom are in long-term 
partnerships. In a Ugandan study of couples who were either married or in stable 
consensual unions, the estimated probability of HIV transmission per act of sex was 











0.0013 in those partnerships in which the initially infected partner was female (Gray 
et al, 2001). More substantial gender differences have been observed in the case of 
HSV-2. In HSV-2-serodiscordant couples in the U.S., the estimated male-to-female 
transmission probability per sex act was estimated to be 0.00089, and the 
corresponding estimate for female-to-male transmission was 0.00015 (Wald et al, 
2001). These estimates have been used to set the prior distribution on transmission in 
spousal relationships in Table 3.3.9. 
 
The HSV-2 transmission probabilities shown in Table 3.3.9 relate only to 
asymptomatically infected individuals. The odds of detectable HSV-2 shedding in 
symptomatic infection is typically 10 to 20 times that in asymptomatic HSV-2 
infection (Straus et al, 1989; Harger et al, 1989; Wald et al, 2000; Wald et al, 1995). 
The multiple by which HSV-2 infectiousness is increased in the presence of HSV-2 
symptoms is therefore assigned a gamma prior with a mean of 15 and a standard 
deviation of 5. 
 
The HIV transmission probabilities in Table 3.3.9 are the average transmission 
probabilities that apply over the course of HIV infection. HIV infectiousness in the 
acute infection stage is assumed to be ten times that in the asymptomatic stage 
(Wawer et al, 2005), and the transmission probabilities in the pre-AIDS and AIDS 
stages are assumed to be 2.5 times and 5 times those in the asymptomatic phase, 
respectively. The pre-AIDS and AIDS parameters are based on observed changes in 
blood plasma viral load over the course of HIV infection (Hubert et al, 2000; Lyles et 
al, 2000; Kassa et al, 1999; Wawer et al, 2005); it is assumed that the HIV 
transmission probability is increased by a factor of 2.5 for each log increase in viral 
load (Quinn et al, 2000; Fideli et al, 2001). The HIV transmission probabilities in 
each stage are set in such a way that when weighted by the average length of time 
spent in each stage of disease, the average transmission probability corresponds to 
that specified in Table 3.3.9. HAART is initiated only in the late stages of disease and 
is associated with an almost 3-log reduction in viral load (Frater et al, 2002; Laurent 
et al, 2002). It is therefore assumed that individuals receiving HAART are only half 
as infectious as individuals in the untreated asymptomatic phase of HIV infection. In 











affected by the presence of other STIs; the potential effects of other STIs on HIV 
transmission probabilities are explored in chapter 5. 
 
Apart from HIV and HSV-2, syphilis is the only other STI for which transmission 
probabilities are assumed to vary according to disease stage. The syphilis transmission 
probabilities shown in Table 3.3.9 apply only in the primary and secondary syphilis 
phases, after which individuals are assumed not to be infectious (Garnett et al, 1997). 
Although it is likely that other STIs are more transmissible when symptomatic than 
when asymptomatic, per act of sex, Garnett and Bowden (2000) argue that 
symptomatic individuals are also more likely to avoid sexual contact, and that it is 
therefore unclear whether symptomatically infected individuals are more likely to 
transmit infection than asymptomatically infected individuals. In the absence of 
reliable evidence regarding the infectiousness of other STIs, it is therefore assumed 
that asymptomatic individuals are as likely to transmit infection as symptomatic 
individuals (i.e. it is assumed that transmission probabilities are the same in 
symptomatic and asymptomatic infection and that coital frequencies are unaltered by 
symptoms of genital ulcers or discharges). 
 
In the case of bacterial STIs, it is assumed that there is no risk of transmission 
between individuals in mutually monogamous long-term relationships (i.e. marital or 
cohabiting relationships in which neither partner has any propensity for concurrent 
relationships). The rationale for this assumption is that if one partner is infected with 
an STI, they would have acquired it before entry into the current partnership. Since 
long-term relationships are assumed to start as short-term relationships, and since 
there is a high cumulative risk of the bacterial STI being transmitted up to the point at 
which the short-term relationship becomes long-term, it seems reasonable to assume 
that any transmission that occurs after the relationship has become long-term would 
be negligible.  
 
In the case of HIV and chlamydial infection, the model also allows for increased 
susceptibility to infection in women at young ages, which is due to the high 
prevalence of cervical ectopy in young women and possibly also immunological 
factors. Women in the 10 to 19 and 20 to 24 age groups are assumed to be 2.5 times 











respectively, per act of sex with a chlamydia-infected partner (Buvé et al, 2001b; 
Quinn et al, 1996; Arno et al, 1994). The same multiples are assumed in the case of 
HIV, based on the rates of transmission observed in studies of serodiscordant couples 
(Carpenter et al, 1999). 
 
3.3.2.2 Non-sexual incidence of infection 
 
Although the organisms associated with bacterial vaginosis and vulvovaginal 
candidiasis appear to be sexually transmissible, bacterial vaginosis and candidiasis are 
generally not regarded as being STIs and are defined as conditions that affect only 
women. The approach adopted here is therefore to model these infections in women 
by assuming a constant weekly incidence that is independent of coital frequency.  
 
In the case of bacterial vaginosis, the beta prior distribution on the weekly incidence 
rate λ (among women who are currently in the ‘abnormal vaginal flora’ state) is 
assigned a mean of 0.1 and a standard deviation of 0.03, consistent with the findings 
of Hillier et al (1992b) (see Table 3.3.6). As there is substantial evidence to suggest 
that women who report multiple partners experience bacterial vaginosis more 
frequently than women who are monogamous (Smart et al, 2004; Ness et al, 2006; 
Yen et al, 2003; Bradshaw et al, 2005; Shoubnikova et al, 1997), it is assumed that 
this incidence rate is doubled in sex workers and women who have more than one 
current partner. There is also evidence to suggest that virgins are significantly less 
susceptible to bacterial vaginosis than sexually experienced women (Yen et al, 2003; 
Amsel et al, 1983), and on the basis of this it is assumed that the above incidence rate 
is halved in women who currently have no sexual partner. 
 
Vulvovaginal candidiasis is rare in women pre-menarche and post-menopause (Geiger 
et al, 1995; Ferrer 2000; Sobel 1993), probably because of the dependence of 
candidiasis on the production of oestrogen, which is limited to the reproductive years. 
Studies also show that the prevalence of candidiasis is particularly high at young ages 
(Greenblatt et al, 1999; Ohmit et al, 2003; Bradshaw et al, 2005; Eckert et al, 1998) 
and in pregnancy (Ohmit et al, 2003; Daus and Hafez 1975). It is therefore reasonable 
to assume that the incidence of yeast infection is proportional to the age-specific 











aged 15-19 is assigned a mean of 0.8 and a standard deviation of 0.2, based on the 
evidence reviewed in section 3.3.1.8. The annual incidence in other age groups is 
estimated by multiplying the 15-19 incidence by the ratio of the average fertility rate 
in the age group to the average fertility rate in the 15-19 age group. 
 
3.3.2.3 Condom efficacy 
 
In a meta-analytic review, Weller and Davis (2004) estimate that the average rate of 
HIV transmission in serodiscordant couples always using condoms is 1.14 per 100 
PY, which compares with 5.75 per 100 PY in serodiscordant couples never using 
condoms. This suggests condoms are about 80% effective in preventing HIV 
transmission. However, this is probably an under-estimate, since it is likely that some 
individuals who report ‘always’ using condoms in fact do not use them as consistently 
as they claim (Holmes et al, 2004; Meekers and Van Rossem 2005). Condoms have 
been shown to be less effective in preventing the transmission of HSV-2 (Wald et al, 
2001), and it is believed that this is because the shedding of HSV-2 through the skin is 
not limited to the parts of the genitals covered by the condom. Although numerous 
studies have been conducted to determine whether condoms are effective in 
preventing the transmission of other STIs (Holmes et al, 2004; National Institute of 
Allergy and Infectious Diseases 2000), the other STIs considered here are acute, 
curable infections, and this makes it almost impossible to estimate rates of condom 
effectiveness per sex act.  
 
In the model it is assumed that condoms are 90% effective in preventing HIV 
transmission and 75% effective in preventing HSV-2 transmission, per sex act. In the 
absence of good data on condom efficacy in preventing other STIs, it is assumed that 
condoms are as effective in preventing other STIs as they are in preventing HIV (i.e. 
90% efficacy is assumed). Condom use is assumed to have no effect on the incidence 
of bacterial vaginosis or yeast infection. 
 
3.3.3 The effect of HIV on the natural history and transmission of other STIs 
 
A large number of studies have investigated the effect of HIV on the incidence and 











consistently been shown to be affected by HIV. There is weak evidence to suggest 
that the course of primary and secondary syphilis is altered in the presence of HIV 
(Hutchinson et al, 1994; Rompalo et al, 2001), and that neurosyphilis may be more 
common in HIV-infected individuals (Musher et al, 1990), but these associations are 
not considered in the model developed here. 
 
In the case of HSV-2, there is strong evidence to suggest that HIV increases 
infectiousness by promoting the shedding of HSV-2 in the genital tract. For example, 
LeGoff et al (2007) found that HIV doubled the odds of HSV-2 shedding, and 
Augenbraun et al (1995) detected HSV-2 shedding in 3.6% of HIV-negative, HSV-2–
positive women, compared with 12.5%, 8.5% and 22.2% of HIV-HSV-2–coinfected 
women with CD4+ counts of ≥500, 200-499 and <200 cell/mm3 respectively. The rate 
at which HSV-2 ulcers recur is also increased in HIV-positive individuals, particularly 
in the late stages of HIV infection (Greenblatt et al, 1999; Ghys et al, 1995). In the 
model it is assumed that there is a doubling of the frequency of HSV-2 shedding and 
HSV-2 infectiousness in all HSV-2 disease states if the individual is coinfected with 
HIV. It is also assumed that the rate at which genital ulcers recur, ξ, is increased by a 
multiple of 2 in individuals in the acute HIV infection and asymptomatic HIV 
infection stages, by a multiple of 3 in the pre-AIDS symptomatic phase, and by a 
multiple of 4 in the AIDS phase. HAART appears to have little effect on the 
frequency of HSV-2 shedding, but does appear to reduce the frequency of genital 
ulcers in HIV-infected patients (Posavad et al, 2004). It is therefore assumed that ξ is 
increased by a multiple of 2 in individuals on HAART (the same frequency as in the 
asymptomatic HIV stage). In addition, it is assumed that individuals co-infected with 
HIV do not progress from the transiently asymptomatic state to the permanently 
asymptomatic state (this ensures that individuals do not experience reductions in 
HSV-2 recurrences as their HIV infection progresses, unless they start HAART). 
 
In the case of candidiasis, there is strong evidence to suggest that immune suppression 
is associated with both increased yeast colonization and increased experience of 
symptomatic vulvovaginal candidiasis. Relevant studies are summarized in Table 
3.3.11. On the basis of these studies, it is assumed that the incidence of yeast infection 
is the same in asymptomatic HIV infection as in HIV-negative women, but that the 











AIDS stage, and is double that in asymptomatic infection after entry into the AIDS 
stage (these assumptions imply similar increases in the incidence of symptomatic 
infection). As HAART appears to have little effect on the incidence of candidiasis 
after controlling for CD4 count (van Benthem et al, 2000; Ohmit et al, 2003) and is 
associated with significant restoration of CD4 levels, it is assumed that the incidence 
of yeast infection in women on HAART is the same as that in HIV-negative women. 
 
Table 3.3.11: Effects of HIV on the incidence and prevalence of vulvovaginal 
candidiasis (VVC) 
Study Outcome HIV-
HIV-positive with CD4 
> 500 200-500 < 200 
Duerr et al (1997) Prevalence of VVC 18% 19% 25% 41% 
Clark et al (1993) Prevalence of VVC  30.9% 31.8% 60% 
Greenblatt et al (1999) OR for VVC 1.00 1.37 1.55 1.52 
Ohmit et al (2003) OR for VVC 1.00 1.01 1.16 1.30 
McClelland et al (2005) RR for VVC 1.0 0.9 1.6 2.5 
Rugpao et al (1998) Prevalence of  
   symptomatic VVC 
5.9% 5.6% 7.5% 16.0%
Minkoff et al (1999) Prevalence of  
   symptomatic VVC 
6.6% 11.1% 7.5% 19.4%
Farizo et al (1992) Cumulative 12-month 
   incidence of 
   symptomatic VVC 
 9.6% 11.6% 16.8%
van Benthem et al 
(2000) 
RR for VVC or 
   self-reported VVC 
 1.00 1.16 1.17 
 
3.3.4 STI health-seeking behaviour and treatment 
 
The sections that follow describe the assumptions used to model the effects of STI 
treatment in South Africa and the sources on which these assumptions are based. In 
Appendix B, a more formal mathematical explanation is given of how these 












3.3.4.1 Health-seeking behaviour 
 
To estimate the weekly rate at which individuals experiencing STI symptoms seek 
treatment, υ , suppose that symptoms resolve spontaneously at rate σ per week. 
Further suppose that of individuals reporting experience of STI symptoms over some 
past period, the proportion who report having sought treatment is R. Assuming that 
symptoms have resolved spontaneously in those who did not seek treatment, and 
assuming that both υ  and σ are constant with respect to the duration of infection, 
( )συυ +=R . This equation can be re-expressed as ( )RR −= 1συ , and it can also 
be shown that the mean time to seeking treatment is ( ) σR−1 . It is therefore possible 
to determine the rate at which individuals seek treatment if the rate of spontaneous 
resolution and the proportion of individuals seeking treatment are both known. Since 
the latter parameter is difficult to determine for each STI separately, we attempt to 
determine ‘average’ parameters for a generic STI, rather than separate parameters for 
each STI. 
 
African studies consistently show that men are more likely to report seeking treatment 
for STI symptoms than women, with proportions usually being around 80% in men 
and around 65% in women (Voeten et al, 2004; Lewis et al, 2005; Paxton et al, 1998; 
Williams et al, 2000; Reddy et al, 2003). In a study conducted in Carletonville (South 
Africa), the proportions of men and women who reported seeking treatment for STI 
symptoms (of those who reported experience of symptoms) were 83% and 77% 
respectively, and a higher proportion (86%) was recorded among sex workers 
(Williams et al, 2000). However, in a study of South African learners, it was found 
that the proportions who reported seeking treatment were relatively low: 67% in male 
learners and 59% in female learners (Reddy et al, 2003). These results are consistent 
with a Zimbabwean study, which found that youth sought treatment for STIs at a 
lower rate than older adults, and that sex workers sought treatment very promptly 
(Lewis et al, 2005). The proportions of individuals who seek treatment, assumed on 
the basis of these studies, are shown in Table 3.3.12. As the assumed average duration 
of most STI symptoms, in the absence of treatment, is around 10 weeks, σ is set at 0.1 
per week for the purpose of calculating the implied rate at which treatment is sought 











roughly consistent with various African studies, which have generally estimated the 
mean time to seeking treatment to be around 14 days in men and around 30 days in 
women (Wilkinson et al, 1998; Voeten et al, 2004; O'Farrell et al, 1991a; O'Farrell et 
al, 1991b). 
 





Implied rate at 
which treatment is 
sought, per week (υ )
Implied average 
time to seeking 
treatment (days)
Males    
     Aged <20 70% 0.23 21 
     Aged 20+ 85% 0.57 11 
Females (not sex workers)    
     Aged <20 55% 0.12 32 
     Aged 20+ 70% 0.23 21 
Sex workers 90% 0.90 7 
 
Studies also suggest that men and women differ in terms of the sources from which 
they seek treatment. Women are more likely than men to seek treatment from public 
health facilities, while men are more likely than women to seek treatment from private 
practitioners, traditional healers and the ‘informal’ health sector (Voeten et al, 2004; 
Moses et al, 1994; Ndhlovu et al, 2005). South African studies suggest that just over 
half of STI cases are treated in the public health sector, between 5% and 20% are 
treated by traditional healers, and the balance of about a third are treated in the formal 
private health sector (Wilkinson et al, 1998; Wilkinson and Wilkinson 1998; Wilson 
et al, 2000; Ndhlovu et al, 2005). Antibiotic access is tightly controlled in South 
Africa (Hudson 1999), and it is therefore unlikely that other ‘informal’ providers of 
STI treatment would treat significant numbers of STI patients. It is assumed that the 
public health sector treats 45% of male STI cases and 60% of female STI cases, and 
that the private health sector treats 40% and 30% of male and female STI cases 
respectively. The remainder of STI cases (15% in men and 10% in women) are 












3.3.4.2 Use of syndromic management protocols 
 
Prior to 1994, syndromic management protocols were not used in the treatment of 
STIs in South Africa. Syndromic management protocols were introduced rapidly in 
public health facilities after 1994, and by 1999 almost all public STI clinics were 
following these protocols (D. Coetzee, personal communication). However, drug 
shortages and heavy patient loads at some public STI clinics have limited capacity to 
implement syndromic management protocols (Sonko et al, 2003), and surveys suggest 
that even when syndromic management protocols are in use, nurses do not necessarily 
prescribe the correct number of effective drugs at the correct dosage. Recent surveys 
suggest, for example, that only about 70% of nurses know the correct syndromic 
treatment for genital ulcer disease and roughly 85% know the correct treatment for 
male urethral discharge and vaginal discharge (Ramkissoon et al, 2004; Reagon et al, 
2004). Proportions of public clinics reporting shortages of STI drugs have declined 
from around 10% in 1998 (Pick et al, 1998) to less than 5% since 2002 (Ramkissoon 
et al, 2004; Reagon et al, 2004), and greater reductions in drug shortages probably 
occurred prior to 1998. The proportions of clinics using syndromic management 
protocols correctly, assumed on the basis of these studies, are shown in Table 3.3.13. 
 
The private health sector has been relatively slow to introduce syndromic 
management protocols in STI treatment, partly due to the high costs of treating STI 
patients with multiple drugs, and partly due to the lack of training provided to private 
practitioners regarding syndromic management. A national survey of private 
practitioners, conducted in 1997, found that the number of practitioners who 
prescribed the correct number of effective drugs for a particular syndrome varied 
between 4% and 29% (Dartnall et al, 1997). More recent studies in Gauteng suggest 
that there have been slight improvements in the use of syndromic management 
protocols (Chabikuli et al, 2002; Schneider et al, 2005b), and Schneider et al (2005b) 
found that private practitioners who had qualified since the development of syndromic 
management protocols in 1993 provided significantly more effective treatment than 
those who had qualified previously. This suggests that the proportion of private 
practitioners treating STIs according to syndromic protocols will continue to increase 
gradually in future, as the proportion of practitioners who have received education in 











3.3.13; these proportions are assumed to increase by 2% (absolute) per annum after 
2003. 
 
Table 3.3.13: Assumed use of syndromic management protocols 
Year 









1993 0% 0% 20%  
1994 3% 10% 20%  
1995 7% 30% 18%  
1996 11% 50% 16% Harrison et al (1998)* 
1997 15% 65% 13% Dartnall et al (1997)† 
1998 18% 75% 10% Pick et al (1998)* 
1999 21% 78% 8% Chabikuli et al (2002)† 
2000 23% 80% 6%  
2001 25% 80% 5% Schneider et al (2005b)† 
2002 27% 80% 4% Ramkissoon et al (2004)*
2003 29% 80% 4% Reagon et al (2004)* 
* Public health sector. † Private health sector. 
 
3.3.4.3 Effectiveness of treatment 
 
Prior to the introduction of syndromic management protocols, STI treatment in Africa 
was based mainly on clinical diagnosis, which was often inaccurate. Surveys of health 
workers’ prescriptions for common STI syndromes prior to the introduction of 
syndromic management suggest that more than half of syphilis, gonorrhoea and 
chlamydial cases were appropriately treated (Somsé et al, 2000; Buvé et al, 2001a; 
Chilongozi et al, 1996; Mathews et al, 1998; Chabikuli et al, 2002). Treatment of 
other causes of vaginal discharge (bacterial vaginosis, trichomoniasis and candidiasis) 
was found to be appropriate in roughly half of cases in a Central African Republic 
study (Somsé et al, 2000), higher than in a South African study (Mathews et al, 
1998). In another South African study, treatment of male urethral discharge was found 











Although there are no South African estimates of appropriateness of treatment for 
chancroid prior to syndromic management, it appears that early treatment protocols 
were effective in many chancroid cases (Department of National Health and 
Population Development 1991; Ye et al, 2007). These studies provide some clues 
regarding the appropriateness of treatment prior to the adoption of syndromic 
management protocols in South Africa, but there remains much uncertainty, and the 
model parameters determining the appropriateness of treatment have therefore been 
included in the Bayesian uncertainty analysis. For each STI, a beta prior distribution 
was specified for the proportion treated appropriately, with means and standard 
deviations shown in Table 3.3.14. 
 
It is assumed that health workers following syndromic management guidelines would 
treat appropriately all STIs, with three exceptions. Firstly, South African syndromic 
management guidelines do not include treatment of genital herpes in the management 
of genital ulcer disease (Department of Health 2003), although recent WHO protocols 
recommend the inclusion of antiviral treatment in the management of genital ulcer 
disease in countries with a high HSV-2 prevalence (World Health Organization 2003). 
It is therefore assumed that genital herpes is not treated at all under syndromic 
management guidelines. Secondly, most protocols recommend that treatment for male 
urethral discharge include drugs effective against trichomoniasis only as a second-
line, i.e. only if treatment against gonorrhoea and chlamydial infection proves 
ineffective (World Health Organization 2003). It is therefore assumed that only half 
of symptomatic male trichomoniasis cases are correctly treated under syndromic 
management (on the optimistic assumption that all men would return to the same 
provider to be retreated if their symptoms did not resolve). Lastly, syndromic 
management guidelines generally recommend that antifungal treatment against 
vulvovaginal candidiasis only be provided if the disease is clinically suspected (i.e. if 
there is vulval oedema, erythema and/or a curd-like discharge). This is effectively no 
different from standard treatment practices prior to the introduction of syndromic 
management, and the assumed proportion of cases that are appropriately treated is 
therefore the same as that prior to syndromic management. 
 
If appropriate antibiotic treatment is prescribed, it is assumed that the probability of 











(Ballard et al, 1990), gonorrhoea (Moodley et al, 2003b; Rustomjee et al, 2002), 
chlamydial infection (Moodley et al, 2003b; Rustomjee et al, 2002) and 
trichomoniasis (Moodley et al, 2003b). In the cases of bacterial vaginosis and 
vulvovaginal candidiasis, separate parameters determine the probability of ‘complete 
cure’ and ‘partial cure’. For bacterial vaginosis, ‘complete cure’ is defined as having 
normal vaginal flora after treatment and ‘partial cure’ is defined as having 
intermediate vaginal flora. The rates of cure are set on the basis of a study of pregnant 
women with baterial vaginosis, of whom 22% still had bacterial vaginosis and 60% 
had normal vaginal flora two to four weeks after receiving metronidazole treatment 
(Klebanoff et al, 2004). In the case of vulvovaginal candidiasis, ‘complete cure’ is 
defined as resolution of both symptoms and yeast infection after treatment, and 
‘partial cure’ is defined as resolution of symptoms without clearance of yeast 
infection. The effectiveness parameters are based on a number of studies of the 
effectiveness of antifungal treatment (del Palacio et al, 2000; Brown et al, 1986; El-
Din et al, 2001). Treatment provided by traditional healers is assumed not to be 
effective for any of the STIs. 
 
Table 3.3.14: Assumed effectiveness of treatment 
Parameter HSV-2 TP HD NG CT TV BV VC 
% cases correctly treated 















% cases treated under SM         
     Male 0% 100% 100% 100% 100% 50% - - 
     Female 0% 100% 100% 100% 100% 100% 100% 50%a 
Probability of cure if 
     effective drugs prescribed 




Probability of cure if treated 
     by traditional healer 
0 0 0 0 0 0 0 0 
BV = bacterial vaginosis. CT = Chlamydia trachomatis (chlamydial infection). HD = Haemophilus 
ducreyi (chancroid). NG = Neisseria gonorrhoeae (gonorrhoea). SM = syndromic management. TP = 
Treponema pallidum (syphilis). TV = Trichomonas vaginalis (trichomoniasis). VC = vaginal 
candidiasis 
a The value is the same as that simulated to represent practice pre-SM. b Complete cure. c Partial cure. 
 
Symptoms that occur during secondary syphilis are extremely variable, and do not 











that the individuals who seek treatment for secondary syphilis are only half as likely 
to be cured as the individuals who seek treatment for primary syphilis. 
 
3.3.4.4 Treatment of asymptomatic infection 
 
The model does not allow for treatment of asymptomatic STIs, except in two special 
cases: antenatal screening for syphilis and treatment of STIs in sex workers. 
 
The rates at which women are screened for syphilis are determined by their fertility 
rates, i.e. the rates at which women are screened for syphilis are assumed to be 
proportional to their age-specific fertility rates. South African studies suggest that on 
average around 75% of pregnant women receive screening for syphilis, though rates 
are extremely variable (Jackson et al, 2007; Dawadi et al, 2001; Searle et al, 2003). 
Of those women who are screened for syphilis and test positive, the proportion who 
receive treatment varies between 57% and 96% (Bam et al, 1994; Swingler and van 
Coeverden de Groot 1993; Wilkinson and Sach 1998; Myer et al, 2003; Dawadi et al, 
2001). It is assumed that the proportion of pregnant women who are screened is 75% 
and the proportion of those testing positive who receive treatment is 80%. As is the 
case for treated symptomatic syphilis, treatment is assumed to be effective in 90% of 
cases. The rate at which women are cured of syphilis through antenatal screening is 
therefore 54% (75% × 80% × 90%) of their age-specific fertility rate. 
 
Because sex workers are highly exposed to STIs, they are likely to seek treatment for 
STIs at a much higher frequency than the rest of the population. It is therefore realistic 
to assume that asymptomatic STIs in sex workers would resolve more rapidly than 
asymptomatic STIs in other women, due to frequent receipt of treatment for other 
symptomatic STIs, which will in some cases be effective against the asymptomatic 
STI. Studies of sex workers in other African countries suggest that between 5% and 
17% of sex workers seek STI treatment every month (Morison et al, 2001). On the 
basis of this evidence, it is assumed that asymptomatic STIs in sex workers are treated 
at a rate of 0.025 per week. Since this treatment is not directed specifically at the 















The model was initially programmed in Excel/VBA. As this model was too slow for 
the purpose of the Bayesian uncertainty analysis, it was reprogrammed in Visual C++ 
.NET. A reconciliation of the C++ and Excel models was performed, by projecting 
both models for 40 years and comparing 27 arbitrarily chosen model outputs at the 
end of this projection period. The largest difference in outputs was 0.012%, which is 
likely to be due to rounding differences between Excel and C++. 
 
For the purpose of the uncertainty analysis, two libraries of C++ functions were 
copied into the C++ code. The DCDFLIB library (downloaded on 4 March 2005 from 
http://www.csit.fsu.edu/~burkardt/cpp_src/dcdflib/dcdflib.html) is used for its 
statistical functions, notably the cumulative beta and gamma distributions. The 
‘randomc’ library (downloaded from http://www.agner.org/random/randomc.htm on 3 
May 2005) is used to generate random numbers from the uniform (0,1) distribution. 
The ‘Mersenne Twister’ random number generator is used for this purpose. 
 
3.5 Strengths and limitations 
 
The model presented here follows a deterministic frequency-dependent approach to 
sexual behaviour and STI transmission. Although the pair-formation approach might 
be more realistic (Eames and Keeling 2002; Lloyd-Smith et al, 2004), a pair-
formation approach would probably not be computationally feasible when attempting 
to model interactions between HIV and other STIs. For example, if one were to model 
gonorrhoea using a four-state process and HIV using a six-state process in a very 
simple two-sex model, the total number of cohorts one would need to define in a 
frequency-dependent model would be 4 × 6 = 24 for each sex, i.e. 48 in total. Using a 
pair-formation approach, however, one would need to define couple cohorts for all 
possible permutations of HIV and gonorrhoea infections states in both partners, i.e. 24 
× 24 couple cohorts, plus 24 cohorts for single individuals of both sexes – a total of 











would require an even greater number of cohorts (Ferguson and Garnett 2000; Bauch 
and Rand 2000; Eames and Keeling 2004), which would clearly not be feasible. 
 
The model presented here avoids the serial monogamy assumption implicit in most 
frequency-dependent models. In addition to stratifying the population on the basis of 
rates of partnership formation (the conventional approach in frequency-dependent 
models), the model stratifies the population on the basis of the actual number of 
current partners, the risk groups of partners and the nature of partnerships 
(spousal/non-spousal), allowing individuals to move between these strata as they form 
new partnerships, marry and separate. This more realistic approach has several 
advantages over the approach conventionally adopted in deterministic models. Firstly, 
it allows a more detailed assessment of which sexual behaviours are contributing most 
to the spread of HIV and other STIs, and which forms of behaviour change would 
have the greatest impact. Secondly, sexual behaviour data can be used to determine 
model parameters more reliably. STI models have typically been calibrated to 
retrospective data on numbers of partners over some past period (Merli et al, 2006; 
Korenromp et al, 2000b; Garnett et al, 1999), whereas our model is calibrated to data 
on current numbers of partners. These data are arguably more important than 
retrospective data because they provide information on the extent of concurrent 
partnerships, which are considered to be particularly important drivers of HIV 
transmission (Halperin and Epstein 2004). Retrospective data are affected by recall 
bias, and since most surveys ask respondents about the number of partners they have 
had in the last year, rather than the number of new partners in the last year, they 
provide little information on the rate at which new partnerships are formed. 
 
Relatively few previously developed deterministic models allow for the distinction 
between spousal and non-spousal relationships. Sexual behaviour data such as coital 
frequency and condom usage are often reported separately for married and unmarried 
individuals (Kelly 2000; Department of Health 1999; Meekers and Van Rossem 
2005), and a model that distinguishes between spousal and non-spousal relationships 
is capable of incorporating such data more accurately. Our model also assumes that 
spousal and non-spousal relationships differ significantly in their rate of formation, 












Although the model of sexual behaviour is relatively detailed, a number of important 
simplifications have been necessary in the interests of computational speed. It is 
assumed that no individual ever has more than two current sexual partners. Although 
qualitative studies suggest that it is not uncommon for individuals to have more than 
two current partners (Parker et al, 2007; Varga 1997b; Twa-Twa et al, 1997), a recent 
survey in Botswana suggests that the proportion of individuals with more than two 
current partners is only about 1% (Carter et al, 2007). This suggests that extending the 
model to allow for more than two current partners would not change the results 
substantially. Another simplification is the broad division of the population into two 
risk groups: those with a propensity for concurrent partnerships and those who never 
engage in concurrent partnerships. In reality there is likely to be much greater 
heterogeneity; some ‘high risk’ individuals may be involved in multiple partnerships 
for short periods of time on an irregular basis, while others may be inclined towards 
longer-term concurrency. Similarly, some ‘low risk’ individuals may be inclined 
towards long periods of sexual abstinence, while others may be sexually active almost 
all the time, with relatively short gaps between partnerships. Another limitation of our 
model is that it does not allow for ‘casual sex’; although the model allows for non-
spousal relationships and sex between commercial sex workers and clients, once-off 
sexual encounters that do not involve exchange of money are arguably a different type 
of sexual activity. Qualitative studies suggest that casual sex is common in South 
Africa (Parker et al, 2007; Harrison et al, 1997), but there is a lack of quantitative 
data to support this. It may be possible to extend the model to allow for casual sex if 
better data become available in future. 
 
There is also substantial uncertainty regarding several of the sexual behaviour 
parameters. For example, there is little information on sexual behaviour at older ages, 
as most studies report on sexual activity in the 15 to 49 age range. Another set of 
parameters about which there is substantial uncertainty is the commercial sex 
assumptions. Most of the studies on which the sex worker activity assumptions are 
based have been conducted in urban areas or on highways, and the assumed frequency 
of client contact would probably not be appropriate for women who exchange sex for 
money in more remote rural areas or women who engage in transactional sex on an 
infrequent basis (Peltzer et al, 2004). The model parameterization is therefore based 











most of their income by having sex in exchange for money. Alternative definitions of 
commercial sex could yield very different estimates of the prevalence of commercial 
sex activity and the behaviour of commercial sex workers (Morison et al, 2001). 
 
A further limitation of our sexual behaviour model is that age of partner preferences 
are assumed to be independent of risk group preferences, and in addition, age of 
partner preferences are not dynamically updated. This implies that changes in the 
relative sizes of different age groups (as a result of demographic change and the effect 
of AIDS mortality) do not change the distribution of partner ages over time, in any 
given age group. More sophisticated approaches to modelling dependency between 
age mixing and risk group mixing, allowing for dynamic updating, have been 
proposed in several modelling studies (Garnett and Anderson 1993; Hallett et al, 
2007; Pourbohloul et al, 2003). However, model results are generally not very 
sensitive to the assumed form of age mixing (Hallett et al, 2007; Garnett and 
Anderson 1993), and it is therefore unlikely that a more sophisticated approach would 
change our results substantially. 
 
In spite of the sophistication of the model of sexual behaviour, the modelling of STI 
transmission is fairly simple. For a susceptible individual in a given cohort, the 
probability of acquiring infection over a small time interval is assumed to depend on 
the prevalence of infection in the cohort of individuals of the opposite sex with the 
corresponding risk group, partnership type and partner risk group. This means that the 
infection probabilities of individuals and their partners are assumed to be independent, 
conditional upon the risk groups of both partners, the nature of the relationship and 
the numbers of other partners each partner has. This assumption may be unrealistic, 
particularly for STIs with high transmission probabilities, in the context of 
partnerships involving frequent unprotected sex. It has therefore been assumed that 
there is no transmission of bacterial/protozoan STIs in mutually monogamous spousal 
relationships (effectively, it is assumed that if transmission hasn’t occurred in the 
interval between partnership formation and marriage, it wouldn’t occur after 
marriage). The assumption of conditional independence could be justified in non-
spousal relationships if these are characterized by relatively low coital frequency and 
high rates of condom usage (Meekers and Van Rossem 2005). Ultimately, though, the 











comparing the deterministic model described here with a more realistic 
microsimulation model with the same parameter values. 
 
As noted in section 3.1, STIs other than HIV are modelled independently of one 
another, so that in any given individual, the probability of infection with a particular 
STI is assumed to be independent of any other STIs they may have, after controlling 
for the individual’s age, sex, sexual activity state and HIV stage. This is achieved by 
modelling the change in the proportion of individuals in each infection state, for a 
given demographic/behavioural/HIV cohort, separately for each STI. This assumption 
of independence is made in order to reduce the amount of computation and memory 
required. For example, if one was to model interactions between syphilis, genital 
herpes and chancroid (seven-state, five-state and four-state processes respectively), it 
would be necessary to consider all possible permutations of infection states – a total 
of 7 × 5 × 4 = 140 calculations. Modelling the three STIs independently would require 
only 7 + 5 + 4 = 16 calculations. However, the assumption of independence is not 
completely realistic. For example, many studies have noted the strong positive 
associations that exist between bacterial vaginosis and trichomoniasis, even after 
adjusting for confounding behavioural factors (Bukusi et al, 2006; Jamieson et al, 
2001; Cu-Uvin et al, 2002). This may be due to their common treatment 
(metronidazole) or the effect of bacterial vaginosis-associated changes in lactobacilli 
on susceptibility to trichomoniasis (Hillier et al, 1992a; Martin et al, 1999; Hesseltine 
et al, 1942). Studies have also noted significant negative associations between vaginal 
candidiasis and bacterial vaginosis (Eckert et al, 1998; Jamieson et al, 2001; Hillier et 
al, 1992b). These interactions are not allowed for in the model, but could be 
considered in future modelling work. 
 
There exists much uncertainty regarding the STI natural history parameters. In 
addition to the problem of lack of evidence, there is much uncertainty regarding the 
applicability of the available evidence. For example, most of the published studies on 
the natural history of genital herpes are from Seattle, U.S.A., and there are relatively 
few studies from developing countries. Infection with HSV-1 appears to provide some 
protection against symptoms in incident HSV-2 (Stanberry et al, 2002) and chronic 











higher in Africa than in industrialized nations, HSV-2 symptoms may tend to be 
milder in the African setting than the available evidence suggests. Another example is 
primary syphilis: the experience in industrialized nations is that primary syphilis is 
characterized by a single, painless ulcer. South African studies, however, have found 
that between 36 and 75% of primary syphilis cases involve multiple ulcers, many of 
which are painful (Coovadia et al, 1985; Duncan et al, 1984; Duncan et al, 1981; 
Crewe-Brown et al, 1982). In view of the uncertainty regarding the natural history 
parameters, Bayesian techniques that allow for a priori specification of uncertainty 
regarding model parameters are particularly appropriate. 
 
The model has very substantial computational requirements. The sexually experienced 
population is divided into 16 age groups, with 17 sexual activity states for males and 
18 sexual activity states for females, and 6 HIV states considered within each 
subgroup, i.e. a total of 16 × (17 + 18) × 6 = 3 360 possible states. Within each state, 
we calculate the proportion of individuals in each STI state, separately for 6 different 
infections in males and 8 different infections in females, at weekly intervals. This is 
clearly very computationally demanding. When the model was first programmed in 
Excel/VBA, it took approximately 10 hours to run a 20-year projection on a Pentium 
4 with 2 GB of RAM and 2.8 GHz CPU. After reprogramming the model in Visual 
C++, the time taken to run a 20-year projection was reduced to approximately 10 
seconds. However, even at 10 seconds per run, it is not feasible to conduct a Bayesian 
analysis of all sources of uncertainty simultaneously (the analysis in section 4.1, for 
example, shows that even when only 12 of the HIV and sexual behaviour parameters 
are considered, 100 000 simulations are required to achieve convergence). We 
therefore conduct separate Bayesian analyses of different groups of parameters, 
holding other parameters constant at their baseline level or at the levels estimated in 
previous analyses. It is possible to reduce run times by switching off the modelling of 
STIs other than HIV, or by modelling only one STI in addition to HIV, if the effect of 
STIs on HIV transmission probabilities is ignored. This is the approach taken in 
chapter 4, where we first conduct a Bayesian analysis of the HIV and sexual 
behaviour parameters, ignoring other STIs, and then conduct separate Bayesian 
analyses for each STI. The effect of STIs on HIV transmission probabilities is then 











Chapter 4: Estimation of HIV and STI prevalence levels in 
South Africa 
 
This chapter describes the Bayesian techniques used to fit the previously described 
model to the South African HIV and STI prevalence data and sexual behaviour data. 
In addition to showing the resulting predictions of HIV and STI prevalence levels, this 
chapter compares prior and posterior estimates of parameters and assesses the 
correspondence between the model predictions and the survey estimates. Section 4.1 
describes the method used to estimate HIV prevalence, while section 4.2 describes the 
method used in respect of other STIs. Section 4.3 considers alternative models of 
immunity to STIs, and this is followed by a discussion of the results. 
 
4.1 Fitting the model to HIV prevalence data and sexual behaviour 
data 
 
The objective of the initial Bayesian analysis is to identify the sexual behaviour 
parameters and HIV parameters that give the best fit to the HIV prevalence data and 
sexual behaviour data collected in South Africa, before allowing for the effects of 
other STIs on HIV transmission probabilities. Other STIs are initially excluded 
because the addition of other STIs into the model introduces many new sources of 
uncertainty, and it is not practical to consider all sources of uncertainty 
simultaneously. The sections below describe the method used to define the priors and 
the likelihood function and the method used to compute the posterior distribution. 
This is followed by the results of the Bayesian analysis: a comparison of the prior and 
posterior distributions, and a comparison of the model predictions with the 
corresponding survey estimates. 
 
4.1.1 Prior distributions 
 
Twelve parameters are included in the initial Bayesian analysis. With the exception of 
the initial HIV prevalence (discussed below), all of these parameters have been 











been specified (see sections 3.2.2, 3.2.6 and 3.3.2.1). For ease of reference, the prior 
distributions for all 12 parameters are repeated in Table 4.1.1 below. 
 






Male-to-female transmission probability in short-term 
     relationships 
Beta (5.68, 467.6) 0.012, 0.005 
Male-to-female transmission probability in spousal 
     relationships 
Beta (3.99, 1991) 0.002, 0.001 
Female-to-male transmission probability in short-term 
     relationships 
Beta (10.99, 1088) 0.01, 0.003 
Female-to-male transmission probability in spousal 
     relationships 
Beta (3.99, 1991) 0.002, 0.001 
Initial HIV prevalence in high risk group Uniform (0, 0.002) 0.001, 0.00058 
Degree of sexual mixing (ε) Beta (5.8, 3.867) 0.6, 0.15 
Ratio of desired partner acquisition rate in high risk males 
     with 1 short-term partner to that in single high risk males 
Uniform (0, 1) 0.50, 0.29 
Ratio of desired partner acquisition rate in high risk females 
     with 1 short-term partner to that in single high risk females 
Uniform (0, 1) 0.50, 0.29 
Ratio of desired partner acquisition rate in high risk males 
     with 1 spousal partner to that in single high risk males 
Uniform (0, 1) 0.50, 0.29 
Ratio of desired partner acquisition rate in high risk females 
     with 1 spousal partner to that in single high risk females 
Uniform (0, 1) 0.50, 0.29 
Ratio of desired partner acquisition rate in single low risk 
     males to that in single high risk males 
Uniform (0, 1) 0.50, 0.29 
Ratio of desired partner acquisition rate in single low risk 
     females to that in single high risk females 
Uniform (0, 1) 0.50, 0.29 
 
The HIV/AIDS epidemic in South Africa is ‘started’ by assuming a low initial 
prevalence of HIV in all individuals in the high risk group in the 15-49 age range in 
1985 (in all other age groups and in the low risk group, the initial HIV prevalence is 
assumed to be 0). Surveys conducted between 1985 and 1987 found no evidence of 
HIV in the general population (Abdool Karim and Abdool Karim 1992; Hoosen et al, 
1989; O'Farrell et al, 1989), and in an early survey of 56 sex workers and 195 STI 
clinic attenders, only one HIV case was identified (Schoub et al, 1987). Considering 











and this grew by a multiple of 1.8 in each of the next two years (Küstner et al, 1994), 
it is unlikely that HIV prevalence in pregnant women in 1985 would have been more 
than 0.04% ( 58.10076.0 −× ), since the early antenatal surveys were biased towards 
urban areas in which HIV prevalence was relatively high. Assuming that 25% of 
pregnant women were in the high risk group (in line with the model assumption), the 
prevalence of HIV in these high risk women would therefore probably have been less 
than 0.16%. The initial HIV prevalence in the 15-49 high risk group has therefore 
been assigned a uniform (0, 0.002) prior. 
 
4.1.2 Likelihood formulation 
 
In the initial uncertainty analysis, three data sources are considered in defining the 
likelihood function: HIV prevalence data from the national antenatal clinic surveys, 
HIV prevalence data from the 2005 HSRC household survey, and sexual behaviour 
data from the 2005 HSRC household survey. The formulation of the likelihood in 
respect of each of these data sources is described in the sections that follow. 
 
(a) Antenatal clinic data 
 
Suppose that ( )φtxH ,  represents the prevalence of HIV that we would expect to 
measure in pregnant women aged x to x + 4, in year t, based on the model predictions 
when the input parameters are represented by vector φ . Further suppose that the 
corresponding prevalence of HIV measured in the survey is tx,ζ . It is assumed that if 
φ  is the true set of parameter values, then the difference between the logit-
transformed model prediction and the logit-transformed observed prevalence is 
normally distributed. The mean of this normal distribution represents the extent of 
antenatal bias. The variance of the distribution is assumed to be composed of a 
‘survey error’ term, representing the uncertainty around the survey estimate due to 
binomial variation and cluster variation in the survey, and a ‘model error’ term. The 
latter term is included in many analyses (e.g. Sevcikova et al (2006) and Raftery et al 
(2003)) to represent differences between true population means and model predictions 




















































,   (4.1) 
 
where b is the antenatal bias parameter, ( )2, ,0~ ϖσϖ Ntx  and ( )2,, ,0~ txtx N σε . The 
latter two terms represent the model error and the survey error respectively. The logit 
transformations ensure that the error terms are closer to normality and the model error 
terms are roughly independent of the level of HIV prevalence. For a given parameter 



















































,   (4.2) 
 
where Y is the number of antenatal prevalence estimates to which the model is 
calibrated. The 2,txσ  values are estimated from the 95% confidence intervals that have 
been published for the various survey estimates. Once these have been obtained, the 
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The likelihood in respect of observation tx,ζ  is then calculated based on the 
assumption that the error terms are normally distributed: 
 
 ( )




















































The aggregate likelihood for the antenatal clinic data is then calculated by taking the 
product of the ( )φ|,txL ζ  values across age bands 15-19 to 35-39, and across calendar 
years 1997 to 2005. Antenatal survey data collected prior to 1997 and after 2005 were 
not included, as these were obtained using different survey protocols, and are 
therefore (potentially) subject to different levels of antenatal bias. Prior to 1997, for 
example, the antenatal surveys were biased towards antenatal clinics in urban areas 
(Abdool Karim et al, 1997; Webb 1994), which may have led to some over-estimation 
of HIV prevalence in pregnant women generally. Confirmatory HIV testing was also 
discontinued after the 1996 survey (Department of Health 1997; Department of 
Health 1998), which may have led to a change in bias due to false positive reactions 
on ELISA tests. Another reason for excluding the antenatal data collected prior to 
1997 is that the 95% confidence intervals around the published prevalence estimates 
did not take into account the clustering in the survey design (Department of Health 
1997), and the 2,txσ  values therefore cannot be reliably determined from the published 
estimates. 
 
(b) HSRC prevalence data 
 
The approach to defining the likelihood function is the same as for the antenatal data, 
except that the bias term (b) and model error term (ϖ ) are both omitted. The model 
error term is omitted because the 95% confidence intervals around the HIV 
prevalence estimates are very wide, and introducing a model error term therefore 
reduces the weight given to the HSRC data to unreasonably low levels. The omission 
of the bias term is consistent with the approach adopted in other uncertainty analyses 
of HIV data in developing countries (Morgan et al, 2006), in which it is assumed that 
household prevalence data provide an unbiased estimate of HIV prevalence in the 
general population. The plausibility of this assumption is questionable in the case of 
the 2002 HSRC household survey, which had a low response rate (71% of households 
visited were interviewed and 58% of eligible individuals agreed to be tested) and did 
not include confirmatory HIV testing (Human Sciences Research Council 2002). The 
2005 HSRC survey, on the other hand, achieved a higher rate of response (84% of 
households visited were interviewed and 65% of eligible individuals agreed to be 











(Shisana et al, 2005). The present analysis is therefore based only on the data 
collected in the 2005 household survey, and the 2002 data are not considered in 
defining the likelihood function. The likelihood is calculated separately for males and 
females, for each age band from 15-19 up to 55-59. 
 
(c) Sexual behaviour data 
 
Three types of sexual behaviour data are incorporated in the uncertainty analysis: 
• Proportions of sexually experienced unmarried individuals who report more 
than one current sexual partner, 
• Proportions of sexually experienced married individuals who report more than 
one current sexual partner, and 
• Proportions of sexually experienced unmarried individuals who report no 
current partner. 
The data were collected in face-to-face interviews (FTFIs) during the 2005 HSRC 
household survey, and the proportions (together with 95% confidence intervals) have 
been calculated separately for males and females, for each of five age groups (15-24, 
25-34, 35-44, 45-59 and 60+)4. The method used to define the likelihood is similar to 
that used to define the antenatal likelihood function: the difference between the logit-
transformed survey proportion and the logit-transformed model estimate is assumed to 
be comprised of a bias term and a survey error term. However, there is no model error 
term, as the 95% confidence intervals around the reported proportions are wide 
enough to include most model predictions, once adjusted for bias.  
 
As with the other data sources, the variance of the survey error term is estimated from 
the 95% confidence interval around the reported proportion. The bias terms have been 
estimated separately for each sex and for each of the three types of sexual behaviour 
data, using a formula analogous to that in equation (4.2).  
 
                                                 











4.1.3 Posterior simulation 
 
The posterior density cannot be evaluated analytically, since it is necessary to run the 
model in order to obtain the likelihood for a single set of φ  values. The posterior 
density is therefore simulated numerically using the Metropolis algorithm, a Markov 
Chain Monte Carlo technique that is commonly used in Bayesian analysis (Gelman et 
al, 2004). The steps listed below follow closely those recommended by Gelman and 
colleagues: 
 
1. An initial sample of 1 000 parameter combinations was drawn from the prior 
distributions described in 4.1.1, the likelihood was calculated for each 
parameter combination, and ten parameter combinations were sampled 
(without replacement) from the initial set of 1 000 combinations, using the 
likelihood functions as weights. This sample of 10 parameter combinations 
was used to determine the starting points for ten sequences (Markov chains). 
2. For each sequence and for each step of the iteration, an alternative parameter 
combination was proposed by sampling from a jumping distribution with the 
same mean as the previous parameter combination in the sequence. All 
parameters were logit-transformed so that the jumping distribution could be 
assumed to take the form of a multivariate normal distribution. The posterior 
value (the product of the likelihood and the prior) was calculated for the 
proposed parameter combination and compared to that of the previous 
parameter combination in the sequence. If the posterior value of the new 
parameter combination was greater than that of the old, it was accepted as the 
next parameter combination in the sequence. If not, it was accepted with 
probability proportional to the ratio of its posterior value to that of the 
posterior value of the previous parameter combination. If the proposed 
parameter combination was rejected, the parameter combination for the 
iteration was set equal to that for the previous iteration. 
3. The covariance matrix of the jumping distribution was updated at regular 
intervals, (a) to ensure that the acceptance rate lay between 0.1 and 0.4, and 
(b) to ensure that correlations between parameters were adequately reflected. 











acceptance rate (calculated for all ten sequences) was above 0.4, and were 
multiplied by 0.25 if the acceptance rate was below 0.1. This continued until 
the 2000th iteration. At every 200th iteration, the covariance matrix was 
recalculated from the latter half of the iterations up to that point (for all ten 
sequences combined), and multiplied by the covariance scaling factor of 
12/4.2 2 . This continued until the 1400th iteration. These adjustments to the 
jumping distribution improve the efficiency of the algorithm and are 
acceptable as long as they are confined to the burn-in phase of the algorithm. 
4. A total of 10 000 iterations were performed for each sequence, and 
convergence over the last half of the iterations was checked. The parameter 
combinations generated over the burn-in phase (the first 5 000 iterations of 
each sequence) were discarded, and the remaining iterations were thinned by 
drawing every 50th parameter combination. This yielded a posterior sample of 
1 000 parameter combinations. 
 
Convergence of the Metropolis algorithm is generally considered to have been 
reached when the scale reduction factor R̂  (a function of the ratio of the variation 
between sequences to the average variation within sequences) is below the threshold 
1.1, for each of the parameters of interest (on the transformed scale) and for the log-
transformed posterior values. Table 4.1.2 shows that this convergence criterion has 
been satisfied, and the parameter combinations sampled therefore provide a good 












Table 4.1.2: Scale reduction factors calculated for the last 5 000 iterations 
Parameter R̂  
Posterior value 1.0313
Male-to-female transmission probability in short-term relationships 1.0072
Male-to-female transmission probability in mutually monogamous spousal 
     relationships 
1.0096
Female-to-male transmission probability in short-term relationships 1.0090
Female-to-male transmission probability in mutually monogamous spousal 
     relationships 
1.0038
Initial HIV prevalence in high risk group 1.0271
Degree of sexual mixing (ε) 1.0277
Ratio of partner acquisition rate in high risk males with 1 short-term 
     partner to that in single high risk males 
1.0122
Ratio of partner acquisition rate in high risk females with 1 short- 
     term partner to that in single high risk females 
1.0152
Ratio of partner acquisition rate in high risk males with 1 spousal 
     partner to that in single high risk males 
1.0105
Ratio of partner acquisition rate in high risk females with 1 spousal 
     partner to that in single high risk females 
1.0081
Ratio of partner acquisition rate in single low risk males to that in 
     single high risk males 
1.0105
Ratio of partner acquisition rate in single low risk females to that in 
     single high risk females 
1.0190
 
4.1.4 Comparison of prior and posterior distributions 
 
Prior and posterior distributions for the probabilities of HIV transmission per sex act 
are compared in Figure 4.1.1. The prior and posterior distributions are reasonably 
similar in the case of the HIV transmission probabilities in spousal relationships, but 
are very different in the context of non-spousal relationships. For both male-to-female 
and female-to-male transmission, the posterior mean transmission probability in non-















































































































































































































































































































































































































Figure 4.1.1: Prior and posterior distributions for HIV transmission probabilities (per 
sex act)  
Prior distributions have been scaled to be comparable with posterior histogram plots. 
 
The posterior distribution for the initial proportion of the high risk group that is HIV-
positive is compared with the corresponding uniform prior in Figure 4.1.2(a). The 
data suggest that the initial prevalence of HIV in the high risk group is close to 0.2%. 
The posterior distribution for the sexual mixing parameter is similar to the prior 

































































































































































Figure 4.1.2: Prior and posterior distributions for initial HIV prevalence in high risk 
group and sexual mixing parameter 
Prior distributions have been scaled to be comparable with posterior histogram plots. 
 
Posterior distributions for the remaining sexual behaviour parameters are shown in 
Figure 4.1.3. The posterior distributions suggest that among high risk women, there is 
little reduction in the rate of partner acquisition if the woman is already in a non-
spousal relationship, but there is a very substantial reduction in the rate of partner 
acquisition if the woman is in a spousal relationship. Women in the low risk group 
have a slightly lower rate of partner acquisition than their counterparts in the high risk 
group. Men in the low risk group, on the other hand, tend to have rates of partner 




















































































































































































































































































































Figure 4.1.3: Prior and posterior distributions for rates of partner acquisition, 
expressed as a multiple of the corresponding rates in single high risk individuals 
Prior distributions have been scaled to be comparable with posterior histogram plots. 
 
4.1.5 Comparison of model predictions and survey estimates 
 
Figure 4.1.4 compares the levels of HIV prevalence measured in the national antenatal 
clinic surveys with the corresponding posterior mean estimates of HIV prevalence in 
pregnant women. Following the approach of Sevcikova et al (2006), the posterior 
model estimates have been adjusted to reflect the antenatal bias. Although data from 
the 1990-1996 and 2006 surveys were not used in defining the likelihood function, 











posterior means in 2006 and before 1997 should be interpreted as the antenatal 
prevalence that would be predicted if the antenatal bias in these years were the same 
as that over the 1997-2005 period. Although the change in antenatal bias is unknown, 
the model predictions are reasonably consistent with the survey estimates over these 
periods. Age-specific comparisons of posterior means and antenatal survey results 
(Figures 4.1.4(b)-(f)) show that a high proportion of model predictions lie outside of 
the published 95% confidence intervals, and it is for this reason that it is necessary to 


































































































Figure 4.1.4: HIV prevalence in pregnant women attending public antenatal clinics 
Reported prevalence levels represented by closed circles (with 95% confidence intervals) if used to 
define the likelihood function, or by open diamonds if not used in likelihood definition. Mean of 
posterior distribution represented by solid black line.  
 
Figures 4.1.5(a) and (b) compare the HIV prevalence levels observed in the 2005 











posterior predictions are reasonably consistent with the survey results, both in males 
and females. Although the results of the 2002 HSRC household survey were not 
included in the definition of the likelihood, the posterior estimates for 2002 are 
compared with the 2002 survey results in Figures 4.1.5(c) and (d). The model 
predictions are reasonably consistent with the 2002 survey results. However, in both 
the 2002 and 2005 surveys, the prevalence of HIV among males aged 15 to 19 was 
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Figure 4.1.5: HIV prevalence in the general population 
Reported prevalence levels represented by closed circles (with 95% confidence intervals) if used to 
define the likelihood function, or by open diamonds if not used in likelihood definition. Mean of 
posterior distribution represented by solid black line. 2.5 and 97.5 percentiles of posterior distribution 
(95% prediction intervals) represented by dashed lines. 
 
The model HIV prevalence estimates are also validated by comparison with HIV 
prevalence estimates from the 2003 Reproductive Health Research Unit/loveLife 
youth survey (Fig 4.1.6(a)) and estimates of HIV prevalence in studies of commercial 
sex workers (Fig 4.1.6(b)). As with the 2002 and 2005 HSRC surveys, the RHRU 
survey measured a higher HIV prevalence among males aged 15 to 19 than predicted 
by the model. Model estimates of HIV prevalence in sex workers tend to be slightly 
higher than those measured in surveys, but most survey estimates are roughly 











workers measured by Leggett (2001), 43%, may be due to over-representation of non-
African sex workers in this study. 
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Figure 4.1.6: HIV prevalence among youth and sex workers 
Survey estimates in panel (a) are from the 2003 RHRU/loveLife youth survey (Pettifor et al, 2005b), 
and survey estimates in panel (b) are from studies of sex workers (Schoub et al, 1987; Ramjee et al, 
2005; Dunkle et al, 2005; Leggett 2001; Williams et al, 2000; Ndhlovu et al, 2005). In the second 
panel, posterior means are represented by the solid black line and 95% prediction intervals are 
represented by dashed lines. Open diamonds represent survey estimates. 
 
Model predictions of proportions of individuals with more than one current partner or 
no current partner are compared with the corresponding results from the 2005 HSRC 
household survey in Figure 4.1.7. Only the means of the posterior distributions are 
shown, as the 95% prediction intervals are very narrow.  The average posterior model 
estimates of proportions of individuals with different numbers of partners are 




















15-24 25-34 35-44 45-59 60+












15-24 25-34 35-44 45-59 60+











15-24 25-34 35-44 45-59 60+








15-24 25-34 35-44 45-59 60+











15-24 25-34 35-44 45-59 60+












15-24 25-34 35-44 45-59 60+
 
Figure 4.1.7: Sexual behaviour of sexually experienced individuals 
Reported proportions represented by closed circles (with 95% confidence intervals). Mean of posterior 
distribution represented by solid black line.  
 
Although marriage data have not been used in defining the likelihood function, it is 
useful to validate the model against survey estimates of proportions of individuals 
who are married or in cohabiting relationships. Figure 4.1.8 compares the model 
estimates of the proportions of the population in long-term relationships with the 
results from the 1996 census, 2001 census and 2007 community survey5. In all cases, 
the proportions compared are the proportions of individuals who are married or in 
cohabiting relationships. These posterior means are reasonably consistent with the 
proportions reported in the three surveys, although in the 1996 census the proportions 
of older women who reported being in spousal relationships were higher than 
estimated by the model. In addition, the proportions of individuals in spousal 
relationships in the 2007 community survey are lower than those predicted by the 
                                                 











model. This may be due to declining rates of entry into marriage over time (Garenne 















































































































































































































































































































































Figure 4.1.8: Proportions of individuals who are married or in cohabiting relationships 
Mean of posterior distribution represented by solid black line. Reported proportions married or in 
cohabiting relationships represented by open diamonds. 
 
4.1.6 Posterior model estimates of the impact of HIV/AIDS in South Africa 
 
Having fitted the model and validated the model against various data sources, we now 
present summary outputs of the model. Figure 4.1.9(a) shows that HIV prevalence 
levels in South Africa have risen rapidly over the last two decades, with an estimated 
10.1% (95% prediction interval: 9.4-10.9%) of the population infected in 2005. HIV 
prevalence levels in 2005 are estimated to be particularly high in the 15 to 49 age 











substantially higher in adult women than in adult men in 2005, at 19.8% and 14.0% 
respectively (Figures 4.1.9(c) and (d)). Although HIV prevalence levels have risen 
steadily up to 2005, HIV incidence appears to have been on the decline since 1999, 
partly due to the rising levels of condom use assumed in the model and partly due to 
the natural course of the HIV/AIDS epidemic. Figure 4.1.9(e) shows that by 2005, 
HIV incidence rates had dropped to 1.2% of the uninfected population per annum. 
AIDS mortality rates in South Africa appear to be levelling off, mainly as a result of 
the rapid rollout of antiretroviral treatment in the public health sector (Figure 
4.1.9(f)). 
































































































































































































Figure 4.1.9: Trends in HIV prevalence, HIV incidence and AIDS mortality 
Mean of posterior sample is represented by solid black line and 95% prediction intervals are 












4.2 Fitting the model to STI prevalence data 
 
Having fitted the model to HIV prevalence data and sexual behaviour data, we now 
have reasonable estimates of the sexual behaviour and HIV parameters in the model. 
The next step is to estimate trends in STI prevalence over time, given the previous 
estimates of sexual behaviour and HIV parameters. The approach adopted in fitting 
the model to STI prevalence data is again Bayesian. The sources of uncertainty are the 
STI natural history, STI transmission and STI treatment parameters (the prior 
distributions for these parameters are specified in Tables 3.3.1-3.3.9 and 3.3.14). The 
sexual behaviour and HIV parameters are fixed at the posterior means estimated in 
section 4.1. As in section 4.1, the effects of STIs on HIV transmission probabilities 
are ignored, and the projected HIV and demographic outcomes are thus the same 
across all the scenarios considered. The sections that follow describe the STI 
prevalence data sources, the method used to define the likelihood, and the method 
used to simulate the posterior distribution. This is followed by a presentation of the 
results: a comparison of the prior and posterior distributions for each STI, and a 
comparison of the model predictions with the levels of STI prevalence measured in 
various surveys. 
 
4.2.1 Data sources 
 
Unlike HIV, other STIs are seldom monitored in nationally representative surveys. 
Except in the case of syphilis, which is monitored together with HIV in the annual 
national survey of women attending public antenatal clinics, the only STI prevalence 
data available are the data collected in sentinel surveys of individual communities 
(Johnson et al, 2005). For the purpose of the analysis that follows, five types of data 
are considered: 
• STI prevalence data from surveys of women attending antenatal clinics 
• STI prevalence data from surveys of women attending family planning clinics 
• STI prevalence data from surveys of sex workers 
• STI prevalence data from household surveys 












The first three data sources relate only to women, while for the last two sources, data 
are usually published for men and women separately. GUD data are included because 
almost all GUD is due to either herpes, syphilis or chancroid, while data in respect of 
other STI syndromes are excluded because non-ulcerative symptoms are relatively 
non-specific indicators of infection, and discharges can often be caused by organisms 
other than those considered in this analysis (e.g. Mycoplasma genitalium and 
Ureaplasma urealyticum).  
 
South African STI prevalence data were identified through a Medline search, through 
a hand search of the Southern African Journal of Epidemiology and Infection, through 
searches of abstracts of relevant conferences and through an earlier review of STI 
prevalence data in South Africa (Pham-Kanter et al, 1996). This search was 
conducted in 2004 and subsequently published (Johnson et al, 2005). The database of 
STI sentinel surveillance studies has been augmented as new studies were identified, 
and details of the data used in the present analysis appear in Appendix C. In cases in 
which the year of the survey was not stated, the year of the survey was imputed to be 
three years prior to the date of publication if published in a peer-reviewed journal, or 
one year prior to the date of publication if presented at a conference (based on the 
median publication lags for those studies in which the year of the survey was stated). 
 
4.2.2 Likelihood formulation 
 
The objective of this section is to derive an expression for the likelihood of measuring 
a particular STI prevalence level in a particular community, conditional upon a set of 
model estimates that are assumed to represent the true population prevalence of that 
STI at a national level. Suppose that there are J admissible studies in which the 
prevalence of the STI has been measured. For the ith study, available information 
includes the number of individuals tested (ni), the number of individuals who test 
positive (yi) and covariate information (xi). Included in the covariate information is: 
• the year in which the study was conducted (ti), 
• the location in which the study was conducted, 












• the number of individuals tested (ni), and 
• the method used to detect the STI.  
 
Suppose that )(φiM  represents the model estimate of the prevalence of the STI in 
year ti in sub-population si, given a set of assumptions represented by the parameter 
vector φ . This represents the prevalence of the STI that might be expected in a 
randomly selected sentinel site. 
 
A number of technical points regarding the calculation of )(φiM  should be noted. In 
deriving )(φiM  estimates for health facilities, it is necessary to make assumptions 
about relative rates of health facility usage in different groups. Model estimates of STI 
prevalence in antenatal clinic attenders are calculated as a weighted average of the 
age- and HIV stage-specific STI prevalence levels in women, where the weights are 
the numbers of women multiplied by their age- and HIV stage-specific fertility rates. 
Similarly, model estimates of STI prevalence in family planning clinic attenders are 
calculated as a weighted average of the age-specific STI prevalence levels in women, 
where the weights are the numbers of women multiplied by their age-specific rates of 
modern contraceptive usage, as reported in the 1998 DHS (Department of Health 
1999). Model estimates of ulcerative STI prevalence in GUD patients are calculated 
as the number of individuals with symptoms of the ulcerative STI divided by the 
model estimate of the total number of individuals with GUD, on the assumption that 
individuals would seek treatment at the same rate for all ulcers, regardless of their 
aetiology.  
 
A simple approach to defining the likelihood function would be to assume that for the 
ith study, the number of individuals found to be infected with the STI is binomially 
distributed with parameters ni and )(φiM . This approach has two major limitations. 
Firstly, STI prevalence levels are unlikely to be the same in all communities, and thus 
the prevalence of the STI estimated at a national level, )(φiM , is unlikely to be the 
same as the STI prevalence in the sampled community. Variation in STI prevalence 
levels between different communities is therefore likely to be greater than binomial 











sensitive or 100% specific, and hence the number of individuals testing positive in a 
particular sample is not necessarily the number of people who are actually infected. 
Not only do different studies use different diagnostic techniques, but the same 
diagnostic technique can have different sensitivity and specificity profiles in the hands 
of different investigators, depending on their experience, their sample collection 
procedures and their subjective interpretation of the test results. There is thus 
substantial variation in STI prevalence levels between surveys that can be attributed to 
differences in testing procedures. 
 
A better approach to formulating the likelihood would therefore be to specify the STI 
prevalence one expects to measure in study i, θi, as follows: 
 
 ( ) ( )( )iiiiiii SpbMSebM −−−++= 1)(1)( φφθ .   (4.5) 
 
Here bi represents the difference between the actual pr valence in the subpopulation 
from which study i has sampled and the national average. Sei represents the sensitivity 
of the test used in study i, and Spi represents the specificity of the test used in study i. 
Parameter bi accounts for geographical variation in STI prevalence mainly, but it 
could also represent differences in sampling methods between studies and differences 
in sub-populations within the same location. The ‘study effect’ bi is unknown a priori, 
but it might be assumed that it has 0 mean and variance 2bσ . Sei and Spi are also 
random variables, but the mean and variance of these variables can be estimated from 
various studies. Estimates of the expectation and variance of the sensitivity and 
specificity parameters used in this analysis are given for each STI and for each STI 
diagnostic technique in Appendix D.  
 
A limitation of the model represented by equation (4.5) is that the variance in θi due to 
the bi term is the same at all STI prevalence levels. In reality, one might expect less 
variation if the model estimate of prevalence, )(φiM , is close to 0 or 1. In addition, it 
is possible that the addition of bi to )(φiM  could result in a prevalence less than zero 
or greater than one. To avoid both of these problems, a logit transformation is applied 










































 ( ) ( ) ( )iiii SpbfSpSe −+−+= 11      (4.6) 
 
where bi, as before, is assumed to have 0 mean and variance 2bσ . The function ( )ibf  































.     (4.7) 
 
In order to determine the mean and variance of θi, it is necessary to estimate the mean 
and variance of ( )ibf . These can best be approximated using the delta method (Rice 
1995). The third-order Taylor approximation to (4.7) about the mean E[bi] is 
 
 



















  (4.8) 
 
and from this it follows that 
 
 ( )[ ] ( )( ))(5.0)(1)()(E 2 φφφφ iiibii MMMMbf −−+≈ σ ,  (4.9) 
 
if it is assumed that bi is normally distributed. The expectation of θi is then 
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Using the formulas for the moments of the normal distribution with zero mean (Rice 
1995), and the approximate formulas for ( )ibf  and ( )[ ]ibfE  in equations (4.8) and 
(4.9), the variance of ( )ibf  can then be estimated as 
 
 

















The variance of θi is obtained by noting that 
 
 [ ] [ ][ ] [ ][ ]iiiii bb |EVar|VarEVar θθθ += .    (4.12) 
 
From equation (4.6), 
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  (4.13) 
 [ ][ ] ( ) ( )( ) ( )[ ]iiiii bfSpSeb Var1EE|EVar 2−+=θ    (4.14) 
 
These results are obtained by assuming that bi, Sei and Spi are mutually independent. 
Substituting the approximate values of ( )[ ]ibfE  and ( )[ ]ibfVar  into equations (4.13) 
and (4.14), and substituting these results into equation (4.12) gives an approximation 
to the variance of θi. This approximation appears to be reasonable across a range of 
different scenarios, as Table 4.2.1 shows. For each scenario, 10 000 values of Sei and 
Spi were sampled from beta distributions (with means and variances that differed by 
scenario) and 10 000 values of bi were sampled from a normal distribution (with 
standard deviation that differed by scenario). In all cases, the difference between the 












Table 4.2.1: Difference between approximate variance and simulated variance (as a 
percentage of the simulated variance) 
)(φiM  [ ]iSeE  [ ]iSeSD  [ ]iSpE  [ ]iSpSD  2.0=bσ  4.0=bσ  6.0=bσ  
5% 0.75 0.10 0.99 0.008 -1.5% -0.8% -0.4%
5% 0.95 0.03 0.98 0.016 1.3% 0.4% 3.9%
5% 0.95 0.03 0.99 0.008 -2.4% 1.2% -0.7%
15% 0.75 0.10 0.99 0.008 0.5% 2.4% 4.4%
15% 0.95 0.03 0.98 0.016 0.3% -1.4% 4.6%
15% 0.75 0.03 0.99 0.008 0.6% 0.0% 3.3%
25% 0.75 0.10 0.99 0.008 -1.2% 0.0% 0.1%
25% 0.95 0.03 0.98 0.016 1.4% 3.0% 4.4%
25% 0.75 0.03 0.99 0.008 0.3% 2.5% 3.2%
40% 0.75 0.10 0.99 0.008 -0.5% 0.8% -1.9%
40% 0.95 0.03 0.98 0.016 -0.7% -2.7% -0.8%
40% 0.75 0.03 0.99 0.008 -2.1% 3.8% -3.3%
70% 0.75 0.10 0.99 0.008 1.9% -0.4% 1.1%
70% 0.95 0.03 0.98 0.016 -1.3% 1.7% 3.1%
70% 0.75 0.03 0.99 0.008 -2.5% 0.7% -0.2%
SD = standard deviation 
 
Having determined the mean and variance of θi, one can set a beta prior distribution 
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     (4.15) 
 
The prior distribution for θi is then: 
 

























where *φ  is the combination of the vector φ  and the parameter bσ . This is a 
hierarchical Bayesian approach, as the prior distributions on the θi parameters are 
conditional upon the parameter vector *φ , which has a prior distribution of its own 
(Gelman et al, 2004).  
 
To determine the prior distribution on bσ , it is helpful to examine the total variation 
in logit-transformed study prevalence levels for each of six STIs, noting that the total 
variation is likely to be an upper bound on the variance 2bσ , since much of the total 
variation is attributable to variation in study diagnostics, variation in sample types, 
changes in prevalence over time and binomial variation. The standard deviations of 
the logit-transformed prevalence levels are 0.69 for gonorrhoea, 0.55 for chlamydial 
infection, 0.64 for trichomoniasis, 0.86 for syphilis, 0.68 for bacterial vaginosis, and 
0.61 for candidiasis. (Herpes and chancroid are not included, since most of the 
prevalence data for these STIs are from GUD patients, and it will be shown that these 
GUD data cannot be incorporated in the specification of the likelihood.) The prior 
chosen for bσ  is a gamma distribution with mean of 0.3 and standard deviation of 
0.15, as the 97.5 percentile of this distribution is 0.66, which conforms with the upper 

































































The number of individuals testing positive in study i, yi, is assumed to be binomially 
distributed, and thus the likelihood function is 
 











= θθθ 1,| ,     (4.17) 
 
supposing that the θi value is known. However, since the θi value is unknown a priori, 
the likelihood function should be conditional upon only the parameter vector *φ  and 
the covariate information (the xi values), i.e. 
 
 ( ) ( ) ( )∫=
1
0
** ,|,|,| iiiiiiii dxpxypxyp θθθ φφ .   (4.18) 
 
(Note that the likelihood for yi is independent of *φ , conditional upon θi being 
known.) By substituting equations (4.16) and (4.17) into equation (4.18), we find: 
 

















































  (4.19) 
 




























xφy ,  (4.20)* 
 
where x and y represent the vectors of xi and yi values respectively. The likelihood is 
thus a function of the numbers tested and the numbers testing positive in each study, 
as well as the iα  and iβ  parameters (calculated from equations (4.15) and (4.16)), 
which are the parameters of the beta priors on the θi parameters. The parameters of the 
beta priors are in turn a function of the level of prevalence predicted by the model 
                                                 











( )(φiM ), the assumed variance of the study effects, and the assumed means and 
variances of the diagnostic performance characteristics. 
 
The approach to defining the likelihood is modified slightly in the case of bacterial 
vaginosis, as this condition is usually diagnosed using Nugent’s scoring method 
(Nugent et al, 1991), and there is no objective benchmark against which the 
sensitivity or specificity of this technique can be assessed. The scoring method is 
nevertheless subjective, and there is variation between raters’ assessments of Nugent 
scores (Nugent et al, 1991; Joesoef et al, 1991; Nelson et al, 2003). Equation (4.6) 
can therefore be reformulated as 
 
 ( )( ) iiii NSbM += )(logitlogit -1 φθ ,     (4.21) 
 
where NSi is the factor by which the Nugent score prevalence in study i differs from 
the average Nugent score prevalence that would be obtained if a large number of 
investigators were to examine independently the s me specimens. The mean of NSi is 
1, and its standard deviation is estimated to be 0.087, based on empirical estimates of 
variation between clinicians (Nugent et al, 1991; Joesoef et al, 1991; Nelson et al, 
2003). The approach adopted is therefore the same as before, but with [ ]iNSVar  
taking the place of [ ]iSeVar , and [ ]iSeE , [ ]iSpE  and [ ]iSpVar  being replaced by 1, 1 
and 0 respectively. 
 
The method used to define the likelihood is not applicable to GUD data, since the 
proportion of GUD cases attributable to the STI of interest is a function of both the 
study effect in respect of that STI (in the numerator and denominator) and the study 
effects in respect of other ulcerative STIs (in the denominator), which complicates the 
calculation of the variance of the proportion. GUD data are therefore not used in 
defining the likelihood function, though they are used in validating the model. 
Because the only data available for chancroid are those collected from GUD patients, 
it is not possible to conduct a formal Bayesian analysis for chancroid, and the default 
values assumed for the chancroid parameters are therefore used throughout this 
analysis. Most HSV-2 data are also data from GUD patients, though there are 











analysis. Syphilis data from GUD patients are not considered at all, either in defining 
the likelihood function or in validating the model, due to the absence of any consistent 
diagnostic method across studies. 
 
4.2.3 Posterior simulation 
 
The posterior density ( )yxφ ,|*p  is proportional to the product of the prior 
distribution on the *φ  parameters, ( )*φp , and the likelihood function, as represented 
in equation (4.20). As in section 4.1.3, however, the posterior density cannot be 
evaluated analytically, since it is necessary to run the model in order to obtain the 
likelihood for a single set of *φ  values. The posterior density is therefore evaluated 
numerically, using Sampling Importance Resampling (Smith and Gelfand 1992). This 
involves randomly sampling parameter combinations from ( )*φp , calculating the 
likelihood for each parameter combination, and then resampling from the generated 
set of parameter combinations using the likelihood values as sample weights. In each 
of the analyses presented here, an initial sample of 20 000 parameter combinations 
was drawn and a ‘resample’ of 500 parameter combinations was drawn from the 
initial sample. The sample of 500 parameter combinations thus represents a sample 
from the posterior distribution. The procedure was carried out separately for each STI. 
 
Table 4.2.2 shows the numbers of distinct parameter combinations in each posterior 
sample, and the greatest number of times that any single parameter combination was 
sampled. For all eight analyses, more than half of the posterior sample was composed 
of distinct parameter combinations, and no single parameter combination accounted 
for more than 3% of the posterior sample. The Sampling Importance Resampling 
approach therefore yields a reasonable approximation to the posterior distribution, and 
the chosen sample size appears to be acceptable. However, it would probably be 
necessary to increase the sizes of the initial sample and resample in order to estimate 












Table 4.2.2: Number of distinct parameter combinations and frequency of most 





Most frequently sampled 
parameter combination 
n % n % 
Syphilis 257 51.4% 15 3.0% 
Gonorrhoea 313 62.6% 9 1.8% 
Chlamydial infection 350 70.0% 14 2.8% 
Trichomoniasis 385 77.0% 5 1.0% 
Bacterial vaginosis 439 87.8% 3 0.6% 
Vaginal candidiasis 491 98.2% 2 0.4% 
Genital herpes 308 61.6% 7 1.4% 
 
4.2.4 Comparison of prior and posterior distributions 
 
The prior distributions and posteriors distributions for gonorrhoea, chlamydial 
infection and trichomoniasis are summarized in Table 4.2.3. In general, there is a fair 
degree of consistency between the prior and posterior distributions. In the case of 
trichomoniasis, however, the posterior mean of the study effect standard deviation 
(0.51) is substantially greater than the prior mean (0.30), indicating that there is a 












Table 4.2.3: Comparison of prior and posterior distributions for gonorrhoea, chlamydial infection and trichomoniasis 
Parameter 
Gonorrhoea Chlamydial infection Trichomoniasis 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Male-to-female transmission probability 0.40 (0.21-0.60) 0.46 (0.30-0.62) 0.16 (0.02-0.40) 0.18 (0.08-0.31) 0.15 (0.03-0.34) 0.22 (0.10-0.40) 
Female-to-male transmission probability 0.20 (0.11-0.31) 0.23 (0.16-0.32) 0.12 (0.03-0.26) 0.11 (0.03-0.31) 0.04 (0.01-0.09) 0.05 (0.02-0.10) 
Proportion of cases becoming symptomatic:       
     Males 0.90 (0.78-0.97) 0.88 (0.78-0.96) 0.30 (0.06-0.63) 0.33 (0.07-0.60) 0.40 (0.21-0.60) 0.38 (0.20-0.58) 
     Females 0.40 (0.13-0.71) 0.35 (0.12-0.64) 0.15 (0.03-0.34) 0.17 (0.04-0.31) 0.30 (0.13-0.51) 0.29 (0.12-0.48) 
Average duration of untreated infection (weeks):       
     Symptomatic males 15.0 (6.9-26.3)a 17.8 (10.0-27.3)a 16.0 (4.4-35.1)b 17.0 (4.5-35.1)b 2.0 (0.9-3.6) 2.0 (0.8-3.7) 
     Symptomatic females 15.0 (6.9-26.3)a 14.8 (10.1-21.2)a - - 15.0 (6.9-26.3) 14.9 (6.7-26.7) 
     Asymptomatic males - - 90 (63-122)b 89 (66-117)b 20.0 (8.7-35.9) 21.2 (11.2-34.4) 
     Asymptomatic females - - - - 150 (69-263) 157 (87-247) 
Average duration of immunity (weeks) 52 (14-114) 68 (40-113) 520 (205-979) 490 (277-773) 52 (14-114) 63 (22-121) 
Proportion of cases immune after treatment 0 - 0.50 (0.03-0.98) 0.72 (0.21-0.99) 0 - 
Proportion of cases correctly treated prior to 













Standard deviation of study effects 0.30 (0.08-0.66) 0.30 (0.17-0.44) 0.30 (0.08-0.66) 0.33 (0.21-0.47) 0.30 (0.08-0.66) 0.53 (0.33-0.75) 













The prior and posterior distributions for syphilis are compared in Table 4.2.4. The 
posterior distributions suggest a shorter duration of infectious syphilis (primary and 
secondary syphilis) and a longer average duration of latent syphilis. In addition, for 
the inter-study variation in syphilis prevalence, the female-to-male transmission 
probability and the proportion of syphilis cases treated correctly prior to syndromic 
management, the posterior mean is considerably greater than the prior mean. 
 
Table 4.2.4: Comparison of prior and posterior distributions for syphilis 
Parameter 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Male-to-female transmission probability 0.18 (0.09-0.29) 0.17 (0.12-0.23) 
Female-to-male transmission probability 0.15 (0.07-0.26) 0.19 (0.13-0.27) 
Average time (in weeks) from   
     Primary to secondary 6.6 (3.3-11.1) 6.1 (3.0-10.7) 
     Secondary to latent 15.6 (8.8-24.4) 14.9 (9.1-22.1) 
     Latent to spontaneous resolution 520 (269-853) 572 (355-883) 
     Recovery in early disease to seronegativity 26.0 (12.8-43.9) 23.0 (12.8-42.6) 
     Recovery in latent infection to seronegativity 52.0 (25.5-87.7) 51.5 (25.5-84.4) 
Proportion of primary cases seronegative 





Proportion of cases correctly treated prior to syndromic 





Standard deviation of study effects 0.30 (0.08-0.66) 0.38 (0.28-0.50) 
 
Table 4.2.5 summarizes the prior and posterior distributions for bacterial vaginosis. 
The posterior distributions suggest a more rapid progression from normal flora to 
bacterial vaginosis, and a slower recovery from bacterial vaginosis to normal flora, 
than the prior assumptions indicate. In addition, the posterior mean of the standard 
deviation of the study effects is substantially greater than the prior mean (0.48 vs 
0.30), indicating that there is substantial variation in bacterial vaginosis prevalence 












Table 4.2.5: Comparison of prior and posterior distributions for bacterial vaginosis 
Parameter 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Proportion of cases that are initially symptomatic 0.25 (0.08-0.47) 0.22 (0.06-0.44) 
Weekly rates of transition (in absence of treatment)   
     Intermediate flora to bacterial vaginosis 0.100 (0.050-0.167) 0.117 (0.073-0.174) 
     Bacterial vaginosis to normal flora 0.008 (0.003-0.015) 0.008 (0.003-0.014) 
     Bacterial vaginosis to intermediate flora 0.051 (0.026-0.084) 0.044 (0.024-0.072) 
     Normal flora to intermediate flora 0.030 (0.014-0.053) 0.035 (0.022-0.055) 
     Intermediate flora to normal flora 0.069 (0.036-0.113) 0.064 (0.034-0.104) 
Standard deviation of study effects 0.30 (0.08-0.66) 0.48 (0.28-0.72) 
  
The prior and posterior distributions for the vulvovaginal candidiasis natural history 
parameters are quite similar, as shown in Table 4.2.6. However, the posterior 
distributions suggest a higher incidence of asymptomatic yeast infection and a slower 
rate of clearance of asymptomatic yeast infection in the absence of treatment. 
 




(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
Average duration of symptoms (weeks) 12.0 (6.9-18.6) 12.0 (7.2-18.5) 
Average time to clearance of asymptomatic infection in 





Annual incidence of yeast infection 0.80 (0.46-1.24) 0.94 (0.63-1.34) 
Annual incidence of symptoms (in women with  





Standard deviation of study effects 0.30 (0.08-0.66) 0.30 (0.09-0.66) 
 
Table 4.2.7 compares the prior and posterior distributions for the genital herpes 
(HSV-2) natural history and transmission parameters. Although the prior and 
posterior distributions are similar in respect of most parameters, the standard 
deviation of the study effects has a high posterior mean (0.69). This should be seen in 
the context of the high standard deviation of the logit-transformed HSV-2 











probabilities of HSV-2 transmission in non-spousal relationships than the prior 
distributions indicate. 
 
Table 4.2.7: Comparison for prior and posterior distributions for genital herpes 
Parameter 
Prior 
(mean, 95% CI) 
Posterior 
(mean, 95% CI) 
HSV-2 transmission probability   
   Male-to-female, non-spousal partnership 0.0075 (0.0057-0.0096) 0.0083 (0.0065-0.0106) 
   Female-to-male, non-spousal partnership 0.0025 (0.0016-0.0036) 0.0029 (0.0021-0.0039) 








   Male-to-female, client-sex worker 0.0020 (0.0011-0.0031) 0.0018 (0.0010-0.0027) 
Proportion of cases becoming symptomatic 0.15 (0.07-0.26) 0.18 (0.09-0.29) 
Annual incidence of symptomatic recurrences 





                                                               Female 3.0 (2.1-4.1) 3.1 (2.3-4.1) 
Factor by which infectiousness increases if  





Annual rate of transition from transiently  





Standard deviation of study effects 0.30 (0.08-0.66) 0.69 (0.44-0.96) 
 
Since the differences between the prior and posterior distributions tend to be greatest 
in the case of the standard deviation of the study effects, the prior and posterior 
distributions in respect of this model parameter are compared in Figure 4.2.2, for six 
of the analyses. (Results for vulvovaginal candidiasis have not been included, since 
the prior and posterior distributions of the standard deviation of study effects are very 
similar.) The variance of the posterior distribution is lower in the case of syphilis than 
for other STIs, partly because there is relatively more syphilis prevalence data, and 
partly because the variability in diagnostic accuracy is lower than for most other STIs, 









































































































































































































































































































































































































































































































































































Figure 4.2.2: Comparison of prior and posterior distributions for the standard 
deviation of study effects 
Prior distributions have been scaled to be comparable with posterior histogram plots. 
 
4.2.5 Comparison of model predictions and survey estimates 
 
Figure 4.2.3 compares the predicted seroprevalence of syphilis with the measured 
seroprevalence of syphilis in various studies. The 95% prediction intervals represent 
the ranges of uncertainty around the population mean and are thus narrower than the 
ranges of prevalence measurements in surveys, because they do not reflect variation 











estimates and model estimates. Although the syphilis seroprevalence estimates from 
the national antenatal surveys were not included in the definition of the likelihood 
function, they are compared with the model estimates in Figure 4.2.3(a), and appear to 
validate the model. Household survey estimates shown in Figures 4.2.2(c) and (d) are 
not strictly comparable with the model predictions because a number of the surveys 
sampled over age ranges other than 15 to 49, but the comparisons nevertheless give a 
crude sense of the extent of consistency between model predictions and survey 
estimates. 
 





























































































































































Figure 4.2.3: Syphilis seroprevalence in different sub-populations 
Dots represent measurements from sentinel surveys. Open diamonds represent measurements from 
national surveys (not included in the definition of the likelihood). Mean of posterior distribution 
represented by solid black line. 2.5 and 97.5 percentiles of posterior distribution (95% prediction 
intervals) represented by dashed lines. 
 
Figure 4.2.4 compares model predictions of the prevalence of gonorrhoea with 











and specificity of the diagnostics used. Measurements of gonorrhoea prevalence in 
women attending antenatal and family planning clinics tend to be below the levels 
predicted by the model, but measurements of gonorrhoea prevalence in women in 
households tend to be above the levels predicted by the model. The data do not 
suggest any clear trend in the prevalence of gonorrhoea over time. 
 


























































































































































Figure 4.2.4: Gonorrhoea prevalence in different sub-populations 
Dots represent measurements from sentinel surveys, after adjustment for sensitivity and specificity of 
diagnostic used. Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles 
of posterior distribution (95% prediction intervals) represented by dashed lines. 
 
Figure 4.2.5 compares the observed prevalence of chlamydial infection in various 
studies (after adjustment for diagnostic sensitivity and specificity) with the 
corresponding model predictions. The prevalence of chlamydial infection measured in 
surveys of family planning clinic attenders tends to be greater than that predicted by 











than that predicted by the model. As with gonorrhoea, the data do not suggest any 
clear trend in the prevalence of chlamydial infection. 
 

























































































































































Figure 4.2.5: Prevalence of chlamydial infection in different sub-populations  
Dots represent measurements from sentinel surveys, after adjustment for sensitivity and specificity of 
diagnostic used. Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles 
of posterior distribution (95% prediction intervals) represented by dashed lines. 
 
Figure 4.2.6 compares the posterior estimates of trichomoniasis prevalence with those 
measured in surveys, after adjusting the latter for the sensitivity and specificity of the 
diagnostic used. The prevalence of trichomoniasis measured in surveys of pregnant 
women tends to be greater than the posterior model prediction, while the prevalence 
levels measured in women attending family planning clinics tends to be below that 
predicted by the model. In many cases the differences between the observations and 
the model predictions are extreme, thus accounting for the large standard deviation of 
study effects estimated in section 4.2.4. The posterior prediction intervals are very 












































































































































































Figure 4.2.6: Trichomoniasis prevalence in different sub-populations 
Dots represent measurements from sentinel surveys, after adjustment for sensitivity and specificity of 
diagnostic used. Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles 
of posterior distribution (95% pr diction intervals) represented by dashed lines. 
 
Figure 4.2.7 compares model estimates of the prevalence of bacterial vaginosis 
(defined according to Nugent’s scoring method) with survey estimates. Although 
there are relatively few studies in which bacterial vaginosis was measured using 










































































Figure 4.2.7: Bacterial vaginosis prevalence in different sub-populations 
Dots represent measurements from sentinel surveys. Mean of posterior distribution represented by solid 
black line. 2.5 and 97.5 percentiles of posterior distribution (95% prediction intervals) represented by 
dashed lines. 
 
Figure 4.2.8 compares survey estimates of the prevalence of vulvovaginal candidiasis 
(including asymptomatic yeast infection) with the model posterior prediction 
intervals. As with bacterial vaginosis, there are relatively few studies, but model 


































































































Figure 4.2.8: Vulvovaginal candidiasis prevalence in different sub-populations 
Dots represent measurements from sentinel surveys, after adjustment for sensitivity and specificity of 
diagnostic used. Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles 
of posterior distribution (95% prediction intervals) represented by dashed lines. 
 
Data are particularly sparse in the case of genital herpes, after the exclusion of the 











seroprevalence survey estimates that have been published (adjusted for the sensitivity 
and specificity of the diagnostics used). As in previous figures, the model estimates of 
HSV-2 prevalence in the 15 to 49-year old population are not strictly comparable with 
the household survey estimates for different age groups, particularly in the case of the 
1999 survey, which was conducted among 14 to 24-year olds (the prevalence of HSV-
2 in 14 to 24-year olds would be expected to be lower than that in the population aged 
15 to 49). The differences between the model predictions of the national average and 
the survey proportions are in many cases extreme, and the standard deviation of the 
study effects estimated in section 4.2.4 is therefore very high. 
 
















































































































































Figure 4.2.9: HSV-2 seroprevalence in different sub-populations 
Dots represent measurements from sentinel surveys, after adjustment for sensitivity and specificity of 
diagnostic used. Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles 
of posterior distribution (95% prediction intervals) represented by dashed lines. 
 
Although not included in the definition of the likelihood function, the GUD data are 











genital herpes and chancroid in Figure 4.2.10. For the purpose of calculating the 
model estimates of the proportion of GUD attributable to genital herpes and 
chancroid, it is assumed that 25% of all GUD cases are attributable to causes other 
than herpes, syphilis and chancroid, based on findings of studies that used highly 
sensitive PCR tests to investigate GUD aetiology (Chen et al, 2000; Moodley et al, 
2003a; Lai et al, 2003; Kharsany et al, 2000; Muller et al, 2007b; Muller et al, 
2007a). Syphilis parameter combinations were randomly paired with HSV-2 
parameter combinations to generate the prediction intervals, but because the 
chancroid parameters are not included in the Bayesian analysis, the 95% prediction 
intervals understate the true extent of the uncertainty surrounding the GUD estimates. 
 
Figure 4.2.10 shows that the model predictions are reasonably consistent with 
empirical findings, after taking into account the limited sensitivity of the culture 
methods used to test for chancroid and herpes in the studies conducted prior to 1993. 
Although the predicted proportion of female GUD cases attributable to chancroid 
appears to be implausibly high prior to 2000, these predictions are consistent with an 
earlier study that estimated the proportion to be 46% (Duncan et al, 1984), and the 0 
observation for 1997 is based on a small sample of only 23 GUD cases. 
 



































































































































Figure 4.2.10: Proportion of GUD cases attributable to genital herpes and chancroid 
Open diamonds represent measurements from sentinel surveys (not included in the definition of the 












The model also predicts an overall prevalence of GUD in females consistent with 
levels measured in surveys of women attending family planning clinics (Wilkinson et 
al, 1997; Kleinschmidt et al, 2007) and antenatal clinics (O'Farrell et al, 1989). Figure 
4.2.11 shows that the model estimates of the GUD prevalence in women between the 
ages of 15 and 49 are roughly consistent with survey estimates of the prevalence of 
GUD in women of reproductive age, after taking into account the variability of the 
study effects estimated for ulcerative STIs. The model also predicts that the 
prevalence of GUD in sex workers in 1996 was 8.8% (95% CI: 7.4-10.3%), which is 
roughly consistent with the observed prevalence of GUD in sex workers at this time: 
12.7% among sex workers in KwaZulu-Natal (Ramjee et al, 1998), 9.7% among sex 
workers in Virginia (Steen et al, 2000) and 3.8% among sex workers in Johannesburg 
































Figure 4.2.11: Prevalence of GUD among women aged 15 to 49 
Open diamonds represent measurements from sentinel surveys (not included in the definition of the 
likelihood). Mean of posterior distribution represented by solid black line. 2.5 and 97.5 percentiles of 
posterior distribution (95% prediction intervals) represented by dashed lines. 
 
The model is also validated against age-specific STI prevalence data, where available. 
Figure 4.2.12 shows that the modelled seroprevalence of syphilis follows a similar age 
pattern to the national antenatal survey (Department of Health 2000), with the 
seroprevalence of syphilis being highest in the 20 to 34 age group. Few other reliable 
age-specific STI prevalence estimates are available in South Africa, as sample sizes 
are generally too small to allow meaningful age-specific comparisons. However, it is 
useful to compare the age-specific seroprevalence of HSV-2 in Zambia (Weiss et al, 











on the plausibility of the HSV-2 assumptions. The Zambian survey, as well as other 
HSV-2 prevalence surveys in other southern and eastern African countries (Smith and 
Robinson 2002), suggest that male HSV-2 prevalence peaks at over 50% after the age 
of 40, and that female HSV-2 prevalence peaks at over 75% after the age of 35. The 
model results are consistent with these age-specific HSV-2 prevalence trends in other 
African countries, although the modelled estimate of HSV-2 prevalence in young 
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Figure 4.2.12: Age-specific seroprevalence of syphilis in pregnant women in 1999 
Open diamonds (with 95% CI) represent measurements from national antenatal survey. Mean of 
posterior distribution for South Africa represented by solid black line. 2.5 and 97.5 percentiles of 
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Figure 4.2.13: Age-specific seroprevalence of HSV-2 in 2000, compared with that in 
Ndola (Zambia) 
Open diamonds (with 95% CI) represent measurements from survey in Ndola. Mean of posterior 
distribution for South Africa represented by solid black line. 2.5 and 97.5 percentiles of posterior 














4.2.6 Comparison of STI prevalence estimates 
 
Figure 4.2.14 summarizes the posterior predictions shown in the previous section, 
comparing the relative prevalence levels of different infections. HSV-2, bacterial 
vaginosis and vulvovaginal candidiasis are highly prevalent in South African women, 
and the prevalence of these infections has remained relatively constant over the 1995-
2005 period. Trichomoniasis is the most common curable STI in women, infecting 
approximately 29% (95% prediction interval: 24-34%) of women aged 15 to 49 in 
1995. However, trichomoniasis is relatively uncommon in men. The prevalence of 
gonorrhoea and chlamydial infection is also substantially lower in men than in 
women, while the prevalence of syphilis6 is similar in men and women. The model 
predicts substantial declines in the prevalence of syphilis and chancroid over the 1995 
to 2005 period, consistent with those observed in the antenatal clinic surveys and in 
studies of GUD patients. The model also predicts moderate declines in the prevalence 
of gonorrhoea, trichomoniasis and chlamydial infection. 
 





























































Figure 4.2.14: Comparison of STI prevalence in males and females aged 15 to 49 
Error bars represent 95% prediction intervals. 
                                                 
6 The prevalence of syphilis presented here is the actual prevalence of syphilis predicted by the model, 
not the seroprevalence shown in section 4.2.5. The seroprevalence is adjusted to take into account 
absence of syphilis antibodies during the incubation phase of syphilis and the presence of syphilis 











4.3 Alternative models of STI immunology 
 
STI models have not traditionally allowed for immunity after STI recovery, although 
the existence of temporary immunity after recovery from syphilis is well accepted 
(Korenromp et al, 2000b; Garnett et al, 1997; Pourbohloul et al, 2003), and a few 
models have also allowed for immunity after recovery from chlamydial infection 
(White et al, 2004; Garnett and Anderson 1996). The model described in chapter 3 
differs from most other STI models in that it allows for temporary immune protection 
after recovery from syphilis, chlamydial infection, gonorrhoea, trichomoniasis and 
chancroid. Although there is empirical evidence suggesting that this approach may be 
valid (as discussed in section 3.3.1), it is important to examine whether allowing for 
immunity to STIs significantly improves the fit of the model to the available STI 
prevalence data. If there is an improvement in fit, this would support the view that 
partial immunity is significant in STI epidemiology. This section therefore compares 
the fit of the model to the available gonorrhoea, chlamydial infection and 
trichomoniasis prevalence data, under various assumptions about STI immunology. 
(Syphilis is not included because the existence of partial immunity is already well 
accepted, and chancroid is not included because we have not been able to define a 





For each of the three STIs, three different models are fitted: 
• Model A: There is assumed to be no immunity, i.e. individuals return to the 
susceptible state as soon as they recover from their STI. 
• Model B: Spontaneous resolution of STIs is assumed to be the result of a 
successful immune response to the infection, and hence all individuals are 
assumed to be temporarily immune to reinfection after spontaneous resolution. 
Individuals who are successfully treated are assumed not to develop immunity, 











• Model C: As for model B, all individuals who experience spontaneous 
resolution are temporarily immune to reinfection. In addition, a proportion of 
those who are successfully treated are immune to reinfection. 
Model B is thus the model used for gonorrhoea and trichomoniasis in section 4.2, 
while model C is the model used for chlamydial infection in section 4.2. 
 
All three models are fitted using the method described in section 4.2, i.e. using a 
sampling importance resampling (SIR) approach that yields an approximation to the 
posterior distribution of model outputs. Model B is the same as model A, but with one 
additional parameter (the average duration of immunity), and model C is the same as 
model B, except for the parameter that determines the proportion of successfully 
treated individuals who are immune to reinfection. Model A is thus nested in model 
B, which in turn is nested in model C. The prior distribution on the average duration 
of immunity is gamma with mean 52 weeks and standard deviation 26 weeks for 
gonorrhoea and trichomoniasis, and gamma with mean 520 weeks and standard 
deviation 200 weeks for chlamydial infection (since there is stronger evidence of 
immunity for chlamydial infection than for gonorrhoea and trichomoniasis). This 
prior is the same in models B and C. In model C, the prior distribution on the 
proportion of individuals who are immune after treatment is uniform on the interval 
(0, 1) for all three STIs. Prior distributions on other parameters are the same as those 
described in previous sections. 
 
In comparing the different models, three sets of statistics are examined: 
1. The distribution of likelihood values in the posterior sample. The greater the 
difference in distributions, when comparing two nested models, the more 
significant is the improvement in the ‘goodness of fit’ to the STI prevalence 
data that is achieved through the additional parameter. Although it does not 
appear to be possible to conduct a formal statistical test to establish 
significance, it is worth noting that when comparing nested models that have 
been fitted by maximum likelihood, where the two models differ by a single 
parameter, a difference in log likelihood values of 1.9 would be considered 
significant at the 5% level, and a difference of 6.1 would be considered 











2. The number of distinct parameter combinations in the posterior sample. The 
more efficient the SIR technique is in simulating the posterior distribution, the 
greater one would expect the number of distinct parameter combinations to be. 
The SIR posterior simulation technique is most efficient when the prior and 
posterior distributions are similar, i.e. when the STI prevalence data support 
the a priori assumptions. Hence, if the number of distinct parameter 
combinations in the posterior sample is large, this is an indication that our 
prior beliefs about model parameters are consistent with the STI prevalence 
data, for a given model structure. 
3. The estimated standard deviation of the study effects. The lower the variance 
of the study effects, the greater is the proportion of the total variation in STI 
prevalence levels that is accounted for by the model. Models that provide a 
better fit to the STI prevalence data therefore tend to have lower posterior 
estimates of the standard deviation of study effects. 
 
In addition, the correspondence between the means of the posterior distributions and 
the observed STI prevalence levels (after adjustment for the expected sensitivity and 
specificity of diagnostics) is examined visually for both ‘low risk’ females (women in 
households and women attending antenatal and family planning clinics) and ‘high 
risk’ females (commercial sex workers), for all three models. This shows the 
particular features of the data that most significantly determine the differences in 
‘goodness of fit’ between the models. For the sake of convenience, antenatal, family 
planning and household prevalence data are combined in this comparison, since the 
simulations in section 4.2 suggest that they would be expected to be roughly similar. 
Male STI prevalence data are not included in the comparison since there are relatively 




Table 4.3.1 compares the parameter estimates for each of the three models and for 
each of the three STIs. In the case of gonorrhoea, model B provides a significantly 
better fit than model A. The difference in likelihood values between models A and B 
is highly significant. The fact that there are relatively few distinct parameter 











does not conform with our prior beliefs about the gonorrhoea parameters. The 
estimated standard deviation of the study effects in model B is also substantially 
smaller than that in model A. Models B and C, however, have similar likelihood 
values and similar study effect standard deviations, which suggests that allowing for 
immunity after successful treatment does not significantly improve the model in the 
case of gonorrhoea.  
 
In the case of chlamydial infection, the differences between models A and B are again 
very significant. Only one parameter combination is sampled in the posterior sample 
for model A. The likelihood values for model B are significantly greater than those 
for model A, and the standard deviation of the study effects is significantly lower for 
model B than for model A. The difference between model B and model C is of 
borderline significance (a difference in log likelihood values of 1.9 would normally be 
considered significant at the 5% level), and the standard deviation of study effects in 
model C is slightly lower than that in model B. Allowing for immunity after 
successful treatment therefore improves the fit of the model, though it is questionable 
whether the improvement is significant enough to justify the additional model 
parameter. 
 
In the case of trichomoniasis, there appears to be a significant difference between 
models A and B in terms of their likelihood values, but there is relatively little 
difference in either the number of distinct parameter combinations or the standard 
deviation of the study effects. When comparing models B and C, however, there is no 
significant difference in likelihood values, numbers of distinct parameter 
combinations or standard deviations of study effects. Allowing for partial immunity 
following successful treatment of trichomoniasis therefore does not improve the fit of 
the model. 
 
Figure 4.3.1 compares the model predictions with the observed STI prevalence levels, 
after adjusting the latter for expected levels of sensitivity and specificity (the results 
for model B are not shown because they are barely distinguishable from the results for 
model C on the scale presented). For all three STIs, model A provides a poor fit to the 











Table 4.3.1: Comparison of models A, B and C in terms of ‘goodness of fit’ statistics 
and posterior parameter estimates 
 Model A Model B Model C 
Gonorrhoea    
Log likelihood values from posterior sample    
   Median -3875.0 -3850.0 -3850.0 
   Maximum -3874.0 -3848.1 -3848.3 
   Minimum -3885.7 -3857.5 -3858.0 
# distinct parameter combinations in 
   posterior sample 
52 313 285 
Standard deviation of study effects* 0.58 (0.42-0.74) 0.30 (0.17-0.44) 0.31 (0.17-0.46) 
Average duration of immunity (weeks)* - 68 (40-113) 58 (29-105) 
Proportion of cases immune after treatment* - - 0.41 (0.02-0.91) 
    
Chlamydial infection    
Log likelihood values from posterior sample    
   Median -6184.5 -6144.7 -6142.3 
   Maximum -6184.5 -6142.6 -6139.5 
   Minimum -6184.5 -6152.6 -6148.0 
# distinct parameter combinations in 
   posterior sample 
1 364 350 
Standard deviation of study effects* 1.07 0.36 (0.24-0.49) 0.33 (0.21-0.47) 
Average duration of immunity (weeks)* - 558 (338-894) 490 (277-773) 
Proportion of cases immune after treatment* - - 0.72 (0.21-0.99) 
    
Trichomoniasis    
Log likelihood values from posterior sample    
   Median -3352.6 -3348.9 -3348.2 
   Maximum -3351.4 -3347.2 -3346.5 
   Minimum -3357.9 -3354.6 -3353.5 
# distinct parameter combinations in 
   posterior sample 
397 385 382 
Standard deviation of study effects* 0.51 (0.31-0.77) 0.53 (0.33-0.75) 0.52 (0.33-0.75) 
Average duration of immunity (weeks)* - 63 (22-121) 56 (21-114) 
Proportion of cases immune after treatment* - - 0.58 (0.05-0.98) 













substantially better fit. Models A, B and C all provide reasonable fits to the STI 
prevalence data in ‘low risk’ women, though model A predicts a more rapid decline in 
the prevalence of gonorrhoea after 1995 than the gonorrhoea prevalence data suggest. 
Models A, B and C also all provide reasonable fits to the STI prevalence data for men 
sampled in household surveys, except in the case of model A, which substantially 
overestimates the prevalence of chlamydial infection (results not shown). Most of the 
differences between models, in terms of distributions of likelihood values, therefore 
appear to be explained by differences in the fit to the observed STI prevalence levels 
in ‘high risk’ women, though differences in fit also appear to be significant in ‘low 
risk’ women in the case of gonorrhoea, and in ‘low risk’ men in the case of 
chlamydial infection.  
 































































































































































































Figure 4.3.1: Comparison of predicted and observed STI prevalence levels, for models 
A and C 
Posterior means are represented by solid black line for model A and dashed line for model C. Observed 














4.4.1 The impact of HIV/AIDS in South Africa 
 
This analysis confirms that HIV/AIDS is having a major demographic impact in 
South Africa, with the crude mortality rate attributable to AIDS reaching 
approximately 6 per 1000 person years in 2005, and the proportion of the 15 to 49-
year old population infected with HIV rising to roughly 17% in 2005. Although HIV 
incidence rates appear to have declined since 1999, they remain high, and there is thus 
still an urgent need for advances in HIV prevention. 
 
The model has been fitted to HIV prevalence data and sexual behaviour data from the 
antenatal clinic surveys conducted between 1997 and 2005 and the HSRC household 
survey that was conducted in 2005. In addition, the model has been validated against 
several data sources that were not used in defining the likelihood function: antenatal 
HIV prevalence estimates from surveys conducted prior to 1997, HIV prevalence 
estimates from national household surveys conducted in 2002 and 2003, HIV 
prevalence estimates from studies of sex workers, and proportions of the population in 
spousal relationships (as reported in two censuses and a national community survey). 
Although there were a few instances in which this validation process revealed 
significant discrepancies between model predictions and survey measurements, there 
was good overall agreement between the posterior model estimates and the survey 
results. The fact that this agreement was achieved in spite of these data not being 
incorporated into the likelihood definition increases our confidence in the results of 
the model. 
 
The model is also in broad agreement with other HIV/AIDS models that have been 
developed for South Africa. Table 4.4.1 compares the posterior estimates from the 
current model with estimates from uncertainty analyses of the ASSA2002 AIDS and 
Demographic model (Johnson et al, 2007) and the EPP/Spectrum model (UNAIDS 
2006), and estimates from the ASSA2003 model (Dorrington et al, 2006). HIV 
prevalence estimates in the STI-HIV interaction model are slightly lower than those 











prevalence estimates from the 2005 HSRC household survey in the current analysis 
than in the fitting of the ASSA2002 and ASSA2003 models (the 2005 HSRC 
household survey measured a lower male HIV prevalence than that predicted by the 
ASSA2002 and ASSA2003 models). The models produce similar estimates of HIV 
incidence in 2005, but very different estimates of the effect of AIDS on the crude 
mortality rate. The lower AIDS mortality rate predicted by the STI-HIV interaction 
model can probably be explained by (a) the lower HIV prevalence in the current 
model, (b) the greater assumed effectiveness of antiretroviral treatment in the current 
model, and (c) the more gradual increase in AIDS mortality in the current model, as a 
result of HIV survival times being modelled as a sum of exponentially-distributed 
random variables rather than a sum of Weibull-distributed random variables. Since the 
modelling of the effect of AIDS on mortality is not as sophisticated in the STI-HIV 
interaction model as in the ASSA2002 and ASSA2003 models, the ASSA AIDS and 
Demographic model estimates of the impact of AIDS on mortality should be regarded 
as more reliable. 
 
Table 4.4.1: Comparison of HIV/AIDS indicators for South Africa, as estimated by 
different models 
Indicator Model Estimate (95% range) 
HIV prevalence in 2005 
   (total population) 
STI-HIV interaction model 10.1% (9.4-10.9%) 
ASSA2002 11.1% (9.1-13.1%) 
ASSA2003 11.0% 
HIV prevalence in 2005 
   (15 to 49-year olds) 
STI-HIV interaction model 16.9% (15.7-18.1%) 
EPP/Spectrum 18.8% (16.8-20.7%) 
ASSA2003 18.0% 
HIV incidence rate in 2005 
   (total population) 
STI-HIV interaction model 1.2% (1.1-1.3%) 
ASSA2002 1.2% (0.9-1.5%) 
ASSA2003 1.3% 
Increase in crude death rate 
   due to AIDS in 2005 
   (per 1 000 person years) 
STI-HIV interaction model 5.8 (5.3-6.3) 













Table 4.4.1 also shows that the 95% prediction intervals estimated in the ASSA2002 
uncertainty analysis are wider than those obtained in the current uncertainty analysis. 
This is because the likelihood function in the ASSA2002 uncertainty analysis was 
adjusted subjectively to obtain 95% prediction intervals wide enough to include 95% 
of observations. The 95% prediction intervals in the current analysis reflect the 
uncertainty around key model parameters, but they do not take into account 
uncertainty regarding many other behavioural and biological parameters in the model, 
and they do not reflect the uncertainty regarding the choice of model structure. Taking 
these factors into account would widen the prediction intervals. 
 
A possible criticism of the method used to estimate HIV prevalence is that it does not 
allow for the possibility that HIV prevalence levels measured in household surveys 
may be biased. Some under-estimation of HIV prevalence may occur due to the 
exclusion from the sampling frame of the population in institutions (prisons, military 
bases, hospitals, etc), in which the prevalence of HIV might be expected to be 
relatively high. It is also possible that non-responders and respondents who refuse to 
be HIV-tested may be at a higher risk of HIV infection than those survey respondents 
who are HIV-tested (Boerma et al, 2003). However, analyses of household HIV 
prevalence surveys in other African countries show that allowing for non-response 
bias does not substantially change overall estimates of HIV prevalence (Mishra et al, 
2006; McNaghten et al, 2007). In the 2005 HSRC household survey, the source of the 
household prevalence data in the current analysis, the only significant differences 
between individuals who agreed to be tested and those who refused testing were that 
those who agreed to be tested were more likely to report STI symptoms in the last 
three months, more likely to be female, and more likely to consider themselves not at 
risk of HIV infection (Shisana et al, 2005). It is therefore not clear in which direction 
the bias would lie, but in the absence of better information, the observed HIV 
prevalence is treated as an unbiased estimate of the true population prevalence of 
HIV. 
 
4.4.2 Assessing uncertainty in HIV/AIDS projection models 
 
Much research has recently been conducted to assess uncertainty in HIV/AIDS 











not constrained to produce outputs consistent with observed HIV prevalence levels, 
through the use of techniques such as Latin hypercube sampling and Monte Carlo 
simulation (Blower and Dowlatabadi 1994; Boily et al, 2004; Davenport et al, 2004; 
Law et al, 2001). More recent work has focussed on the assessment of uncertainty in 
HIV/AIDS projections models that are calibrated to observed HIV prevalence levels 
using ‘goodness of fit’ or ‘likelihood’ measures (Alkema et al, 2007; Morgan et al, 
2006; Grassly et al, 2004; Salomon and Murray 2001; Hsieh et al, 2006). These HIV 
prevalence data are usually obtained from particular clinics or sentinel sites, which are 
usually not systematically sampled to give nationally representative HIV prevalence 
estimates. In South Africa, however, antenatal and household surveys of HIV 
prevalence are based on nationally representative samples, and this requires a 
different approach to defining the ‘goodness of fit’ to the survey data. 
 
Relatively few assessments of uncertainty in HIV/AIDS models follow Bayesian 
approaches (Alkema et al, 2007; Goubar et al, 2008; Gilks et al, 1999; Tan and Ye 
2000). The fundamental advantage of adopting the Bayesian approach is that it allows 
the modeller to incorporate prior knowledge about epidemiological parameters and to 
make inferences about these parameters, in addition to assessing the range of 
uncertainty around the model predictions. In earlier work based on the ASSA2002 
model, a generalized likelihood uncertainty estimation (GLUE) technique was used, 
as a means of integrating data from multiple data sources (Johnson et al, 2007). This 
approach might be considered ‘pseudo-Bayesian’ insofar as it allows for the 
specification of prior distributions to represent prior knowledge, but it falls short of 
being truly Bayesian because the likelihood function is an arbitrarily defined 
‘goodness of fit’ measure and not a likelihood function in the true statistical sense. In 
this analysis, we adopt a more rigorous approach to defining the likelihood function, 
including bias terms and model error terms to represent different components of the 
differences between observations and model predictions (Sevcikova et al, 2006).  
 
The antenatal bias parameters that have been estimated on a logit scale can be 
exponentiated to obtain an odds ratio relating the observed HIV prevalence to the true 
HIV prevalence (as predicted by the model). The average value of this odds ratio is 
1.48 (95% prediction interval: 1.30-1.69). This difference between the observed and 











factors. Firstly, the antenatal clinic surveys represent only women seeking antenatal 
care in public health facilities, and women who seek private antenatal care (who are 
generally believed to be at a lower risk of HIV infection) are not included. Secondly, 
false positive reactions on standard antibody tests may lead to an exaggeration of HIV 
prevalence levels in pregnant women; ELISA specificities in African populations tend 
to be lower than those in the developed world (Van Kerckhoven et al, 1991), and in 
many African studies specificities of 98% or lower have been recorded (Nkengasong 
et al, 1999; Meda et al, 1999a; Urassa et al, 1999). Lastly, it is possible that the model 
may under-estimate the true prevalence of HIV in pregnant women because it 
assumes that in sexually experienced women, fertility rates depend only on age and 
HIV stage. Since fertility rates probably also depend on the amount of unprotected sex 
that women have, and since the frequency of unprotected sex is also likely to be 
associated with HIV risk, the model may fail to capture some of the association 
between pregnancy and HIV risk. Alternative fertility assumptions will need to be 
explored in future analyses of the model. 
 
Bias parameters have also been estimated for the sexual behaviour data. These 
parameters can be exponentiated to obtain odds ratios relating the true prevalence of a 
particular sexual behaviour to the reported prevalence of that behaviour. The odds 
ratios that have been estimated in this way are represented in Table 4.4.2. The results 
suggest that there is substantial under-reporting of concurrent partnerships, 
particularly among women and among married individuals. The magnitude of this 
under-reporting is perhaps not surprising, considering that self-reported sexual 
behaviour data were obtained in face-to-face interviews (FTFIs) conducted by retired 
nurses. Social desirability bias can be expected to lead to the under-reporting of 
certain risk behaviours in FTFIs, especially when those administering the 
questionnaires are considerably older than the respondents (Mensch et al, 2003). 
Several alternative interview formats have been tested in an attempt to reduce this 
bias, including audio-computer-assisted self-interviews (ACASI), informal 
confidential voting interviews (ICVI) and self-administered questionnaires (SAQ). 
Using these more impersonal interview techniques, it has been found that the 
women’s odds of reporting multiple sexual partners are between 1.0 and 5.2 times 
those reported in FTFIs (Ghanem et al, 2005; Kissinger et al, 1999; Rogers et al, 











considerably higher in married women than in unmarried women (Gregson et al, 
2002b). Men’s odds of reporting multiple partners in the more impersonal interview 
formats are between 1.1 and 1.7 times those in FTFIs (Ghanem et al, 2005; Rogers et 
al, 2005; Gregson et al, 2004; Gregson et al, 2002b). The odds ratios that are shown 
in Table 4.4.2 are roughly consistent with the empirical estimates of bias, though the 
latter tend to be closer to one. It is likely that the alternative interview formats only 
partially reveal the extent of social desirability bias, since subjects will tend to worry 
about the confidentiality of their responses even when impersonal interview formats 
are used, and individuals who have had limited contact with computer technology are 
likely to be distrustful and fearful of computer-assisted methods (Mensch et al, 2003).  
 
Table 4.4.2: Posterior estimates of the ratio of the odds of engaging in a particular 
behaviour to the odds of reporting that behaviour 
Behaviour 
Odds ratio (95% prediction interval) 
Males Females 
More than one current partner 
   (unmarried individuals) 
1.26 (0.87-1.54) 6.3 (3.9-8.2) 
More than one current partner 
   (married individuals) 
3.3 (2.0-4.3) 20.6 (9.5-31.0) 
No current partner 
   (unmarried individuals) 
1.16 (0.60-2.00) 0.66 (0.46-1.06) 
 
Model error terms have been included in the likelihood function definition for the 
antenatal clinic data, but not for the HSRC household survey data. This is because the 
95% confidence intervals around the levels of HIV prevalence measured in the 
antenatal clinic surveys are too narrow to include most model estimates, and there is 
thus a need to allow for differences between model predictions and survey estimates 
in excess of what can be attributed to sampling variation alone. The 95% confidence 
intervals around the HSRC household survey data, on the other hand, are wide enough 
to include most model estimates, and there is thus less of a need for model error terms 
when specifying the likelihood function for the HSRC data. Initial attempts to include 
model error terms in the likelihood function for the HSRC survey data resulted in 











parameter combinations that gave good fits to the large antenatal HIV prevalence 
dataset, at the expense of the fit to the smaller HSRC dataset, the significance of 
which was diminished to low levels by imputing large model error terms. Model error 
terms should therefore be used with discretion in likelihood specification. 
 
Most previous Bayesian analyses of HIV/AIDS models have been based on only one 
source of data, typically HIV prevalence data or reported numbers of AIDS cases. 
Goubar et al (2008) note that it is ideal to incorporate a number of data sources in the 
Bayesian analysis, as this helps to validate the model structure and can also yield 
important insights into biases that might not be apparent when considering one data 
set in isolation of others. In the analysis presented in section 4.1, HIV prevalence data 
from antenatal clinic surveys, HIV prevalence data from household surveys and 
sexual behaviour data have all been used in defining the likelihood function. All data 
are sex- and age-specific, which helps to improve confidence in the modelling of age 
and gender differences in sexual behaviour. It would also be possible to include 
reported death data in the definition of the likelihood function, as in our previous 
analysis (Johnson et al, 2007), but since the STI-HIV interaction model is not 
designed to be a demographic model, and since the HIV survival assumptions are not 
included in the present Bayesian analysis, there would probably be little benefit from 
doing so. 
 
4.4.3 Estimating STI prevalence levels from sentinel surveillance data 
 
Relatively little work has been published on appropriate methodologies for calibrating 
models of STIs other than HIV. Past attempts to calibrate STI models to STI 
prevalence data have involved subjectively selecting a single set of model parameters 
in such a way that the model produces estimates of STI prevalence close to the levels 
of STI prevalence observed (Korenromp et al, 2002c; Boily et al, 2002; White et al, 
2004; Turner et al, 2004). In some cases this fitting process has implicitly recognized 
the imperfect sensitivity and/or specificity of the STI diagnostics used. However, 
modellers have not explicitly taken into account the potential variability in diagnostic 
performance and the potential binomial variation in STI prevalence, and as a result 
have not identified ranges of plausible model predictions or quantified the relative 












The more formal statistical approach that we have proposed has several advantages. 
Firstly, it allows one to judge the plausibility of a particular model prediction 
according to an objective likelihood function, which takes into consideration both the 
potential binomial variation and the potential variation in diagnostic performance, in 
the data to which the model is calibrated. This in turn is important in uncertainty 
analysis. Considering that there is substantial uncertainty regarding many of the STI 
transmission and natural history parameters, it is desirable that STI model conclusions 
be tested across a range of different plausible parameter combinations, and that 
conclusions not be based on a single parameter combination. The Bayesian approach 
provides a natural means of identifying a plausible set of parameter combinations that 
can be used to make model predictions. 
 
The hierarchical Bayesian approach that we have proposed also takes into account 
variation in STI prevalence between locations, which is important when attempting to 
estimate national or regional STI prevalence levels on the basis of STI prevalence 
data collected in selected communities. In estimating the prevalence of STIs in 
different global regions, the WHO appears to have used a subjective method to weight 
the STI prevalence estimates from various studies (Gerbase et al, 1998; Rowley and 
Berkley 1998). The hierarchical Bayesian approach is effectively a random effects 
weighting method that allows the weights given to different prevalence estimates to 
vary in relation to the estimated variability in STI prevalence between studies. A 
similar hierarchical Bayesian approach has been applied by Alkema et al (2007), to 
HIV prevalence data from antenatal sites in African countries. However, Alkema et al 
model a ‘clinic effect’ rather than a ‘study effect’, effectively assuming that all 
variation between different prevalence measurements (after controlling for the year of 
measurement) can be explained by the location of the clinic sampled. A potential 
criticism of the approach that we have adopted is that there is no allowance for 
correlation between bi terms for studies conducted in the same location (see equation 
(4.6) in section 4.2.2), as there is in the analysis of Alkema et al. However, when the 
empirical STI prevalence estimates were adjusted for sensitivity and specificity, logit-
transformed and then regressed on time and sample type, the residuals did not appear 
to differ significantly between locations. This suggests that the inclusion of location 












The posterior distribution in this Bayesian analysis has been approximated using the 
Sampling Importance Resampling (SIR) technique. This technique differs from the 
Metropolis algorithm used to approximate the posterior distribution in section 4.1; 
while the Metropolis algorithm involves sampling successive parameter combinations 
based on the posterior densities of the preceding parameter combinations, the 
parameter combinations that are sampled under the SIR approach are all sampled 
independently of one another. Although the SIR approach was initially applied to the 
analysis in section 4.1, it was found that the posterior sample consisted of only a few 
distinct parameter combinations, even when the initial sample consisted of 100 000 
parameter combinations. It is likely that the inefficiency of the SIR approach is due to 
the extreme differences between the prior and posterior distributions in section 4.1; 
parameter combinations randomly sampled from the prior distribution tend to have 
very low posterior densities. In this situation, the Metropolis algorithm performs 
better because the sampling is adaptive, and the sampling algorithm will therefore 
avoid the parts of the posterior distribution that have low posterior density. The SIR 
approach works reasonably well in section 4.2 because the prior and posterior 
distributions are similar in most cases, and it is therefore not necessary to resort to 
using the Metropolis algorithm. The initial sample size of 20 000 parameter 
combinations is the same as that used by Smith and Gelfand (1992), but is smaller 
than that used in other SIR applications, which have used samples of 100 000 to 
200 000 parameter combinations (Johnson et al, 2007; Alkema et al, 2007). Table 
4.2.2 shows that the sample size of 20 000 is sufficient to yield a posterior sample 
with a large proportion of distinct parameter combinations, and no single parameter 
combination influencing the posterior sample excessively. However, in cases in which 
the model fits the data poorly (for example, the model of chlamydial infection in 
which there is no immunity), the posterior sample may consist of only a single unique 
parameter combination, and in such cases the SIR approach is clearly not appropriate. 
 
A limitation of the hierarchical Bayesian approach we have described is that it does 
not allow for systematic bias in the sampling of sentinel surveillance sites. Far from 
being randomly selected, sentinel sites appear to be disproportionately selected from 
urban areas and from the Gauteng and KwaZulu-Natal provinces, and the few studies 











KwaZulu-Natal. In addition, a significant number of STI prevalence estimates are 
from the Khutsong community, which is located close to the world’s largest gold 
mining complex, with extremely high HIV prevalence levels (Ndhlovu et al, 2005). It 
is therefore possible that the STI sentinel surveillance data may provide a very biased 
picture of STI prevalence levels in the general population of South Africa. The 
direction of this bias, however, is unclear. In their review of STI prevalence data in 
Sub-Saharan Africa, Rowley and Berkeley (1998) note that the prevalence of syphilis 
and chlamydial infection tends to be higher in rural areas than in urban areas, while 
the prevalence of gonorrhoea tends to be similar in urban and rural areas. The 
significance of the bias towards surveillance in settings with high HIV prevalence is 
also not clear; although one might expect a strong positive correlation between HIV 
prevalence and STI prevalence at a community level, there is little evidence to support 
this. In fact, a number of African surveys have found weak negative correlation 
between HIV and syphilis prevalence at a regional level (Swai et al, 2006; 
Department of Health 2006; Department of Health 2005; Department of Health 
2004a). For other STIs, there are too few data to estimate correlations between STI 
and HIV prevalence at a regional level, and it is important that such data be collected 
in order to judge the reliability of estimates derived from sentinel surveillance data. 
 
Another potential limitation of the approach we have proposed is that it does not take 
into account biases specific to women attending antenatal clinics and family planning 
clinics. Pregnancy and the use of hormonal contraception are both associated with 
hormonal and immunological changes (Sonnex 1998; Witkin 1987), and these factors 
could affect women’s susceptibility to STIs. The following associations have been 
noted in the epidemiological literature: 
• Symptomatic vulvovaginal candidiasis has been found to be more prevalent in 
pregnant women (Ohmit et al, 2003; Daus and Hafez 1975) and women using 
oral contraceptives (Spinillo et al, 1993; Geiger and Foxman 1996). However, 
culture-confirmed yeast infection is not significantly associated with 
pregnancy (Duerr et al, 1997) or oral contraceptive use (Goldacre et al, 1979; 
Hilton and Warnock 1975; Rashid et al, 1991; Eckert et al, 1998), and it is 
therefore unlikely that studies of the prevalence of Candida in antenatal and 











• There is substantial evidence suggesting that the use of hormonal 
contraceptives reduces the risk of bacterial vaginosis (Yen et al, 2003; 
Holzman et al, 2001; Smart et al, 2004; Nagot et al, 2007a). Studies of women 
attending family planning clinics could therefore be biased towards 
understating the true prevalence of bacterial vaginosis. 
• Oral contraceptive use has been found to increase significantly the risk of 
chlamydial infection (Cottingham and Hunter 1992), and prospective studies 
also suggest that injectable contraceptives increase the risk of chlamydial 
infection (Mohllajee et al, 2006). Studies of women attending family planning 
clinics could therefore exaggerate the average prevalence of chlamydial 
infection in the female population. 
• Mohllajee et al (2006) note that several studies have found negative 
associations between trichomoniasis and use of oral contraceptives, though 
few have adjusted for likely confounding factors such as bacterial vaginosis 
and socioeconomic status. If there is indeed a negative association between 
trichomoniasis and hormonal contraceptive use, it could explain the relatively 
poor fit of the model to the trichomoniasis prevalence levels observed in 
women attending family planning clinics (see Figure 4.2.6). 
The model also does not take into account potential differences in sexual behaviour 
and socioeconomic status between women attending these public clinics and women 
in the general population. It may therefore be necessary, in future, to adapt the method 
used to calculate antenatal and family planning clinic STI prevalence levels, by 
adjusting in some way for hormonal contraceptive use, sexual behaviour and 
socioeconomic factors. 
 
The hierarchical Bayesian method that we have proposed does not take into account 
data from GUD patients, and as a result it has not been possible to apply the method 
to chancroid. This is an unfortunate limitation, as chancroid is estimated to be one of 
the most significant STIs promoting the spread of HIV in the early stages of the 
HIV/AIDS epidemic (Orroth et al, 2006; Freeman et al, 2007), and it therefore 
deserves special attention. A possible approach to calculating the proportion of genital 


















=,,* ,    (4.22) 
 
where ( )iC cf , ( )iH hf  and ( )iS sf  are the model estimates of the prevalence of 
symptomatic chancroid, symptomatic genital herpes and primary syphilis 
respectively, after addition of study effects (ci, hi and si) through a logit 
transformation (see equation (4.7) in section 4.2.2). For the purpose of calculating the 
likelihood in respect of the ith study estimate, it is necessary to calculate the mean and 
variance of ( )iiiC shcf ,,* . This was attempted using both first and second order Taylor 
series approximations, but neither approximation was found to be sufficiently 
accurate in the case of the variance (differences of up to 25% of the simulated 
variance were obtained). In addition to the difficulties associated with obtaining a 
reasonable approximation to the variance, there are several complications to consider: 
the formula for ( )iiiC shcf ,,*  does not take into account the possibility of ulcers of 
mixed aetiology, nor does it take into account ulcers due to causes other than 
chancroid, syphilis and herpes. More significantly, it is not possible to conduct the 
Bayesian analysis using chancroid data from GUD patients independently of the 
Bayesian analysis for syphilis and genital herpes, unless it is assumed that the syphilis 
and genital herpes parameters are known with certainty. For these reasons, it has not 
been feasible to include the GUD data in the present analysis. Future research should 
consider the feasibility of alternative approaches to incorporating the GUD data. 
 
4.4.4 STI prevalence levels in South Africa 
 
This analysis confirms that South Africa has an exceptionally high prevalence of 
STIs. Table 4.4.3 compares levels of STI prevalence in 15 to 49 year olds in 1995, as 
estimated by our model for South Africa, with those estimated by the WHO for Sub-
Saharan Africa (Gerbase et al, 1998). In most cases, the STI prevalence predicted for 
South Africa is more than double that estimated for the Sub-Saharan African region. 
The WHO estimates that levels of STI prevalence are higher in Sub-Saharan Africa 
than in any other region, and South Africa’s STI prevalence levels thus appear even 













Table 4.4.3: STI prevalence levels in males and females aged 15 to 49 in 1995 




Males Sub-Saharan Africa1 3.1% 2.0% 4.8% 1.4% 
South Africa 









Females Sub-Saharan Africa1 3.9% 2.8% 7.1% 14.1% 
South Africa 









1 World Health Organization estimates (see Gerbase et al (1998)). 
 
Although the differences between our estimates for South Africa and the WHO 
estimates for Sub-Saharan Africa may be partly due to differences in methodology, it 
is likely that they reflect real differences in STI prevalence. South Africa has a 
relatively low prevalence of male circumcision when compared with most of Sub-
Saharan Africa (Williams et al, 2006a), and since male circumcision has been found 
to be protective against a number of STIs (Weiss et al, 2006; Moses et al, 1998), the 
low prevalence of male circumcision in South Africa could be a significant factor 
explaining the high STI burden in South Africa. Other possible explanations for the 
relatively high STI prevalence in South Africa include the high levels of migrant 
labour (Lurie 2000), and the relatively high prevalence of commercial sex activity in 
southern Africa (Caraël et al, 2006). It is also possible that the relatively high STI 
prevalence levels in South Africa in 1995 may be a consequence of the relatively late 
start to the South African HIV/AIDS epidemic. This analysis has shown that AIDS 
mortality and behaviour change in response to HIV/AIDS can bring about substantial 
reductions in STI prevalence, but since these changes occurred later in South Africa 
than in other African countries, a higher STI prevalence in South Africa would be 
expected. Our model estimates of STI prevalence in South Africa in 2005 are 
certainly closer to those estimated by the WHO for Sub-Saharan Africa in 1995, 












4.4.5 Modelling immunity to STIs 
 
Traditionally, mathematical models of STI transmission dynamics have assumed that 
there is no immunity following recovery (Lena et al, 2005). This assumption is 
supported by evidence showing that many individuals become reinfected with STIs 
shortly after successful treatment (Moodley et al, 2002; Lyng and Christensen 1981). 
However, such evidence does not disprove the possible existence of either (a) partial 
protection against reinfection, or (b) the gradual development of immunity, with 
individuals treated in early infection being less likely to acquire immunity than those 
who are treated later in infection or those who experience spontaneous resolution of 
infection. 
 
The latter possibility has been described as the “arrested immunity hypothesis” by 
Brunham et al (2008), who have used this hypothesis to explain the observed failure 
of chlamydial control programmes to reduce the incidence of chlamydial infection 
over the long term (Rekart and Brunham 2008; Brunham et al, 2005). Evidence that 
individuals treated in early infection are more susceptible to reinfection than those 
treated in late infection is available in the case of syphilis (Magnuson et al, 1956) and 
gonorrhoea (Schmidt et al, 2001), and in a murine model of chlamydial infection (Su 
et al, 1999). There is also evidence to suggest that immune responses may be 
relatively slow to develop in the case of syphilis (Lewinski et al, 1999; Salazar et al, 
2002) and chancroid (Chen et al, 1997). 
 
Our results suggest that there is indeed immune protection following recovery from 
gonorrhoea, trichomoniasis and chlamydial infection. Our model produces 
significantly better fits to the South African STI prevalence data than the “no 
immunity” model when it is assumed that individuals who experience spontaneous 
resolution are temporarily immune following recovery. Although our model also 
allows for temporary immunity following successful treatment, this was not found to 
improve the fit of the model in the case of gonorrhoea and trichomoniasis, and in the 
case of chlamydial infection, the improvement in fit was only of borderline 
significance. This is consistent with the arrested immunity hypothesis. Although it 
was not possible to compare formally different models of immunity to chancroid, it 











when it was assumed that there was immunity following spontaneous resolution; 
when no immunity was assumed, the decline in chancroid prevalence in the mid-
1990s was found to be too rapid relative to that observed (results not shown). 
 
It may seem surprising that the assumptions about immunity should so significantly 
influence the fitting of the model, especially in the cases of gonorrhoea and 
trichomoniasis, for which the average duration of protection is fairly short (less than 
two years). However, in groups that are highly exposed to STIs, such as commercial 
sex workers, even immunity of short duration can significantly reduce the prevalence 
of the STI. In addition, immunity tends to lessen the impact of changes in sexual 
behaviour and improvements in STI treatment, since the direct effect of such 
interventions, in terms of reduced transmission risk or reduced duration of infection, 
is partially offset by the effect of reduced prevalence of immunity. The model 
therefore predicts a more gradual decline in the prevalence of gonorrhoea, 
trichomoniasis and chlamydial infection, following the behavioural and STI treatment 
changes in the mid-1990s, when it is assumed that there is immunity. Similar 
dynamics affect other infections such as malaria; mathematical models suggest that 
even when there is only partial immunity to malaria, interventions may fail to have a 
significant impact in the long term because of reducing levels of acquired immunity 
following the introduction of the intervention (Anderson and May 1992). 
 
Although there has been a recent tendency to allow for immunity in models of 
chlamydial infection (Brunham et al, 2005; White et al, 2004), there do not appear to 
have been any previously published models of gonorrhoea or trichomoniasis that 
allow for immunity. Garnett et al (1999) acknowledge that the standard model of 
gonorrhoea produces estimates of gonorrhoea prevalence that are “unrealistically 
sensitive to small changes in parameter values” in a U.S. population, but argue against 
extending the model to allow for immunity on the basis that this would make it even 
more difficult to simulate the persistence of gonorrhoea in the population modelled. In 
contrast, our results suggest that extending the standard model of gonorrhoea to allow 
for immunity makes the overall prevalence of gonorrhoea significantly less sensitive 
to changes in behavioural parameters and treatment parameters, thus increasing the 












The fact that the “no immunity” model provides a poor fit to the South African STI 
prevalence data is largely due to the implausibly high STI prevalence in sex workers, 
predicted by the model when there is no immunity assumed. A possible criticism of 
this analysis is that the implausibly high STI prevalence levels in sex workers may be 
due to unrealistic assumptions about (a) sexual activity among sex workers or (b) 
health-seeking behaviour in sex workers, rather than unrealistic assumptions about 
immunity. The first possibility seems unlikely, since the assumptions about sex 
worker sexual behaviour are by and large based on the same studies from which sex 
worker STI prevalence levels are obtained, and the assumed levels of risk behaviour 
would thus only be inconsistent with the observed STI prevalence levels if sex 
workers were systematically exaggerating their risk behaviours. The second 
possibility also seems unlikely, since the model already allows for a higher rate of 
health seeking among sex workers than among women in the general population, for 
both symptomatic and asymptomatic STIs (at rates of 0.90 per week and 0.025 per 
week respectively). Antibiotic treatment is tightly controlled in South Africa (Hudson 
1999), and there is little evidence to suggest that South African sex workers self-treat 
with antibiotics (Abdool Karim et al, 1995). The assumed treatment frequency of 
0.025 per week in asymptomatic sex workers is based on treatment frequencies 
observed among sex workers in other African countries (Morison et al, 2001), though 
treatment frequencies among South African sex workers may be lower than this 
(Abdool Karim et al, 1995). 
 
Although this analysis supports the arrested immunity hypothesis, the hypothesis still 
requires further testing. It is important that other mathematical models of STI 
transmission dynamics examine which models of immunity give the best fit to STI 
prevalence data from other settings. It may also be necessary to generalize the fairly 
simple models of immunity that have been considered here by allowing for partial 
protection (rather than complete protection) in the immune phase, by allowing for 
reinfected individuals to have a shorter average duration of infection, and by allowing 
for stronger protection following a second episode of infection than that following the 
first episode. If models are extended to allow for multiple strains, it may also be 
necessary to consider strain-specific immunity, which is likely to be particularly 
significant in the case of gonorrhoea (Plummer et al, 1989). Models could also 











infected partner, in the absence of transmission (Rowland-Jones et al, 1998; Mazzoli 
et al, 1999; Lo Caputo et al, 2003; Posavad et al, 2003). Mathematical assessments of 
these different models of immunity are unlikely to be helpful if they are not 
complemented by further empirical work, and there is clearly a need for a better 
understanding of the ways in which immune responses alter the transmission and 













Chapter 5: The contribution of STIs to the transmission of HIV 
 
The objective of this chapter is to assess the extent to which STIs are contributing to 
the spread of HIV in South Africa. The chapter begins with a review of studies that 
have quantified the increase in the HIV transmission probability in the presence of 
STIs, and this review is then used as the basis for the assumptions made in section 
5.2. The model described in chapters 3 and 4 is extended to allow for the effect of 
STIs on HIV transmission, and the model is then used to determine population 
attributable fractions (PAFs) that represent the proportion of incident HIV infections 
attributable to other STIs. These PAFs are then compared with empirical PAF 
estimates and PAFs estimated by other models of HIV-STI interactions in section 5.3, 
and results are discussed in section 5.4. 
 
5.1 STIs as cofactors in HIV transmission: a review of cofactor 
estimates 
 
There is substantial evidence to suggest that STIs in HIV-negative individuals 
increase their susceptibility to HIV infection. In addition, HIV-infected individuals 
are more likely to transmit HIV if they are co-infected with STIs. This section reviews 
evidence of the effect of STIs on both HIV susceptibility and HIV infectiousness, and 
aims to determine the factor by which HIV transmission probabilities are multiplied in 
the presence of STIs (the ‘STI cofactor effect’). 
 
5.1.1 Effect of STIs on susceptibility to HIV 
 
STIs may increase susceptibility to HIV through a number of biological mechanisms. 
STIs often lead to a disruption of the mucous membranes in the reproductive tract, 
which act as a barrier to HIV infection. STIs also result in the recruitment of 
leucocytes to the reproductive tract, as has been shown in the cases of gonorrhoea, 
chlamydial infection and trichomoniasis (Krieger et al, 1993; Hobbs et al, 1999; 
Bump et al, 1986; Cohen et al, 1999). Many of these leucocytes and associated 











reproductive tract therefore makes transmission more probable. In addition, certain 
non-ulcerative STIs have been shown to increase the production of interleukin-10, a 
cytokine that increases the susceptibility of macrophages to HIV infection and that 
may suppress the HIV-specific cellular immune response (Cohen et al, 1999). 
Bacterial vaginosis is also associated with reduced production of lactic acid and 
hydrogen peroxide, both of which are thought to protect against HIV (Martin et al, 
1999). 
 
A large number of studies have estimated the extent to which STIs increase 
susceptibility to HIV. Cross-sectional studies are usually not considered to be reliable 
in estimating the effect of STIs on HIV susceptibility, as they are not able to 
determine whether current STIs were present at the time of HIV acquisition. 
Longitudinal studies, which track initially HIV-negative individuals and determine the 
effect of STIs on their risk of HIV acqusition, are more useful. However, these studies 
estimate the effect of an STI, identified at some point in a time interval, on the 
cumulative probability of HIV transmission over that time interval. The modeller is 
concerned primarily with the effect of the STI on the per contact probability of HIV 
transmission. The STI cofactor effect is therefore difficult to determine from 
longitudinal studies, for a number of reasons: 
• The most obvious problem is that the probabilities of HIV infection and STI 
infection are both related to the amount of sex and condom usage occurring 
over the time interval. Although most studies attempt to overcome this 
problem by controlling for reported sexual behaviour in a multivariate analysis 
(Røttingen et al, 2001), the sexual behaviour variables are usually defined 
categorically, often with only two levels. To the extent that there is residual 
variation in sexual behaviour after these variables are controlled for, and to the 
extent that sexual behaviour is misreported, the problem of confounding 
remains. 
• It is often implicitly assumed that the HIV prevalence and STI prevalence are 
the same in all partners of HIV-negative subjects. However, having an STI 
may indicate that one’s partner has multiple partners, and is thus more likely 
to be HIV positive. Ignoring likely sexual mixing patterns may therefore also 











• A related problem is that STI cofactor effects estimated in these studies are 
often taken as evidence of increased susceptibility to HIV infection in the 
presence of an STI (Hayes et al, 1995b), though the cofactor effect may in fact 
represent the effect of the same STI in the HIV-infected partner. 
• The time of HIV infection is known only approximately, which makes it 
difficult to determine whether the HIV infection came before, after or at the 
same time as the STI infection. 
 
Table 5.1.1 summarizes the results of two meta-analyses of longitudinal studies 
(Sexton et al, 2005; Røttingen et al, 2001). The earlier meta-analysis employed a 
fixed effects model, and noted that there was significant publication bias (smaller 
studies tended to report larger STI cofactor effects). The more recent meta-analysis 
employed a random effects model, which gives relatively more weight to smaller 
studies and thus produces slightly higher STI cofactor estimates in most cases. A 
further meta-analysis (Wald and Link 2002) examined the relationship between 
herpes and HIV incidence, and also found that herpes significantly increased HIV 
incidence (OR 2.1, 95% CI: 1.4-3.2). Another more recent HSV-2 meta-analysis 
(Freeman et al, 2006) found that combined odds ratios differed substantially between 
high-risk females (OR 1.0, 95% CI: 0.5-2.0), females in the general population (OR 
3.1, 95% CI: 1.7-5.6), males in the general population (OR 2.7, 95% CI: 1.9-3.9) and 
men who have sex with men (OR 1.7, 95% CI: 1.2-2.4). 
 
Effect estimates tend to be higher in HIV-susceptible males than in HIV-susceptible 
females. This is demonstrated in a meta-regression by Sexton et al, who found that 
effect estimates tended to be higher in studies of men than in studies of women, 
though the difference was not statistically significant (OR 1.27, 95% CI: 0.9-1.8). A 
possible explanation for this is that STI effects on HIV incidence may ‘saturate’ when 
there are multiple STIs present. If this were the case, the greater prevalence of 
multiple STIs in females could account for the sex differential in STI effects. 
Alternatively, STIs may affect male susceptibility to HIV to a greater extent than 
female susceptibility, due to STIs in males being more frequently symptomatic and 












Table 5.1.1: Combined estimates of effect of STIs on HIV susceptibility 








Source Sexton Røttingen Røttingen Røttingen 
     
Any STI 3.7 (2.5-5.4) 3.7 (2.7-5.0) 5.6 (3.2-9.7) 3.1 (2.1-4.5) 
GUD 3.8 (2.5-5.7) 2.7 (2.2-3.3) 2.8 (2.0-4.0) 4.4 (2.9-6.6) 
Herpes 2.3 (1.2-4.2) 2.7 (1.5-4.8)  2.7 (1.5-4.8) 
Syphilis 2.4 (1.8-4.2) 2.5 (2.1-3.1) 2.1 (1.4-3.1) 2.5 (1.4-4.4) 
Chancroid 2.4 (1.4-4.2) 2.1 (1.2-3.4)  2.1 (1.2-3.5) 
NUD 1.8 (1.3-2.6) 1.7 (1.5-2.1) 1.6 (1.3-2.0) 2.6 (1.8-4.0) 
Gonorrhoea 3.4 (2.1-5.4) 2.1 (1.7-2.5) 2.6 (1.9-3.4)  
Chlamydia 2.9 (1.7-4.8) 2.2 (1.4-3.3) 2.8 (1.8-4.4)  
Trichomoniasis 2.0 (1.4-2.8) 1.5 (1.2-2.0) 1.5 (1.2-1.9)  
Candidiasis 2.7 (1.1-6.3)  2.2 (1.6-2.8)  
Bacterial vaginosis   1.4 (1.0-2.0)  
Source: Sexton et al (2005), Røttingen et al (2001) 
GUD = genital ulcer disease, NUD = non-ulcerative disease (symptoms of discharge, urethritis or PID) 
 
There is much uncertainty regarding the relative significance of symptomatic and 
asymptomatic infections in determining susceptibility to HIV. To the extent that 
symptomatic infections are more likely to lead to disruption of mucosal membranes in 
the reproductive tract, and to the extent that symptomatic infections are associated 
with higher concentrations of immune cells in the reproductive tract, symptomatic 
STIs might be expected to increase HIV susceptibility to a greater extent than 
asymptomatic STIs. This appears to be true in the case of ulcerative STIs; Table 5.1.1 
shows that the average effect of GUD symptoms is greater than the average effects of 
herpes and syphilis (both of which are mostly asymptomatic). However, the same is 
not true for non-ulcerative STIs; the combined estimate for discharge/urethritis/PID 
symptoms tends to be similar to or lower than the combined effects for the 
corresponding STIs. This may be due to these non-ulcerative symptoms being 
relatively non-specific and thus poor indicators of actual STI infection. Both in males 
and females, GUD symptoms appear to influence HIV susceptibility to a greater 












Longitudinal studies do not indicate the true STI cofactor effect, but the STI cofactor 
effect can be approximated from these studies by using mathematical modelling. 
Three studies have used mathematical models to determine the likely magnitude of 
the STI cofactor effect. The first, by Boily and Anderson (1996), assumed that the 
HIV transmission probability per partnership increased by a factor of 4 in the 
presence of an STI, and simulated the various conditions under which STI cofactors 
might be measured empirically. It was found that when STI exposure was treated as a 
time-varying covariate in the regression model, the measured STI cofactor was around 
2.5. When STI exposure was not treated as a time-varying covariate, the STI cofactor 
was typically less than 1.5 if the follow-up time was greater than 6 months, but closer 
to 2.5 if the follow-up time was less than 6 months. This suggests that the measures of 
association between STIs and HIV incidence, computed in longitudinal studies, are 
likely to under-estimate substantially the true STI cofactors. The potential for bias is 
particularly significant when it is considered that in 15 of the 31 studies included in 
the meta-analysis of Sexton et al (2005), STI exposure was not treated as a time-
varying covariate, and in 13 of these 15 studies, the length of follow-up was greater 
than 6 months. A limitation of Boily and Anderson’s analysis, however, is that the 
model assumes STIs affect the probability of HIV transmission per partnership, and it 
is not clear to what extent the findings would hold if it were instead assumed that STIs 
affect the probability of HIV transmission per act of sex. 
 
The second attempt to estimate the STI cofactor effect using mathematical modelling 
is that of Hayes et al (1995b). Using detailed data from a longitudinal study of HIV 
incidence in Kenyan sex workers (Plummer et al, 1991), Hayes et al estimated that 
GUD increased the probability of male-to-female transmission of HIV by a factor of 
between 12 and 49, with the midpoint estimate being a factor of 23. This was 
substantially greater than the odds ratio of 3.3 (95% CI: 1.2-10.1) for the association 
between HIV incidence and GUD that had been estimated by Plummer et al. 
However, the analysis of Hayes et al has a number of limitations, illustrated by the 
model developed by Korenromp et al (2001). Korenromp et al refined the model of 
Hayes et al to allow for: 











b) lower rates of male circumcision in male partners of women with GUD (the 
model assumes that male-to-female HIV transmission probabilities are three 
times greater when male partners are uncircumcised than when male partners 
are circumcised); and 
c) greater exposure to partners with GUD in women with GUD (the model 
assumes that male GUD increases the efficiency of male-to-female 
transmission five-fold). 
When all three refinements were allowed for simultaneously, it was found that the 
cofactor effect reduced from 23 to 3, similar to the level that had been reported by 
Plummer et al. Although there is some arbitrariness in the assumptions made by 
Korenromp et al, and although the assumed effect of male circumcision on male-to-
female transmission appears implausible (Wawer et al, 2008), the analysis does 
nevertheless demonstrate that the STI cofactor effect can be substantially over-
estimated if certain sources of bias are not taken into account. 
 
Hayes et al (1995b) have also estimated the GUD cofactor effect in the case of 
female-to-male transmission. This is based on a study of Kenyan men with GUD, who 
reported a single act of sex with a commercial sex worker (Cameron et al, 1989). 
Hayes et al estimate that the HIV transmission probability in this study was 0.16 
(95% CI: 0.06-0.32). Assuming the female-to-male HIV transmission probability is 
0.001 in the absence of GUD, they thus calculate that the GUD cofactor effect is 
likely to be 160 (with a range of 60 to 320). However, 0.001 is likely to under-
estimate significantly the probability of HIV transmission in a once-off encounter 
with an HIV-positive sex worker, even if it is assumed that the woman has no GUD. 
A GUD cofactor estimate of 160 is therefore likely to be an over-estimate. In addition, 
it is probable that many of the men with GUD acquired GUD during the single 
exposure to the sex worker, rather than prior to the contact with the sex worker. To 
some extent, therefore, the GUD cofactor effect estimated by Hayes et al represents 
the effect of female GUD on HIV infectiousness rather than the effect of male GUD 












5.1.2 Effect of STIs on HIV infectiousness 
 
HIV-infected individuals are more likely to transmit HIV if they are co-infected with 
other STIs than they are in the absence of other STIs. This is partly due to the 
disruption of mucosal barriers caused by ulcerative STIs; genital ulcers can bleed 
during intercourse, and HIV is often detected in ulcer specimens (Gadkari et al, 1998; 
Schacker et al, 1998a; Kreiss et al, 1989; Plummer et al, 1990). Independently of their 
effect on mucosal barriers, STIs also appear to increase HIV infectiousness by 
promoting HIV viral shedding in the reproductive tract. This may be due to the 
recruitment of HIV-infected leucocytes to the genital tract in response to local 
infection, or it may be the result of increased production of inflammatory cytokines, 
which may stimulate HIV replication (Al-Harthi et al, 2001; Zara et al, 2004; Lawn et 
al, 2000; Cummins et al, 2006). Herpes simplex virus type 2 (HSV-2) can co-infect 
HIV-infected CD4+ cells and cause increased HIV replication (Kucera et al, 1990; 
Moriuchi et al, 2000), and bacterial vaginosis-associated flora may stimulate HIV 
replication through a heat-stable HIV-inducing factor (Cohn et al, 2005). 
 
Several studies have examined the effect of STIs on HIV shedding in genital 
secretions. A meta-analysis of these studies (Rotchford et al, 2000) estimated that the 
odds of detecting HIV in the genital tracts of HIV-infected individuals was increased 
in the presence of gonorrhoea (OR 2.4, 95% CI: 1.8-3.3) and chlamydial infection 
(OR 1.5, 95% CI: 0.9-2.5). To update these estimates and obtain pooled estimates for 
other STIs, a systematic review and meta-analysis was conducted. The PubMed, 
Embase and AIDSearch databases were searched, and the details of those studies that 
were found to estimate the effect of STIs on the detection of HIV in genital specimens 
are summarized in Appendix E. Random effects meta-analyses were conducted for 
each STI using STATA 9.2 (StataCorp, College Station, Texas, USA). A more 
detailed description of the analysis has been published elsewhere (Johnson and Lewis 
2008). The summary odds ratios are shown in Table 5.1.2, and the associated forest 












Table 5.1.2: Combined estimates of effect of STIs on the odds of detectable HIV 
shedding in the genital tract 
STI/symptom 
All studies Studies in women 
# studies OR (95% CI) # studies OR (95% CI) 
Gonorrhoea 7 1.8 (1.2-2.7) 6 1.6 (1.1-2.4) 
Chlamydial infection 5 1.8 (1.1-3.1) 5 1.8 (1.1-3.1) 
Candidiasis 13 1.8 (1.3-2.4) 13 1.8 (1.3-2.4) 
Bacterial vaginosis 11 1.0 (0.7-1.5) 11 1.0 (0.7-1.5) 
Trichomoniasis 9 0.9 (0.7-1.3) 9 0.9 (0.7-1.3) 
Vaginal discharge 6 1.5 (0.9-2.6) 6 1.5 (0.9-2.6) 
Cervical discharge/ 
    cervical mucopus 





Cervicitis 5 2.7 (1.4-5.2) 5 2.7 (1.4-5.2) 
Urethritis 3 3.1 (1.1-8.6) 0 - 
Genital ulcer disease 4 1.8 (0.8-3.8) 3 2.4 (1.2-4.9) 
HSV shedding 6 1.3 (0.7-2.5) 6 1.3 (0.7-2.5) 
Syphilis 4 1.3 (0.9-1.9) 3 1.3 (0.9-1.9) 
 
Table 5.1.2 suggests that there is a strong association between HIV shedding and the 
concentration of leucocytes in the reproductive tract. This is evident from the high 
odds ratios calculated for urethritis (3.1, 95% CI: 1.1-8.6) and cervicitis (2.7, 95% CI: 
1.4-5.2), both of which are defined in terms of the concentration of white blood cells 
(WBCs) or polymorphonuclear leucocytes (PMNLs). It is reinforced by several 
studies that have found PMNL or WBC counts in the reproductive tract to have a 
‘dose-response effect’ on HIV shedding (Cohen et al, 1997; Mostad et al, 1997; Moss 
et al, 1995; Kreiss et al, 1994). Studies have found that trichomoniasis is associated 
with lower leucocyte counts in genital secretions than gonorrhoea and chlamydial 
infection (Krieger et al, 1993a; Hobbs et al, 1999; Levine et al, 1998), and bacterial 
vaginosis has also been shown to have little or no effect on leucocyte counts in 
cervicovaginal secretions (Levine et al, 1998; Cook et al, 1992; Eschenbach et al, 
1988; Wang et al, 2001). The absence of any effect of trichomoniasis and bacterial 
vaginosis on HIV-1 shedding in the genital tract could therefore be explained by the 












Few studies have assessed the relative significance of symptomatic and asymptomatic 
infections on HIV shedding in the genital tract. As noted in section 5.1.1, however, 
symptomatic infections tend to be associated with greater leucocyte concentrations 
than asymptomatic infections, and one might therefore expect symptomatic infections 
to have a more significant effect on HIV-1 shedding. The fact that the detection of 
HIV-1 shedding in the genital tract is significantly associated with GUD but not with 
HSV-2 or serological evidence of syphilis suggests that HSV-2 and syphilis could 
increase HIV-1 shedding when symptomatic, but have relatively little effect when 
asymptomatic. The effect of syphilis on HIV shedding is therefore probably only 
significant during the primary syphilis stage, as symptoms and immune activation in 
the genital tract are rare after the primary stage. Although trichomoniasis does not 
significantly affect the detection of HIV-1 in the genital tracts of women, 
symptomatic trichomoniasis does have a substantial effect on the concentration of 
HIV-1 RNA in the genital tracts of both men and women (Hobbs et al, 1999; Price et 
al, 2003; Wang et al, 2001). Wang et al (2001) have also shown that the reductions in 
HIV-1 RNA concentrations after the treatment of candidiasis and bacterial vaginosis 
are significantly greater in the women with symptoms or signs of infection. 
 
The associations between HSV-2 shedding, candidiasis and HIV-1 shedding may be 
confounded by CD4+ count and/or blood plasma viral load, since both HSV-2 
recurrences and candidiasis are more frequent in the advanced stages of HIV 
infection. This review did not find any significant evidence to suggest that univariate 
associations differ consistently from multivariate associations, after controlling for 
CD4+ count and blood plasma viral load. However, one cannot exclude the possibility 
of confounding. It is also possible that the association between candidiasis and HIV 
shedding may be confounded by the stage of the menstrual cycle, as some studies 
suggest that HIV shedding is most intense during the luteal phase and at the time of 
menstruation (Reichelderfer et al, 2000; Benki et al, 2004; Money et al, 2003), the 
same period in which candidiasis is believed to be most frequent (Bradshaw et al, 
2005; Eckert et al, 1998; Hurley 1981; Kalo-Klein and Witkin 1989). The high odds 
ratio estimated for vulvovaginal candidiasis (1.8, 95% CI: 1.3-2.4) could therefore be 












For most of the infections considered in this meta-analysis, there is little information 
relating to HIV shedding in males, and it is therefore not possible to establish whether 
there are gender differences in the effects of these infections on genital HIV shedding. 
However, since urethritis occurs in almost all male cases of gonorrhoea (Krieger et al, 
1993a; Hobbs et al, 1999; Sturm et al, 2004b), and since urethritis is associated with a 
greater increase in the detection of HIV shedding (OR 3.1, 95% CI: 1.1-8.6) than 
female gonococcal infection (OR 1.6, 95% CI: 1.1-2.4), it seems likely that 
gonococcal infection has a more pronounced effect on HIV shedding in males than in 
females. The evidence also suggests that there may be a gender difference in the 
effect of GUD on HIV shedding, since the one study conducted in males did not find 
a significant association (OR 0.8, 95% CI: 0.3-2.2), while the three studies conducted 
in females suggest a significant effect (combined OR 2.4, 95% CI: 1.2-4.9). However, 
this is likely to reflect a difference in sampling methods rather than a true gender 
difference. In patients with GUD, HIV shedding is likely to be greatest in ulcers; this 
shedding is unlikely to be picked up in male urethral specimens (since male ulcers are 
external) but would be picked up in cervicovaginal specimens (all three female studies 
considered only cervicovaginal ulcers). The effect estimated for males is therefore 
likely to under-state the true effect of GUD on male HIV infectiousness. 
 
Although the pooled odds ratios presented in Table 5.1.2 provide a useful indication 
of the relative effects of different STIs on HIV detection in the genital tract, there has 
been no attempt to quantify the relationship between HIV detection in the genital tract 
and HIV transmissibility, and it is therefore unclear how these odds ratios relate to the 
STI cofactor effect. The model of Chakraborty et al (2001) provides an alternative 
means of estimating the cofactor magnitudes. In this model of male-to-female 
transmission, it is estimated that if the amount of non-synctium-inducing HIV-1 RNA 
per ejaculate increases by a factor of ten, the HIV transmission probability would 
increase by a factor of six (100.778). In the studies of Cohen et al (1997) and Sadiq et 
al (2005), urethritis is estimated to be associated with increases of 0.91 and 0.72 log 
HIV RNA copies per ml of semen respectively. Applying the model of Chakraborty et 
al to these estimates gives STI cofactors of 5.1 and 3.6 respectively. These are slightly 
higher than the pooled odds ratio for urethritis in Table 5.1.2 (3.1, 95% CI: 1.1-8.6), 
which suggests that the odds ratios in Table 5.1.2 could slightly under-state the true 











around the estimate of 0.778, and it is therefore not possible to determine the range of 
uncertainty around the estimated cofactor effects. In addition, the model of 
Chakraborty et al applies only to male-to-female transmission, and it is not clear how 
STI cofactors for female-to-male transmission of HIV would relate to the odds ratios 
in Table 5.1.2. 
 
5.1.3 Multiplicative, additive and saturation effects 
 
Three different models have been proposed for the increase in the HIV transmission 
probability when multiple STIs are present (Korenromp et al, 2001). To illustrate 
these models, suppose that p is the HIV transmission probability per act of sex, in the 
absence of other STIs. Suppose that an individual is exposed to HIV in the presence 
of two other STIs, A and B. Further suppose that δx is the percentage increase in the 
HIV transmission probability if STI x alone is present. The probability of HIV 
transmission in the presence of both A and B, ABp , could be modelled in at least three 
ways: 
• Multiplicative model: ( )( )BAAB pp δδ ++= 11  
• Additive model: ( )BAAB pp δδ ++= 1  
• Saturation model: ( )( )BAAB pp δδ ,max1+=  
 
Statistical models, such as the Cox proportional hazards and Poisson regression 
models, assume multiplicative or additive effects. However, there is very little 
empirical evidence to indicate which of these models is likely to be most realistic. 
Korenromp et al (2001) argue that if the biological mechanisms responsible for the 
increase in the transmission probability differ between A and B, a multiplicative 
model would be biologically plausible. On the other hand, if A and B affect HIV 
transmission through the same mechanism, their effects are more likely to saturate. 
 
5.2 Model estimates of the contribution of STIs to HIV incidence 
 
In Chapter 4, HIV, STI and sexual behaviour parameters were estimated in the 











The purpose of this section is to assess the extent to which different STIs have 
contributed to the spread of HIV, when allowance is made for the effect of STIs on 
HIV transmission probabilities. Because the model is relatively slow to run when HIV 
and all other STIs are being modelled simultaneously, and because there are a large 
number of sources of uncertainty affecting these results, we do not attempt to conduct 
a formal Bayesian analysis in this chapter. For the purpose of this analysis, the most 
important source of uncertainty is the STI cofactor effects (Freeman et al, 2007). The 
approach adopted here is therefore to fix the sexual behaviour parameters at the 
posterior means estimated in section 4.1 and to fix the STI natural history parameters 
at the posterior medians estimated in section 4.2. HIV transmission parameters are 
then estimated for a number of different STI cofactor scenarios. The sections that 
follow describe these STI cofactor scenarios and present the estimated proportions of 
HIV cases attributable to each STI, for each STI cofactor scenario. 
 
5.2.1 STI cofactor scenarios 
 
As discussed in section 5.1.1, the multiple by which HIV susceptibility is increased by 
other STIs could be under-estimated in epidemiological studies, due to lack of 
precision regarding the timing of STI exposure and lack of precision regarding the 
timing of HIV infection. However, it is also possible that epidemiological studies 
could over-estimate the true STI cofactor effects, due to residual confounding with 
unmeasured sexual behaviour and sexual network variables, confounding with the 
effect of STIs in the HIV-infected partner, and publication bias. There is also little 
clarity regarding the relationship between the odds ratios estimated in section 5.1.2 
and the true effect of STIs on HIV infectiousness. Given this uncertainty regarding the 
true STI cofactor effects, it is appropriate to consider a range of possible scenarios 
when modelling HIV-STI interactions. Three scenarios are considered here: 
• Baseline scenario: assumed STI cofactors are similar to those in Tables 5.1.1 
and 5.1.2; 
• High cofactor scenario: STI cofactors are calculated as the STI cofactors in the 
baseline scenario, raised to the power of 1.5; and 
• Low cofactor scenario: STI cofactors are calculated as the STI cofactors in the 












Because the evidence reviewed in section 5.1 suggests that STI cofactors differ 
according to the severity of the symptoms involved, separate STI cofactors are 
assumed for symptomatic ulcerative STIs, symptomatic non-ulcerative STIs, and 
asymptomatic STIs. It is assumed that STI cofactors saturate at the individual level; 
for example, HIV-positive men who are experiencing both ulcerative and non-
ulcerative symptoms are assumed to have the same probability of transmitting HIV as 
men who have ulcerative symptoms alone. However, when STIs are present in both 
sexual partners, the male and female cofactors calculated for each partner are 
multiplied when determining the probability of HIV transmission. Although it is 
possible to allow for multiplicative effects at the individual level, it was found that it 
was not possible to obtain a reasonable fit to HIV prevalence trends in South Africa if 
there was no allowance for saturation of STI cofactors at the individual level. 
 
In the baseline scenario, STI cofactors are set equal to the odds ratios estimated by 
Røttingen et al (2001) and those estimated in Table 5.1.2 as far as possible. The 
assumed STI cofactors are shown in Table 5.2.1. The assumed multiple by which 
female HIV infectiousness is increased in the presence of GUD (3.5) is greater than 
the OR relating HIV shedding in females to the presence of GUD (2.4), because the 
latter does not reflect the effect of direct contact with genital ulcers on the probability 
of HIV transmission. In the absence of reliable data for males, the same STI cofactor 
for male GUD is assumed. The assumed multiple by which HIV infectiousness is 
increased in the presence of female non-ulcerative symptoms (1.7) is close to the odds 
ratios estimated for vaginal discharge (1.5) and cervical discharge (1.8), while the 
corresponding multiple for males has been set equal to the odds ratio for urethritis 
(3.1), since virtually all men with symptomatic gonorrhoea, trichomoniasis or 
chlamydial infection have urethritis (Krieger et al, 1993a; Hobbs et al, 1999). The 
assumed multiple by which asymptomatic STIs increase HIV infectiousness (1.2) is 
based on the odds ratios estimated for bacterial vaginosis (1.0), trichomoniasis (0.9), 
HSV shedding (1.3) and syphilis (1.3), all of which are mostly asymptomatic. In men, 
most asymptomatic infection is related to HSV-2, and the assumed effect of 
asymptomatic STIs on male susceptibility to HIV is therefore set at 2.0, slightly lower 
than the OR relating HSV-2 to male HIV susceptibility (2.7). The assumed multiple 











the odds ratios estimated for bacterial vaginosis (1.4), trichomoniasis (1.5) and 
candidiasis (2.2). In the case of syphilis, no cofactor effect is assumed to apply in the 
latent stage of disease, as there are no symptoms or immune activation in the genital 
tract to increase either HIV susceptibility or HIV infectiousness during the latent 
stage. 
 






Male Female Male Female 
Baseline 
scenario 
Ulcerative symptoms 4.4 2.8 3.5 3.5 
Discharge/dysuria symptoms 2.6 1.6 3.1 1.7 
Asymptomatic infection 2 1.5 1.2 1.2 
High cofactor 
scenario 
Ulcerative symptoms 9.2 4.7 6.5 6.5 
Discharge/dysuria symptoms 4.2 2.0 5.5 2.2 
Asymptomatic infection 2.8 1.8 1.3 1.3 
Low cofactor 
scenario 
Ulcerative symptoms 2.1 1.7 1.9 1.9 
Discharge/dysuria symptoms 1.6 1.3 1.8 1.3 
Asymptomatic infection 1.4 1.2 1.1 1.1 
 
For each scenario, HIV transmission probabilities in the absence of STIs and initial 
HIV prevalence levels in the high risk group are set at levels that produce model 
results consistent with the HIV prevalence observed in surveys. These assumed HIV 
transmission probabilities and initial HIV prevalence levels in the high-risk group are 
shown in Table 5.2.2. For comparison purposes, the posterior means of these 
parameters, from the analysis in which STI cofactors were not included (section 4.1), 
are also shown. Although it might be expected that HIV transmission probabilities in 
the absence of other STIs would be similar for all relationship types, different HIV 
transmission probabilities are specified for each relationship type because HIV 
susceptibility would be expected to vary in relation to the cumulative level of HIV 
exposure, and because it is difficult to obtain reasonable fits to South African HIV 
prevalence data if the HIV transmission probabilities are assumed to be the same for 












Table 5.2.2: Assumed initial HIV prevalence and HIV transmission probabilities in 













Initial HIV prevalence in high risk group 0.17% 0.16% 0.19% 0.1827% 
Male-to-female HIV transmission 
   probability if no STIs present 
    
      Client-sex worker contacts 0.0012 0.0005 0.0022 0.003 
      Short-term relationships 0.0048 0.0034 0.0076 0.006483
      Long-term relationships 0.001 0.0007 0.0015 0.002434
Female-to-male HIV transmission 
   probability if no STIs present 
    
      Client-sex worker contacts 0.02 0.01 0.025 0.03 
      Short-term relationships 0.003 0.0017 0.0045 0.003586
      Long-term relationships 0.0006 0.0004 0.001 0.00173 
 
5.2.2 Calibration to HIV prevalence data 
 
Figure 5.2.1 shows the calibration of the model to the antenatal prevalence and sex 
worker prevalence data, for each of the STI cofactor scenarios described previously. 
On the whole, the calibration is reasonable, with levels of HIV prevalence similar to 
those estimated in section 4.1. It was found to be difficult to reproduce the HIV 
prevalence trends observed in the 15 to 19 age group, particularly when high STI 
cofactors were assumed. This is probably because the reductions in the prevalence of 
syphilis, chancroid, gonorrhoea and trichomoniasis in recent years (section 4.2) imply 
a substantial reduction in HIV incidence if high STI cofactors are assumed, and the 
HIV prevalence trends in the 15 to 19 age group are not consistent with such a steep 
decline in HIV incidence. It was also found to be difficult to match the “levelling off” 
of HIV prevalence levels in the general population in recent years if low STI cofactors 
were assumed. This is probably because low STI cofactors imply relatively little 











with the result that the incidence of HIV in the low risk group is higher than in other 
STI cofactor scenarios, and HIV prevalence therefore stabilizes at a relatively high 
level, at a relatively late stage in the epidemic. The difficulties experienced in fitting 
the model in the high and low cofactor scenarios suggest that the STI cofactors 


























































































































































































Figure 5.2.1: Calibration of model to HIV prevalence data from national antenatal 
clinic surveys and studies of sex workers 
 
Figure 5.2.2 shows the calibration of the model to HIV prevalence data from the 
national household survey that was conducted in 2005 (Shisana et al, 2005). The 
model estimates are again reasonably consistent with the levels of HIV prevalence 



























































































Figure 5.2.2: Calibration of model to HIV prevalence data from the 2005 HSRC 
household survey 
 
5.2.3 Population attributable fractions 
 
The population attributable fraction (PAF) of a particular STI for HIV transmission is 
estimated by running the model up to a particular year, calculating the number of new 
HIV infections in that year, and then recalculating the number of new HIV infections 
that would be expected in that year if the STI of interest were eliminated at the start of 
the year. The PAF is then calculated as the percentage reduction in the number of new 
HIV infections that occurs as a result of the removal of the STI. This calculation was 
performed for each STI, for each STI cofactor scenario and for four different years 
(1990, 1995, 2000 and 2005). The results of these calculations are shown in Figure 
5.2.3. 
 
Figure 5.2.3 shows that at all stages in the South African HIV/AIDS epidemic, genital 
herpes is the STI that has contributed most substantially to the transmission of HIV, 
accounting for roughly 20% of all new HIV cases in the baseline scenario, throughout 
the 1990-2005 period. Gonorrhoea and chancroid also contributed significantly to the 
transmission of HIV in the early stages of the HIV/AIDS epidemic (PAFs of 13% and 
12% respectively, in the baseline scenario in 1990), probably because they are both 
highly symptomatic infections and are thus associated with high STI cofactors. 
However, the contribution of chancroid and gonorrhoea to the transmission of HIV 
has diminished considerably since the initiation of behaviour changes and 
improvements in STI treatment in the mid-1990s. Syphilis, trichomoniasis and 











baseline scenario, but their importance has also diminished as a result of subsequent 
declines in the prevalence of these infections. Bacterial vaginosis and vulvovaginal 
candidiasis have the smallest PAFs (less than 5% in all scenarios and in all years), 
probably because these infections occur only in women and are mostly asymptomatic. 
Although bacterial vaginosis and vulvovaginal candidiasis are both highly prevalent 
in women, there is a high prevalence of other asymptomatic infections in women, and 
hence the removal of one infection has relatively little effect on the overall prevalence 
of asymptomatic infection in women. This means that the removal of one 
predominantly asymptomatic infection in women has relatively little effect on HIV 
transmission probabilities, if it is assumed that STI cofactors saturate at the individual 
level. 
 
The PAFs of all STIs for HIV transmission were calculated in the same way as before, 
except that the effect of eliminating all STIs was modelled by setting all STI cofactor 
multiples to one at the start of the year of interest. Similarly, the PAFs of ulcerative 
symptoms for HIV transmission were calculated by setting only the ulcerative 
symptom cofactor to one at the start of the relevant year. The results of these PAF 
calculations are shown in Figure 5.2.4. It is estimated that in 1990, 69% of all new 
HIV infections were attributable to other STIs, but that by 2005 this proportion had 
declined to 48% (baseline scenario). A more substantial reduction is estimated in the 
case of the proportion of new HIV cases attributable to genital ulcer disease: from 
25% in 1990 to 6% in 2005, in the baseline scenario. The substantial reduction in the 
PAF of ulcerative symptoms for HIV transmission is a reflection of the steep declines 
in the prevalence of chancroid and syphilis, which were previously the leading causes 



























































































1990 1995 2000 2005
 
Figure 5.2.3: Population attributable fractions of STIs for HIV transmission 
Grey bars represent results from baseline scenario. Upper and lower error bars represent results from 




































1990 1995 2000 2005
 
Figure 5.2.4: Population attributable fractions of STIs for HIV transmission 
Grey bars represent results from baseline scenario. Upper and lower error bars represent results from 
‘high STI cofactor’ and ‘low STI cofactor’ scenarios respectively. 
 
5.3 Comparison with other estimates of population attributable 
fractions 
 
Since there is much uncertainty regarding STI cofactors, it is useful to compare the 
population attributable fractions (PAFs) estimated in section 5.2.3 with empirical 
estimates of PAFs and other model-based estimates of PAFs. PAFs of STIs for HIV 
transmission can be expected to vary between populations and even between different 
groups within the same population (Vittinghoff and Padian 1996), and these 
comparisons should therefore be treated with some caution. Section 5.3.1 compares 
our model estimates with empirical PAF estimates, and section 5.3.2 compares our 
estimates with other model-based PAF estimates. 
 
5.3.1 Comparison with empirical estimates of population attributable fractions 
 
The method used to derive empirical estimates of PAFs differs in several respects 
from the method used in model-based evaluations of PAFs. Empirical estimates of the 
PAF of a particular STI for HIV transmission are usually calculated using the 



















RRCFPAF 1        (5.1) 
 
where CF is the ‘case fraction’ (the prevalence of the STI in those who acquire HIV 
over the study period), and RR is the relative risk of HIV acquisition in individuals 
with the STI, compared to those without the STI. The PAF thus represents the 
proportion of incident cases that would not have occurred if the STI of interest was 
absent. In model-based evaluations, however, the PAF of an STI for HIV transmission 
is calculated as the reduction in HIV incidence that would be expected over one year 
if the STI were eliminated at the start of that year (Robinson et al, 1997; Orroth et al, 
2006; Boily et al, 2002). 
 
Empirical estimates of PAFs might under-estimate the ‘true’ proportion of HIV cases 
attributable to other STIs for several reasons: 
• The limited sensitivity of STI diagnostics and self-reporting of STI symptoms 
implies that empirical estimates of PAFs are likely to be based on under-
estimates of CF. 
• The limited sensitivity of STI diagnostics and self-reporting of STI symptoms 
also weakens the strength of association, as measured by RR. Empirical 
estimates of PAFs are therefore also likely to be based on under-estimates of 
RR. 
• Empirically derived PAFs only measure the effect of STIs when present in the 
HIV-negative partner and not the effects of STIs when present in the HIV-
positive partner (Orroth et al, 2006). 
 
However, empirical estimates of PAFs could also over-estimate the true fractions. 
Firstly, the relative risk estimates used in the PAF calculation could exaggerate the 
true association if sexual behaviour variables and sexual network characteristics have 
not been adequately controlled for. Secondly, it is common for empirical estimates of 
PAFs to be based on the odds ratio, as an approximation to the relative risk 
(Hennekens and Buring 1987). Although the approximation is acceptable when the 
rate of HIV incidence is low, the odds ratio is likely to overstate the risk ratio when 











the ‘true’ PAF, particularly when the HIV incidence in the cohort being studied is 
high (as is typically the case in studies of sex workers and their clients). 
 
Empirically derived PAFs are summarized in Table 5.3.1. Several of these estimates 
have been calculated by Fleming and Wasserheit (1999). Although 95% confidence 
intervals are generally not calculated due to the difficulties associated with 
determining these (Miettinen 1974), a crude measure of spread can be obtained by 
substituting the upper and lower 95% confidence interval limits around the RR/OR 
into equation (5.1). This understates the true range of uncertainty, as it does not take 
into account the uncertainty regarding the CF variable. The ranges of uncertainty are 
nevertheless very wide, indicating that it is difficult to determine PAFs precisely in 
empirical studies. 
 
The studies of Cameron et al (1989), Plummer et al (1991) and Laga et al (1993) 
were all conducted in high-risk populations in the late 1980s. The PAFs estimated in 
these studies therefore correspond to the very early stages of the AIDS epidemic, and 
can be compared with the South African model estimates for 1990 (see Figures 5.2.3 
and 5.2.4). The study of Orroth et al (2000) was conducted in the early stage of the 
Tanzanian epidemic, in the general population, and is therefore comparable with the 
South African model estimates for 1995. The study of Gray et al (1999) was 
conducted in the general population in the later stages of the Ugandan epidemic, after 
significant behaviour change had already occurred, and is therefore comparable with 













Table 5.3.1: Empirically-determined PAFs of STIs for HIV incidence 
Study Population, date 
Disease/ 
symptoms 




et al (1989) 
Male clients of 
Nairobi sex workers, 




69% (20-82%)a ORc 
Plummer 
et al (1991) 
Female sex workers 
in Nairobi, 1985-7 
GUD Genital 
examination 
44% (10-56%)a ORc 
Chlamydial 
   infection 
Culture 25% (0-34%)a ORc 
Syphilis Serology 10% (0-27%)a ORd 
Laga et al 
(1993) 
Female sex workers 
in Kinshasa, 1988 
Gonorrhoea Culture 44% (33-50%)a ORc 
Chlamydial 
   infection 
EIA 22% (9-28%)a ORc 




Syphilis Serology 6% (0-8%)a ORd 
Chancroid Serology 1% ORd 
Gray et al 
(1999) 
Men and women in 




13% (4-20%)b RRc 
Discharge/ 
   dysuria 
4% (0-12%)b RRc 
Orroth 
et al (2000) 
Men in control arm 




30% (12-45%)b ORd 
Discharge 25% (2-42%)b ORd 
Syphilis Serology 4% (0-17%)b ORd 
Women in control arm 




7% (0-15%)b ORd 
Discharge 4% (0-19%)b ORc 
Syphilis Serology 7% (0-25%)b ORc 
a Approximate, based on 95% confidence interval around RR/OR. b Published 95% CI. c Controlling 
for sexual behaviour. d Not controlling for sexual behaviour. 
EIA = enzyme immunoassay. GUD = genital ulcer disease. PAF = population attributable fraction. 
 
Model estimates in the baseline scenario suggest that the PAF of GUD for HIV 
transmission would be expected to decline from 25% in 1990 to 6% in 2005. These 
estimates are roughly consistent with the high empirical PAFs estimated in studies of 
sex workers and their clients (69%, 44% and 4%, with wide ranges of uncertainty), 











advanced epidemics (30%, 13% and 7%, also with wide ranges of uncertainty). 
Empirical PAFs of syphilis are between 4% and 10%, consistent with the model 
baseline predictions of the proportion of HIV cases attributable to syphilis up to 1995 
(4-7%). The model estimates that in 1990, 6% of new HIV infections were 
attributable to chlamydial infection, which is lower than the empirical estimates of 
22% and 25% in sex workers, though the ranges of uncertainty around the empirical 
estimates are very wide. Plummer et al (1991) found that gonorrhoea did not increase 
the risk of HIV acquisition among sex workers in Nairobi, but gonorrhoea was 
estimated to have accounted for almost half of new HIV cases among sex workers in 
Kinshasa (Laga et al, 1993). The model estimates that 14% of new HIV infections in 
1990 are attributable to gonorrhoea, which is between these two empirical estimates 
for early-stage epidemics. The incidence of chancroid in the study of Kinshasa sex 
workers was unusually low, which explains the low PAF calculated for chancroid in 
this study. Self-reported symptoms of discharge are generally not considered to be 
reliable indicators of sexually transmitted infection, and empirical PAFs for 
discharge/dysuria are therefore not considered in this comparison, though the 
empirical PAFs are shown in Table 5.3.1. 
 
In summary, empirical estimates of the proportion of incident HIV attributable to 
STIs are likely to be biased for several reasons, and ranges of uncertainty around 
these empirical estimates are extremely wide. The true proportion of HIV cases 
attributable to STIs can also be expected to vary substantially between populations, 
and the empirical estimates of PAFs in other African settings therefore cannot be used 
to validate the assumed STI cofactors in a South African model of HIV-STI 
interactions. Nevertheless, our model estimates of the proportions of incident HIV 
cases attributable to other STIs appear to be roughly consistent with most empirical 
estimates. 
 
5.3.2 Comparison with other model-based estimates of population attributable 
fractions 
 
The PAF estimates presented in section 5.2 are compared here with estimates from the 
SimulAIDS model (Robinson et al, 1997), applied to Uganda; estimates from the 











et al, 2006); and estimates of a model of HIV-HSV interactions (Abu-Raddad et al, 
2008), applied to Kenya. The STI cofactor assumptions in these analyses are shown in 
Table 5.3.2. Due to the uncertainty regarding STI cofactors, Robinson et al present 
estimates for both ‘high’ and ‘low’ STI cofactor scenarios. In both the SimulAIDS 
and STDSIM models, the multiple by which the HIV transmission probability per sex 
act is increased is assumed to be the same whether the STI is present in the HIV-
infected or HIV-susceptible partner. No gender differences in STI cofactors are 
assumed in any of the models. 
 
Table 5.3.2: Assumed STI cofactors 
Study STI Cofactor 
Robinson et al 
(1997) 
Ulcerative STIs: High cofactor 100 
                            Low cofactor 10 
Non-ulcerative STIs: High cofactor 5 
                                   Low cofactor 2 
Orroth et al 
(2006) 
Chancroid 25 
Herpes: Primary ulcer 25 
              Recurrent ulcer 10 
              Asymptomatic 1 
Syphilis: Primary/secondary 7.5 
               Latent infection 1 
Chlamydial infection 3 
Gonorrhoea 3 
Trichomoniasis: Symptomatic 2 
                           Asymptomatic 1 
Abu-Raddad et al 
(2008) 
Herpes: HSV-2 shedding in HIV-positive partner 3 
              HSV-2 shedding in HIV-negative partner 4 
              No HSV-2 shedding 1 
 
All model-based PAF estimates presented here are calculated in the same way, i.e. as 
the percentage reduction in the incidence of HIV over one year as a result of the 
removal of the relevant STI(s) at the start of that year. Because PAFs of STIs for HIV 











HIV/AIDS epidemic, the PAFs estimated in different analyses are arranged according 
to the number of years from the assumed start of the HIV/AIDS epidemic (Figure 
5.3.1).  
 
Our model estimates of the proportion of new HIV infections attributable to all STIs 
combined are roughly consistent with results from other analyses (Figure 5.3.1(a)). 
Although our estimates of the proportion of incident HIV attributable to genital herpes 
is consistent with the STDSIM model in the early stages of the HIV/AIDS epidemic, 
the STDSIM model suggests a substantial rise in the PAF of HSV-2 for HIV 
transmission in the later stages of the HIV/AIDS epidemic, which our model does not 
predict (Fig 5.3.1(b)). This is probably because the STDSIM model assumes a much 
greater cofactor than our model in the case of symptomatic HSV-2, and symptomatic 
HSV-2 infection becomes more prevalent as the HIV/AIDS epidemic progresses. The 
model of Abu-Raddad et al (2008), which assumes that the HSV-2 cofactor only 
applies during periods of HSV-2 shedding, predicts that about 25% of incident HIV 
can be attributed to HSV-2, with no significant increase in the proportion of incident 
HIV attributable to HSV-2 as the HIV/AIDS epidemic matures. These results for 
Kenya are more consistent with our model predictions for South Africa. 
 
STDSIM projections of PAFs for chancroid and chlamydial infection are compared 
with our model predictions in Figures 5.3.1(c) and (d). The STDSIM model predicts a 
higher proportion of incident HIV attributable to chancroid than our model in the 
early stages of the HIV/AIDS epidemic, probably because of the high cofactor 
assumed for chancroid in the STDSIM model (25). In most of the applications of the 
STDSIM model, a dramatic decline in the proportion of HIV attributable to chancroid 
is predicted, which is consistent with our model. The STDSIM model also predicts a 
slightly higher proportion of HIV attributable to chlamydial infection when compared 
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Figure 5.3.1: Comparison of population attributable fractions of STIs for HIV 
transmission, estimated in different models 
PAFs are arranged according to the number of years from the assumed start of the HIV/AIDS epidemic 
(x axis). 
 
In summary, our model estimates of the overall proportion of new HIV infections 
attributable to other STIs are roughly consistent with estimates from other models. 
However, our estimates of the proportions of incident HIV attributable to chancroid 
and herpes are lower than those estimated by STDSIM in the early and late stages of 
the HIV/AIDS epidemic respectively. This is likely to be a reflection of the 















The results presented in section 5.2.3 show clearly that a high proportion of new HIV 
infections are directly attributable to other STIs. Consistent with the results of other 
models (Orroth et al, 2006; Robinson et al, 1997), this proportion appears to decline 
over the course of the HIV/AIDS epidemic. There are two likely explanations for this 
decline: (a) behavioural change and change in STI treatment, in response to the 
HIV/AIDS epidemic, can be expected to reduce STI prevalence; and (b) in the early 
stages of the HIV/AIDS epidemic, it is the individuals with the highest risk of other 
STIs who are the first to get infected with HIV. The PAFs of genital herpes and 
vulvovaginal candidiasis increase slightly after 1995, largely as a result of the 
assumed effect of HIV immunosuppression on the incidence of symptomatic HSV-2 
and candidiasis. 
 
Considering that around 20% of new HIV infections are currently attributable to 
genital herpes, it is particularly important that interventions be introduced to prevent 
and treat HSV-2. Gonorrhoea and chlamydial infection also account for a significant 
proportion of new HIV infections, and these should also be the focus of prevention 
efforts. Possible strategies for limiting the spread of these infections are assessed in 
chapter 6. Syphilis and chancroid, however, account for a negligible fraction of new 
HIV cases, and improvements to treatment for these STIs would therefore not affect 
future HIV incidence to any significant extent.  
 
In assessing the contribution of different STIs to the incidence of HIV, we have 
considered a simple one-way sensitivity analysis rather than a formal uncertainty 
analysis. The ‘baseline’, ‘high’ and ‘low’ scenarios therefore do not reflect the full 
range of uncertainty around the PAFs of STIs for HIV transmission. This is partly 
because uncertainty surrounding the true STI prevalence is not reflected in these 
calculations. In addition, uncertainty regarding the relative magnitude of 
asymptomatic and symptomatic STI cofactors is not reflected, and this could be 
significant for STIs such as HSV-2, which are largely asymptomatic. For example, 
Orroth et al (2006) estimate that if the cofactor for asymptomatic HSV-2 were to 











of HSV-2 for HIV transmission would increase from 12% to 32% in the context of the 
Mwanza trial, and from 23% to 53% in the context of the Rakai trial. 
 
There is also much uncertainty regarding STI cofactors when multiple STIs are 
present, and this significantly affects PAF calculations because of the high proportion 
of the population that has multiple infections. We have assumed that STI cofactors 
‘saturate’ at the individual level, i.e. if the same individual is infected with multiple 
STIs, only the STI with the greatest cofactor affects the HIV transmission probability. 
If one were to assume instead that the multiplicative effect of a particular STI remains 
the same regardless of the other STIs present, the PAFs would be higher, particularly 
for those infections that are largely asymptomatic, and particularly in females (since 
females have a much higher prevalence of multiple infections than males). The PAFs 
for bacterial vaginosis and vulvovaginal candidiasis could therefore be under-
estimated substantially if STI cofactors were indeed fully multiplicative and did not 
saturate at the individual level. However, attempts to fit the model using 
multiplicative STI cofactors did not produce reasonable results when using the 
cofactor estimates presented in Tables 5.1.1 and 5.1.2. Under the fully multiplicative 
model, the substantial reductions in the prevalence of chancroid, syphilis, gonorrhoea 
and trichomoniasis since 1995 would imply substantial reductions in the incidence of 
HIV in recent years, in excess of the reductions suggested by the available HIV 
prevalence data. Under the ‘saturation’ model, however, the effect of the decline in 
curable STIs is weaker because of the relatively stable prevalence of HSV-2, bacterial 
vaginosis and vulvovaginal candidiasis. In addition to the saturation model producing 
HIV incidence trends more consistent with the available data, it is arguably a more 
biologically plausible model than the fully multiplicative model (Korenromp et al, 
2001). 
 
It is possible that different STIs may have different STI cofactors, even after 
controlling for whether they are symptomatic. This is another source of uncertainty 
not reflected in the PAF calculations. For example, if asymptomatic candidiasis has a 
higher STI cofactor than asymptomatic bacterial vaginosis and asymptomatic 
trichomoniasis (as Tables 5.1.1 and 5.1.2 suggest), the PAF of candidiasis for HIV 
transmission could be under-estimated substantially. However, given the wide 











and the sources of bias inherent in STI cofactor estimation, it is difficult to argue that 
there is indeed heterogeneity between STIs in terms of their effects on HIV 
transmission, after controlling for symptoms. We have adopted the parsimonious 
approach of setting STI cofactor assumptions for each STI syndrome, as it would be 
difficult to set STI cofactor assumptions separately for each STI (both symptomatic 
and asymptomatic) on the basis of the limited data available.  
 
Most models of HIV-STI interactions assume that the probability of HIV transmission 
per act of sex is constant with respect to the relationship type and the cumulative 
number of exposures to the infected partner. Our model is unusual in that it assumes 
that the probability of HIV transmission, in the absence of other STIs, is dependent on 
the nature of the relationship. Although initial attempts were made to fit the model 
with HIV transmission probabilities that were constant with respect to the relationship 
type, this was found to give poor fits to the age- and sex-specific HIV prevalence 
data. This suggests that variation in HIV transmission probabilities cannot be 
explained only by variation in viral load over the course of HIV disease or variation in 
HIV transmission probabilities due to other STIs, since both factors are already 
allowed for in the model. As discussed in section 3.3.2, there is much evidence 
showing that the probability of HIV transmission per sex act reduces as the 
cumulative number of sexual exposures to the HIV-infected partner increases (Downs 
and De Vincenzi 1996; Padian et al, 1990). Consistent with these empirical 
observations, we have estimated substantially lower HIV transmission probabilities, 
per act of sex, in long-term spousal relationships than in short-term non-spousal 
relationships. We have also estimated that the risk of female-to-male transmission in a 
single act of sex is higher in once-off encounters between sex workers and clients than 
in short-term relationships. However, the estimated probability of male-to-female 
transmission per sex act is substantially lower in contacts between sex workers and 
clients than in short-term relationships. Sex workers do not generally have many 
contacts with the same partner, and might therefore be expected to have a greater risk 
of transmission per act of sex with an infected partner than women in short-term 
relationships. The fact that they do not supports the hypothesis that individuals who 
are highly exposed to HIV may develop immune responses that protect against HIV 











These sources of variation in HIV transmission probabilities should be further 













Chapter 6: Prospects for HIV and STI prevention 
 
This chapter assesses the impact of past HIV and STI prevention programmes (section 
6.1), and then examines the potential effect of future changes to STI treatment and 
sexual behaviour (sections 6.2 and 6.3 respectively). Results are compared with 
empirical estimates and results from other models, and policy implications are 
discussed in section 6.4. 
 
6.1 The effect of past changes in sexual behaviour and STI 
treatment on STI prevalence and HIV incidence 
 
The Bayesian analysis presented in section 4.2 suggests that there have been 
significant declines in the prevalence of most STIs in South Africa, over the last two 
decades. There are three possible explanations for these declines. Firstly, the declines 
may be due to the effects of improvements in the quality of STI treatment, especially 
the introduction of syndromic management protocols. Secondly, declines in STI 
prevalence could be due to increases in condom use, which have been the result of 
information and education campaigns (IEC) and condom promotion programmes. 
Lastly, declines in the prevalence of STIs may be the result of rising levels of AIDS 
mortality, which would be expected to deplete the ‘high risk’ groups to a greater 
extent than the ‘low risk’ groups, and thus change the overall STI prevalence. The 
purpose of this section is to evaluate the relative significance of each of these three 
explanations, for each of the STIs, through the consideration of a number of different 




In order to quantify the relative significance of each of the three factors affecting the 
trends in STI prevalence, four scenarios are considered: 
• ‘Baseline’ scenario: This is the same as the scenario presented in Chapter 4 
and described in Chapter 3, i.e. it represents our most realistic assessment of 











• ‘No syndromic management’ scenario: This is the same as the ‘baseline’ 
scenario, except that there is assumed to be no introduction of syndromic 
management protocols in South Africa and no reduction in the extent of STI 
drug shortages. 
• ‘No IEC’ scenario: This is the same as the ‘no syndromic management’ 
scenario, except that levels of condom use are assumed to remain unchanged 
from their levels in 1985, i.e. it represents what might have been expected if 
there had been no information and education campaigns, no change in sexual 
behaviour in response to HIV/AIDS, and no change in STI treatment practices. 
• ‘No AIDS’ scenario: This is the same as the ‘No IEC’ scenario, except that 
HIV is assumed never to have entered the population. 
 
The means of the posterior predictions are compared graphically for each scenario. In 
addition, the percentage reduction in STI prevalence attributable to each of the three 
factors is calculated in 2005, by comparing the first and second scenarios (to assess 
the role of improvements in STI treatment), the second and third scenarios (to assess 
the role of increased condom use) and the third and fourth scenarios (to assess the role 
of HIV/AIDS). The effects of the three factors could be calculated in different ways, 
and the percentage reductions in STI prevalence would change slightly if one were to 
alter the order in which the different model parameters are changed.  
 
The first three scenarios are also considered when examining the effects of past 
changes in sexual behaviour and STI treatment on HIV incidence. Trends in annual 
numbers of new HIV infections are calculated for each of these three scenarios, for 
each of the three cofactor settings described in section 5.2.1. Percentage reductions in 
annual numbers of new HIV infections are then calculated for each cofactor setting. 
 
6.1.2 Factors accounting for past changes in STI prevalence 
 
Figure 6.1.1 shows the posterior mean STI prevalence trends, for each of the four 
scenarios defined previously. Results are shown for women aged 15 to 49 (prevalence 
levels in men follow similar trends). The percentage reductions in STI prevalence in 












Syndromic management has substantially reduced the prevalence of chancroid, 
syphilis and gonorrhoea, probably because all of these infections become 
symptomatic in a high proportion of cases, and are thus particularly amenable to 
improvements in the quality of treatment for symptomatic STIs. However, current 
syndromic management protocols do not represent any improvement over past STI 
treatment practices in the cases of genital herpes and vaginal candidiasis, and hence 
the prevalence of these infections is virtually unchanged with the introduction of 
syndromic management. Although there have been marked improvements in the 
quality of treatment for trichomoniasis and chlamydial infection under the new 
syndromic management protocols, the trends in the prevalence of these two infections 
are virtually indistinguishable under the ‘baseline’ and ‘no syndromic management’ 
scenarios. This is because in both cases the estimated duration of untreated 
symptomatic infection is substantially shorter than the duration of untreated 
asymptomatic infection, and most infections do not become symptomatic. As a result, 
reductions in the duration of symptomatic infection have relatively little effect, 
especially when counterbalanced by reductions in the prevalence of immunity (in both 
cases it is assumed that immunity is less likely to develop after treatment than after 
spontaneous resolution of infection). 
 
Increases in condom usage also appear to have brought about substantial reductions in 
STI prevalence, and in many cases, this reduction is greater than that achieved 
through improvements in STI treatment alone. The prevalence of bacterial vaginosis 
and vaginal candidiasis is not significantly affected by changes in condom use, since 
neither infection is assumed to be sexually transmissible, and the ‘No IEC’ scenario is 























































































































































































































































Figure 6.1.1: Trends in STI prevalence among women aged 15-49, over the 1990-
2006 period, under different scenarios 
 ‘Baseline’ is the actual past trend in STI prevalence, ‘no SM’ is the trend that would have been 
expected in the absence of change in STI treatment practices, ‘no IEC’ is the trend that would have 
been expected if no changes in STI treatment or sexual behaviour occurred, and ‘no AIDS’ is the trend 























































































Figure 6.1.2: Percentage reductions in STI prevalence in 2005, among individuals 
aged 15-49, attributable to different factors 
Error bars represent 95% prediction intervals. The percentage reduction in prevalence due to syndromic 
management is the difference between the ‘no SM’ and ‘baseline’ scenarios, expressed as a percentage 
of the prevalence in the ‘no SM’ scenario. Similarly, the percentage reduction in prevalence due to 
increased condom use is the difference between the ‘no IEC’ and ‘no SM’ scenarios, expressed as a 
percentage of the prevalence in the ‘no IEC’ scenario, and the percentage reduction due to AIDS 
mortality is the difference between the ‘no AIDS’ and ‘no IEC’ scenarios, expressed as a percentage of 












Lastly, HIV/AIDS has brought about modest reductions in the prevalence of most 
STIs. Two exceptions are HSV-2 and vaginal candidiasis. The prevalence of HSV-2 is 
expected to rise as a result of HIV/AIDS because HSV-2-infected individuals who are 
co-infected with HIV are assumed to experience greater frequency of HSV-2 
shedding and HSV-2 symptoms, and are thus more likely to transmit HSV-2 than they 
would be in the absence of HIV infection. The prevalence of vaginal candidiasis is 
also expected to rise slightly, due to the assumed increase in the frequency of vaginal 
candidiasis in the later stages of HIV infection.  Figure 6.1.1 shows that for most 
STIs, the prevalence in the ‘no AIDS’ scenario is stable over time. However, the 
prevalence of syphilis increases slightly over time, probably because of declining 
levels of fertility and associated declines in the rate at which women receive antenatal 
screening for syphilis. 
 
6.1.3 The effect of past interventions on HIV incidence 
 
Figure 6.1.3 shows the annual percentage reduction in HIV incidence attributable to 
(a) improvements in STI treatment and (b) increases in condom use, for each of the 
STI cofactor scenarios. The improvements in STI treatment that have occurred to date 
are estimated to have achieved a modest 6.0% reduction in the total number of new 
HIV infections over the period from mid-1994 to mid-2004 (i.e. the ten years 
following the introduction of syndromic management protocols in South Africa). 
Corresponding reductions in the low and high cofactor scenarios are 3.0% and 10.0% 
respectively. The reduction in HIV incidence is greatest around 1998, when the 
rollout of syndromic management protocols in the public health sector is close to its 
maximum, but thereafter the effect on HIV incidence starts to diminish. A possible 
interpretation of this result is that syndromic management delays new HIV infections 
without bringing about a substantial reduction in individuals’ long-term risk of HIV 
acquisition. The reduction after 1998 could also be due to the decline in the 
proportion of new HIV infections attributable to curable STIs. 
 
Much greater reductions in HIV incidence have been achieved as a result of increases 
in condom use, and these reductions are relatively insensitive to the assumed 











infections over the period from mid-1994 to mid-2004 is 27.3% in the baseline 
cofactor scenario, 26.3% in the low cofactor scenario and 28.8% in the high cofactor 
scenario. These reductions in HIV incidence have increased steadily over time, in line 
with the assumed trends in condom use. By 2005, the annual number of new HIV 
infections is between 46% and 51% lower in the ‘no syndromic management’ 
scenario than in the ‘no IEC’ scenario. 
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Figure 6.1.3: Percentage reductions in annual HIV incidence due to past interventions, 
over the 1990-2006 period 
Percentage reductions are calculated by comparing the ‘baseline’ and ‘no syndromic management’ 
scenarios in panel (a) and the ‘no syndromic management’ and ‘no IEC’ scenarios in panel (b). 
 
6.2 The potential effects of future improvements in STI treatment 
 
The analysis thus far has examined the effects of past improvements in STI treatment 
practices in South Africa. As discussed in section 3.3.4, however, many significant 
obstacles still prevent the prompt and effective treatment of STIs in South Africa. 
Section 6.2.1 reviews some of the strategies that have been proposed for improving 
treatment of STIs and expanding current programmes, and explains how the model 
has been extended to allow for the effect of these interventions. In section 6.2.2, the 
effects of these interventions on STI prevalence are assessed, and in section 6.2.3 the 












6.2.1 Assumed future changes to STI treatment 
 
Several changes to STI treatment in South Africa have been proposed by various 
experts in STI epidemiology. These potential changes can be divided into five 
categories: 
• Increases in adoption of syndromic management protocols 
• Modifications to existing syndromic management protocols 
• Patient-initiated treatment for genital herpes 
• Changes in health-seeking behaviour 
• Improvements in screening and/or presumptive STI treatment 
Each of these potential changes is discussed in the sections that follow, together with 
an explanation of the assumptions made in modelling these changes. In each case, it is 
assumed that the intervention is phased in uniformly over the period from mid-2010 
to mid-2014, thus allowing for a realistic delay in the formulation and implementation 
of new health interventions. The levels of rollout that can ultimately be achieved are 
open to debate, and these rollout assumptions should therefore be seen as illustrative. 
 
6.2.1.1 Increases in adoption of syndromic management protocols 
 
As shown in Table 3.3.13, it is assumed in the baseline scenario that the proportion of 
public practitioners following syndromic management protocols levels off at 80%, 
and that the proportion of public STI clinics with STI drug shortages levels off at 4%, 
based on data from recent surveys (Ramkissoon et al, 2004; Reagon et al, 2004; 
Colvin et al, 2006). The proportion of private practitioners following syndromic 
management protocols is assumed to rise to 33% by 2005 and to increase by 2% per 
annum (absolute) thereafter, as the proportion of private practitioners trained in 
syndromic management increases (Schneider et al, 2005b). 
 
In order to increase adoption of syndromic management protocols, a range of 
interventions will be required. Heavy patient loads in the public health sector may 
compromise the quality of treatment provided (Sonko et al, 2003), and interventions 











been proposed as a means of improving overall STI case management; studies 
conducted in South Africa and Uganda have shown that the use of packaged treatment 
for STI syndromes can increase the proportion of STI cases that are correctly treated 
(Harrison et al, 2000; Jacobs et al, 2003), though another South African study found 
that syndrome packets only improved the counselling component of the STI case 
management, not the STI treatment (Colvin et al, 2006). In the private health sector, 
the high costs of treating STI patients with multiple drugs, and the lack of training 
provided to private practitioners regarding recent STI treatment methods are major 
obstacles to the adoption of syndromic management guidelines. An education 
programme for private practitioners in South Africa did not appear to improve the 
quality of STI treatment significantly (Schneider et al, 2005a), though a similar 
programme in Jamaica achieved significant improvements in knowledge of correct 
STI treatment (Green et al, 1998). 
 
Although it is not clear how effective the above interventions would be if 
implemented in South Africa on a national scale, we consider a hypothetical scenario 
in which the proportion of cases treated according to syndromic management 
protocols increases to 80% in the private health sector and to 100% in the public 
health sector, over the 2010-2014 period. Drug shortages in public health facilities are 
also assumed to be eliminated over the same period. 
 
6.2.1.2 Modifications to existing syndromic management protocols 
 
Three different revisions to current South African treatment protocols have been 
proposed, and are considered here. Firstly, recent WHO guidelines recommend the 
inclusion of antiviral treatment in the treatment of patients with GUD, in countries 
with an HSV-2 prevalence of over 30% (World Health Organization 2003). This is in 
recognition of the increasingly high proportion of GUD cases that are due to genital 
herpes. Studies have shown that the incorporation of acyclovir (the cheapest antiviral 
effective against herpes) into syndromic management guidelines can significantly 
reduce ulcer duration and HIV shedding in HIV-coinfected subjects (Paz-Bailey et al, 
2007b). Recent South African protocols, however, do not make provision for antiviral 
treatment of GUD patients (Department of Health 2003), and it does not appear that 











is assumed that 90% of practitioners treating according to syndromic management 
protocols include the provision of acyclovir to patients presenting with GUD. This is 
assumed to be phased in uniformly over the 2010-2014 period. As with other STI 
drugs, acyclovir is assumed to be 90% effective. 
 
The second proposed change is to replace ciprofloxacin with ceftriaxone in the 
treatment of male patients with urethral discharge and female patients with vaginal 
discharge or lower abdominal pain. This is recommended due to the rising prevalence 
of ciprofloxacin resistance in South African gonococcal isolates (Lewis et al, 2007; 
Black et al, 2008; Moodley and Sturm 2005). In order to model the effect of this 
intervention, it is necessary to specify the assumed proportions of gonorrhoea cases 
that are ciprofloxacin-resistant and the proportion of cases treated with ciprofloxacin, 
in each year. The treatment effectiveness parameter is then reduced in proportion to 
the product of the ciprofloxacin-resistant fraction and the ciprofloxacin-treated 
fraction. Based on the available surveillance data (Lewis et al, 2007; Black et al, 
2008; Moodley and Sturm 2005), resistance is assumed to have been absent prior to 
2003, then increased to 4% of cases in 2003, 10% in 2004, 16% in 2005, 25% in 2006 
and 38% in 2007. Future trends in ciprofloxacin resistance are unclear, but in the 
absence of significant changes to treatment practices, selection pressures would be 
expected to lead to a continued upward rise. It is assumed that the proportion of cases 
resistant to ciprofloxacin would rise to 55% in 2008, 70% in 2009, 82% in 2010, 90% 
in 2011, 96% in 2012 and 100% in all subsequent years. In the absence of 
interventions, it is assumed that 50% of treated gonorrhoea cases receive drugs other 
than ciprofloxacin, since private practitioners often use ceftriaxone and spectinomycin 
in the treatment of gonorrhoea (Chabikuli et al, 2002) and alternatives to 
ciprofloxacin are often used in second-line drug regimens (Moodley and Sturm 2005). 
This proportion is assumed to rise to 90% over the 2010-2014 period if interventions 
to promote alternatives to ciprofloxacin are introduced in the private and public health 
sectors. 
 
The last proposed change is to add metronidazole to the treatment of male patients 
presenting with urethral discharge, as a first-line treatment. This has been advocated 
on the grounds that the existing drug combination is not effective against 











populations (Price et al, 2004). However, in a randomized controlled trial to test the 
effect of including treatment for trichomoniasis in the syndromic management 
protocol for male urethral discharge, it was found that the inclusion of trichomoniasis 
treatment had no positive effect on the rate at which discharge resolved (Price et al, 
2003). The effect of extending the syndromic management protocols to include 
metronidazole in the first-line treatment of male urethral discharge is simulated by 
assuming that the proportion of male trichomoniasis cases treated correctly rises from 
50% to 90%, over the 2010-2014 period. 
 
6.2.1.3 Patient-initiated treatment for genital herpes 
 
Although the incorporation of antiviral treatment into syndromic management 
protocols for GUD may be an effective strategy for treating herpetic lesions, it may 
not be the optimal approach to dealing with genital herpes, as it relies on individuals 
with recurrent HSV-2 symptoms attending health services and it avoids counselling 
HSV-2-infected individuals on the nature of their infection. An alternative approach 
may be to test GUD patients for HSV-2, counsel those infected with the virus on the 
nature of their infection, and provide them with a supply of antivirals so that they can 
self-initiate treatment when they experience future recurrences, rather than return to 
the health facility for treatment (O'Farrell et al, 2007a; Apoola and Radcliffe 2004; 
Hudson 1999). In addition to reducing case loads, this would avoid unnecessarily 
providing antibiotics to patients with herpetic lesions. Studies have shown that 
patient-initiated treatment of HSV-2 recurrences can reduce the proportion of 
recurrences that develop into ulcers, shorten the duration of ulcers and improve 
quality-of-life outcomes (Aoki et al, 2006; Fife et al, 2007; Whatley and Thin 1991; 
Wald et al, 2002). In addition, counselling of patients on the importance of reducing 
their risk of HSV-2 transmission to their sexual partners could significantly reduce 
HSV-2 incidence (Wald et al, 2006).  
 
To model the effect of such an intervention, it is assumed that the rate of HSV-2 
recurrence reduces by 80% over the 2010-2014 period. Although in reality it is the 
duration of recurrences rather than the incidence of recurrences that would reduce, 
patients would be counselled to abstain from unprotected sex while experiencing 











equivalent to reducing the duration of 80% of ulcers, from the point of view of HIV 
and HSV-2 transmission, assuming that counselled individuals do indeed abstain from 
unprotected sex while experiencing recurrences of genital herpes. 
 
6.2.1.4 Changes in health-seeking behaviour 
 
Delays in seeking treatment for STIs are a significant problem, particularly since 
symptomatic STIs play a greater role in HIV transmission than asymptomatic STIs. In 
developed countries such as the US and the UK, the average time to seeking STI 
treatment is typically around 4 days for men and around 12 days for women (Garnett 
et al, 1999; Schofield 1982), while in African countries, the average delay is around 
14 days for men and 30 days for women (Wilkinson et al, 1998; Voeten et al, 2004; 
O'Farrell et al, 1991a; O'Farrell et al, 1991b). This problem could be partly addressed 
through the extension of health services, particularly in rural areas. However, it would 
also be important to increase the promotion of prompt health-seeking for STI 
symptoms through social marketing programmes. In the Mwanza trial, for example, 
campaigns to improve health-seeking behaviour were introduced in intervention 
communities. It was observed that numbers of public STI clinic attendances were 
roughly 25% higher in intervention communities than in control communites 
(Grosskurth et al, 2000) and the proportion of individuals with genital ulcer or 
discharge syndromes who sought treatment was 31% higher in the intervention 
communities (Buvé et al, 2001a). 
 
Since it is not clear what would be a realistic target for the reduction in the treatment 
delay, we consider a scenario in which the average treatment delay is reduced by 
50%. (This does not apply to sex workers, as they already have a high rate of health-
seeking behaviour in the baseline scenario.) Such a reduction would bring the average 
treatment delays assumed in the model close to those observed in the developed 
world. 
 
6.2.1.5 Improvements in screening and/or presumptive STI treatment  
 
Several studies have examined the potential effects of monthly screening or 











that behavioural interventions are often combined with the periodic 
treatment/screening, which makes it difficult to isolate the independent effect of the 
STI treatment component of the intervention (Shahmanesh et al, 2008; Steen and 
Dallabetta 2003). In the few studies in which the effect of STI treatment could be 
isolated, it was generally found to reduce STI prevalence, although often not 
significantly so. Two randomized controlled trials have examined the effect of 
monthly presumptive treatment on HIV incidence in sex workers (Kaul et al, 2004; 
Ghys et al, 2001), but neither detected any significant decrease in HIV incidence as a 
result of the intervention. 
 
In order to model the effect of periodic presumptive treatment (PPT) in sex workers, it 
is assumed that the rate at which enrolled sex workers get treated for asymptomatic 
STIs rises to 0.25 per week over the 2010-2014 period (0.25 per week corresponds 
roughly to the monthly frequency of screening in most studies). It is also assumed that 
the treatment provided to sex workers is as effective as the STI treatment provided to 
women treated according to syndromic management protocols. Since sex work is 
illegal and sex workers are a difficult group to reach with health interventions, it is 
assumed that the PPT programme would enrol only 50% of active sex workers by 
mid-2014, and thereafter the proportion participating in the programme would remain 
constant at 50%. 
 
The evidence reviewed in section 3.3.4.4 suggests that there is a need for 
improvements in the antenatal screening for syphilis. Although the antenatal 
prevalence of syphilis has declined substantially in recent years, the proportion of 
pregnant women who receive syphilis testing needs to increase, and the proportion of 
women testing positive who receive treatment also needs to increase. It is assumed 
that both proportions would increase to 100% over the 2010-2014 period (from the 
default levels of 75% and 80% respectively), if adequate management systems were 
introduced. 
 
6.2.2 Effect of future changes in STI treatment on STI prevalence 
 
The effects of different improvements in STI treatment are compared by examining 











percentage reductions (together with 95% prediction intervals), for each STI and for 
each intervention, in the case of females aged between 15 and 49. Similar reductions 
are shown for males aged between 15 and 49 in Table 6.2.2. Results are not shown for 
chancroid, as this STI has been virtually eliminated (the predicted prevalence in 2005 
is around 0.001%), and improvements in STI treatment would therefore have no 
noticeable impact on the prevalence of this STI in absolute terms. 
 
Overall, the intervention that is likely to have the greatest impact on STI prevalence is 
the campaign to halve the time to seeking treatment for STI symptoms. This would 
substantially reduce the prevalence of syphilis (by an average of 35% in men and 52% 
in women) and the prevalence of gonorrhoea (by an average of 29% in men and 21% 
in women), but would have relatively little effect on the prevalence of other STIs, 
which are mostly asymptomatic. Most interventions have no effect on the prevalence 
of genital herpes, as it is not affected by the antibiotics currently used in syndromic 
management. The inclusion of acyclovir treatment in syndromic management 
protocols for genital ulcer disease could reduce HSV-2 prevalence slightly (by about 
1% in both men and women), but a much more effective strategy would be to 
encourage patient-initiated treatment of genital herpes. It is predicted that this would 
reduce the prevalence of genital herpes by an average of 6.6% in women and 7.5% in 
men; greater reductions would be expected over the longer term. 
 
Increased adoption of syndromic management protocols and elimination of drug 
shortages would be expected to have a substantial effect on the prevalence of syphilis, 
but other STIs would be relatively unaffected. The effects of changes in the public 
health sector are greater than the effects of changes in the private health sector, 
probably because the proportion of STI patients using the public health sector is 
higher than the proportion using the formal private health sector. Extending 
syndromic management protocols for male urethral discharge to include 
metronidazole would have no significant effect on the prevalence of trichomoniasis, 
and could possibly even increase the prevalence of trichomoniasis as a result of 
delayed development of immunity to the infection. Monthly presumptive treatment of 
sex workers would have little effect on STI prevalence at a population level, but could 











antenatal screening for syphilis would reduce the prevalence of syphilis in females by 
12% on average, but would have little effect on the prevalence of syphilis in men. 
 
To assess the effect of combining interventions, a combined intervention scenario is 
considered. This scenario includes all interventions except presumptive treatment for 
sex workers, metronidazole treatment for male urethral discharge, and incorporation 
of acyclovir into syndromic management guidelines (the latter intervention is 
excluded because it would be obviated if the more effective patient-initiated acyclovir 
strategy were introduced). The combined intervention strategy would have a 
significant impact on the prevalence of gonorrhoea, syphilis and genital herpes, but 












Table 6.2.1: Percentage reductions in STI prevalence in 2020, among females aged 15 to 49 
Intervention Syphilis HSV-2 Gonorrhoea Chlamydia Trichomoniasis BV Candidiasis
Increased adoption of SM in private 













Increased adoption of SM in public 













Incorporation of acyclovir into SM 
     protocols for GUD 
- 0.9% 
(0.5, 1.3) 
- - - - - 
Replacement of ciprofloxacin with 
     ceftriaxone in treatment of gonorrhoea 
- - 17.6% 
(11.0, 27.3) 
- - - - 
Incorporation of metronidazole into SM 
     protocols for MUD 
- - - - -0.4% 
(-0.9, 0.3) 
- - 
Patient-initiated treatment of genital 
     herpes 
- 6.6% 
(3.3, 10.1) 
- - - - - 












Monthly presumptive treatment for sex 













Improved antenatal screening for 
     syphilis 
12.0% 
(10.3, 13.3) 
- - - - - - 

























Table 6.2.2: Percentage reductions in STI prevalence in 2020, among males aged 15 to 49 
Intervention Syphilis HSV-2 Gonorrhoea Chlamydia Trichomoniasis
















Incorporation of acyclovir into SM protocols for GUD - 0.8% 
(0.4, 1.2) 
- - - 
Replacement of ciprofloxacin with ceftriaxone in treatment of gonorrhoea - - 25.3% 
(17.5, 35.9) 
- - 
Incorporation of metronidazole into SM protocols for MUD - - - - -1.0% 
(-2.3, 0.4) 
Patient-initiated treatment of genital herpes - 7.5% 
(3.7, 11.6) 
- - - 
















Improved antenatal screening for syphilis 0.4% 
(-0.2, 1.0) 
- - - - 





















6.2.3 Effect of future changes in STI treatment on HIV incidence 
 
Table 6.2.3 shows the percentage reductions in the total number of new HIV 
infections over the period from mid-2010 to mid-2020, as a result of improvements in 
STI treatment, for each of the STI cofactor scenarios described in section 5.2.1. The 
projected absolute number of new HIV infections over the 2010-2020 period, in the 
absence of further changes to STI treatment, is 4.1 million in the baseline cofactor 
scenario, 3.8 million in the high cofactor scenario and 4.6 million in the low cofactor 
scenario. The greatest reductions in HIV incidence, in all three cofactor scenarios, 
would be achieved through patient-initiated acyclovir, followed by the halving of 
treatment delays, followed by the substitution of ciprofloxacin in the treatment of 
gonorrhoea. Increases in the adoption of syndromic management in the private and 
public health sectors and incorporation of acyclovir into syndromic management 
guidelines for GUD would have a modest effect on HIV incidence (less than a 1% 
reduction). Other interventions (metronidazole for male urethral discharge, 
presumptive treatment for sex workers and improved antenatal screening for syphilis) 
would have no appreciable effect on HIV incidence. The combined strategy described 
in section 6.2.2 would achieve an overall reduction in HIV incidence equal to 7.9% of 
new HIV infections in the baseline cofactor scenario (330 000 HIV infections averted 
over the 2010-2020 period), 3.6% of new infections in the low cofactor scenario 
(170 000 HIV infections averted), and 13.5% of new infections in the high cofactor 












Table 6.2.3: Percentage reduction in new HIV infections, 2010-2020, as a result of 











Increased adoption of SM in private health sector 0.2% 0.1% 0.3% 
Increased adoption of SM in public health sector 
     + no drug shortages 
0.3% 0.1% 0.5% 
Inclusion of acyclovir in SM protocols for GUD 0.5% 0.2% 0.8% 
Replacement of ciprofloxacin with ceftriaxone in 
     treatment of NG 
1.9% 0.8% 3.2% 
Incorporation of metronidazole into SM protocols 
     for MUD 
0.0% 0.0% 0.0% 
Patient-initiated treatment of genital herpes 3.7% 1.6% 6.5% 
Halving of time to seeking treatment 2.8% 1.3% 4.7% 
Monthly presumptive treatment for sex workers 0.0% 0.0% 0.0% 
Improved antenatal screening for syphilis 0.0% 0.0% 0.0% 
Combined strategy 7.9% 3.6% 13.5% 
GUD = genital ulcer disease. MUD = male urethral discharge. NG = Neisseria gonorrhoeae. SM = 
syndromic management. 
 
The projected reductions in HIV incidence are not uniform over the 2010-2020 
period, as Figure 6.2.1 shows. For all three of the most effective interventions, as well 
as the combined intervention, the annual percentage reduction in the number of new 
















































































































Figure 6.2.1: Annual percentage reductions in new HIV infections, as a result of 
improvements in STI treatment 
 
6.3 The potential effects of behaviour change 
 
As shown in section 6.1, increases in condom usage have already contributed 
significantly to reducing HIV incidence and STI prevalence in South Africa. The 
objective of this section is to evaluate how further changes in behaviour could 
potentially influence the incidence of HIV and the prevalence of STIs. The intention 
of this analysis is not to identify specific programmes to reduce the incidence of HIV, 
but rather to identify the forms of behaviour that are contributing most significantly to 
the transmission of HIV and other STIs, and that should be addressed through social 
marketing programmes. The behaviour change scenarios presented in this section are 
therefore purely illustrative, and should not be considered realistic. The section begins 
with a brief review of the forms of sexual behaviour that have been most often linked 
to the spread of HIV infection in the Sub-Saharan African context, then describes the 











results of different forms of behaviour change in terms of both HIV incidence and STI 
prevalence.  
 
6.3.1 Review of behaviours linked to the spread of HIV in Sub-Saharan Africa 
 
Uganda is frequently cited as an example of an African country in which reductions in 
HIV risk behaviour have brought about significant declines in HIV prevalence. 
However, different studies produce conflicting explanations for these declines. 
Asiimwe-Okiror et al (1997) found that in urban Uganda there had been significant 
increases in condom usage, increases in age at sexual debut and marriage, and 
reductions in proportions of men reporting sex involving exchange for money. It was 
also found that there was no significant change in the reporting of non-regular 
partners or extramarital sex. Similar findings in rural Uganda were reported by 
Kamali et al (2000); this study also found increased condom use and delayed sexual 
debut and marriage, but no reduction in numbers of partners. In contrast, Stoneburner 
and Low-Beer (2004) attribute the significant declines in HIV prevalence in Uganda 
to the reductions in the proportions of individuals reporting sex with non-regular 
partners in national behavioural surveys, and attach relatively little importance to the 
increases in levels of condom use. 
 
More recently, there has been evidence of reductions in HIV prevalence in Zimbabwe, 
which have been attributed mainly to reductions in the rate at which individuals 
acquire new partners – particularly casual partners – and delays in sexual debut 
(Gregson et al, 2006). There has also been evidence of declines in HIV prevalence in 
urban Kenya, which has been attributed to the same factors (Hallett et al, 2006). In 
Zambia, nationally representative household surveys suggest that there has been an 
overall increase in the age at sexual debut and a reduction in unprotected sex with 
non-cohabiting partners, as well as a reduction in numbers of partners (Slaymaker and 
Buckner 2004). However, another Zambian study found that this behaviour change 
was limited to urban areas (Fylkesnes et al, 2001). The existence of urban-rural 
differences in the extent of behaviour change is also suggested by data from Tanzania. 
In a study of male factory workers in urban Tanzania, Ng'weshemi et al (1996) found 
significant reductions in numbers of partners and contacts with casual partners, as 











Tanzania, however, no significant changes were observed over time, either in age at 
sexual debut, numbers of partners per annum, or condom use with casual partners 
(Mwaluko et al, 2003). 
 
Studies have generally not considered the role of concurrent partnerships in the spread 
of HIV, as information on concurrency is often not captured in sexual behaviour 
surveys. Although a comparison of data from five African cities showed that 
differences in the prevalence of concurrency did not account for differences in HIV 
prevalence between the cities (Lagarde et al, 2001), it has been argued that the 
prevalence of concurrency in Sub-Saharan Africa is higher than that in other global 
regions and that concurrent partnerships may therefore be one of the most important 
factors explaining the high prevalence of HIV in Sub-Saharan Africa (Halperin and 
Epstein 2004). Mathematical models support the view that partner concurrency is a 
major factor promoting the spread of HIV (Morris and Kretzschmar 1997), but there 
is relatively little empirical evidence to support the hypothesis. 
 
It has also been hypothesized that late age at first marriage – and more specifically, a 
long average interval between sexual debut and first marriage – is a key factor driving 
the spread of HIV, particularly in the countries of Southern Africa, where marriage 
tends to occur relatively late (Bongaarts 2007). The assumption underlying this 
argument is that marriage is protective against HIV. However, African studies that 
have examined the relationship between HIV and marital status have yielded 
conflicting findings, some suggesting that marriage is associated with an increased 
risk of HIV (Auvert et al, 2001b; Clark 2004; Zuma et al, 2003) and some suggesting 
the opposite (Shisana et al, 2004; Bongaarts 2007). The significance of the relatively 
late age at first marriage in South Africa is therefore not clear. 
 
Attempts to explain observed HIV prevalence trends in terms of changes in reported 
behaviours are problematic for a number of reasons. Most importantly, social 
desirability bias may differentially affect the reporting of risk behaviours in different 
periods and different locations, depending on the extent of social marketing 
programmes (Gregson et al, 2002b; Curtis and Sutherland 2004; Cleland et al, 2004). 
Secondly, differences in HIV prevalence trends may reflect differences in epidemic 











observed reductions in risk behaviours could be a direct consequence of AIDS 
mortality and morbidity (since HIV/AIDS mortality effectively removes those 
individuals who have the highest levels of sexual risk behaviour), rather than a result 
of spontaneous changes in sexual behaviour (Gregson et al, 2006; Hallett et al, 2006). 
In light of these limitations, mathematical models have an important role to play in 
evaluating whether reported changes in sexual behaviour are consistent with observed 




To assess the potential effect of behaviour changes, the following scenarios are 
considered: 
• ‘Halve concurrency’: It is assumed that the rate at which new partners are 
acquired is halved among those individuals who are already in partnerships. 
(Men in relationships still visit sex workers at the same rate, however.) 
• ‘Halve partner acquisition’: The rate at which new non-spousal partners are 
acquired is halved, but the rate at which marriage occurs is unchanged (this 
has the effect of reducing the number of non-spousal partnerships). The rate at 
which men visit sex workers is also unchanged. 
• ‘Halve rate of sexual debut’: The rate at which virgins enter their first sexual 
relationship is halved (this is equivalent to a roughly two-year increase in the 
median age at first sex). 
• ‘Halve sex worker contacts’: The rate at which men visit commercial sex 
workers is assumed to be halved. 
• ‘Double incidence of marriage’: The age-specific rates of marriage are 
doubled (this is equivalent to a roughly three-year decrease in the median age 
at first marriage). 
• ‘Halve unprotected non-spousal sex’: The proportion of sex acts that are 
unprotected in non-spousal relationships (excluding sex worker-client 
contacts) is assumed to be halved. 
• ‘Halve unprotected spousal sex’: The proportion of sex acts that are 












All changes in behaviour are introduced in the middle of 2010, and the impact of the 
behaviour change is evaluated by examining the percentage reduction in the number 
of new HIV infections over the period from mid-2010 to mid-2020. To assess whether 
the effects of these behaviours change over the course of the HIV/AIDS epidemic, we 
also consider hypothetical scenarios in which the changes occur in the middle of 1990 
and effects are measured over the period from mid-1990 to mid-2000. The last two 
scenarios are not included among these hypothetical scenarios, since the baseline 
scenario already allows for significant increases in condom use after 1990. 
 
The reductions in HIV incidence are calculated for the initial analysis presented in 
section 4.1 (which does not allow for STI cofactor effects) and for the three STI 
cofactor scenarios presented in section 5.2 (for which there is no formal uncertainty 
analysis). However, the reductions in STI prevalence are calculated only for the 
baseline cofactor scenario, since the formal uncertainty analysis in section 4.2 does 
not reflect the uncertainty with respect to the sexual behaviour parameters, and is 
therefore of little value when assessing the uncertainty regarding the effect of 
behaviour change on STI prevalence. 
 
6.3.3 The effect of behaviour change on HIV incidence 
 
Figure 6.3.1 shows the percentage reduction in HIV incidence over the 2010-20 
period, for each of the behaviour change scenarios described previously. The 
percentage reductions predicted by the STI cofactor model (i.e. the baseline cofactor, 
high cofactor and low cofactor scenarios) are generally similar to or greater than those 
predicted by the model that does not allow for STI cofactors, except in the case of 
delayed sexual debut. Model results suggest that a high level of HIV transmission is 
occurring within non-spousal relationships, with the greatest reductions in HIV 
incidence being achieved through reductions in unprotected sex in non-spousal 
partnerships and through reductions in the rate at which new non-spousal partnerships 
are formed. Halving the incidence of concurrent partnerships would reduce the total 
number of new HIV infections by an average of 11.4% (95% prediction interval: 9.8-
13.1%). Halving the rate of sexual debut and doubling the incidence of marriage 
would have relatively little effect on the incidence of HIV. The latter could possibly 











frequently in marriage and the frequency of sex in the early years of marriage is 
higher than that in non-spousal relationships. Male contact with sex workers also does 
not significantly influence the transmission of HIV in the advanced stages of the 
epidemic.  
 
The combined effect of halving the rate of non-spousal partner acquisition by 50%, 
reducing the rate of secondary partner acquisition by an additional 50% (i.e. a net 
reduction of 75% in the rate at which concurrent partnerships are formed) and halving 
the proportion of sex acts in non-spousal partnerships that are unprotected, would be 
to reduce the total number of new HIV cases over 2010-2020 by 49% (95% prediction 
interval: 43-54%). Allowing for STI cofactors, the same set of changes would reduce 
HIV incidence by 55%, 56% and 54% in the baseline cofactor, high cofactor and low 

































Baseline cofactor High cofactor Low cofactor No cofactor
 
 
Figure 6.3.1: Percentage reductions in new HIV infections over the 2010-2020 period, 
as a result of changes in sexual behaviour 
 
The relationship between the model parameters controlling behaviour change and the 
percentage reduction in HIV incidence is seldom linear. Figure 6.3.2 shows the effect 
of varying the percentage reduction in the risk parameter in two cases: the reduction 











the proportion of sex acts in non-spousal partnerships that are unprotected. There are 
increasing marginal returns to reducing the rate at which concurrent partnerships are 
formed; the effect of reducing the rate of secondary partner acquisition by 100% 
(39%, 95% interval: 32-45%) is more than double the effect of reducing the rate by 
50% (11%, 95% interval: 10-13%). In contrast, there are diminishing marginal returns 
to reducing the proportion of non-spousal sex acts that are unprotected; the effect of 
reducing the proportion by 100% (65%, 95% interval: 57-72%) is less than double the 
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Figure 6.3.2: Percentage reductions in new HIV infections over the 2010-2020 period, 
for different levels of behaviour change 
Results are generated using the model that does not allow for STI cofactors (see section 4.1). 
 
The effect of high risk sexual behaviours on the spread of HIV is more significant in 
the early stages of the HIV/AIDS epidemic than in the more advanced stages of the 
epidemic. This is shown in Figure 6.3.3, which compares the reductions in HIV 
incidence that would have been achieved if the behaviour changes had occurred in 
1990, with the reductions that would be achieved if the behaviour changes occurred in 
2010. The difference is particularly stark in the case of the effect of reductions in 
commercial sex worker contacts, which suggests that client-sex worker contact is 
important in driving the spread of HIV in the early stages of the HIV/AIDS epidemic, 
but is a relatively unimportant determinant of HIV spread in the later stages of the 






































Figure 6.3.3: Percentage reductions in new HIV infections that would occur if 
behaviour changes occurred in 1990 and 2010 
Results are generated using the model that does not allow for STI cofactors (see section 4.1). 
 
6.3.4 The effect of behaviour change on STI prevalence 
 
Table 6.3.1 shows the predicted percentage reductions in STI prevalence in the 
population aged 15-49, by 2020, when compared with the scenario in which there is 
no behaviour change after 2010, for each of the behaviour change scenarios described 
in section 6.3.2. Chancroid is not included, as its prevalence has already been reduced 
to negligibly low levels, and bacterial vaginosis and vulvovaginal candidiasis are also 
not included, as neither is assumed to be sexually transmitted.  
 
The results shown in Table 6.3.1 suggest that the effects of different forms of 
behaviour change differ significantly between STIs. In the case of syphilis, halving 
unprotected sex in spousal relationships would achieve the greatest reduction in 
prevalence, while doubling the incidence of marriage would significantly increase the 
prevalence of syphilis. This suggests that syphilis transmission is occurring mainly in 
spousal relationships, probably because past increases in condom use have already 
reduced the basic reproductive number of syphilis below one in the unmarried 











frequent in spousal relationships, with increases in the incidence of marriage predicted 
to increase the overall prevalence of gonorrhoea. For the other three STIs, 
transmission in non-spousal relationships appears to be relatively more important, 
with the effect of reduced unprotected sex being substantially greater in the case of 
non-spousal partnerships than in the case of spousal partnerships. Consistent with the 
results shown for HIV, changes in commercial sex activity appear to have little effect 
on the overall prevalence of any of the STIs. In the case of chlamydial infection, 
delays in sexual debut, increases in the rate of marriage and reductions in unprotected 
non-spousal sex would be particularly important in reducing the prevalence of 
infection, probably because of the high susceptibility to chlamydial infection in young 
females and the relatively high concentration of chlamydial infection in non-spousal 
relationships.  
 
Table 6.3.1: Percentage reduction in STI prevalence by 2020, when comparing the 











Halve unprotected  
   non-spousal sex 
15.9% 14.2% 40.1% 19.5% 36.2% 
Halve partner acquisition 8.0% 6.9% 12.5% 6.3% 12.1% 
Halve concurrency 8.7% 3.5% 9.7% 0.8% 6.2% 
Halve unprotected spousal sex 50.8% 1.5% 29.0% 2.4% 12.4% 
Halve rate of sexual debut 0.3% 3.6% 6.9% 11.4% 8.0% 
Halve sex worker contacts 0.1% 0.2% 0.2% 0.0% 0.1% 
Double incidence of marriage -33.6% 5.0% -8.2% 6.3% 0.8% 
Results are generated using the baseline cofactor scenario (see section 5.2). 
 
6.3.5 The effect of AIDS mortality and morbidity on levels of sexual risk 
behaviour 
 
In the context of generalized HIV/AIDS epidemics, it is often assumed that reductions 
in levels of sexual risk behaviour – as reflected in comparisons of cross-sectional 











information and education programmes and other interventions. However, some of the 
reduction in levels of sexual risk behaviour may be a direct result of the selective 
effect of AIDS morbidity and mortality (i.e. high-risk individuals are more likely to 
acquire HIV, and their removal from the sexually active population reduces the 
average levels of sexual risk behaviour). In our model of the South Africa population, 
it is assumed that the only form of deliberate behaviour change up to the current time 
is increased condom usage, and there is thus no allowance for reductions in 
concurrent partnerships or increases in abstinence. This section quantifies the extent 
of the reduction in reported risk behaviour that might be expected as a result of the 
high levels of AIDS morbidity and mortality in South Africa. 
 
Figure 6.3.4 compares the levels of sexual risk behaviour in 1995, before significant 
AIDS mortality and morbidity occurred, and in 2005, after significant increases in 
morbidity and mortality. AIDS appears to have reduced significantly the proportion of 
men and women with multiple partners, with the reduction in men being greatest 
between the ages of 40 and 44 (15%) and the reduction in women being greatest 
between the ages of 35 and 39 (23%). AIDS has also increased significantly the 
proportion of men and women who report that they have no current partner, with the 
increase in men being greatest between the ages of 50 and 54 (21%) and the increase 
in women being greatest between the ages of 35 and 39 (16%). AIDS has also reduced 
slightly the proportion of the population that is married, though this effect is relatively 
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Figure 6.3.4: Changes in sexual behaviour between 1995 and 2005, by age and sex 





6.4.1 Comparison with changes in STI prevalence in other African countries  
 
Our model suggests that there have been significant declines in the prevalence of 
syphilis, chancroid, gonorrhoea, chlamydial infection and trichomoniasis in South 
Africa since the early 1990s, as result of improvements in STI treatment, increases in 
condom use and the selective effect of AIDS mortality and morbidity. However, the 
prevalence of HSV-2, bacterial vaginosis and vulvovaginal candidiasis has remained 











trends in other African countries, similar trends in STI prevalence might be expected 
in other African settings. Table 6.4.1 summarizes the evidence from studies that have 
tracked STI prevalence trends over time in different Sub-Saharan African populations.  
 
Consistent with the model estimates and the South African national antenatal survey 
results (Department of Health 2007), most African surveys show significant declines 
in the prevalence of syphilis over time. Several African studies have also found 
significant declines in the prevalence of gonorrhoea and trichomoniasis, coinciding 
with significant changes in sexual behaviour. These are consistent with the predictions 
of the model, which estimates that most of the reduction in the prevalence of 
gonorrhoea and trichomoniasis is likely to be the result of behaviour change rather 
than syndromic management. Although a number of the observational studies show 
no significant reduction in the prevalence of chlamydial infection (Sturm et al, 2003; 
Ndhlovu et al, 2005; Alary et al, 2002; Nagot et al, 2004), significant reductions have 
been observed in Botswana (Creek et al, 2005), Kenya (Moses et al, 2000) and 
Senegal (Meda et al, 1999b). Chlamydial prevalence trends therefore appear to be 
fairly heterogeneous. Lastly, no African study has identified statistically significant 
changes in the prevalence of bacterial vaginosis over time, which is consistent with 
the relatively stable prevalence of bacterial vaginosis predicted by the model. 
 
No African studies have examined recent trends in the seroprevalence of HSV-2 
(Smith and Robinson 2002). However, there is evidence from other African countries 
of significant changes in the aetiology of genital ulcer disease over the last two 
decades. The model predictions of rising GUD attributable to HSV-2 and reductions 
in GUD attributable to chancroid are consistent with observed changes in GUD 
aetiologies in South Africa (Ye et al, 2007; Kharsany et al, 2000), Botswana (Paz-
Bailey et al, 2005), Rwanda and Kenya (Mayaud and Mabey 2004), as well as an 86% 
drop in chancroid cases in Harare between 1990 and 1998 (O'Farrell 1999). The 
model prediction that chancroid is close to being eradicated in South Africa therefore 














Table 6.4.1: Trends in STI prevalence in other Sub-Saharan African populations 







Factors potentially explaining 
change in prevalence 






Gonorrhoea 7% (1999) 4% (2002) >0.05  
Chlamydia 11% 11% >0.05 
Trichomoniasis 32% 27% - 
Bacterial vaginosis 38% (1995) 31% (2002) >0.05 






Syphilis 6% (1998) 5% (2001) 0.29  
Gonorrhoea 3% 4% 0.32 
Chlamydia 5% 7% 0.17 
Women aged 
13-59 
Syphilis 10% 13% 0.05 Increases in casual partners 
Gonorrhoea 7% 11% 0.01 
Chlamydia 8% 12% 0.01 






Syphilis 12.4% (1992) 4.3% (2003) ≤0.001 Syndromic mngt (since 1992), delayed 
sexual debut, increased condom use 
Paz-Bailey et al 
(2005) 





Syphilis 18.0% (1993) 1.5% (2002) <0.0001 Syndromic mngt (since 1992), delayed 
sexual debut, increased condom use Gonorrhoea 9.1%b 2.9%b 0.04 
Chlamydia 30.9%b 13.9%b 0.001 
Trichomoniasis 26.2%b 9.2%b <0.0001 
Bacterial vaginosis 47.0% 49.0% 0.74 






Syphilis 13.4% (1990) 11.1% (1996) 0.027 Possibly improved STI treatment, 
but no increase in condom usage Gonorrhoea 4.9% (1990) 2.5% (1995) <0.001 











Table 6.4.1 (continued) 







Factors potentially explaining 
change in prevalence 




Sex workers Syphilis 8.9% (1993) 1.5% (1998-9) 0.0002c Improved STI treatment for sex workers, 
fewer clients per week, greater condom 
use with clients 
Gonorrhoea 43.2% 20.5% 0.0001c 
Chlamydia 9.4% 5.1% 0.13c 




Syphilis 7.3% (2001-2) 7.2% (2003-4) -  







Syphilis 5.4% (1992) 2.5% (1999) <0.001 Improvements in STI treatment, 
reduced numbers of sexual partners, 
increases in condom use 
Gonorrhoea 5.3% 1.7% <0.001 
Chlamydia 30.1% (1992) 20.6% (1994) 0.001 







Syphilis 12.5% (1989-91) 0.8% (1998-00) <0.001 Syndromic mngt (since 1996),  
increases in condom distribution, 
increases in antibiotic self-treatment 
Chlamydia 10.0% 6.6%  0.16 
Trichomoniasis 32.0% 9.7% <0.001 
Gonorrhoea 13% (1994) 1% (1998-00) <0.001 
Bacterial vaginosis 37%d 27%d - 






Syphilis 7.5% (1991) 4.4% (1996) 0.04 Increased condom distribution, 
improved STI treatment services Gonorrhoea 2.0% 0.9% 0.21 
Chlamydia 11.9% 6.7% <0.01 
Trichomoniasis 30.1% 18.1% <0.001 
Where dates are not given for prevalence estimates, the date should be assumed to be the same as that for the preceding estimate. 
a 2003 sample included cities and clinic types that were not in the 1993 sampling frame. b Adjusted for changes in sensitivity and specificity of STI diagnostics. c After 











Empirical estimates of the impact of syndromic management on STI prevalence are 
also available from randomized controlled trials. In the intervention arm of the 
Mwanza trial, in which syndromic management was introduced in the absence of any 
major change in sexual behaviour, the prevalence of gonorrhoea, chlamydial infection 
and trichomoniasis did not change significantly over the course of the trial, either 
among men or among pregnant women in a separate sub-study (Mayaud et al, 1997). 
This supports our model results, which suggest that syndromic management has not 
reduced the prevalence of any of these three infections to any significant extent. The 
trial results in respect of syphilis are difficult to interpret, since syphilis treatment was 
provided at baseline to all individuals who were infected with syphilis, both in the 
intervention and control arms. However, the prevalence of active syphilis (RPR titre ≥ 
1:8) at follow-up was significantly lower in the intervention arm than in the control 
arm. This suggests that syndromic management significantly reduces the prevalence 
of syphilis, which is consistent with the model predictions.  
 
The effect of syndromic management was also evaluated in the Masaka trial (Kamali 
et al, 2003), though the syndromic management intervention was combined with an 
information and education campaign (IEC), making it difficult to isolate the 
independent effect of syndromic management on STI prevalence. The IEC was found 
to increase condom use with casual partners significantly, and the net effect of this 
behaviour change, together with syndromic management, was a significant reduction 
in the incidence of active syphilis (RPR titre ≥ 1:8), a significant reduction in the 
prevalence of gonorrhoea, and no change in the prevalence of chlamydial infection. 
These findings are consistent with the results of our model, which predicts that the 
combined effect of IEC and syndromic management is substantial in the case of 
syphilis and gonorrhoea but relatively modest in the case of chlamydial infection. 
 
6.4.2 Comparison with other model estimates of the effects of behaviour change 
on HIV in Sub-Saharan Africa  
 
Although several HIV/AIDS models have evaluated the potential effects of behaviour 
change in Sub-Saharan Africa, published results are difficult to compare. Evaluations 
have differed in terms of the assumed timing of the change in behaviour, the assumed 











of the change is measured in terms of incidence or prevalence. Consistent with our 
model simulations, other models show that changes in behaviour that are initiated in 
the early stages of the HIV/AIDS epidemic tend to reduce the incidence of HIV to a 
greater extent than those initiated in the later stages of the epidemic (Boily et al, 
2002). Reductions in HIV incidence tend to be more significant than reductions in 
prevalence in the short term, though over the long term, one would expect the two to 
converge. These issues need to be considered when comparing the effects of 
behaviour change simulated by different HIV/AIDS models. 
 
One of the most commonly modelled forms of behaviour change is reduced male 
contact with sex workers. A 50% reduction in the frequency of unprotected sex with 
commercial sex workers is predicted to reduce HIV prevalence by roughly 25% in the 
STDSIM model, if introduced 15 years into an urban African HIV/AIDS epidemic 
(Korenromp et al, 2000a). The same change is predicted to reduce HIV incidence by 
23-68% in the SimulAIDS model, if introduced 10 years after the start of the Ugandan 
HIV/AIDS epidemic (Robinson et al, 1995), and by 38% in the model of Boily et al 
(2002), if introduced 13 years after the start of a ‘high prevalence’ HIV/AIDS 
epidemic. In the model of Bracher et al (2004), a 50% reduction in male contact with 
sex workers is predicted to reduce Malawian women’s lifetime risk of HIV infection 
by 19% – a greater reduction would be expected in men, but this is not reported.  
 
Our model predicts a smaller reduction in HIV incidence following reductions in sex 
worker contact. The percentage reductions in HIV incidence, following a 50% 
reduction in male contacts with sex workers five years into the epidemic, are between 
11 and 15%, if calculated using the three cofactor scenarios described in section 5.2. 
The reductions in incidence are lower when the behaviour change occurs at later 
epidemic durations, or when the reductions are calculated using the model that does 
not allow for STI cofactors. The relatively low impact predicted in our model can be 
attributed to the relatively low assumed frequency of male contact with sex workers: 
0.13 contacts per annum among men aged 15-49, compared with 1.4 per annum in the 
STDSIM model, 3-12 per annum in the SimulAIDS model, approximately 4 per 
annum in the model of Boily et al (2002) and 0.6-3.8 per annum in the model of 
Bracher et al (2004). The average proportion of men reporting contact with a sex 











0.063 (Caraël et al, 2006). This appears to support the relatively low frequency of sex 
worker contact assumed in our model, though there remains much uncertainty 
regarding the frequency of sex worker contact among those men who do report such 
contacts, and there is also much uncertainty regarding the likely extent of social 
desirability bias in male reporting of sex worker contacts. 
 
A few models have also evaluated the effects of reducing the frequency of 
unprotected sex in spousal and non-spousal relationships. Van Vliet et al (2001) 
predict that halving the level of unprotected sex in long-term marital relationships 
would reduce HIV incidence by approximately 20%, and halving the level of 
unprotected sex in short-term relationships (excluding commercial sex encounters) 
would reduce HIV incidence by approximately 45%, if introduced 15 years into an 
urban African HIV/AIDS epidemic. Bracher et al (2004) predict that halving 
unprotected sex in extramarital relationships (again excluding commercial sex) would 
reduce women’s lifetime risk of HIV infection by 31%. These simulations are roughly 
consistent with our model, which suggests that halving unprotected sex in short-term 
relationships would reduce HIV incidence by 74% (95% interval: 70-78%) if 
introduced 5 years into the South African HIV/AIDS epidemic, and by 36% (95% 
interval: 32-40%) if introduced 25 years into the South African HIV/AIDS epidemic. 
Corresponding estimates for long-term relationships are 9% (95% interval: 4-16%) 
and 9% (95% interval: 5-13%) respectively.  
 
Our model suggests that the actual increases in condom use that have occurred in 
South Africa have had a significant impact, reducing HIV incidence in 2005 by 46-
51%. This is in spite of the assumed levels of condom use being lower than those 
reported; as noted in section 3.2.8, setting the assumed levels of condom usage at 
those reported would result in HIV prevalence trends in youth that are inconsistent 
with observed HIV prevalence trends. It is likely that responses to survey questions 
about condom use at last sex exaggerate the true proportion of sex acts that are 
protected, principally because condom use tends to be more common in those 
relationships in which sex is less frequent (Pettifor et al, 2004a; Hargreaves et al, 
2007). However, it is also possible that condoms may be less effective than is 
commonly assumed. Garnett and Anderson (1995) show that if the marginal risk of 











partner increases (as evidence suggests), then a very high level of condom use would 
be required in order to achieve a modest reduction in the average HIV transmission 
probability, i.e. the relationship between proportion of sex acts that are protected and 
the HIV transmission probability per partnership is highly non-linear. If this is indeed 
the case, then the goal of condom promotion should be to increase the proportion of 
individuals who use condoms consistently, rather than simply to increase the 
proportion of sex acts in which condoms are used. 
 
A number of models have also evaluated the effects of reductions in the rate at which 
new partners are acquired. Both Korenromp et al (2000a) and Garnett and Anderson 
(1995) show that halving the rate at which new sexual partners are acquired would 
roughly halve the long-term prevalence of HIV, if the change occurs around 15 years 
into an African HIV/AIDS epidemic. Our model, in contrast, predicts that even if the 
change were to occur 5 years into the epidemic, the reduction in HIV incidence would 
be only 21-30% if not allowing for STI cofactors and 34-42% if allowing for STI 
cofactors. A likely explanation for the relatively small impact predicted by our model 
is the constraint that individuals in the ‘low risk’ group never have more than one 
current sexual partner and individuals in the ‘high risk’ group never have more than 
two current sexual partners – no such constraint exists in the other two models. Since 
our model predicts that a high proportion of people already have their maximum 
number of partners, our model is not as sensitive as other models to changes in the 
assumed rate at which new partners are acquired. 
 
Relatively few models have examined the effects of delays in sexual debut on the 
incidence of HIV. Hallett et al (2007) predict that in the context of the HIV/AIDS 
epidemic in rural Zimbabwe, a two-year delay in the average age at sexual debut 
would reduce the lifetime risk of HIV infection by 6-8%, assuming men do not seek 
to maintain the same number of sexual partners when women delay sexual debut. This 
is consistent with the estimates of our model, which shows that a roughly two-year 
delay in median age at first sex would reduce HIV incidence by 7-9% if introduced 5 
years after the start of the South African HIV/AIDS epidemic, and by 2-5% if 
introduced in 2010. However, the STDSIM model suggests that a two-year delay in 
sexual debut would have a much more significant impact in the urban African setting; 











drop by approximately 40% over the next 15 years (Korenromp et al, 2000a). The 
relatively large predicted impact can probably be explained by the assumed high level 
of risk behaviour among youth; the rate of partnership formation among youth below 
the age of 25 is assumed in STDSIM to be four times that in adults aged 25 and older. 
 
Although previous modelling work has established that the level of concurrency in a 
population is a significant determinant of the extent of HIV spread (Watts and May 
1992; Kretzschmar and Morris 1996), previous models have not examined the 
potential effect of reducing the level of concurrency after the epidemic has already 
started. Our simulations suggest that encouraging individuals to remain faithful to one 
partner could have a significant impact, with HIV incidence estimated to be reduced 
by 32-45% if the formation of concurrent partnerships were to cease completely in 
2010. Concurrency plays an even more important role in the transmission of HIV in 
the early stages of the HIV/AIDS epidemic; the reduction in HIV incidence that 
would have occurred if concurrent partnerships had ceased 5 years after the start of 
the South African HIV/AIDS epidemic is 74% (95% CI: 69-78%) in the model that 
does not allow for STI cofactors and 76-87% in the model that does allow for STI 
cofactors. Concurrent partnerships therefore appear to be a major factor explaining the 
high levels of HIV prevalence in South Africa.  
 
The model results show that there are increasing marginal returns to reducing the rate 
of concurrent partnership formation. This may be because the length of time to 
acquiring a secondary partner is hyperbolically related (not linearly related) to the rate 
of concurrent partnership formation. Another possible explanation is that there are 
two distinct factors explaining the effect of reduced concurrency: the reduced rate of 
partner acquisition in the high risk group and the reduced contact between high and 
low risk groups, as a result of high risk individuals having fewer partners. If these two 
factors have a multiplicative effect, then the net effect of reduced concurrency would 
be non-linearly related to the reduction in the rate of secondary partner acquisition. 
The results presented in Figure 6.3.2 show that the effect of halving the rate of 
secondary partner acquisition is only slightly smaller than the effect of halving the 
rates at which all partnerships are formed. The latter does not imply any change in 
sexual mixing patterns, while the former implies a reduction in contact between the 











partnerships have such a significant impact, despite concurrent partnerships 
accounting for a relatively small proportion of total non-spousal partnerships. 
 
6.4.3 The effect of syndromic management on the incidence of HIV  
 
Our model suggests that the syndromic management programme in South Africa has 
had a modest but significant impact on HIV incidence, reducing the total number of 
new HIV infections over the 1994-2004 period by 6% in the baseline cofactor 
scenario (and by 3% and 10% in the low and high cofactor scenarios respectively). 
This may be considered disappointing when compared with the substantial reduction 
in HIV incidence estimated in the randomized controlled trial of syndromic 
management in Mwanza (38%, 95% CI: 15% to 55%) (Hayes et al, 1995a). However, 
our model results are much more similar to the results of the randomized controlled 
trial in Masaka (0% reduction, 95% CI: -58% to 37%) (Kamali et al, 2003). White et 
al (2004) have used a mathematical model of the HIV/AIDS epidemics in Mwanza 
and Masaka to show that the substantial difference in the effectiveness of the Mwanza 
and Masaka trials can be explained by differences in the timing of the intervention, 
and by the behaviour changes that had already reduced STI prevalence to low levels 
before the start of the trial in Masaka.  
 
To assess whether these factors explain the differences between our model results and 
the results of the Mwanza and Masaka trials, we consider two scenarios that might be 
considered representative of the Mwanza and Masaka interventions. It is assumed that 
all private and public practitioners use syndromic management protocols after the date 
of introduction – 1994 in the first scenario and 2002 in the second scenario – and that 
all drug shortages in public clinics are eliminated after the date of introduction. The 
1994 and 2002 start dates correspond to the assumptions made by White et al, which 
were that the Mwanza intervention was introduced 9 years after the start of the 
HIV/AIDS epidemic and that the Masaka intervention was introduced 17 years after 
the start of the epidemic. In our baseline model, significant increases in condom usage 
occur prior to 2002, but there is relatively little increase in condom usage prior to 
1994; the 2002 scenario therefore allows for a significant degree of behaviour change 
similar to that preceding the Masaka trial. For both scenarios, reductions in new HIV 











again in the interests of consistency with the simulations of White et al. Results are 
compared in Table 6.4.2. 
 
Our model confirms the conclusion of White et al (2004) that syndromic management 
is less effective when introduced in advanced HIV/AIDS epidemics, in which changes 
in sexual behaviour have already occurred. However, our model estimates of the 
impact of syndromic management in the early stages of an epidemic are lower than 
those simulated by White et al, and are towards the lower end of the 95% confidence 
interval around the Mwanza trial results. The most likely explanation for the 
difference between our model estimates and those of White et al are the relatively 
high STI cofactor multiples assumed in the latter analysis, particularly in the case of 
genital ulcers. However, when applying the same model in four other African settings, 
White et al (2008) estimate that HIV incidence would have been reduced by between 
2 and 20% if the Mwanza intervention had been introduced 9 years into the epidemic. 
This range is much more consistent with our model estimates for a syndromic 
management programme introduced 9 years into the South African HIV/AIDS 
epidemic.  
 
Table 6.4.2: Comparison of observed and simulated reductions in HIV incidence in 
Mwanza and Masaka conditions, as a result of syndromic management 
 Mwanza Masaka 
Observed reduction in HIV incidence  





Assumed number of years since start of 
   HIV/AIDS epidemic 
9 17 
Effect of syndromic management simulated 
   by White et al (2004) 
28% 2% 
South African model simulations   
   Baseline cofactor scenario 15% 3% 
   Low cofactor scenario 7% 2% 












The difference between our model and the observed reductions in HIV incidence in 
the Mwanza trial could merely be due to chance, since the 95% confidence interval 
around the observed reduction is very wide. There have been some doubts expressed 
about whether the reduction in HIV incidence in the Mwanza study was really due to 
improved STI treatment, especially since the effect of the intervention on the 
prevalence of most STIs was small relative to the observed effect on HIV incidence 
(Rygnestad et al, 1995; Whitaker and Renton 1995). Indeed, a number of STIs 
increased in prevalence over the course of the trial, but because the increase was 
greater in the control arm than in the intervention arm, the reported relative risk 
estimate was less than one (Mayaud et al, 1997). It is therefore possible that the 
Mwanza study may have exaggerated the independent effect of syndromic 
management on HIV incidence. 
 
Our model may slightly understate the benefit of the syndromic management 
programme, as syndromic management guidelines often recommend that health 
workers examining and treating STI-infected patients should also promote condom 
usage and risk reduction to patients, and provide them with partner notification slips 
to encourage potentially infected partners to seek treatment (Pettifor et al, 2000). Our 
model does not assess the potential effect of these components of the STI treatment 
service. However, it would appear that South African health workers often avoid 
condom promotion in order to deal more swiftly with heavy patient loads. In a 
national survey of public health facilities, Ramkissoon et al (2004) observed that 
although 80% of STI patients were provided with condoms, only 31% of service 
providers discussed condom usage with STI patients. It was also found that partner 
notification slips were only issued to 18% of clients. Even when notification slips are 
issued, relatively few partners are informed and seek treatment. In a study of STI 
treatment services in Cape Town, for example, it was found that only 20% of partner 
notification slips were returned (Mathews et al, 2002). These are clearly major 
problems that need to be addressed, but they are beyond the scope of our modelling. 
In deterministic frequency-dependent models, it is not possible to link the STI status 
of the individual to that of their partner, and the effect of partner notification is 












Another important benefit of syndromic management, which has not been assessed in 
this model, is its potential effect on asymptomatic STIs. Although syndromic 
management is usually thought of as being relevant only to the treatment of 
symptomatic STIs, individuals who seek treatment for symptomatic STIs are often co-
infected with other STIs that are not causing symptoms; treatment with multiple 
antibiotics is therefore often effective in eliminating these asymptomatic STIs. 
However, there are also dangers associated with high levels of antibiotic use, which 
we have not included in our modelling. Antibiotic use is known to increase 
significantly the risk of vaginal candidiasis (Reed et al, 2000; Ohmit et al, 2003; 
Schwebke 2000; Stein et al, 1993; Hillier et al, 1993), and the introduction of 
syndromic management protocols could therefore increase the prevalence of vaginal 
candidiasis. The effect of syndromic management on asymptomatic STIs and vaginal 
candidiasis has not been considered in previous mathematical modelling work, but 
may be worth investigating. 
 
6.4.4 The effect of other STI interventions  
 
We have identified a number of forms of STI treatment that could achieve significant 
reductions in HIV incidence over the next decade. These changes in STI treatment 
practices have been advocated previously by various experts, but their potential 
impact has not previously been assessed using mathematical modelling. Future studies 
will need to examine the costs and the logistical implications of these proposed 
changes to STI treatment policy, and to assess how the cost-effectiveness of these 
interventions compares with that of other STI treatment strategies (Gilson et al, 1997; 
White et al, 2008) and other HIV prevention strategies (Creese et al, 2002). 
Interventions such as periodic presumptive STI treatment for sex workers and 
enhanced antenatal syphilis screening, which we predict to have little impact at a 
population level, may nevertheless be cost-effective and therefore worthy of 
consideration (Terris-Prestholt et al, 2003). 
 
One of the most promising strategies identified is the establishment of a patient-
initiated acyclovir treatment programme for individuals who are infected with HSV-2. 
This is projected to have a significant impact on HIV incidence because a high 











the baseline cofactor scenario). Since increases in HIV susceptibility and 
infectiousness appear to be greater during symptomatic genital herpes than during 
asymptomatic HSV-2 infection, it is particularly important that symptomatic infection 
be treated, and that this treatment be initiated as soon as possible after the symptoms 
appear. This is best achieved if treatment is self-initiated, rather than delayed until the 
patient is able to attend health services. In addition to the short-term benefits of 
reduced symptomatic HSV-2 (which is important in reducing HIV transmission), 
there would also be reductions in the transmission of HSV-2, which would reduce 
HSV-2 prevalence over the long term (by an average of 7% in 2020). One would 
therefore expect the benefit from the programme to grow over the longer term, as the 
transmission of HSV-2 is further reduced. We have not modelled the potential 
additional effect of individuals knowing their HSV-2 status and changing their sexual 
risk behaviour in order to reduce their risk of transmitting the virus to their sexual 
partners (Wald et al, 2006), and the effect of the counselling and testing component of 
the programme is therefore not reflected in our estimates. 
 
An obvious concern regarding the proposed patient-initiated acyclovir programme is 
that it might not be feasible, considering the high proportion of the population that is 
infected with HSV-2. However, it is important to note that less than 30% of 
individuals who acquire HSV-2 ever experience symptoms, and in most cases, 
symptoms reduce in frequency over time. Our model suggests that at any point in 
time, only about 0.5% of women aged 15 to 49 are experiencing symptoms of genital 
herpes. It is therefore unlikely that the number of people enrolled on the programme 
or the total drug requirements would become unmanageable. Blower et al (2004) have 
also shown that by targeting antiviral treatment at a relatively small “core group” of 
HSV-2 transmitters, significant reductions in HSV-2 transmission can be achieved at 
the population level. 
 
A logical extension of patient-initiated episodic antiviral treatment is suppressive 
(continuous) antiviral treatment of individuals with HSV-2. This has been shown to 
halve the risk of HSV-2 transmission to sexual partners and reduce the rate of 
symptomatic recurrence by 70% (Corey et al, 2004), with potentially significant 
effects on HSV-2 incidence at a population level (Williams et al, 2007). In addition, 











that suppressive HSV-2 treatment can significantly reduce the detection and 
concentration of HIV in the genital tract, thereby reducing HIV infectiousness 
(Delany et al, 2007; Nagot et al, 2007b; Baeten et al, 2008). The effect of long-term 
suppressive antiviral treatment has not been modelled in this analysis, because it is 
likely to be a much more costly and logistically challenging strategy than episodic 
antiviral treatment. However, if initial experience with the rollout of an episodic 
patient-initiated acyclovir treatment programme were favourable, a suppressive 
antiviral treatment programme might be considered. Since suppressive acyclovir is 
effective in reducing mortality in HIV-infected individuals (Ioannidis et al, 1998), in 
addition to reducing their HIV infectiousness, it might be cost-effective to limit 
suppressive acyclovir to HSV-2 and HIV-co-infected individuals, while providing 
episodic acyclovir to HSV-2-infected patients who are HIV-negative. 
 
Another change in STI treatment that we have found to be highly effective is the 
replacement of ciprofloxacin in syndromic management protocols. In view of the 
rapidly emerging resistance to ciprofloxacin in gonococcal isolates, this change 
should be introduced as a matter or urgency. Ceftriaxone has been proposed as an 
alternative to replace ciprofloxacin, and indeed, current syndromic management 
protocols recommend that it be used to treat patients with discharges or dysuria who 
fail to respond to their first-line treatment. However, resistance to cephalosporins such 
as ceftriaxone is already emerging in gonococcal isolates in the West Pacific region 
(Workowski et al, 2008), and it is likely that resistance to ceftriaxone would 
eventually become an issue if this drug were to become the standard therapy for 
gonorrhoea in South Africa. Treatment options for gonorrhoea are becoming 
increasingly limited as a result of a steady accumulation of drug resistance worldwide 
(Workowski et al, 2008), and our simulations of the potential effects of switching to 
ceftriaxone, up to 2020, should therefore be interpreted with caution. If resistance to 
ceftriaxone were to develop before 2020, our model simulations would overstate the 
impact of this particular intervention.  
 
Although our model suggests that there would be significant benefits to replacing 
ciprofloxacine with ceftriaxone, it should be noted that our approach to modelling 
resistance is slightly simplistic. Based on surveillance data from a few urban centres, 











average gonorrhoea treatment efficacy is reduced by the proportion of cases that are 
ciprofloxacin-resistant but treated with ciprofloxacin. Although this approach may be 
appropriate when the prevalence of ciprofloxacin resistance is known, its future 
prevalence is clearly not known. The more standard approach to modelling drug 
resistance is to model dynamically the development and transmission of drug-resistant 
strains, using separate ‘states’ to represent individuals infected with drug-resistant and 
wild-type strains (Gershengorn and Blower 2000; Turner and Garnett 2002; Blower et 
al, 2001). Calibrating such a model to past levels of ciprofloxacin resistance would 
permit a more reasonable prediction of the future prevalence of ciprofloxacin 
resistance and the potential effect of switching to other drugs, and this should be 
considered in future work. 
 
Our model suggests that there would also be significant benefits to reducing treatment 
delays. The Khomanani social marketing campaign that was introduced in South 
Africa in 2002 has aimed to improve knowledge of STI symptoms and the importance 
of prompt STI treatment through dramas performed at soccer stadia and other venues, 
through TV and radio slots, and through the print media (Health and Development 
Africa 2004). In a national evaluation of the Khomanani campaign, it was found that 
roughly a third of respondents had been exposed to STI messages through one of 
these media, and that knowledge of STI symptoms was better in men who had been 
exposed to the campaign than in men who had not been exposed to the campaign 
(Health and Development Africa 2004). Life skills programmes in schools have also 
been introduced since 1998, and have been shown to have a significant positive effect 
on knowledge of STI symptoms among youth (Magnani et al, 2005). Whether these 
interventions have had any impact on rates of health seeking for STI symptoms is not 
yet clear, but such programmes should clearly continue. It is also necessary to make 
STI treatment services more accessible, particularly for adolescents, who are often 
afraid of seeking STI treatment because of health workers’ attitudes towards teenage 
sexuality. The loveLife social marketing programme has aimed to improve youth 
access to health services through the establishment of adolescent-friendly clinics, and 
it is estimated that in 2003 roughly 33 000 visits were made to these clinics per month 
(Collinge 2005). Improved access to health services in rural areas will also be 
important, and mobile STI clinics may be an effective strategy for improving access 












This analysis is limited to STI interventions that have been advocated by experts in 
STI treatment and prevention. Important forms of STI treatment that we have not 
modelled are mass STI treatment and regular STI screening. Mass STI treatment has 
not been found to be effective in reducing HIV incidence in a randomized controlled 
trial in Uganda (Wawer et al, 1999), and given the substantial resources required to 
repeat mass treatment at regular intervals, it is unlikely that this would be feasible in 
South Africa. However, STI screening may be feasible in groups such as women 
attending antenatal and family planning clinics. The benefit in the former group 
would be particularly significant, since there would be an associated reduction in the 
risk of adverse pregnancy outcomes and infections such as neonatal herpes and 
gonococcal opthalmia neonatorum in their newborn. However, such antenatal 
screening does not appear to have been advocated in developing countries, except in 
the case of syphilis, and this STI prevention strategy has therefore not been evaluated. 
 
Another potential strategy for STI prevention that we have not considered is male 
circumcision. Although three African randomized controlled trials have shown this to 
be a highly effective strategy for reducing the incidence of HIV (Auvert et al, 2005; 
Bailey et al, 2007; Gray et al, 2007), there has been relatively little attention paid to 
the potential for this strategy to reduce the incidence of other STIs. In two of the 
trials, the incidence of genital ulcer disease was found to be reduced significantly in 
the intervention arm (Bailey et al, 2007; Gray et al, 2007), though the incidence of 
urethral discharges and individual STIs was not significantly affected. This finding is 
supported by a meta-analytic review, which has shown that men who are circumcised 
are at a reduced risk of syphilis, HSV-2 and chancroid (Weiss et al, 2006), although 
the reduction in risk is relatively small in the case of HSV-2 (RR 0.88, 95% CI: 0.77-
1.01). It therefore seems likely that most of the reduction in the incidence of genital 
ulcers in the male circumcision trials was due to syphilis and chancroid. Since syphilis 
and chancroid have already been reduced to very low levels in South Africa, and now 
account for a negligible fraction of incident HIV cases, it seems unlikely that any 
current effect of male circumcision on HIV incidence in South Africa is attributable to 
the effect of male circumcision on syphilis and chancroid. However, it is possible that 
male circumcision may protect against herpes, gonorrhoea and trichomoniasis (Moses 











may be appropriate to extend our model to allow for the effect of male circumcision 
on these STIs.  
 
Vaccines against STIs are another potential STI prevention strategy that we have not 
modelled, as there are as yet no effective vaccines against any of the STIs considered 
in this analysis. An HSV-2 vaccine has been developed, but its efficacy is limited to 
women who are uninfected with HSV-1 (Stanberry et al, 2002). Since HSV-1 
infection is virtually universal in Africa, such a vaccine would have little impact in 
the South African setting, though mathematical modelling suggests that it could 
reduce HSV-2 incidence by as much as 30% in the United States (Garnett et al, 2004). 
Various attempts have been made to develop vaccines against the bacterial STIs, but 
thus far none have proven effective. Mathematical models suggest that vaccines may 
be particularly important in controlling STIs such as chlamydial infection, which are 
difficult to control through treatment programmes (Brunham et al, 2005). There is 
thus an urgent need for effective vaccines against STIs, and models can play an 














Chapter 7: Conclusions 
 
Although much previous research has been conducted to estimate the prevalence of 
HIV in South Africa (Dorrington et al, 2006; UNAIDS 2006; Rehle and Shisana 
2003), this thesis presents the first attempt to estimate the prevalence of other STIs in 
South Africa, at a national level. We have developed a novel approach to estimate STI 
prevalence from sentinel surveillance data, integrating a mathematical model of STI 
transmission dynamics with a statistical model that takes into account both variation 
between sentinel sites and variation in diagnostic accuracy. The results suggest that 
STI prevalence in South Africa is unusually high, even when compared with WHO 
estimates for the Sub-Saharan African region (Gerbase et al, 1998; Rowley and 
Berkley 1998). This is likely to be a reflection of the high levels of migration in South 
Africa, the high frequency of concurrent partnerships, the low prevalence of male 
circumcision and also the relatively late start to the HIV/AIDS epidemic in South 
Africa. The same technique for estimating national STI prevalence from sentinel 
surveillance data could be applied in other developing countries, though it is likely 
that in most other countries, there would be insufficient STI prevalence data to allow 
reasonable estimation of national STI prevalence. 
 
Our model is the first to evaluate all eight genital tract infections that are known to 
influence the risk of HIV transmission (Røttingen et al, 2001). Results suggest that 
STIs have contributed significantly to the spread of HIV in South Africa, with an 
estimated 69% of new HIV infections in 1990 being attributable to other STIs, in the 
baseline cofactor scenario. Consistent with other models of HIV-STI interactions 
(Robinson et al, 1997; Orroth et al, 2006), the contribution of STIs to HIV 
transmission is predicted to diminish over the course of the HIV/AIDS epidemic, as 
the prevalence of other STIs declines and as more HIV transmission occurs in ‘low 
risk’ groups. However, genital herpes consistently accounts for roughly 20% of new 
HIV infections at all stages of the epidemic, making it the most significant STI 
driving the transmission of HIV. It is therefore particularly important that strategies 












Results show significant declines in the prevalence of certain STIs since the mid-
1990s. In the case of syphilis and chancroid, these declines appear to have been 
brought about by the introduction of syndromic management protocols in the public 
health sector and by increases in condom use, and to a lesser extent, by AIDS 
morbidity and mortality in ‘high risk’ groups. In the case of gonorrhoea, syndromic 
management has brought about a slight decline in prevalence, but most of the decline 
appears to be due to increases in condom use. The prevalence of trichomoniasis and 
chlamydial infection, however, appears to have been unaffected by syndromic 
management programmes, and only behaviour change accounts for the slight 
reductions in prevalence. The prevalence of HSV-2, bacterial vaginosis and vaginal 
candidiasis is estimated to have remained relatively stable over the last two decades. 
Syndromic management has therefore had a significant impact on the prevalence of 
those STIs that become symptomatic in a high proportion of cases, but has virtually 
no impact on those STIs that are mostly asymptomatic, and clearly has no impact on 
genital herpes and vaginal candidiasis, which are assumed to be managed in the same 
way under syndromic management as they are in the absence of syndromic 
management. 
 
The model results suggest that there may be significant resistance to reinfection 
following recovery from gonorrhoea, trichomoniasis and chlamydial infection. The 
evidence is strongest in the case of resistance following spontaneous resolution, but 
evidence of resistance following successful treatment is relatively weak. This supports 
the “arrested immunity” hypothesis of Brunham and colleagues (Brunham and Rekart 
2008; Rekart and Brunham 2008), although there remains much uncertainty regarding 
the exact nature of the immune protection. The long-term persistence of gonorrhoea, 
trichomoniasis and chlamydial infection at high prevalence levels – in spite of 
significant improvements in STI treatment and significant reductions in sexual risk 
behaviour – appears to be easier to explain when using a model that allows for 
immunity, as the reductions in risk that are associated with the behavioural and 
treatment changes are partially offset by reduced prevalence of immunity. Models that 
allow for immunity also produce predictions of STI prevalence in sex workers that are 












Syndromic management appears to have had a modest but significant impact on HIV 
incidence in South Africa, reducing the total number of new HIV infections over the 
first ten years of the programme by approximately 6% in the baseline cofactor 
scenario. The reduction would have been closer to 14% if syndromic management had 
been scaled up rapidly in 1994, in both the private and public health sectors. 
Consistent with the results of the STDSIM model (White et al, 2004), our model 
shows that the impact of improved STI treatment on HIV incidence is substantially 
greater when introduced in the early stages of the HIV/AIDS epidemic, prior to 
behaviour change, than when introduced in an advanced epidemic in which significant 
behaviour change has already occurred. This partially explains the significant 
differences between the effects of syndromic management measured in the 
randomized controlled trials conducted in Mwanza and Masaka (Grosskurth et al, 
1995; Kamali et al, 2003).  
 
Our model of STI treatment handles several of the factors known to contribute to the 
low rate of effective treatment in South Africa: delays in health seeking, treatment by 
untrained or unqualified providers, limitations of syndromic management protocols, 
poor drug supply, antibiotic failure and drug resistance. This makes the model a 
particularly useful tool in deciding on STI treatment policy. Results suggest that there 
is significant potential for further reductions in HIV incidence through changes to 
existing STI treatment practices. It is especially important that strategies to manage 
genital herpes be established, as HSV-2 is the most significant STI promoting the 
transmission of HIV and there is currently no HSV-2 strategy in place in South 
Africa. One possible strategy may be to include acyclovir in the combination of drugs 
that is routinely provided to patients presenting with genital ulcers, but a more 
effective strategy is likely to be the establishment of a programme to screen GUD 
patients for HSV-2 and encourage self-initiated acyclovir treatment in those who test 
positive (O'Farrell et al, 2007a). Syndromic management protocols also need to be 
revised so that ciprofloxacin is no longer used in the treatment of patients presenting 
with urethral or vaginal discharges. There is also a need for greater adoption and 
implementation of syndromic management protocols in the private and public health 
sectors; this could be achieved through better training and through CPD schemes, 
through packaged syndromic management, and through elimination of drug shortages 











health-seeking be encouraged, through the strengthening of existing social marketing 
and school education programmes, and through the expansion of health services in 
previously under-serviced areas. 
 
By the standards of existing deterministic models, our model of sexual behaviour is 
relatively detailed, distinguishing between spousal and non-spousal relationships, 
allowing for concurrent partnerships, and allowing for movements between different 
behavioural states over the life course. The model is also calibrated to data on sexual 
behaviour from a variety of South African data sources, allowing for likely biases in 
the reporting of sexual behaviour in face-to-face interviews. This is an advance on 
earlier models of HIV transmission in South Africa, which were forced to rely on 
fairly arbitrary assumptions about sexual behaviour, due to a lack of reliable sexual 
behaviour data (Doyle and Millar 1990; Schall 1990; Groeneveld and Padayachee 
1992; Dorrington 2000; Johnson and Dorrington 2006). Results suggest the role of 
‘core groups’ (i.e. sex workers and their clients) in HIV and STI transmission at a 
population level is smaller than previously thought. Interventions to reduce male 
contact with sex workers and treat sex workers for STIs regularly are predicted to 
have relatively little effect, in terms of both HIV incidence and STI prevalence, at a 
population level. This differs from the results of previously published AIDS models, 
which suggest that commercial sex is a major driver of HIV/AIDS epidemics in Sub-
Saharan Africa (Korenromp et al, 2000a; Robinson et al, 1995; Boily et al, 2002; 
Bracher et al, 2004). 
 
We do find, however, that when a broader definition of ‘core group’ is used 
(individuals who have a propensity for concurrent partnerships), the role of the core 
group becomes much more significant. Concurrent partnerships are major drivers of 
HIV and STI transmission in South Africa, accounting for 74-86% of new HIV 
infections over the 1990-2000 period, in the STI cofactor model. Eliminating 
concurrency would reduce HIV incidence in South Africa between 2010 and 2020 by 
30-45%, by reducing the total number of non-spousal partnerships and – less 
obviously – by reducing the extent to which core and non-core groups interact. 
Changes to the age at sexual debut and the age at marriage appear to have relatively 
small effects on the incidence of HIV, and earlier marriage could even have a 











years of marriage. However, STIs differ significantly in terms of the particular 
behaviours that favour their transmission. For example, reducing unprotected sex in 
spousal relationships would be particularly important in reducing the prevalence of 
syphilis, while delaying sexual debut would be particularly important in reducing the 
prevalence of chlamydial infection. 
 
Increases in condom use appear to have had a significant impact on HIV incidence in 
South Africa, reducing the incidence of HIV in 2005 by almost half in the STI 
cofactor model. However, the modelled increase in condom use is smaller than that 
reported in recent surveys (Shisana et al, 2005; Pettifor et al, 2005b). Setting the 
levels of condom use at those reported would have resulted in a modelled decline in 
HIV prevalence in youth much greater than has actually been observed in South 
Africa. This implies that either (a) the fraction of people who report using a condom 
at last sex is a relatively poor indicator of the actual proportion of sex acts that are 
protected, or (b) condoms are less effective than has been assumed. We hypothesize 
that explanation (a) is likely, though modelling work by Garnett and Anderson (1995) 
suggests that the cumulative efficacy of condoms may be low if they are not used 
consistently, and explanation (b) may therefore also have some validity. Apart from 
the increases in reported condom use, there is little empirical evidence to suggest that 
sexual behaviour in South Africa has changed substantially over the last two decades. 
However, our model suggests that modest declines in the reporting of multiple 
partnerships and modest increases in the reporting of sexual abstinence might be 
expected to result from the high levels of AIDS mortality and AIDS morbidity in 
‘high risk’ groups, in the absence of any spontaneous change in these behaviours. 
This has implications for second-generation HIV/AIDS surveillance, as it suggests 
that changes in reported sexual behaviours may, in part, be a reflection of the impact 
of AIDS rather than a reflection of the success of interventions. 
 
This thesis advances the use of Bayesian techniques in quantifying uncertainty in HIV 
and STI simulation models, by proposing a framework for incorporating STI 
prevalence data and sexual behaviour data, in addition to the HIV prevalence data 
incorporated in previous Bayesian analyses (Alkema et al, 2007). The Bayesian 
approach has been used to quantify uncertainty in respect of the HIV transmission 











parameters. Considering that these parameters are difficult to measure accurately, it is 
particularly important that evaluation of different policy options be based on the 
consideration of a range of plausible parameter values, and the Bayesian approach is 
therefore important in identifying these plausible parameter values. However, there 
remain many sources of uncertainty that have not been formally evaluated. 
Uncertainty regarding the chancroid parameters has not been considered due to the 
difficulty experienced in defining an appropriate likelihood function. The uncertainty 
with respect to the effect of STIs on HIV transmission probabilities has also not been 
evaluated, except through a simple comparison of three scenarios representing high, 
medium and low STI cofactors. It has also not been possible to consider all sources of 
uncertainty simultaneously, due to the long time taken to run the model when HIV 
and all other STIs are simulated together. Perhaps most significantly, uncertainty 
regarding the choice of model structure has received hardly any attention; the only 
cases in which it is assessed are in the comparison of different models of immunity 
and (less formally) the comparison of multiplicative and saturation models of STI 
cofactor effects. Further exploration of alternative model structures is necessary. For 
example, it would be useful to examine whether allowing for casual sex (“one night 
stands”) and greater heterogeneity in sexual behaviour significantly alters the model 
results. It would also be useful to assess the potential effect of switches between 
symptomatic and asymptomatic states in the cases of STIs such as gonorrhoea and 
chlamydial infection. 
 
Our model estimates of HIV and syphilis prevalence appear to be reasonably well 
validated when compared with HIV and syphilis prevalence data that were not used in 
defining the likelihood function. However, a limitation of this analysis is that we lack 
STI prevalence data with which to validate the model predictions of the prevalence of 
other STIs. Efforts should be made to obtain such data in future. Alternatively, it may 
be possible to repeat the Bayesian analysis using only half of the available data, and 
compare the resulting predictions with the omitted observations. A further limitation 
of our model fitting procedure is that there is no allowance for the behavioural and 
biological differences between women in the general population and women attending 
antenatal and family planning clinics (although there is allowance for differences in 
their age profiles). These differences might be expected to result in differences in STI 











extensively in the case of HIV (Gregson et al, 2002a; Glynn et al, 2001; Fylkesnes et 
al, 1998), but little is known about the magnitude of these differences in the case of 
other STIs, and this is an area in which further research is required. 
 
The model developed here could be extended to include other STIs. Most important 
among these is human papillomavirus (HPV), the cause of cervical cancer. 
Considering that cervical cancer causes more female deaths than any other cancer in 
South Africa (Norman et al, 2006), and considering that a highly effective HPV 
vaccine has recently been developed (Villa et al, 2005), there is a need for 
investigation into the feasibility of introducing this vaccine in South Africa. Indeed, a 
number of mathematical models of HPV have already been developed to address this 
question in other settings (Dasbach et al, 2006). It is also possible that HPV infection 
may increase HIV transmissibility (Spinillo et al, 2001a), and some evidence has been 
found of increased HIV transmission risk in the presence of other STIs that we have 
not modelled: hepatitis B (Twu et al, 1993), Mycoplasma genitalium (Manhart et al, 
2008) and cytomegalovirus (Speck et al, 1999; Mostad et al, 1999). The current 
evidence is too weak to justify the modelling of these interactions, but if future 
evidence suggests that these other STIs do indeed play an important role in HIV 
transmission, the model could be extended to allow for these other STIs. There is also 
some evidence to suggest that the probability of mother-to-child transmission of HIV 
may be increased in the presence of HSV-2 (Bollen et al, 2008) and genital ulcers 
(John et al, 2001). Our model does not currently allow for any effect of STIs on the 
probability of mother-to-child transmission of HIV, but this interaction could be 
modelled in future. 
 
Our model could also be extended to assess the impact of STIs on infertility and 
pregnancy outcomes, and the potential effects of maternally-transmitted infections in 
infants. This would be particularly important in estimating the burden of disease due 
to STIs other than HIV, as these sequelae account for a significant proportion of the 
STI disease burden (Rowley and Berkley 1998). In previously published burden of 
disease estimates for South Africa, the years of life lost due to STIs other than HIV 
were estimated from 1996 cause of death data, and years lived with disability due to 
STIs other than HIV were estimated from WHO estimates of the relationship between 











More accurate estimates of the STI disease burden might be obtained by entering our 
model-based estimates of STI incidence into the standard WHO models for burden of 
disease estimation (Rowley and Berkley 1998; Berkley 1998; Ebrahim et al, 2005). 
 
As new STI prevention and treatment strategies are developed, it may be appropriate 
to adapt the model to assess the likely impact of these interventions in South Africa. 
Microbicides that are currently being developed to prevent HIV transmission may 
well be effective in preventing the transmission of other STIs (Weber et al, 2005), and 
vaccines against gonorrhoea and chlamydial infection are currently being explored 
(Rupp et al, 2005). Although suppressive HSV-2 treatment has been found to have 
little effect on susceptibility to HIV infection (Watson-Jones et al, 2008; Celum et al, 
2008), it remains to be seen whether suppressive HSV-2 treatment reduces HIV 
infectiousness in individuals who are co-infected with HIV and HSV-2 (Paz-Bailey et 
al, 2007a). Male circumcision is another STI prevention strategy that could be 
incorporated into the model in future, particularly if strong evidence emerges of a 
protective effect against genital herpes and other STIs that are currently promoting the 
transmission of HIV in South Africa. 
 
South Africa remains one of the countries most severely affected by HIV/AIDS, with 
more HIV infections than any other country in the world (UNAIDS 2008). This thesis 
advances our understanding of both the behavioural and the biological factors 
promoting the transmission of HIV in South Africa, integrating South African data 
from a wide variety of sources in order to present a quantitative perspective on sex 
and sexually transmitted infection in South Africa. Although it is encouraging to see 
that past condom promotion and syndromic management interventions have had a 
significant impact on HIV incidence in South Africa, there is much more that needs to 
be done to reduce the incidence of HIV, and this thesis offers a number of practical 
suggestions. It is hoped that government, activists and scientists will work together in 
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Appendix A: Mathematical approach to modelling sexual 
behaviour 
 
The purpose of this appendix is to explain, in mathematical terms, the modelling of 
sexual behaviour. Table A.1 summarizes the index variables that are used throughout 
this appendix. 
 
Table A.1: Index variables 
Symbol Definition State space 
i Individual risk 
group 
01 = virgin with propensity for CS/concurrency 
02 = virgin with no propensity for CS/concurrency 
1 = Non-virgin, with propensity for CS/concurrency 
2 = Non-virgin, with no propensity for CS/concurrency 
3 = CS worker (relevant to f males only) 
j Risk group(s) 
of partner(s) 
0 = no partner; 1 = 1 high risk partner; 2 = 1 low risk 
partner; 11 = 2 high risk partners; 12 = primary high 
risk & secondary low risk; 21 = primary low risk & 
secondary high risk; 22 = 2 low risk partners* 
l Relationship 
type 
1 = short-term (non-marital) 
2 = long-term (marital)† 
x Individual age 
group 
10, 15, 20, …, 85 
y Partner age 10, 15, 20, …, 85 
g Sex 1 = male; 2 = female 
s HIV disease 
state 
0 = uninfected; 1 = acute HIV; 2 = asymptomatic HIV; 
3 = WHO clinical stage 3; 4 = AIDS; 5 = on HAART 
t Time 0 to 40 (in years from mid-1985) 
CS = commercial sex. HAART = highly active antiretroviral treatment.  
* Where the individual is in a marital relationship with one partner and a non-marital relationship with 
another, the first index refers to the risk group of the spouse and the second refers to the risk group of 
the other partner. † Where the individual has two partners, this index refers to the nature of the primary 
partnership (the secondary relationship is always short-term). Where the individual has no partners, the 












Symbols are defined as follows: 
K = number of cycles per year, i.e. the frequency at which sexual behaviour variables 
are updated (the default value is 12, but K can be any integer greater than one) 
π = gender equality factor 
),(,,, txN
s
ljig  = number of individuals of sex g, risk group i, aged x, who are in HIV 
disease state s, in relationship type l with partner(s) in group(s) j, at time t 
 
A.1 Rates at which short-term partnerships are formed 
 
To determine the rates at which short-term partnerships are formed, it is necessary to 
define the following symbols: 
)(,,, xc
s
ljig  = desired rate at which new short-term partnerships are formed, for an 
individual of sex g, risk group i, aged x, who is in HIV disease state s, in relationship 
type l with a partner in group j  (j = 0, 1 or 2 only) 
)(,, tjigρ  = desired proportion of new short-term partners who are in risk group j, if 
individual is of sex s and in risk group i (j = 1 or 2 only) 
 






































t εδερ , (A1) 
 
where ijδ  = 1 if i = j and 0 otherwise, g* is the sex opposite to g, and gε  is the degree 
of assortative mixing for sex g. As explained in section 3.2.6, the degree of assortative 
mixing can assume any value on the interval [0, 1], with lower values of the 
parameter indicating greater tendency to form partnerships with individuals in the 












In order to balance the male and female rates of short-term partnership formation, it is 
necessary to define the following parameter: 
)(1 ,, tB jig  = adjustment factor applied to the rate at which individuals of sex g, in risk 
group i, form short-term partnerships with individuals in risk group j (j = 1 or 2 only). 
 


























































The gender equality factor (π) can assume any value on the interval [0, 1]. The closer 
π is to 1, the closer the adjustment factor )(1 ,,2 tB ji  is to 1. A similar formula is used to 
define the adjustment factor for males ( )(1 ,,1 tB ji ), which approaches 1 as π approaches 
0. The gender equality factor thus determines the extent to which rates of partnership 
formation are driven by male and female desires. An equality factor of 0.5 would 
imply that men and women have equal control over the formation of partnerships, 
while an equality factor of 0 would effectively imply that women are coerced into 
sexual relationships and have no control over the rate at which they enter partnerships. 
Similar approaches to balancing rates of partnership formation in males and females 
have been proposed by Garnett and Bowden (2000) and Turner et al (2004).  
 
The independent probability of forming a new short-term partnership with a partner in 
risk group u, over the time period [ )Ktt 1, + , is calculated as 
 
 ( )KttBxc uiguigs ljig )()()(exp1 ,,1 ,,,,, ρ−−     (A3)  
 
for j = 0, 1 or 2, and is set to 0 for all other values of j (since it is assumed that an 












A.2 Rates at which long-term (marital) partnerships are formed 
 
Analogous to the previous section, the following variables are defined: 
)(,, xm
s
jig  = desired rate at which marriage occurs, for an individual of sex g, risk 
group i, aged x, who is in HIV disease state s, in a short-term relationship with a 
partner in group j (j = 1 or 2 only) 
)(2 ,, tB jig  = adjustment factor applied to the rate at which individuals of sex g, in risk 
group i, marry individuals in risk group j if they are currently in a short-term 
partnership with them (j = 1 or 2 only) 
 























































,  (A4) 
 
where ),(, ljI vu  is the number of partners of type l in risk group j, if the individual has 
partner(s) in group(s) u, with the primary partnership being of type v. It is thus 
assumed that the probability of marriage to a particular partner is independent of any 
other short-term partnerships the individual is in. 
 
The independent probability that an individual in a short-term relationship with a 
partner in group j, at time t, becomes married to that partner over the time period 
[ )Ktt 1, + , is then 
 
( )KtBxm jigs jig )()(exp1 2 ,,,,−− ,     (A5) 
 











A.3 Rates at which partnerships are terminated 
 
Partnerships can be terminated through death of the partner, through divorce (in the 
case of marital relationships) or through ‘break up’ (in the case of short-term 
relationships). In order to calculate rates of termination, it is necessary to define the 
following variables: 
)(, xD lg  = annual rate at which partnerships of type l dissolve, among individuals 
aged x, of gender g (ignoring mortality) 
)|( xyf g  = proportion of partners in age band y, if individual is of gender g and in 
age band x 
),( txsgµ  = force of mortality at time t, in individuals aged x, of gender g, who are in 
HIV disease state s 
 
For a man who is of age x, in group i, in relationship type l with a partner in group j at 
time t, the independent probability of the relationshi  being terminated over the time 























1exp1 µ .   (A6) 
 
A similar formula is used to determine the probability that a woman’s partnership is 
terminated. 
 
A.4 Rates at which women become sex workers 
 
In order to calculate the rate at which women become sex workers, it is necessary to 
specify the following variables: 
C = average annual number of sex acts a sex worker has with clients 
)(,, xw lji  = rate at which men in group i, aged x, visit sex workers when in relationship 
type l with partner(s) in group(s) j ( )(,, xw lji  = 0 if i ≠ 1) 
)(xW s  = factor by which the rate of recruitment into the ‘sex worker’ group is 











( )Kttc 1, +∆  = the number of new sex workers required over the period [ )Ktt 1, +  in 
order to satisfy male demand  
 


















.  (A7) 
 
The independent probability that a woman in the ‘high risk’ group, who has no 
partners and is aged x and in HIV disease state s at time t, becomes a sex worker over 
















.      (A8) 
 
 
A.5 Rates at which youth become sexually experienced 
 
The independent probability that a male virgin aged x at time t, with a propensity for 
commercial sex and concurrent relationships, has his first sexual encounter over the 
time interval [ )Ktt 1, +  is 
 
( )Kxc s )(exp1 0,01,1−− .      (A9) 
 
This expression is a function of s, the HIV disease state of the male, though the only 
HIV-infected virgins would be those infected through mother-to-child transmission. 
Note that the equation is independent of )(0,01 xw , i.e. men are assumed not to have 
their first sexual encounter with sex workers (this assumption is made in order to 
simplify the modelling of STI and HIV transmission). Similar equations are used to 












A.6 Calculating the transition probability matrix 
 
In order to calculate the elements of the transition probability matrix over the 
[ )Ktt 1, +  time interval, it is necessary to convert the independent probabilities 
described previously into dependent probabilities, i.e. probabilities net of competing 
decrements. Suppose that there are m possible movements out of state vS  (excluding 
death and ignoring changes in x and s for now), and the potential states to which an 
individual can move are denoted mSSSS ,...,,, 321 . Suppose that the independent 
probability of moving from state vS  to state uS  is uq  over the [ )Ktt 1, +  time period. 
If it is assumed that in the absence of other decrements, the times of transition from 
state vS  to state uS would be uniformly distributed over the interval [ )Ktt 1, + , then 
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Since the mortality rate is assumed to be independent of changes between states over 
the [ )Ktt 1, +  time interval (ignoring changes in x and s), the dependent rate of 
mortality is effectively the same as the independent rate of mortality. The dependent 
probability of remaining in state vS  over the interval [ )Ktt 1, +  is 
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Appendix B: Mathematical approach to modelling STI 
transmission and cure 
 
This appendix builds on the mathematical developments of Appendix A, to derive 
expressions for an individual’s probability of acquiring a particular STI over a 
particular time period, and the individual’s probability of being cured of a particular 
STI if they seek treatment. Three additional index variables are defined in Table B.1. 
Although bacterial vaginosis and vaginal candidiasis are included in the state space 
for d, none of the transmission variables in section B.1 are defined for the case in 
which d = BV and d = VC, since these infections are assumed not to be sexually 
transmitted. 
 
Table B.1: Index variables 
Symbol Definition State space 
d STI BV = bacterial vaginosis 
CT = chlamydia (Chlamydia trachomatis) 
HD = chancroid (Haemophilus ducreyi) 
HIV = human immunodeficiency virus 
HSV = herpes simplex virus type 2 
NG = gonorrhoea (Neisseria gonorrhoeae) 
TP = syphilis (Treponema pallidum) 
TV = trichomoniasis (Trichomonas vaginalis) 
VC = vaginal candidiasis 
h Health 
sector 
0 = public health sector 
1 = private health sector 
2 = traditional healers 
z STI state 0 (susceptible), 1, 2, … (as defined in section 3.3.1) 
 
The variable k is defined as the number of STI cycles per year, i.e. the frequency at 
which movements between STI states are updated. The default value is 48, but it can 












B.1 Rates of STI transmission 
 




,,β  = probability of transmitting STI d when in state z, in a single act of 
unprotected sex in relationship type l, if the infected individual is of sex g and is in 
risk group i and HIV stage s (if subscript l is omitted, the probability relates to 
commercial sex relationships) 
),(,,, tx
s
ljigα  = multiple by which the probability of transmitting HIV is increased as a 
result of other STIs in the HIV-positive partner, given that the HIV-positive partner is 
of sex g, in risk group i, in HIV disease stage s, in relationship type l with partner(s) 
in group(s) j, at time t  
),(,,, txljig
−α  = multiple by which the probability of acquiring HIV is increased as a 
result of other STIs in the HIV-negative partner, given that the HIV-susceptible 
partner is of sex g, in risk group i, in relationship type l with partner(s) in group(s) j, 
at time t  
),(, txlgγ  = probability that a condom is used in relationship type l at time t, if the 
susceptible partner is of sex g and age x 
dE  = probability that a condom prevents the transmission of STI d 
)(xa dg  = factor by which susceptibility to STI d is increased at age x among 
individuals of sex g 
),(,, ,,, txX
szd
ljig  = proportion of individuals in state z of disease d, out of people of sex g, 
in risk group i, in HIV disease stage s, in relationship type l with partner(s) in group(s) 
j, at time t (in the case of d = HIV, the proportion is 0 for z ≠ s and 1 for z = s) 
),(,,, txT
d
ljig  = the probability that an individual of sex g, in risk group i, aged x, 
transmits STI d to a susceptible partner of type l (short-term or long-term partnerships 
only) in risk group j, in a single act of unprotected sex, over the period [ )ktt 1, +  
 





















































where ),(, ljI vu  is the number of partnerships of type l with partners in risk group j, if 
the individual has partner(s) in group(s) u, with their primary partnership being of 
type v (as in Appendix A). The above equation is the weighted average probability of 
transmitting HIV, where the weights are the numbers of individuals in relationships of 
type l. The same formula is used to calculate ),(,,, txT
d
ljig  for other STIs, except that 
the ),(,,, tx
s
vuigα  factor is omitted.  
 
The next step is to define ),(,,, txP
d
ljig  as the probability that a susceptible individual of 
sex g and age x, in risk group i, becomes infected with STI d through a single act of 
sex with a partner in group j in the context of relationship type l, over the period 
[ )ktt 1, + . In the case of HIV, this represents the probability of becoming infected 
with HIV, before allowing for the effect of other STIs in the HIV-negative individual 
on their susceptibility to HIV. In the context of short-term and long-term 
relationships, ),(,,, txP
d















lijg  by )|( xyf g , the proportion of partners aged y, takes into 
account the individual’s partner age preferences. In the context of interactions 
between sex workers and their clients, a different approach is taken. Since the variable 
),(,,, txT
d
ljig  is not defined for sexual relations between sex workers and their clients, it 

















































































where )(* tγ  is the rate of condom use in acts of sex between sex workers and their 
clients at time t. As noted in Appendix A, it is assumed that there are no age 
preferences in interactions between sex workers and their clients, and hence the 
)|( xyf g  factor does not appear in either of the previous two equations. 
 
The last step is to define ),(,,, tx
d
ljigλ  as the probability that a susceptible individual of 
sex g and age x, in risk group i, n relationship type l with partner(s) in group(s) j, 
becomes infected with STI d over the period [ )ktt 1, + . For STIs other than HIV, this 




















































The average number of sex acts per Kth of a year, )(, xn lg , is a function of only the 
individual’s sex (g), age (x) and the relationship type (l), and is independent of the 
number or type of other relationships the individual is in. The terms in the three sets 
of square brackets represent the probabilities of not being infected in each of the three 











case of women, the same formula applies, except that the last factor representing the 
risk of infection through sex worker contact is omitted. The probability that a sex 
worker becomes infected is 
 
 ( ) kCdd txPtx ),(11),( 1,3,20,3,2 −−=λ , 
 
where C, as mentioned before, is the average annual number of clients a sex worker 
has. For HIV, the same formulas apply, except that the ),(,,, txP
d
ljig  terms are 
multiplied by ),(,,, txljig
−α  in order to determine the effect of other STIs on 
susceptibility to HIV. 
 
B.2 Rates of STI cure 
 
Symbols are defined as follows: 
)(tdgψ  = probability that an individual of sex g, experiencing symptoms of disease d, 
is cured if they seek treatment at time t 
hgr ,  = % of individuals of sex g who seek STI treatment in health sector h 
)(thΩ  = % of health workers in sector h who correctly follow syndromic 
management protocols at time t (h = 0 or 1 only) 
−d
gA  = % of individuals of sex g, with symptoms of STI d, who receive appropriate 
treatment if the health worker is not following syndromic management protocols 
(ignoring the potential effect of drug shortages) 
+d
gA  = % of individuals of sex g, with symptoms of STI d, who receive appropriate 
treatment if the health worker is following syndromic management protocols 
(ignoring the potential effect of drug shortages) 
)(tV  = % reduction in the probability of cure in public STI clinics as a result of drug 
shortages, at time t 
d
Aς  = probability that STI d is cured if treated with appropriate drugs 
d
Tς  = probability that STI d is cured if treated by a traditional healer 
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This is the weighted average probability of cure in the different health sectors, where 
the weights are the proportions of individuals seeking treatment in each sector, hgr , . In 
the case of bacterial vaginosis and vulvovaginal candidiasis, the )(tdgψ , 
d
Aς  and 
d
Tς  
symbols are modified slightly by adding a subscript after the first to indicate whether 
cure is complete (1) or only partial (2), as explained in section 3.3.4.3. 
 
B.3 Initial STI profile 
 
The method used to determine the initial proportion of the population infected with 
HIV at the start of the projection has already been described in section 4.1.1. For each 
simulation of STIs other than HIV, it is necessary to approximate the proportion of 
each age, sex and sexual activity cohort in the different STI states at the start of the 
HIV/AIDS projection period (1985). This is done by first running the model for five 
years, prior to any changes in condom use, STI treatment and HIV prevalence, in 
order to estimate the endemic STI prevalence that would be expected at the start of 
the HIV/AIDS epidemic. This endemic STI profile is calculated for each of the age, 
sex and sexual activity cohorts. The projection is then restarted in 1985, in the same 
way as before, but this time using the previously calculated endemic STI prevalence 
profiles in each cohort as the starting point. Although a five-year projection is 
sufficient to approximate the endemic prevalence of most STIs, it might not be 
adequate for chronic STIs such as genital herpes, which could take decades to reach 












Appendix C: Estimates of STI prevalence from sentinel 
surveillance 
 
The following tables summarize the data used in the Bayesian analysis described in 
section 4.2. Although data from patients with genital ulcer disease (GUD) were not 
used in the Bayesian analysis, they have been used in validating the model, and are 
therefore included here too. For readers interested in identifying the distribution of 
sampled populations between provinces and between urban and rural areas, Table C.1 
provides information on the geographical classification of the various sites. In 
subsequent tables, prevalence estimates are arranged according to sample type and 
then according to the year in which the study was conducted. 
 
Table C.1: Sentinel surveillance sites 
Location Urban/rural Province 
Bloemfontein Urban Free State 
Bushbuckridge Rural Limpopo 
Cape Town Urban Western Cape 
Durban Urban KwaZulu-Natal 
Empangeni Rural KwaZulu-Natal 
Hewu district Rural Eastern Cape 
Hlabisa (/Umkanyakude) Rural KwaZulu-Natal 
Johannesburg Urban Gauteng 
Khutsong (/Carletonville) Urban Gauteng1 
Mbalenhle Rural Mpumalanga 
Orange Farm Urban Gauteng 
Pretoria Urban Gauteng 
Virginia Urban Free State 
Vulindlela Rural KwaZulu-Natal 













Table C.2: Syphilis prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1989) 1986-7 ANC Empangeni 193 11.9% Non-trep. + trep. 
Donders et al (1993b) 1988 ANC Pretoria 256 9.0% Non-trep. + trep. 
Dietrich et al (1992) - ANC Durban 170 7.6% Non-trep. + trep. 
Coetzee (1994) 1990-2 ANC Cape Town 1973 5.2% Non-trep. + trep. 
Opai-Tetteh et al (1993) - ANC Durban 200 11.0% Non-trep. + trep. 
Bam et al (1994) 1990 ANC Bloemfontein 971 15.7% Non-trep. + trep. 
Hoosen et al (1996) - ANC Durban 32 12.0% Non-trep. + trep. 
Qolohle et al (1995) 1993 ANC Durban 363 9.4% Non-trep. + trep. 
Govender et al (1996) 1994 ANC Durban 168 12.0% Non-trep. + trep. 
Kharsany et al (1997) 1994 ANC Durban 52 26.9% Non-trep.  
Sturm et al (2003) 1995 ANC Hlabisa 327 12.0% Non-trep. + trep. 
Sturm et al (1998) 1996 ANC Hlabisa 327 8.4% Non-trep. + trep. 
Mashiane et al (1999) 1997 ANC Pretoria 3000 12.4% Non-trep. + trep. 
Dawadi et al (2001) 1997-8 ANC Hewu 271 8.5% Non-trep.  
Myer et al (2003) 1998- 
2000 
ANC Hlabisa 7391 7.5% Non-trep.  
Sturm et al (2003) 1999 ANC Hlabisa 245 6.0% Non-trep. + trep. 
2002 ANC Hlabisa 449 2.0% Non-trep. + trep. 
Ramjee et al (2005) 1996- 
2000 
CSW KZN 395 31.4% Non-trep. + trep. 
Steen et al (2000) 1996-7 CSW Virginia 407 33.8% Non-trep. + trep. 
Dunkle et al (2005) 1996-7 CSW Johannesburg 295 25.6% Non-trep. + trep. 
Williams et al (2000) 1998 CSW Khutsong 121 23.3% Non-trep. + trep. 
Williams et al (2003) 2000 CSW Khutsong 93 34.4% Non-trep. + trep. 
Ndhlovu et al (2005) 2001 CSW Khutsong 101 21.0% Non-trep. + trep. 
Hoosen et al (1989) 1986 FPC Durban 50 8.0% Non-trep. + trep. 
Schneider et al (1998) 1994 FPC Bushbuck- 
ridge 
249 5.0% Non-trep. + trep. 
Wilkinson et al (1997) - FPC Hlabisa 189 8.0% Non-trep. + trep. 
Kharsany et al (1997) 1994 FPC Durban 55 21.8% Non-trep.  
Hoosen et al (1997) - FPC Durban 40 8.0% Non-trep. + trep. 
Fehler et al (1998) - FPC Johannesburg 210 8.6% Non-trep. + trep. 
Frohlich et al (2003) 2002 FPC Vulindlela 221 2.2% Non-trep. + trep. 
Cronje et al (1994) - HH, F 20-49 Urban FS 403 15.5% Non-trep. + trep. 
 HH, F 20-49 Rural FS 465 12.3% Non-trep. + trep. 
Colvin et al (1998) 1995 HH, F 15-49 Hlabisa 142 8.5% Non-trep. + trep. 












Table C.2 (continued) 
Study Year  Sample Location n Prev. Diagnostic 
Auvert et al (2001a) 1999 HH, F 15-24 Khutsong 622 4.5% Non-trep. + trep. 
Williams et al (2003)* 2000 HH, F 15-19 Khutsong 893 18.7% Non-trep. + trep. 
Ndhlovu et al (2005)* 2001 HH, F 15-59 Khutsong 878 13.0% Non-trep. + trep. 
Auvert et al (2004)* 2002 HH, F 15-49 Orange Farm 492 9.6% Non-trep. + trep. 
Colvin et al (1998) 1995 HH, M 15-49 Hlabisa 86 9.3% Non-trep. + trep. 
Williams et al (2000) 1998 HH, M 15-59 Khutsong 475 6.1% Non-trep. + trep. 
Auvert et al (2001a) 1999 HH, M 15-24 Khutsong 560 1.8% Non-trep. + trep. 
Williams et al (2003) 2000 HH, M 15-19 Khutsong 606 8.1% Non-trep. + trep. 
Ndhlovu et al (2005) 2001 HH, M 15-59 Khutsong 532 5.0% Non-trep. + trep. 
Auvert et al (2004) 2002 HH, M 15-49 Orange Farm 438 3.2% Non-trep. + trep. 
* Outlier estimates, excluded from analysis due to excessive influence. 
ANC = antenatal clinic attenders. CSW = commercial sex workers. F = females. FPC = family 
planning clinic attenders. FS = Free State. HH = households. KZN = KwaZulu-Natal. M = males. Non-
trep. = non-treponemal assay. Prev. = prevalence. Trep. = treponemal assay. 
 
In the case of syphilis, three measurements of syphilis prevalence among women were 
excluded from the analysis because they were found to have excessive influence on 
the fitting of the model. All three outlier estimates of syphilis prevalence were from 
household surveys conducted in townships in Gauteng province between 2000 and 
2002. For the sake of comparison, these outliers are included in Table C.2, and are 
indicated by asterisks. No prevalence estimates were judged to be outliers in the case 











Table C.3: Gonorrhoea prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1989) 1987 ANC Empangeni 193 5.7% Culture 
Donders et al (1993b) 1988 ANC Pretoria 256 3.9% Culture 
Dietrich et al (1992) - ANC Durban 170 4.1% Culture 
Hoosen et al (1996) - ANC Durban 32 6.0% Culture 
Govender et al (1996) 1994-5 ANC Durban 168 3.0% Culture 
Kharsany et al (1997) 1994 ANC Durban 52 5.8% Culture 
Sturm et al (1998) 1996 ANC Hlabisa 327 7.8% Culture 
Sturm et al (2003) 1999 ANC Hlabisa 245 7.0% PCR on swabs 
Sturm et al (2004a) - ANC Hlabisa 185 7.6% -1 
Sturm et al (2003) 2002 ANC Hlabisa 449 4.0% PCR on swabs 
Ramjee et al (2005) 1996- 
2000 
CSW KZN 387 10.3% Culture 
Steen et al (2000) 1996-7 CSW Virginia 407 17.3% LCR on urine 
Dunkle et al (2005) 1996-7 CSW Johannesburg 295 23.3% LCR on urine 
Williams et al (2000) 1998 CSW Khutsong 121 15.7% LCR on urine 
Williams et al (2003) 2000 CSW Khutsong 93 16.1% LCR on urine 
Ndhlovu et al (2005) 2001 CSW Khutsong 101 10.0% LCR on urine 
Hoosen et al (1989) 1986-7 FPC Durban 50 10.0% Culture 
Schneider et al (1998) 1994 FPC Bushbuck- 
ridge 
249 3.0% LCR on urine 
Wilkinson et al (1997) - FPC Hlabisa 189 4.0% Culture 
Kharsany et al (1997) 1994 FPC Durban 55 5.5% Culture 
Hoosen et al (1997) - FPC Durban 40 5.0% Culture 
Fehler et al (1998) - FPC Johannesburg 210 8.6% LCR on urine 
Kleinschmidt et al (2007) 1999- 
2001 
FPC Orange Farm 538 3.9% LCR on urine 
Frohlich et al (2003) 2002 FPC Vulindlela 221 2.2% PCR on swabs 
Colvin et al (1998) 1995 HH, F 15-49 Hlabisa 137 5.8% LCR on urine 
Williams et al (2000) 1998 HH, F 15-59 Khutsong 712 6.9% LCR on urine 
Auvert et al (2001a) 1999 HH, F 15-24 Khutsong 622 10.9% LCR on urine 
Williams et al (2003) 2000 HH, F 15-49 Khutsong 893 8.6% LCR on urine 
Ndhlovu et al (2005) 2001 HH, F 15-59 Khutsong 878 11.0% LCR on urine 
Pettifor et al (2005a) 2002-3 HH, F 15-19 Peri-urban 
townships 
2624 3.5% PCR on urine 
HH, F 20-24 2002 3.5% PCR on urine 
Hurkchand et al (2004) 2002 HH, F 20-49 Mbalenhle 399 4.7% PCR on urine 
Colvin et al (1998) 1995 HH, M 15-49 Hlabisa 85 2.4% LCR on urine 












Table C.3 (continued) 
Study Year  Sample Location n Prev. Diagnostic 
Auvert et al (2001a) 1999 HH, M 15-24 Khutsong 560 2.9% LCR on urine 
Williams et al (2003) 2000 HH, M 15-49 Khutsong 606 3.3% LCR on urine 
Ndhlovu et al (2005) 2001 HH, M 15-59 Khutsong 532 4.0% LCR on urine 
Pettifor et al (2005a) 2002-3 HH, M 15-19 Peri-urban 
townships 
2389 1.1% PCR on urine 
HH, M 20-24 1455 3.2% PCR on urine 
Hurkchand et al (2004) 2002 HH, M 20-49 Mbalenhle 291 3.9% PCR on urine 
1 Diagnosed by culture and a series of genetic tests, which in combination would have had very high 
sensitivity and specificity. 
ANC = antenatal clinic attenders. CSW = commercial sex workers. F = females. FPC = family 
planning clinic attenders. HH = households. KZN = KwaZulu-Natal. LCR = ligase chain reaction test. 
M = males. PCR = polymerase chain reaction test. Prev. = prevalence. 
 
Table C.4: Vulvovaginal candidiasis prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1989) 1987 ANC Empangeni 193 26.9% Culture 
Van Rensburg and  
Odendaal (1992) 
1988 ANC Cape Town 180 20.0% Culture 
Hoosen et al (1996) - ANC Durban 32 59.0% Microscopy 
Kharsany et al (1997) 1994 ANC Durban 52 55.8% Culture 
Funk et al (1996) 1995 ANC Pretoria 798 23.6% Microscopy 
Ramjee et al (1998) 1996-7 CSW KZN 145 40.9% Microscopy 
Dunkle et al (2005) 1996-7 CSW Johannesburg 295 25.9% Microscopy 
Wilkinson et al (1997) - FPC Hlabisa 189 30.0% Microscopy 
Kharsany et al (1997) 1994 FPC Durban 55 27.2% Culture 
Fehler et al (1998) - FPC Johannesburg 210 22.9% Microscopy 
ANC = antenatal clinic attenders. CSW = commercial sex workers. FPC = family planning clinic 











Table C.5: Chlamydial infection prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1989) 1987 ANC Empangeni 193 11.4% DIF 
Dietrich et al (1992) - ANC Durban 170 4.7% DIF 
Hoosen et al (1996) - ANC Durban 32 41.0% DIF 
Kharsany et al (1997) 1994 ANC Durban 52 19.2% DIF 
Sturm et al (1998) 1996 ANC Hlabisa 327 12.9% DIF 
Sturm et al (2003) 1999 ANC Hlabisa 245 11.0% PCR on swabs 
Sturm et al (2004a) - ANC Hlabisa 185 13.5% -1 
Sturm et al (2003) 2002 ANC Hlabisa 449 11.0% PCR on swabs 
Ramjee et al (1998) 1996-7 CSW KZN 145 16.4% DIF 
Steen et al (2000) 1996-7 CSW Virginia 407 14.3% LCR on urine 
Dunkle et al (2005) 1996-7 CSW Johannesburg 295 8.4% LCR on urine 
Williams et al (2000) 1998 CSW Khutsong 121 9.1% LCR on urine 
Williams et al (2003) 2000 CSW Khutsong 93 12.9% LCR on urine 
Ndhlovu et al (2005) 2001 CSW Khutsong 101 8.0% LCR on urine 
Hoosen et al (1989) 1986-7 FPC Durban 50 26.0% DIF 
Schneider et al (1998) 1994 FPC Bushbuck- 
ridge 
249 12.0% LCR on urine 
Wilkinson et al (1997) - FPC Hlabisa 189 8.0% DIF 
Kharsany et al (1997) 1994 FPC Durban 55 12.7% DIF 
Hoosen et al (1997) - FPC Durban 40 15.0% DIF 
Fehler et al (1998) - FPC Johannesburg 210 18.1% LCR on urine 
Kleinschmidt et al (2007) 1999- 
2001 
FPC Orange Farm 539 14.1% LCR on urine 
Frohlich et al (2003) 2002 FPC Vulindlela 221 8.8% PCR on swabs 
Colvin et al (1998) 1995 HH, F 15-49 Hlabisa 140 6.4% LCR on urine 
Williams et al (2000) 1998 HH, F 15-59 Khutsong 712 8.1% LCR on urine 
Auvert et al (2001a) 1999 HH, F 15-24 Khutsong 622 14.6% LCR on urine 
Williams et al (2003) 2000 HH, F 15-49 Khutsong 893 13.8% LCR on urine 
Ndhlovu et al (2005) 2001 HH, F 15-59 Khutsong 878 12.0% LCR on urine 
Auvert et al (2004) 2002 HH, F 15-49 Orange Farm 492 6.9% PCR on urine 
Pettifor et al (2005a) 2002-3 HH, F 15-19 Semi-urban 
townships 
2624 9.1% PCR on urine 
HH, F 20-24 2002 10.8% PCR on urine 
Hurkchand et al (2004) 2002 HH, F 20-49 Mbalenhle 399 6.5% PCR on urine 
Colvin et al (1998) 1995 HH, M 15-49 Hlabisa 90 5.6% LCR on urine 
Williams et al (2000) 1998 HH, M 15-59 Khutsong 475 5.2% LCR on urine 
Auvert et al (2001a) 1999 HH, M 15-24 Khutsong 560 4.8% LCR on urine 












Table C.5 (continued) 
Study Year  Sample Location n Prev. Diagnostic 
Ndhlovu et al (2005) 2001 HH, M 15-59 Khutsong 532 7.0% LCR on urine 
Auvert et al (2004) 2002 HH, M 15-49 Orange Farm 438 6.2% PCR on urine 
Pettifor et al (2005a) 2002-3 HH, M 15-19 Semi-urban 
townships 
2389 3.5% PCR on urine 
HH, M 20-24 1455 10.1% PCR on urine 
Hurkchand et al (2004) 2002 HH, M 20-49 Mbalenhle 291 8.2% PCR on urine 
1 Diagnosed by culture and a series of genetic tests, which in combination would have had very high 
sensitivity and specificity. 
ANC = antenatal clinic attenders. CSW = commercial sex workers. DIF = direct immunofluorescence. 
F = females. FPC = family planning clinic attenders. HH = households. KZN = KwaZulu-Natal. LCR = 
ligase chain reaction test. M = males. PCR = polymerase chain reaction test. Prev. = prevalence. 
 
Table C.6: Chancroid prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1991b) 1988-9 GUD, F Durban 100 14.0% Culture (ulcers) 
Rajagopal et al (1999) 1997 GUD, F Durban 23 0.0% Culture (ulcers) 
Moodley et al (2003a) 2000 GUD, F Durban 149 6.0% PCR (ulcers) 
Dangor et al (1989) 1986 GUD, M Khutsong 240 68.3% Culture (ulcers) 
O’Farrell et al (1991a) 1988-9 GUD, M Durban 100 22.0% Culture (ulcers) 
Ye et al (2007) 1990 GUD, M Khutsong 213 62.4% Culture (ulcers) 
Chen et al (2000) 1993-4 GUD, M Cape Town 180 17.2% PCR (ulcers) 
GUD, M Johannesburg 159 21.4% 
GUD, M Durban 199 53.3% 
Lai et al (2003) 1993 GUD, M Khutsong 232 69.4% PCR (ulcers) 
Mathews et al (1998) 1995 GUD, M Cape Town 40 12.5% Culture (ulcers) 
Lai et al (2003) 1998 GUD, M Khutsong 186 50.5% PCR (ulcers) 
Kharsany et al (2000) 1998 GUD, M Durban 400 6.0% PCR (ulcers) 
Moodley et al (2003a) 2000 GUD, M Durban 438 11.0% PCR (ulcers) 
Muller et al (2007b) 2005-6 GUD, M Gauteng 450 4.7% PCR (ulcers) 












Table C.7: Trichomoniasis prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
O’Farrell et al (1989) 1987 ANC Empangeni 193 49.2% Culture 
Donders et al (1993a) 1988 ANC Pretoria 256 25.4% Wet mount 
Hoosen et al (1996) - ANC Durban 32 19.0% Wet mount 
Govender et al (1996) 1994-5 ANC Durban 168 21.0% Wet mount 
Kharsany et al (1997) 1994 ANC Durban 52 51.9% Culture 
Funk et al (1996) 1995 ANC Pretoria 798 12.3% Wet mount 
Sturm et al (1998) 1996 ANC Hlabisa 327 41.4% Culture 
Sturm et al (2003) 1999 ANC Hlabisa 245 32.0% PCR on swabs 
Sturm et al (2004a) 2001 ANC Hlabisa 185 36.8% -1 
Sturm et al (2003) 2002 ANC Hlabisa 449 27.0% PCR on swabs 
Ramjee et al (2005) 1996- 
2000 
CSW KZN 392 35.7% Wet mount 
Dunkle et al (2005) 1996-7 CSW Johannesburg 295 16.8% Wet mount 
Hoosen et al (1989) 1986-7 FPC Durban 50 20.0% Wet mount 
Schneider et al (1998) 1994 FPC Bushbuck- 
ridge 
249 18.0% Wet mount 
Wilkinson et al (1997) - FPC Hlabisa 189 14.0% Culture 
Kharsany et al (1997) 1994 FPC Durban 55 25.5% Culture 
Hoosen et al (1997) - FPC Durban 40 20.0% Culture 
Fehler et al (1998) - FPC Johannesburg 210 10.6% Culture 
Kleinschmidt et al (2007) 1999- 
2001 
FPC Orange Farm 547 7.5% Culture 
Frohlich et al (2003) 2002 FPC Vulindlela 221 23.8% PCR on swabs 
Cronje et al (1994) - HH, F 20-49 Urban FS 405 29.6% Wet mount 
 HH, F 20-49 Rural FS 470 27.4% Wet mount 
Charumilind et al (2007) 2003 HH2, M 20-54 Johannesburg 1458 5.6% PCR on urine 
1 Diagnosed by culture and a series of genetic tests, which in combination would have had very high 
sensitivity and specificity. 2 Sample was drawn from men in hostels, but is treated as a household 
sample for the purpose of this analysis, as it is the only prevalence estimate for males. 
ANC = antenatal clinic attenders. CSW = commercial sex workers. F = females. FPC = family 
planning clinic attenders. FS = Free State. HH = households. KZN = KwaZulu-Natal. M = males. PCR 













Table C.8: Genital herpes (HSV-2) prevalence estimates 
Study Year  Sample Location n Prev. Diagnostic 
Sturm (2003) 2002 ANC Hlabisa 417 65.0% Western blot 
Ramjee et al (2005) 1996- 
2000 
CSW KZN 416 84.0% ELISA 
Ndhlovu et al (2005) 2001 CSW Khutsong 101 62.0% ELISA 
Mlaba et al (2007) - FPC Johannesburg 210 73.0% ELISA 
O’Farrell et al (1991b) 1988-9 GUD, F Durban 100 18.0% Culture (ulcers) 
Rajagopal et al (1999) 1997 GUD, F Durban 23 18.0% Culture (ulcers) 
Moodley et al (2003a) 2000 GUD, F Durban 149 49.7% PCR (ulcers) 
Auvert et al (2001a) 1999 HH, F 15-24 Khutsong 771 53.3% ELISA 
Ndhlovu et al (2005) 2001 HH, F 15-59 Khutsong 878 71.0% ELISA 
Dangor et al (1989) 1986 GUD, M Khutsong 240 3.3% Culture (ulcers) 
O’Farrell et al (1991a) 1988-9 GUD, M Durban 100 10.0% Culture (ulcers) 
Ye et al (2007) 1990 GUD, M Khutsong 213 3.8% Culture (ulcers) 
Chen et al (2000) 1993-4 GUD, M Cape Town 180 23.9% PCR (ulcers) 
GUD, M Johannesburg 159 49.1% 
GUD, M Durban 199 36.2% 
Lai et al (2003) 1993 GUD, M Khutsong 232 17.2% PCR (ulcers) 
Mathews et al (1998) 1995 GUD, M Cape Town 40 12.5% Culture (ulcers) 
Lai et al (2003) 1998 GUD, M Khutsong 186 36.0% PCR (ulcers) 
Kharsany et al (2000) 1998 GUD, M Durban 400 41.0% PCR (ulcers) 
Moodley et al (2003a) 2000 GUD, M Durban 438 47.9% PCR (ulcers) 
O’Farrell et al (2007b) 2004 GUD, M Durban 165 52.7% PCR (ulcers) 
Muller et al (2007b) 2005-6 GUD, M Gauteng 450 69.3% PCR (ulcers) 
Auvert et al (2001a) 1999 HH, M 15-24 Khutsong 718 17.0% ELISA 
Ndhlovu et al (2005) 2001 HH, M 15-59 Khutsong 532 42.0% ELISA 
ANC = antenatal clinic attenders. CSW = commercial sex workers. ELISA = enzyme linked 
immunosorbent assay. F = females. FPC = family planning clinic attenders. GUD = genital ulcer 
disease patients. HH = households. KZN = KwaZulu-Natal. M = males. PCR = polymerase chain 













Table C.9: Bacterial vaginosis prevalence estimates, based on Nugent scoring 
Study Year  Sample Location n Prevalence 
Hoosen et al (1996) - ANC Durban 32 34.0% 
Govender et al (1996) 1994-5 ANC Durban 168 52.0% 
Sturm et al (2003) 1995 ANC Hlabisa 327 38.0% 
1999 ANC Hlabisa 245 34.0% 
2002 ANC Hlabisa 449 31.0% 
Wilkinson et al (1997) - FPC Hlabisa 189 15.0% 
Fehler et al (1998) - FPC Johannesburg 210 35.1% 
Kleinschmidt et al (2007) 1999-2001 FPC Orange Farm 532 35.9% 
Frohlich et al (2003) 2002 FPC Vulindlela 221 58.4% 














Appendix D: Sensitivity and specificity of STI diagnostic 
techniques 
 
Table D.1 specifies the assumed sensitivity and specificity of the diagnostic 
techniques most commonly used for each STI, together with the assumed standard 
deviation of the sensitivity and specificity parameters when the tests are applied in 
different conditions by different investigators. In most cases the average sensitivity 
and specificity are calculated as the unweighted average of the estimates obtained 
from various studies, and the standard deviation is calculated from the sample 
variance of the same studies. In cases in which there are fewer than three estimates 
from which to calculate a sample variance, the standard deviation has been 
subjectively chosen to be similar to that of the same diagnostic used to detect a 
different STI, or to that of a related diagnostic used to detect the same STI. In the case 
of serological tests, estimates of sensitivity and specificity are usually published for 
males and females combined, and in these cases the same assumptions have been 
made for males and females. Studies have generally not been included if the ‘gold 
standard’ used to calculate the sensitivity and specificity parameters was judged to be 
insufficiently sensitive. A number of the assumptions are based on published reviews 
of sensitivity and specificity estimates (Cook et al, 2005; Orroth et al, 2003a; Wiese 












Table D.1: Assumed sensitivity and specificity of different diagnostics 
STI Diagnostic Sex 
Sensitivity Specificity 
Source 
Mean SD Mean SD 
Syphilis Non-treponemal 
   + treponemal 
   assays 
M, F 0.956 0.02 1 0 Bruisten et al (2001) 
Risbud et al (1999) 
Behets et al (1999) 
Castro et al (2003) 
Non-treponemal 
   assay 
M, F 0.956 0.02 0.98 0.02 Castro et al (2003) 
Orle et al (1996) 
Morse et al (1997) 
Hooper et al (1994) 
West et al (2002) 
Herpes ELISA M, F 0.95 0.03 0.951 0.037 Cusini et al (2000) 
Turner et al (2002) 
Eing et al (2002) 
Gopal et al (2000) 
Spiezia et al (1990) 
Western blot M, F 0.914 0.03 1 0 Eing et al (2002) 
Spiezia et al (1990) 
Gonorrhoea Culture F 0.742 0.193 0.998 0.005 Orroth et al (2003a) 
LCR on urine M 0.921 0.029 1 0 van Doornum et al (2001) 
Buimer et al (1996) 
F 0.838 0.191 1 0 Orroth et al (2003a) 
PCR on urine M 0.904 0.029 0.997 0.007 Cook et al (2005) 
F 0.556 0.202 0.987 0.018 Cook et al (2005) 




   fluorescence 
F 0.763 0.02 0.988 0.008 Thejls et al (1994) 
Mills et al (1992) 
Lefebvre et al (1988) 
LCR on urine M 0.875 0.121 1 0 Orroth et al (2003a) 
F 0.866 0.121 1 0 Orroth et al (2003a) 
PCR on urine F 0.833 0.139 0.995 0.007 Cook et al (2005) 












Table D.1 (continued) 
STI Diagnostic Sex 
Sensitivity Specificity 
Source 
Mean SD Mean SD 
Tricho- 
moniasis 
Wet mount F 0.59 0.123 0.991 0.021 Wiese et al (2000) 
Culture F 0.689 0.131 1 0 Wendel et al (2002) 
Mayta et al (2000) 
Madico et al (1998) 
Sturm et al (2004a) 
PCR on swabs F 0.95 0.05 0.98 0.024 Patel et al (2000) 
PCR on urine M 0.95 0.05 0.98 0.024 - 
Candidiasis Culture F 0.759 0.201 1 0 Bergman et al (1984) 
Giraldo et al (2000) 
Cibley et al (1998) 
Davies and Savage (1975) 
Microscopy F 0.553 0.227 1 0 Sobel et al (1990) 
Darce-Bello et al (2002) 
Bergman et al (1984) 
Weissberg (1978) 
Sonnex and Lefort (1999) 
Eckert et al (1998) 
Ferris et al (1995) 
Giraldo et al (2000) 
ELISA = enzyme-linked immunosorbent assay. LCR = ligase chain reaction. PCR = polymerase chain 











Appendix E: Effect of STIs on the detection of HIV in the 
genital tract 
 
Table E.1 summarizes the results of the studies that estimate the effect of STIs on the 
detection of HIV in the reproductive tract. Meta-analysis was performed on the results 
of these studies, and the summary odd ratios are presented in section 5.1.2. The 
corresponding forest plots are shown in Figure E.1. A more detailed description of 

























OR (95% CI) 
Measure of 
HIV shedding 










97 NG Culture 6 4.3 (0.7-25.3)a HIV DNA in 
cervical swabs Cervicitis ≥2 PMNLs/HPF 16 1.6 (0.4-6.2)a 
Cervical mucopus  10 6.2 (0.9-41.4)b 
TV Microscopy 15 0.8 (0.2-4.1)a HIV DNA in 
vaginal swabs Candidiasis Microscopy 17 0.7 (0.1-3.4)a 
BV Nugent criteria 50 1.4 (0.13-15.8)a 
Vaginal discharge  34 0.5 (0.1-1.8)a 









135 Urethritis ≥5 WBCs/HPF + 
discharge 
86 2.0 (0.7-5.5)a Cell-free HIV-1  
RNA in semen 









124 HSV-2 Shedding (PCR) 29 0.8 (0.2-3.3)c,d HIV-1 RNA in 
CVL or DNA 
in genital swabs 




Women Cohort 97 TV Microscopy 31 2.4 (0.5-11.3)c,d HIV-1 RNA in 
CVL Candidiasis Culture + abnormal 
discharge 
86 1.6 (0.6-4.1)c,d 
BV Amsel criteria 194 0.8 (0.4-1.6)c,d 




Women in HERS Cohort 108 BV Amsel criteria 12 5.9 (1.4-25.0)c,d HIV-1 RNA in 
CVL Candidiasis Culture + abnormal 
discharge 
























OR (95% CI) 
Measure of 
HIV shedding 






205 BV Amsel criteria 12 0.56 (0.06-2.79)a HIV-1 RNA in 
CVL 








122 Candidiasis Culture 17 0.79 (0.25-2.52)a Cell-free HIV-1  
RNA in CVL 









637 NG Culture 194 1.9 (1.2-3.0)c Cell-free HIV-1  
RNA in CVL CT EIA 27 2.5 (1.1-5.8)c 
TV Microscopy 194 0.9 (0.6-1.4)a 
TP RPR + TPHA 138 1.3 (0.8-2.0)a 
GUD (CV)  52 3.9 (2.1-7.4)c 
Cervical mucopus  122 2.3 (1.5-3.4)a 
Vaginal discharge  368 1.0 (0.7-1.5)a 








28 Candidiasis Culture 11 3.9 (0.5-32.1)a HIV-1 DNA in 
vaginal swabs 
1.9 (0.3-13.4)a Cell-free HIV-1  

























OR (95% CI) 
Measure of 
HIV shedding 









223 NG Culture 14 2.2 (0.7-6.4)a HIV-1 DNA in 
cervical swabs CT Microtrak/Clearview 17 1.2 (0.4-3.4)a 
TP RPR + TPHA 11 1.8 (0.5-6.2)a 
Cervical discharge  65 2.1 (1.1-3.9)a 
BV Gram’s staining 95 0.9 (0.3-2.7)a HIV-1 DNA in 
vaginal swabs Candidiasis Microscopy 61 2.0 (0.8-5.2)a 
TV PCR 25 0.9 (0.3-2.7)a 
Vaginal discharge  104 3.3 (1.1-9.4)a 









311 Candidiasis Culture 81 1.2 (0.5-2.9)d HIV-1 RNA in 
CVL or 
endocervical 
swabs (PCR), or 
culture of HIV-1 
in CVL/swabs 
Microscopy 36 5.6 (0.7-45.7)d 
TV Microscopy 9 4.7 (0.6-37.9)a 
BV Nugent criteria 72 0.5 (0.2-1.6)d 
HSV Shedding (culture) 9 0.2 (0.0-1.8)d 
Shedding (PCR) 29 3.1 (0.7-14.5)d 
Vaginal discharge  159 2.0 (0.4-9.6)d 
Cervical discharge  69 1.0 (0.4-2.7)d 




Women in WIHS Cross- 
sectional 


























OR (95% CI) 
Measure of 
HIV shedding 





CSWs Cohort 92 NG Culture 86 0.8 (0.4-1.6)a HIV DNA in 
cervical swabs CT Culture 6 1.4 (0.3-7.4)a 
HD Culture 4 0.1 (0.0-2.9)a 
TP RPR or VDRL 18 0.9 (0.3-2.7)a 
Cervicitis ≥2 PMNLs/HPF 87 11.8 (1.5-96.6)a 
GUD (cervical)  6 0.8 (0.2-4.6)a 
Vaginal discharge  7 2.4 (0.5-10.5)a 
Cervical mucopus  76 1.2 (0.6-2.5)a 











180 HSV-2 Shedding (PCR) 120 2.93 (1.47-5.88)a Cell-free HIV-1  
RNA in CVL 








58 HSV-2 Shedding (PCR) 23 0.3 (0.1-1.3)a Cell-free HIV-1  
RNA in CVL 










200 HSV Shedding (PCR) 42 1.04 (0.50-2.15)a HIV-1 RNA in 
cervical swabs 

























OR (95% CI) 
Measure of 
HIV shedding 







Cohort 36 Cervicitis ≥30 PMNLs/HPF 13 2.8 (1.3-6.0)a HIV-1 DNA in 
cervical swabs NG Culture 16 1.3 (0.4-4.0)a 
CT EIA 7 3.3 (0.7-14.9)a 







Cohort 106 NG Culture/microscopy 71 3.2 (1.6-6.4)c HIV DNA in 
urethral secretions Urethritis ≥5 PMNLs/HPF 80 2.7 (1.3-5.3)c 
NGU Urethritis, no NG 9 0.2 (0.0-1.9)a 
GUD  23 0.8 (0.3-2.2)a 
TP RPR + TPHA 6 2.1 (0.3-16.6)a 









275 HSV Shedding (PCR) 46 1.7 (0.8-3.4)a HIV-1 DNA in 
cervical swabs 









318 NG Culture 24 3.1 (1.1-9.8)a HIV-1 DNA in 
cervical swabs CT EIA 14 1.3 (0.4-4.6)a 
Cervicitis ≥11 PMNLs/HPF 214 2.27 (1.39-3.71)a 
Candidiasis Microscopy 61 2.6 (1.2-5.4)a HIV-1 DNA in 
vaginal swabs TV Microscopy 37 0.5 (0.1-1.8)a 






Cohort 17 BV Nugent criteria ≥12 0.8 (0.4-2.0)a HIV-1 DNA in 
vaginal swabs Candidiasis Microscopy ≥8 0.6 (0.2-2.2)a 

























OR (95% CI) 
Measure of 
HIV shedding 








290 Candidiasis Microscopy 28 1.2 (0.4-3.6)a HIV-1 RNA in 
cervical swabs BV Amsel criteria 59 0.7 (0.3-1.7)a 
TV Microscopy 11 1.3 (0.1-6.4)a 






207 GUD (CV)  62 2.2 (1.1-4.6)a Cell-free HIV-1  
RNA in CVL Vaginal discharge  149 2.2 (0.9-5.3)a 





STI clincs (cases) 





315 Candidiasis Culture + vaginitis 
symptoms 






HIV-1 RNA in  
CV swabs: 
   Cell-free 
   Cell-associated 









122 Candidiasis Culture 25 2.27 (0.75-6.86)d HIV-1 DNA in 
CVL TV Culture 10 1.13 (0.24-5.40)d 
BV Amsel criteria 31 2.47 (0.90-6.79)d 
Candidiasis Culture 25 4.18 (1.29-13.56)d Cell-free HIV-1  
RNA in CV  
swabs 
TV Culture 10 0.24 (0.02-2.73)d 
BV Amsel criteria 31 2.94 (1.00-8.7)d 
Candidiasis Culture 25 2.92 (0.93-9.16)d Cell-associated 
HIV-1 RNA in 
CV swabs 
TV Culture 10 0.16 (0.02-1.74)d 























OR (95% CI) 
Measure of 
HIV shedding 







and STI clinics 
Cohort 203 Candidiasis Microscopy 98 2.8 (1.3-6.5)a HIV-1 DNA in 
vaginal swabs TV Culture/microscopy 67 0.8 (0.3-2.2)a 
BV Nugent criteria 77 0.8 (0.3-2.0)a 








94 Urethritis ≥5 PMNLs/HPF 7 80.2 (2.2-2097)c,d Cell-free HIV-1  
RNA in semen 
 
a Univariate analysis. b Multivariate analysis. c Multivariate analysis controlling for CD4 count or %. d Multivariate analysis controlling for blood plasma viral load. 
BV = bacterial vaginosis. CAR = Central African Republic. CSW = commercial sex worker. CT = Chlamydia trachomatis. CV = cervicovaginal. CVL = cervicovaginal 
lavage. EIA = enzyme immunoassay. GUD = genital ulcer disease. HAART = highly active antiretroviral therapy. HD = Haemophilus ducreyi. HERS = HIV Epidemiologic 
Research Study. HPF = high power field. HSV = herpes simplex virus. NG = Neisseria gonorrhoeae. NGU = non-gonococcal urethritis. PCR = polymerase chain reaction. 
PMNL = polymorphonuclear leukocyte. RPR = rapid plasma reagin. TP = Treponema pallidum. TPHA = Treponema pallidum haemagglutination assay. TV = Trichomonas 














.1 .5 1 5 10 50
 Combined
 Mostad et al (1997)
 Moss et al (1995)
 McClelland et al (2001)
 Kreiss et al (1994)
 John et al (1997)
 Ghys et al (1997)
 Clemetson et al (1993)
(b) Chlamydial infection 
Effect
.1 .5 1 5 10 50
 Combined
 Mostad et al (1997)
 McClelland et al (2001)
 Kreiss et al (1994)
 John et al (1997)
 Ghys et al (1997)
(c) Bacterial vaginosis 
Effect
.1 .5 1 5 10 50
 Combined
 Wang et al (2001)
 Spinillo et al (2001)
 Neely et al (2007)
 Mostad et al (1998)
 Kovacs et al (2001)
 Kovacs et al (1999)
 John et al (1997)
 Cu-Uvin et al (2006)
 Cu-Uvin et al (2001)
 Cu-Uvin et al (2000)
Clemetson et al (1993)
(d) Candidiasis 
Effect
.1 .5 1 5 10 50
 Combined
 Wang et al (2001)
 Spinillo et al (2005)
 Spinillo et al (2001)
 Neely et al (2007)
 Mostad et al (1998)
 Mostad et al (1997)
 Kovacs et al (2001)
 John et al (1997)
 Iversen et al (1998)
 Fiore et al (2003)
 Cu-Uvin et al (2006)
 Cu-Uvin et al (2001)
Clemetson et al (1993)
(e) Trichomoniasis 
Effect
.1 .5 1 5 10 50
 Combined
 Wang et al (2001)
 Spinillo et al (2001)
 Neely et al (2007)
 Mostad et al (1997)
 Kovacs et al (2001)
 John et al (1997)
 Ghys et al (1997)
 Cu-Uvin et al (2006)
Clemetson et al (1993)
(f) Vaginal discharge 
Effect
.1 .5 1 5 10 50
 Combined
 Seck et al (2001)
 Kreiss et al (1994)
 Kovacs et al (2001)
 John et al (1997)
 Ghys et al (1997)
Clemetson et al (1993)
(g) Cervical discharge/mucopus 
Effect
.1 .5 1 5 10 50
 Combined
 Kreiss et al (1994)
 Kovacs et al (2001)
 John et al (1997)
 Ghys et al (1997)
Clemetson et al (1993)
(h) Cervicitis 
Effect
.1 .5 1 5 10 50
 Combined
 Mostad et al (1998)
 Mostad et al (1997)
 McClelland et al (2001)
 Kreiss et al (1994)
 Clemetson et al (1993)
 
























.1 .5 1 5 10 50
 Combined
 Winter et al (1999)
 Moss et al (1995)
 Cohen et al (1997)
(j) Genital ulcer disease 
Effect
.1 .5 1 5 10 50
 Combined
 Seck et al (2001)
 Moss et al (1995)
 Kreiss et al (1994)
 Ghys et al (1997)
(k) HSV shedding 
Effect
.1 .5 1 5 10
 Combined
 Mostad et al (2000)
 McClelland et al (2002)
 Mbopi-Keou et al (2000)
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Figure E.1: Forest plots of effects of genital tract infections on the detection of HIV in 
the genital tract 
Squares represent the results of individual studies, with the size of each square representing the weight 
given to the relevant study. Diamonds represent the combined odds ratios. 
 
 
 
